0001628280-22-021593.txt : 20220808 0001628280-22-021593.hdr.sgml : 20220808 20220808163708 ACCESSION NUMBER: 0001628280-22-021593 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 89 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220808 DATE AS OF CHANGE: 20220808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Twist Bioscience Corp CENTRAL INDEX KEY: 0001581280 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462058888 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38720 FILM NUMBER: 221144968 BUSINESS ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 800-719-0671 MAIL ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 10-Q 1 twst-20220630.htm 10-Q twst-20220630
false0001581280--09-302022Q310 years, 5 monthsP1YP2Y00015812802021-10-012022-06-3000015812802022-08-04xbrli:shares00015812802022-06-30iso4217:USD00015812802021-09-30iso4217:USDxbrli:shares0001581280us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-06-3000015812802022-04-012022-06-3000015812802021-04-012021-06-3000015812802020-10-012021-06-300001581280us-gaap:CommonStockMember2022-03-310001581280us-gaap:AdditionalPaidInCapitalMember2022-03-310001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001581280us-gaap:RetainedEarningsMember2022-03-3100015812802022-03-310001581280us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001581280us-gaap:CommonStockMember2022-04-012022-06-300001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001581280us-gaap:RetainedEarningsMember2022-04-012022-06-300001581280us-gaap:CommonStockMember2022-06-300001581280us-gaap:AdditionalPaidInCapitalMember2022-06-300001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001581280us-gaap:RetainedEarningsMember2022-06-300001581280us-gaap:CommonStockMember2021-03-310001581280us-gaap:AdditionalPaidInCapitalMember2021-03-310001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001581280us-gaap:RetainedEarningsMember2021-03-3100015812802021-03-310001581280us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001581280us-gaap:CommonStockMember2021-04-012021-06-300001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001581280us-gaap:RetainedEarningsMember2021-04-012021-06-300001581280us-gaap:CommonStockMember2021-06-300001581280us-gaap:AdditionalPaidInCapitalMember2021-06-300001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001581280us-gaap:RetainedEarningsMember2021-06-3000015812802021-06-300001581280us-gaap:CommonStockMember2021-09-300001581280us-gaap:AdditionalPaidInCapitalMember2021-09-300001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001581280us-gaap:RetainedEarningsMember2021-09-300001581280us-gaap:CommonStockMember2021-10-012022-06-300001581280us-gaap:AdditionalPaidInCapitalMember2021-10-012022-06-300001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-012022-06-300001581280us-gaap:RetainedEarningsMember2021-10-012022-06-300001581280us-gaap:CommonStockMember2020-09-300001581280us-gaap:AdditionalPaidInCapitalMember2020-09-300001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001581280us-gaap:RetainedEarningsMember2020-09-3000015812802020-09-300001581280us-gaap:CommonStockMember2020-10-012021-06-300001581280us-gaap:AdditionalPaidInCapitalMember2020-10-012021-06-300001581280us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-10-012021-06-300001581280us-gaap:RetainedEarningsMember2020-10-012021-06-300001581280twst:SubsequentPublicOffering1Member2021-10-012022-06-300001581280us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-06-300001581280us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-06-300001581280us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2022-06-300001581280us-gaap:MoneyMarketFundsMember2022-06-300001581280us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2022-06-300001581280us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-06-300001581280us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2022-06-300001581280us-gaap:CommercialPaperMember2022-06-300001581280us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-06-300001581280us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-06-300001581280us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300001581280us-gaap:USTreasurySecuritiesMember2022-06-300001581280us-gaap:FairValueInputsLevel1Member2022-06-300001581280us-gaap:FairValueInputsLevel2Member2022-06-300001581280us-gaap:FairValueInputsLevel3Member2022-06-300001581280us-gaap:FairValueInputsLevel1Membertwst:ContingentConsiderationAndIndemnityHoldbackMember2022-06-300001581280us-gaap:FairValueInputsLevel2Membertwst:ContingentConsiderationAndIndemnityHoldbackMember2022-06-300001581280us-gaap:FairValueInputsLevel3Membertwst:ContingentConsiderationAndIndemnityHoldbackMember2022-06-300001581280twst:ContingentConsiderationAndIndemnityHoldbackMember2022-06-300001581280us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-09-300001581280us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-09-300001581280us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-09-300001581280us-gaap:MoneyMarketFundsMember2021-09-300001581280us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001581280us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2021-09-300001581280us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300001581280us-gaap:USTreasurySecuritiesMember2021-09-300001581280us-gaap:FairValueInputsLevel1Member2021-09-300001581280us-gaap:FairValueInputsLevel2Member2021-09-300001581280us-gaap:FairValueInputsLevel3Member2021-09-300001581280us-gaap:FairValueInputsLevel1Membertwst:ContingentConsiderationAndIndemnityHoldbackMember2021-09-300001581280us-gaap:FairValueInputsLevel2Membertwst:ContingentConsiderationAndIndemnityHoldbackMember2021-09-300001581280us-gaap:FairValueInputsLevel3Membertwst:ContingentConsiderationAndIndemnityHoldbackMember2021-09-300001581280twst:ContingentConsiderationAndIndemnityHoldbackMember2021-09-300001581280twst:IgenomxInternationalGenomicsCorporatioMember2021-10-012022-06-300001581280srt:MaximumMember2021-04-012021-06-300001581280srt:MaximumMember2020-10-012021-06-300001581280us-gaap:DevelopedTechnologyRightsMember2021-10-012022-06-300001581280us-gaap:DevelopedTechnologyRightsMember2022-06-300001581280us-gaap:CustomerRelationshipsMember2021-10-012022-06-300001581280us-gaap:CustomerRelationshipsMember2022-06-300001581280us-gaap:TrademarksAndTradeNamesMember2021-10-012022-06-300001581280us-gaap:TrademarksAndTradeNamesMember2022-06-300001581280us-gaap:DevelopedTechnologyRightsMember2020-10-012021-09-300001581280us-gaap:DevelopedTechnologyRightsMember2021-09-300001581280us-gaap:CustomerRelationshipsMember2020-10-012021-09-300001581280us-gaap:CustomerRelationshipsMember2021-09-30xbrli:pure0001581280twst:SouthSanFranciscoCaliforniaMember2021-07-28utr:sqft0001581280twst:SouthSanFranciscoCaliforniaMember2021-07-282021-07-280001581280twst:SouthSanFranciscoCaliforniaMember2021-10-010001581280twst:QuincyMassachusettsMember2021-08-060001581280twst:QuincyMassachusettsMember2021-08-062021-08-060001581280twst:QuincyMassachusettsMember2022-03-030001581280srt:AffiliatedEntityMember2022-04-012022-06-300001581280srt:AffiliatedEntityMember2021-04-012021-06-300001581280srt:AffiliatedEntityMember2021-10-012022-06-300001581280srt:AffiliatedEntityMember2020-10-012021-06-300001581280twst:AbxBiologicsInc.Member2022-04-012022-06-300001581280twst:AbxBiologicsInc.Member2021-10-012022-06-300001581280twst:AbxBiologicsInc.Member2021-04-012021-06-300001581280twst:AbxBiologicsInc.Member2020-10-012021-06-300001581280twst:SubsequentPublicOffering1Member2020-12-012020-12-310001581280twst:SubsequentPublicOffering1Member2020-12-310001581280us-gaap:OverAllotmentOptionMember2020-12-012020-12-310001581280twst:SubsequentPublicOffering1Member2022-02-012022-02-280001581280twst:SubsequentPublicOffering1Member2022-02-280001581280us-gaap:OverAllotmentOptionMember2022-02-012022-02-280001581280us-gaap:RestrictedStockUnitsRSUMember2021-09-300001581280us-gaap:RestrictedStockUnitsRSUMember2020-10-012021-09-300001581280us-gaap:RestrictedStockUnitsRSUMember2021-10-012022-06-300001581280us-gaap:RestrictedStockUnitsRSUMember2022-06-300001581280srt:MinimumMembertwst:PerformanceStockUnitMember2021-10-012022-06-300001581280srt:MaximumMembertwst:PerformanceStockUnitMember2021-10-012022-06-300001581280twst:PerformanceStockUnitMember2022-06-300001581280twst:PerformanceStockUnitMember2021-10-012022-06-300001581280twst:PerformanceStockUnitMember2021-09-300001581280twst:PerformanceStockUnitMember2020-10-012021-09-300001581280us-gaap:EmployeeStockOptionMember2021-10-012022-06-3000015812802020-10-012021-09-300001581280srt:MinimumMembertwst:ExecutiveOfficersAndSeniorLevelEmployeesMembertwst:PerformanceStockOptionMember2020-09-012020-09-010001581280twst:ExecutiveOfficersAndSeniorLevelEmployeesMembersrt:MaximumMembertwst:PerformanceStockOptionMember2020-09-012020-09-010001581280twst:ExecutiveOfficersAndSeniorLevelEmployeesMembertwst:PerformanceStockOptionMember2022-06-300001581280twst:PerformanceStockOptionMember2021-09-300001581280twst:PerformanceStockOptionMember2020-10-012021-09-300001581280twst:PerformanceStockOptionMember2021-10-012022-06-300001581280twst:PerformanceStockOptionMember2022-06-300001581280us-gaap:CostOfSalesMember2022-04-012022-06-300001581280us-gaap:CostOfSalesMember2021-04-012021-06-300001581280us-gaap:CostOfSalesMember2021-10-012022-06-300001581280us-gaap:CostOfSalesMember2020-10-012021-06-300001581280us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001581280us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001581280us-gaap:ResearchAndDevelopmentExpenseMember2021-10-012022-06-300001581280us-gaap:ResearchAndDevelopmentExpenseMember2020-10-012021-06-300001581280us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-04-012022-06-300001581280us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-04-012021-06-300001581280us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-10-012022-06-300001581280us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-10-012021-06-300001581280twst:TwoThousandAndEighteenEmployeeStockPurchasePlanMember2018-09-260001581280twst:TwoThousandAndEighteenEmployeeStockPurchasePlanMember2018-09-262018-09-260001581280us-gaap:PerformanceSharesMembertwst:AbxBiologicsInc.Member2021-12-012021-12-010001581280twst:AbxBiologicsInc.Member2021-12-012021-12-010001581280us-gaap:PerformanceSharesMembertwst:AbxBiologicsInc.Member2022-06-300001581280us-gaap:PerformanceSharesMembertwst:AbxBiologicsInc.Member2021-10-012022-06-300001581280twst:AbxBiologicsInc.Member2022-06-300001581280us-gaap:EmployeeStockMember2021-10-012022-06-300001581280us-gaap:EmployeeStockMember2022-04-012022-06-300001581280us-gaap:EmployeeStockMember2021-04-012021-06-300001581280us-gaap:EmployeeStockMember2020-10-012021-06-300001581280twst:StockOptionsBasedOnPerformanceMember2022-04-012022-06-300001581280twst:StockOptionsBasedOnPerformanceMember2021-10-012022-06-300001581280twst:StockOptionsBasedOnPerformanceMember2021-04-012021-06-300001581280twst:StockOptionsBasedOnPerformanceMember2020-10-012021-06-300001581280twst:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember2022-04-012022-06-300001581280twst:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember2021-10-012022-06-300001581280twst:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember2021-04-012021-06-300001581280twst:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember2020-10-012021-06-300001581280twst:EarlyExerciseOfStockOptionsMember2022-04-012022-06-300001581280twst:EarlyExerciseOfStockOptionsMember2021-10-012022-06-300001581280twst:EarlyExerciseOfStockOptionsMember2021-04-012021-06-300001581280twst:EarlyExerciseOfStockOptionsMember2020-10-012021-06-300001581280twst:SharesSubjectToEmployeeStockPurchasePlanMember2022-04-012022-06-300001581280twst:SharesSubjectToEmployeeStockPurchasePlanMember2021-10-012022-06-300001581280twst:SharesSubjectToEmployeeStockPurchasePlanMember2021-04-012021-06-300001581280twst:SharesSubjectToEmployeeStockPurchasePlanMember2020-10-012021-06-300001581280srt:AmericasMember2022-04-012022-06-300001581280srt:AmericasMember2021-04-012021-06-300001581280srt:AmericasMember2021-10-012022-06-300001581280srt:AmericasMember2020-10-012021-06-300001581280us-gaap:EMEAMember2022-04-012022-06-300001581280us-gaap:EMEAMember2021-04-012021-06-300001581280us-gaap:EMEAMember2021-10-012022-06-300001581280us-gaap:EMEAMember2020-10-012021-06-300001581280srt:AsiaPacificMember2022-04-012022-06-300001581280srt:AsiaPacificMember2021-04-012021-06-300001581280srt:AsiaPacificMember2021-10-012022-06-300001581280srt:AsiaPacificMember2020-10-012021-06-300001581280twst:SyntheticGenesMember2022-04-012022-06-300001581280twst:SyntheticGenesMember2021-04-012021-06-300001581280twst:SyntheticGenesMember2021-10-012022-06-300001581280twst:SyntheticGenesMember2020-10-012021-06-300001581280twst:OligoPoolsMember2022-04-012022-06-300001581280twst:OligoPoolsMember2021-04-012021-06-300001581280twst:OligoPoolsMember2021-10-012022-06-300001581280twst:OligoPoolsMember2020-10-012021-06-300001581280twst:DnaAndBiopharmaLibrariesMember2022-04-012022-06-300001581280twst:DnaAndBiopharmaLibrariesMember2021-04-012021-06-300001581280twst:DnaAndBiopharmaLibrariesMember2021-10-012022-06-300001581280twst:DnaAndBiopharmaLibrariesMember2020-10-012021-06-300001581280twst:AntibodyDiscoveryMember2022-04-012022-06-300001581280twst:AntibodyDiscoveryMember2021-04-012021-06-300001581280twst:AntibodyDiscoveryMember2021-10-012022-06-300001581280twst:AntibodyDiscoveryMember2020-10-012021-06-300001581280twst:NgsToolsMember2022-04-012022-06-300001581280twst:NgsToolsMember2021-04-012021-06-300001581280twst:NgsToolsMember2021-10-012022-06-300001581280twst:NgsToolsMember2020-10-012021-06-300001581280twst:IndustrialChemicalsMember2022-04-012022-06-300001581280twst:IndustrialChemicalsMember2021-04-012021-06-300001581280twst:IndustrialChemicalsMember2021-10-012022-06-300001581280twst:IndustrialChemicalsMember2020-10-012021-06-300001581280twst:AcademicResearchMember2022-04-012022-06-300001581280twst:AcademicResearchMember2021-04-012021-06-300001581280twst:AcademicResearchMember2021-10-012022-06-300001581280twst:AcademicResearchMember2020-10-012021-06-300001581280us-gaap:HealthCareMember2022-04-012022-06-300001581280us-gaap:HealthCareMember2021-04-012021-06-300001581280us-gaap:HealthCareMember2021-10-012022-06-300001581280us-gaap:HealthCareMember2020-10-012021-06-300001581280twst:FoodOrAgricultureMember2022-04-012022-06-300001581280twst:FoodOrAgricultureMember2021-04-012021-06-300001581280twst:FoodOrAgricultureMember2021-10-012022-06-300001581280twst:FoodOrAgricultureMember2020-10-012021-06-300001581280twst:AbxBiologicsInc.Member2021-12-010001581280twst:AbxBiologicsInc.Member2021-12-012021-12-310001581280twst:ShareBasedAwardsWithVestingRequirementsMembertwst:AbxBiologicsInc.Member2021-12-012021-12-310001581280twst:AbxBiologicsInc.Membertwst:ShareBasedAwardsWithoutVestingRequirementsMember2021-12-012021-12-310001581280us-gaap:PerformanceSharesMembertwst:AbxBiologicsInc.Member2021-12-012021-12-310001581280us-gaap:DevelopedTechnologyRightsMembertwst:AbxBiologicsInc.Member2021-12-012021-12-010001581280us-gaap:DevelopedTechnologyRightsMembertwst:AbxBiologicsInc.Member2021-12-010001581280us-gaap:CustomerRelationshipsMembertwst:AbxBiologicsInc.Member2021-12-012021-12-010001581280us-gaap:CustomerRelationshipsMembertwst:AbxBiologicsInc.Member2021-12-010001581280us-gaap:TradeNamesMembertwst:AbxBiologicsInc.Member2021-12-012021-12-010001581280us-gaap:TradeNamesMembertwst:AbxBiologicsInc.Member2021-12-010001581280twst:ContingentConsiderationMembertwst:AbxBiologicsInc.Member2021-12-010001581280twst:IndemnityHoldbackMembertwst:AbxBiologicsInc.Member2021-12-010001581280twst:ContingentConsiderationMembertwst:AbxBiologicsInc.Member2021-12-022022-06-300001581280twst:IndemnityHoldbackMembertwst:AbxBiologicsInc.Member2021-12-022022-06-300001581280twst:AbxBiologicsInc.Member2021-12-022022-06-300001581280twst:ContingentConsiderationMembertwst:AbxBiologicsInc.Member2022-06-300001581280twst:IndemnityHoldbackMembertwst:AbxBiologicsInc.Member2022-06-300001581280twst:IgenomxInternationalGenomicsCorporationMember2021-12-012021-12-310001581280twst:IgenomxInternationalGenomicsCorporationMember2022-01-012022-01-310001581280us-gaap:VariableInterestEntityPrimaryBeneficiaryMembertwst:RevelarBiotherapeuticsIncMember2021-11-01twst:therapeutic0001581280us-gaap:VariableInterestEntityPrimaryBeneficiaryMembertwst:RevelarBiotherapeuticsIncMember2021-11-012021-11-010001581280us-gaap:VariableInterestEntityPrimaryBeneficiaryMembertwst:RevelarBiotherapeuticsIncMembersrt:MaximumMember2021-11-012021-11-010001581280twst:RevelarBiotherapeuticsIncMember2022-04-062022-04-060001581280twst:RevelarBiotherapeuticsIncMember2022-02-032022-02-030001581280us-gaap:VariableInterestEntityPrimaryBeneficiaryMembertwst:RevelarBiotherapeuticsIncMember2022-04-012022-06-300001581280us-gaap:VariableInterestEntityPrimaryBeneficiaryMembertwst:RevelarBiotherapeuticsIncMember2021-10-012022-06-300001581280us-gaap:VariableInterestEntityPrimaryBeneficiaryMembertwst:RevelarBiotherapeuticsIncMember2022-06-30
    
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022
OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-38720
twst-20220630_g1.jpg
Twist Bioscience Corporation
(Exact Name of Registrant as Specified in its Charter)

Delaware46-2058888
(State or other jurisdiction of(I.R.S. Employer
incorporation or organization)Identification No.)

681 Gateway Blvd, South San Francisco, CA 94080
(Address of principal executive offices and zip code)
(800) 719-0671
(Registrant’s telephone number, including area code)

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockTWSTThe Nasdaq Global Select Market

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
  Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

The number of shares of the Registrant’s common stock outstanding as of August 4, 2022, was 56,363,518.



TWIST BIOSCIENCE CORPORATION
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED JUNE 30, 2022
TABLE OF CONTENTS



1

Forward-looking statements
This Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, or Form 10-Q, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to, among other matters, plans for product development and licensing to third parties, plans and timeframe for the commercial development of DNA data storage capabilities, expectations regarding market penetration, anticipated customer conversions to our products, plans to expand in the international markets, identification and development of potential antibody candidates for the treatment of COVID-19 and other diseases, and the anticipated timeframe for remediating the material weakness in internal control over financial reporting. Forward-looking statements are also identified by the words “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” and variations of such words and similar expressions. You should not rely upon forward-looking statements as predictions of future events. Such statements are based on management’s expectations as of the date of this filing and involve many risks and uncertainties that could cause our actual results, events or circumstances to differ materially from those expressed or implied in our forward-looking statements. Such risks and uncertainties include:
our ability to increase our revenue and our revenue growth rate;
our ability to accurately estimate capital requirements and our needs for additional financing;
our estimates of the size of our market opportunities;
our ability to increase DNA production, reduce turnaround times and drive cost reductions for our customers;
our ability to effectively manage our growth;
our ability to successfully enter new markets and manage our international expansion;
our ability to protect our intellectual property, including our proprietary DNA synthesis platform;
costs associated with defending intellectual property infringement and other claims;
the effects of increased competition in our business;
our ability to keep pace with changes in technology and our competitors;
our ability to successfully identify, evaluate and manage any future acquisitions of businesses, solutions or technologies;
the success of our marketing efforts;
a significant disruption in, or breach in security of our information technology systems and resultant interruptions in service and any related impact on our reputation;
our ability to attract and retain qualified employees and key personnel;
the effects of natural or man-made catastrophic events including those resulting from the novel strain of coronavirus that causes coronavirus disease 2019, or COVID-19;
the effectiveness of our internal controls;
changes in government regulation affecting our business;
uncertainty as to economic and market conditions and the impact of adverse economic conditions, including inflationary pressures and rising interest rates; and

other risk factors included under the section titled “Risk Factors.”
2

You should not rely upon forward-looking statements as predictions of future events. Such statements are based on management’s expectations as of the date of this filing and involve many risks and uncertainties that could cause our actual results, events or circumstances to differ materially from those expressed or implied in our forward-looking statements.
Readers are urged to carefully review and consider all of the information in this Form 10-Q and in other documents we file from time to time with the Securities and Exchange Commission, or SEC. We undertake no obligation to update any forward-looking statements made in this Form 10-Q to reflect events or circumstances after the date of this filing or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.
When we use the terms “Twist,” “Twist Bioscience,” the “Company,” “we,” “us” or “our” in this report, we are referring to Twist Bioscience Corporation and its consolidated subsidiaries unless the context requires otherwise. Sequence space and the Twist logo are trademarks of Twist Bioscience Corporation. All other company and product names may be trademarks of the respective companies with which they are associated.



3

PART I. Financial information

Item 1. Financial statements

Twist Bioscience Corporation
Condensed Consolidated Balance Sheets (unaudited)
(In thousands)June 30,
2022
September 30,
2021
Assets  
Current assets: 
Cash and cash equivalents $376,249 $465,829 
Short-term investments151,34212,034
Accounts receivable, net41,19528,549
Inventories43,02231,800
Prepaid expenses and other current assets12,3098,283
Total current assets$624,117 $546,495 
Property and equipment, net127,01144,122
Operating lease right-of-use assets76,16561,580
Goodwill85,81122,434
Intangible assets, net61,11518,262
Restricted cash, non-current1,5721,530
Other non-current assets3,8727,674
Total assets [1]
$979,663 $702,097 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable $21,014 $14,900 
Accrued expenses9,4996,437
Accrued compensation27,69822,327
Current portion of operating lease liability14,3528,213
Current portion of long-term debt1,552
Other current liabilities20,1239,623
Total current liabilities$92,686 $63,052 
Operating lease liability, net of current portion64,24453,156
Other non-current liabilities2,0565,068
Total liabilities [1]
$158,986 $121,276 
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.00001 par value—100,000 and 100,000 shares authorized at June 30, 2022 and September 30, 2021, respectively; 56,344 and 49,499 shares issued and outstanding at June 30, 2022 and September 30, 2021, respectively
$ $ 
Additional paid-in capital1,599,3551,190,828
Accumulated other comprehensive income(1,377)546
Accumulated deficit(777,301)(610,553)
Total stockholders’ equity$820,677 $580,821 
Total liabilities and stockholders’ equity$979,663 $702,097 
[1] The Company’s consolidated assets as of June 30, 2022 include $7,429 in assets of the variable interest entity, or “VIE”, that can only be used to settle obligations of the VIE. Cash as of June 30, 2022 was $6,989; prepaid expenses as of June 30, 2022 were $433 and deposits as of June 30, 2022 were $7. The Company’s consolidated liabilities as of June 30, 2022 were $10,494 in liabilities of the VIE who creditors have no recourse to the Company. These liabilities include accounts payable of $6,412 as of June 30, 2022; accrued expenses and other current liabilities of $2,082 as of June 30, 2022; and other non-current liabilities of $2,000 as of June 30, 2022.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

Twist Bioscience Corporation
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Three months ended
June 30,
Nine months ended
June 30,
(In thousands, except per share data)20222021 2022 2021
Revenues$56,113 $35,018 $146,259 $94,382 
Operating expenses:
Cost of revenues$30,974 $20,933 $87,744 $58,123 
Research and development36,84019,83890,70149,629
Selling, general and administrative53,69334,478158,79097,658
Change in fair value of contingent considerations and holdbacks(4,231)$1,887 $(13,071)$1,887 
Total operating expenses$117,276 $77,136 $324,164 $207,297 
Loss from operations$(61,163)$(42,118)$(177,905)$(112,915)
Interest income722861,134377
Interest expense(70)(54)(284)
Other income (expense), net(225)(312)(626)(305)
Loss before income taxes$(60,666)$(42,414)$(177,451)$(113,127)
Benefit from income taxes149$2,377 $10,703 $2,271 
Net loss attributable to common stockholders$(60,517)$(40,037)$(166,748)$(110,856)
Other comprehensive loss:
Change in unrealized loss on investments$(404)(12)$(1,794)(10)
Foreign currency translation adjustment(498)250(129)351
Comprehensive loss(61,419)(39,799)(168,671)(110,515)
Net loss per share attributable to common stockholders—basic and diluted$(1.08)$(0.82)$(3.15)$(2.32)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted56,28748,96353,00547,881

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Twist Bioscience Corporation
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

Common
stock
Additional
paid-in
capital
Accumulated
Other
comprehensive
income
Accumulated
deficit
Total
stockholders'
equity
(In thousands)SharesAmount
Balances as of March 31, 202256,234$ $1,580,620 $(475)$(716,784)$863,361 
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses of $17,676
66
Vesting of restricted stock units100
Exercise of stock options48766766
Repurchases of common stock for income tax withholding(38)(2,080)(2,080)
Stock-based compensation20,04320,043
Other comprehensive income(902)(902)
Net loss(60,517)(60,517)
Balances as of June 30, 202256,344$ $1,599,355 $(1,377)$(777,301)$820,677 

Common
stock
Additional
paid-in
capital
Accumulated
Other
comprehensive
income
Accumulated
deficit
Total
stockholders'
equity
(In thousands)SharesAmount
Balances as of March 31, 202148,860$ $1,143,265 $190 $(529,274)$614,181 
Public offering expense adjustment(26)(26)
Vesting of restricted stock units57
Exercise of stock options1322,6192,619
Business acquisitions23726,77326,773
Repurchases of common stock for income tax withholding(23)(2,476)(2,476)
Stock-based compensation9,1769,176
Other comprehensive income238238
Net loss(40,037)(40,037)
Balances as of June 30, 202149,263$ $1,179,331 $428 $(569,311)$610,448 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

Twist Bioscience Corporation
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

Common
stock
Additional
paid-in
capital
Accumulated
Other
comprehensive
income
Accumulated
deficit
Total
stockholders'
equity
(In thousands)SharesAmount
Balances as of September 30, 202149,499$ $1,190,828 $546 $(610,553)$580,821 
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses of $17,676
5,227269,824269,824
Vesting of restricted stock units263
Exercise of stock options4174,7014,701
Issuance of shares under the employee stock purchase plan502,3942,394
Repurchases of common stock for income tax withholding(101)(6,130)(6,130)
Issuance of shares from business acquisition98977,12277,122
Stock-based compensation60,61660,616
Other comprehensive income(1,923)(1,923)
Net loss(166,748)(166,748)
Balances as of June 30, 202256,344$ $1,599,355 $(1,377)$(777,301)$820,677 

Common
stock
Additional
paid-in
capital
Accumulated
Other
comprehensive
income
Accumulated
deficit
Total
stockholders'
equity
(In thousands)SharesAmount
Balances as of September 30, 202045,083$ $794,630 $87 $(458,455)$336,262 
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses of $21,139
3,136323,861323,861
Net exercise of stock warrants22
Vesting of restricted stock units178
Exercise of stock options62911,75611,756
Issuance of shares under the employee stock purchase plan492,7872,787
Repurchases of early exercised stock options(2)
Business acquisitions23726,77326,773
Repurchases of common stock for income tax withholding(69)(8,227)(8,227)
Stock-based compensation27,75127,751
Other comprehensive income341341
Net loss(110,856)(110,856)
Balances as of June 30, 202149,263$ $1,179,331 $428 $(569,311)$610,448 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

Twist Bioscience Corporation
Condensed Consolidated Statements of Cash Flows (unaudited)
Nine months ended
June 30,
(in thousands) 20222021
Cash flows from operating activities
Net loss$(166,748)$(110,856)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization11,5627,319
Deferred tax liability(11,177)
Loss on disposal of property and equipment2
Non-cash lease expense2,5941,044
Stock-based compensation60,61627,751
Discount accretion on investment securities1,056501
Realized gain on investments(5)
Change in fair value of acquisition consideration(13,071)1,887
Non-cash interest expense358
Bad debt expense(146)183
Amortization of debt discount470
Write off property and equipment70
Changes in assets and liabilities:
Accounts receivable, net(10,284)(1,912)
Inventories(11,237)(8,914)
Prepaid expenses and other current assets(2,736)(1,617)
Other non-current assets6,829(2,333)
Accounts payable4665,194
Accrued expenses6081,546
Accrued compensation5,5194,588
Other liabilities2,954(1,947)
Net cash used in operating activities$(123,118)$(77,441)
Cash flows from investing activities
Purchases of property and equipment$(85,395)$(18,972)
Business acquisition, net of cash acquired(8,160)(483)
Purchases of investments(217,639)(58,795)
Proceeds from maturity of investments75,481210,494
Net cash (used in) provided by investing activities$(235,713)$132,244 
Cash flows from financing activities
Proceeds from exercise of stock options$4,764 $11,686 
Proceeds from public offerings, net of underwriting discounts, commissions and offering expenses269,824323,861
Proceeds from issuance of common stock under employee stock purchase plan2,3942,787
Repayments of long-term debt(1,558)(2,500)
Repurchases of common stock for income tax withholding(6,130)(8,227)
Net cash provided by financing activities$269,294 $327,607 
Effect of exchange rates on cash, cash equivalents and restricted cash$(1)$153 
Net increase (decrease) in cash, cash equivalents, and restricted cash(89,538)382,563
Cash, cash equivalents, and restricted cash at beginning of period467,35994,246
Cash, cash equivalents, and restricted cash at end of period$377,821 $476,809 
Supplemental disclosure of cash flow information
Interest paid$9 $145 
Income taxes paid, net of refunds13047
Non-cash investing and financing activities
Property and equipment additions included in accounts payable and accrued expenses$6,562 $1,777 
Operating lease right-of-use assets obtained in exchange for operating lease liabilities19,49433,617
Issuance of common stock in connection with the business acquisition77,12226,773
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8

Twist Bioscience Corporation
Notes to Unaudited Condensed Consolidated Financial Statements
1. The Company
Twist Bioscience Corporation (the Company) was incorporated in the state of Delaware on February 4, 2013. The Company is a synthetic biology company that has developed a disruptive DNA synthesis platform. DNA is used in many applications across different industries: industrial chemicals/materials, academic, healthcare and food/agriculture. The Company’s fiscal year ends on September 30.
The Company has generated net losses in all periods since its inception. As of June 30, 2022, the Company had an accumulated deficit of $777.3 million and has not generated positive cash flows from operations since inception. Losses are expected to continue as the Company continues to invest in product development, manufacturing, and sales and marketing.
Since its inception, the Company has received an aggregate of $1,333.7 million in net proceeds from the issuance of equity securities and an aggregate of $13.8 million from debt. Management believes that these proceeds combined with existing cash balances on hand will be sufficient to fund operations for at least one year from the issuance of these consolidated financial statements. However, if the Company needs to obtain additional financing to fund operations beyond this period, there can be no assurance that it will be successful in raising additional financing on terms which are acceptable to the Company.
If the Company requires but is unable to obtain additional funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.
During the three and nine months ended June 30, 2022, financial results of the Company were not significantly affected by the COVID-19 pandemic, which continues to have global impact. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which continue to evolve and are difficult to predict, including mutations in the SARS-CoV-2 virus, which have resulted and may in the future result in strains that are more contagious and less responsive to current treatment methods, and current or future domestic and international actions to contain it and treat it.

2. Summary of significant accounting policies
Basis of presentation and use of estimates
The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2021 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 23, 2021. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2021 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three and nine months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending September 30, 2022 or any interim period.
The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. The Company consolidates Revelar Biotherapeutics, Inc. (“Revelar”) as a variable interest entity (“VIE”) for which it is the primary beneficiary (see Note 14 “Investment in variable interest entity” for further information). All intercompany balances and accounts are eliminated in consolidation.
9


The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows:

(in thousands)June 30,
2022
September 30,
2021
Cash and cash equivalents$376,249 $465,829 
Restricted cash, non-current1,572 1,530 
Total cash, cash equivalents and restricted cash$377,821 $467,359 

Significant accounting policies
There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K other than the following variable interest entities policy.
Variable interest entities
The Company consolidates a VIE in which the Company is deemed to be the primary beneficiary. An entity is generally a VIE if it meets any of the following criteria: (i) the entity has insufficient equity to finance its activities without additional subordinated financial support from other parties, (ii) the equity investors cannot make significant decisions about the entity’s operations or (iii) the voting rights of some investors are not proportional to their obligations to absorb the expected losses of the entity or receive the expected returns of the entity and substantially all of the entity’s activities involve or are conducted on behalf of the investor with disproportionately few voting rights. The Company periodically makes judgments in determining whether its investees are VIEs and, for each reporting period, the Company assesses whether it is the primary beneficiary of its VIE. As of June 30, 2022, the Company was deemed the primary beneficiary of Revelar. See Note 14 “Investment in variable interest entity.”
Recent accounting pronouncements
Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considered the applicability and impact of all recent ASUs. ASUs not listed below were assessed and determined to be not applicable to the Company’s consolidated financial position and results of operations.
Recent accounting pronouncements adopted
In December 2019, the FASB issued ASU 2019 12, Simplifying the Accounting for Income Taxes. The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders’ equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. The Company adopted this standard effective October 1, 2021. The adoption of ASU 2019 12 did not have an impact on the Company’s consolidated financial statements for either period presented.
Recently issued accounting pronouncement not yet adopted
In November 2021, the FASB issued ASU 2021 10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.
In June 2016, the FASB issued ASU 2016 13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard requires entities to use the new “expected credit loss” impairment model for most financial assets measured at amortized cost, including trade and other receivables and held-to-maturity debt securities, and modifies the impairment model for available-for-sale debt securities. The standard is effective for the
10

Company for the fiscal year ending September 30, 2024, including interim periods within that fiscal year. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

3. Fair value measurement
The Company assesses the fair value of financial instruments based on the provisions of ASC 820, Fair Value Measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company short-term and long-term investments primarily utilize broker quotes in a non-active market for valuation of its investments.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.
As of June 30, 2022, financial assets and liabilities measured and recognized at fair value are as follows:

(in thousands)Level 1Level 2Level 3Fair value
Assets    
Money market funds$324,824 $ $ $324,824 
Commercial paper 39,977  39,977 
U.S. government treasury bills111,365   111,365 
Total financial assets$436,189 $39,977 $ $476,166 
Liabilities
Contingent consideration and holdbacks$ $9,567 $3,300 $12,867 
Total financial liabilities $ $9,567 $3,300 $12,867 

As of September 30, 2021, financial assets and liabilities measured and recognized at fair value are as follows:

(in thousands)Level 1Level 2Level 3Fair value
Assets    
Money market funds$430,438 $ $ $430,438 
U.S. government treasury bills12,034  12,034
Total financial assets$442,472 $ $ $442,472 
Liabilities
Contingent consideration and indemnity holdback$ $9,856 $ $9,856 
Total financial liabilities$ $9,856 $ $9,856 

11

As of June 30, 2022 gross unrealized losses for cash equivalents and investments was $1.8 million. As of September 30, 2021, gross unrealized gains and unrealized losses for cash equivalents and investments were not material. As of June 30, 2022 and September 30, 2021, all marketable securities had a contractual maturity of less than one year.

The following table provides a reconciliation of beginning and ending balances of the Level 3 financial liabilities during the three months ended June 30, 2022:

(in thousands)Total
Balance as of September 30, 2021
$ 
Contingent consideration – additions8,500
Change in fair value (5,200)
Balance as of June 30, 2022
$3,300 

4. Balance sheet components
The Company’s accounts receivable, net balance consists of the following:

(in thousands)June 30,
2022
September 30,
2021
Trade receivables$36,615 $26,549 
Other receivables4,7582,337
Allowance for doubtful accounts(178)(337)
Accounts receivable, net$41,195 $28,549 

Inventories consist of the following:

(in thousands)June 30,
2022
September 30,
2021
Raw materials$30,909 $18,778 
Work-in-process3,8794,837
Finished goods8,2348,185
$43,022 $31,800 

The work-in-process inventory included gross consigned inventory of $1.5 million and $1.9 million as of June 30, 2022 and September 30, 2021, respectively.
Other non-current assets
The other non-current assets consist of the following:
(in thousands)June 30,
2022
September 30,
2021
Convertible note receivable$$3,021
Other non-current assets3,8724,653
$3,872$7,674


12

Accrued expenses
The accrued expenses consist of the following:
(in thousands)June 30,
2022
September 30,
2021
Professional services fees payable$5,044$5,057
Other accrued expenses4,4551,380
$9,499$6,437

Accrued compensation
The accrued compensation consists of the following:
(in thousands)June 30,
2022
September 30,
2021
Accrued vacation$6,285 $4,643 
Accrued bonus9,091 8,584 
Accrued commissions4,257 3,330 
Accrued payroll and related taxes5,932 4,676 
Other accrued compensation2,133 1,094 
$27,698 $22,327 

Other current liabilities
The other current liabilities consist of the following:
(in thousands)June 30,
2022
September 30,
2021
Contingent consideration and holdbacks$12,867$5,186
Income and sales taxes payable3,8512,440
Other current liabilities3,4051,997
$20,123 $9,623 

Other non-current liabilities
The other non-current liabilities consist of the following:

(in thousands) June 30,
2022
September 30,
2021
Holdback$$4,671
Other non current liabilities2,056397
$2,056$5,068


13

5. Goodwill and intangible assets
During the nine months ended June 30, 2022, goodwill and intangible assets increased by $63.4 million and $46.5 million, respectively, as a result of a business acquisition. See Note 13, “Business acquisition”. Total amortization expense related to intangible assets was $1.4 million for the three months ended June 30, 2022 and less than $0.1 million for the three months ended June 30, 2021. Total amortization expense related to intangible assets was $3.6 million and $0.2 million for the nine months ended June 30, 2022 and 2021, respectively.
The intangible assets balances are presented below:

June 30, 2022
(in thousands, except for years)Weighted average
Amortization period
in years
Gross
carrying
amount
Accumulated
amortization
Net book
value
Developed Technology15$50,020 $(3,560)$46,460 
Customer Relationships1015,210 (1,280)13,930 
Tradenames & Trademarks3900 (175)725 
Total indefinite-lived intangible assets$66,130 $(5,015)$61,115 

September 30, 2021
(in thousands, except for years)Weighted average
Amortization period
in years
Gross
carrying
amount
Accumulated
amortization
Net book
value
Developed Technology16$19,120 $(1,361)$17,759 
Customer Relationships2510 (7)503 
Total indefinite-lived intangible assets$19,630 $(1,368)$18,262 

6. Commitments and contingencies
The Company may be subject to litigation, claims and disputes in the ordinary course of business. There is an inherent risk in any litigation or dispute and no assurance can be given as to the outcome of any claims.
Indemnifications
In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by corporate law. The Company also has directors’ and officers’ insurance.
Leases
The Company leases certain of its facilities under non-cancellable operating leases expiring at various dates through 2044. The Company is also responsible for utilities, maintenance, insurance, and property taxes under these leases.
Certain leases include options to renew or terminate at the Company’s discretion. The lease terms include periods covered by these options if it is reasonably certain the Company will renew or not terminate. The Company’s lease agreements do not contain any material residual value guarantees or restrictive covenants.
Supplemental balance sheet information related to the Company’s operating leases as of June 30, 2022 was as follows:

14

(in thousands)June 30,
2022
Assets: 
Operating lease right-of-use asset$76,165 
Current liabilities:
Current portion of operating lease liabilities$14,352 
Noncurrent liabilities:
Operating lease liabilities, net of current portion$64,244 

Future minimum lease payments under all non-cancelable operating leases that have commenced as of June 30, 2022 are as follows:

(in thousands)Operating
leases
Years ending September 30: 
Remainder of 2022
$3,281 
202313,990
202413,385
202513,724
202612,298
Thereafter97,081
Total minimum lease payments$153,759 
Less: imputed interest(57,737)
Less: tenant improvement allowance (receipt anticipated in 2022)
(17,426)
Total operating lease liabilities$78,596 
Less: current portion(14,352)
Operating lease liabilities, net of current portion$64,244 

For the remainder of 2022, future minimum lease payments are comprised of the anticipated receipt of tenant improvement allowances totaling $17.4 million anticipated to be received in 2022, partially offset by non-cancelable operating lease payments of $3.3 million. The statement of cash flows for the nine months ended June 30, 2022, include changes in right-of-use assets and operating lease liabilities of $14.6 million and $17.2 million, respectively. For the nine months ended June 30, 2021, changes in right-of-use assets and operating lease liabilities were $29.1 million and $30.1 million, respectively.
During the three and nine months ended June 30, 2022, operating lease expense was $4.1 million and $11.5 million, respectively. Cash payments for amounts included in the measurement of operating lease liabilities were $3.7 million and $9.1 million for the three and nine months ended June 30, 2022, respectively. As of June 30, 2022, the weighted-average remaining lease term was 15.5 years and the weighted-average discount rate was 6.4%.
On July 28, 2021, the Company entered into a 7-year operating lease for approximately 21,000 square-feet of office space located in South San Francisco, California, to further expand the Company operations. Upon execution of the lease agreement, the Company provided the landlord an approximate $0.2 million security deposit. The Company will pay an initial annual base rent of approximately $1.7 million, which is subject to scheduled 3% annual increases, plus certain operating expenses. The Company has the right to sublease the facility, subject to landlord consent. The lease commenced on October 1, 2021. As of lease commencement date, the total future minimum lease payments under the agreement were $13.1 million.

On August 6, 2021, Abveris, which was subsequently acquired by the Company, entered into a 10-year, 5-month operating lease for approximately 22,000 square-feet of office space located in Quincy, Massachusetts, to further expand operations. Upon execution of the lease agreement, the Company provided the landlord an approximate $0.6 million irrevocable letter of credit as a security deposit. The Company will pay an initial annual base rent of approximately $1.2 million, which is subject to scheduled 2% annual increases, plus certain operating expenses. The Company has the right to sublease the
15

facility, subject to landlord consent. The lease commenced on March 3, 2022. As of lease commencement date, the total future minimum lease payments under the agreement were $13.2 million.

7. Related party transactions
During the three months ended June 30, 2022 and 2021, the Company purchased raw materials from a related party investor in the amount of $3.1 million and $1.2 million, respectively. During the nine months ended June 30, 2022 and 2021, the Company purchased raw materials from a related party in the amount of $6.5 million and $3.5 million, respectively. Payable balances and receivable balances with the related party were immaterial as of June 30, 2022 and September 30, 2021.

8. Income taxes
In determining quarterly provisions for income taxes, the Company uses the annual estimated effective tax rate applied to the actual year-to-date profit or loss, adjusted for discrete items arising in that quarter. The Company’s annual estimated effective tax rate differs from the U.S. federal statutory rate primarily as a result of state taxes, foreign taxes, and changes in the Company’s valuation allowance against its deferred tax assets. For the three and nine months ended June 30, 2022, the Company recorded $0.1 million and $10.7 million income tax benefit mainly due to the deferred tax liability assumed as part of the acquisition of AbX Biologics, Inc. (see Note 13, “Business acquisition”). For the three and nine months ended June 30, 2021, the Company recorded $2.4 million and $2.3 million income tax benefit due to the deferred tax liability assumed as part of the Business acquisition.

9. Common stock
In December 2020, the Company completed an underwritten public offering of 3,136,362 shares of its common stock at a price to the public of $110.00 per share, including the full exercise of underwriters’ option to purchase an additional 409,090 shares of common stock. The Company received total net proceeds from the offering of $323.9 million, net of estimated underwriting discounts and commissions and offering expenses.

In February 2022, the Company completed an underwritten public offering of 5,227,272 shares of its common stock at a price to the public of $55.00 per share, including the full exercise of underwriters’ option to purchase an additional 681,818 shares of common stock. The Company received total net proceeds from the offering of $269.8 million, net of underwriting discounts and commissions and offering expenses.

10. Stock-based compensation
2018 Equity Incentive Plan

Any shares subject to outstanding awards under the 2013 Plan that are canceled or repurchased subsequent to the 2018 Plan’s effective date are returned to the pool of shares reserved for issuance under the 2018 Plan. Awards granted under the 2018 Plan may be non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, and performance units.

Restricted Stock Units

Restricted stock primarily consists of restricted stock unit awards (RSUs) which have been granted to employees. The value of an RSU award is based on the Company’s stock price on the date of grant. Forfeitures of RSUs are recognized as they occur. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock.

Activity with respect to the Company’s restricted stock units during the nine months ended June 30, 2022 was as follows:

16

(in thousands, except per share data)Number
of
Shares
Weighted
average
grant date
fair value
per share
Weighted
average
remaining
contractual
term (years)
Aggregate
Intrinsic
Value
Outstanding at September 30, 2021
698$73.27 2.7$74,613 
Restricted stock units granted94672.37
Restricted stock units vested(263)72.53
Restricted stock units forfeited(125)75.37
Outstanding at June 30, 2022
1,256$72.54 2.9$43,883 
Expected to vest at June 30, 2022
1,256$72.54 2.9$43,883 

As of June 30, 2022, there was $83.4 million of total unrecognized compensation cost related to these issuances that is expected to be recognized over a weighted average period of 2.9 years.
Performance Stock Units
Performance stock unit awards (“PSUs”) were granted to certain employees that will vest upon achievement of operational milestones related to the Wilsonville facility, to Company executives that will vest upon achievement of revenue and gross profit metrics as determined by the board, and to certain consultants that will vest upon achievement of operational milestones. Stock compensation expense for PSUs is recorded over the vesting period based on the grant date fair value of the awards and probability of the achievement of specified performance targets. The grant date fair value is equal to the closing share price of the Company’s common stock on the date of grant. PSUs generally vest over a one to three-year service period following the grant date, provided that the recipient is a Company employee at the time of vesting and the achievement of performance targets applicable to each award. The percentage of PSUs that vest will depend on the achievement of specified performance targets at the end of the performance period and can range from 0% to 150% of the number of units granted. Forfeitures of PSUs are recognized as they occur. As of June 30, 2022, the unrecognized compensation costs related to these awards was $29.4 million. The Company expects to recognize those costs over a weighted average period of 1.7.

Activity under the PSUs during the nine months ended June 30, 2022 is summarized below:
(in thousands, except per share data)Number of sharesWeighted average grant date fair valueWeighted average remaining contractual termAggregate intrinsic value
Outstanding at September 30, 2021
10$3.59 2.3$1,016 
Performance stock units granted63178.83
Performance stock units vested(13)31.29
Performance stock units forfeited(53)85.32
Outstanding at June 30, 2022
575$84.93 1.7$20,099 
Vested or expected to vest and exercisable at June 30, 2022
575$84.93 1.7$20,099 

Options
Stock options entitle the holder to purchase, at the end of the vesting term, a specified number of shares of Company common stock at an exercise price per share equal to the closing market price of the common stock on the date of grant. Stock options typically have a contractual life from the date of the grant and a vesting schedule as established by the board of directors. The fair value of each services based stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company historically had been a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, it estimated its expected stock price volatility based on the historical volatility of publicly traded peer companies through the period ended June 30, 2022 and utilized the “simplified” method for awards that qualify as “plain-vanilla” options. As determined under the simplified method, the expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award, the risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award, the expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Forfeitures of options are recognized as they occur.
17

(in thousands, except per share data)Number of sharesWeighted average exercise priceWeighted average remaining contractual termAggregate intrinsic value
Outstanding at September 30, 2021
2,875 $22.83 7.1$242,012 
Options granted22326.36
Options vested(416)11.509,845 
Options forfeited(135)32.02
Outstanding at June 30, 2022
2,547$24.80 6.6$34,111 
Vested or expected to vest and exercisable at June 30, 2022
2,547$24.80 6.6$34,111 
As of June 30, 2022, the unrecognized compensation costs related to these awards was $15.4 million. The Company expects to recognize those costs over a weighted average period of 1.3.
Performance Stock Options
On September 1, 2020, the board of directors approved the implementation of a revised annual equity award program for executive officers, senior level employees and consultants to be granted as performance-based stock options ("PSOs") under the 2018 Plan. The number of PSOs ultimately earned under the awards to executive officers and senior level employees is calculated based on the achievement of a certain total revenue threshold during the fiscal year ending September 30, 2022. The percentage of performance stock options that vest will depend on the board of directors’ determination of total revenue at the end of the performance period and can range from 0% to 150% of the number of options granted. The number of PSOs ultimately earned under the awards to a consultant is calculated based on the achievement of certain operational milestones.

The provisions of the PSO are considered a performance condition, and the effects of that performance condition are not reflected in the grant date fair value of the awards. The Company used the Black-Scholes method to calculate the fair value at the grant date without regard to the vesting condition and will recognize compensation cost for the options that are expected to vest. Forfeitures of PSOs are recognized as they occur. The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. As of June 30, 2022, the Company determined that 293,730 shares are expected to vest based on the probability of the performance condition that will be achieved under this equity award program.

Activity under the equity incentive plans during the nine months ended June 30, 2022 is summarized below:

(in thousands, except per share data)Number of sharesWeighted average exercise priceWeighted average remaining contractual termAggregate intrinsic value
Outstanding at September 30, 2021
257$70.62 8.9$9,331 
Performance stock options granted7520.02
Performance stock options vested(19)19.16296 
Performance stock options forfeited(19)67.85
Outstanding at June 30, 2022
294$63.27 8.5$206 
Vested or expected to vest and exercisable at June 30, 2022
294$63.27 8.5$206 


As of June 30, 2022, the unrecognized compensation costs related to these awards was $2.3 million. The Company expects to recognize those costs over a weighted average period of 0.7 years.

Total stock-based compensation expense recognized was as follows:

18

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Cost of revenues$1,228 $773 $3,347 $1,990 
Research and development5,6422,75314,5067,180
Selling, general and administrative12,9895,65042,41018,581
Total stock-based compensation$19,859 $9,176 $60,263 $27,751 

2018 Employee Stock Purchase Plan
On September 26, 2018, the board of directors adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"). The number of shares reserved for issuance under the 2018 ESPP upon approval was 275,225 shares of the Company’s common stock, and it increases automatically on the first day of each fiscal year, following the fiscal year in which the 2018 ESPP becomes effective, by a number equal to the least of 249,470 shares, 1% of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. The number of shares reserved for issuance at June 30, 2022 was as follows:

(In thousands)Shares
available
Outstanding at September 30, 2021
355
Additional shares authorized249
Shares issued during the period(50)
Outstanding at June 30, 2022
554

Subject to any plan limitations, the 2018 ESPP allows eligible service providers (through qualified and non-qualified offerings) to contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The offering periods begin in February and August of each year, except for the initial offering period which commenced with the initial public offering in October 2018 and ended on August 20, 2019. The common shares issuable under the 2018 ESPP were registered pursuant to a registration statement on Form S-8 on November 26, 2018.
Unless otherwise determined by the board of directors, the Company’s common stock will be purchased for the accounts of employees participating in the 2018 ESPP at a price per share that is the lesser of 85% of the fair market value of the Company’s common stock on the first and last trading day of the offering period. During the three and nine months ended June 30, 2022 and 2021, activity under the 2018 ESPP was immaterial.

Abveris Acquisition
As discussed further in Note 13 “Business acquisition”, on December 1, 2021, the Company completed the acquisition of AbX Biologics, Inc. and granted certain equity awards to new employees. These equity awards included up to 231,876 restricted shares of the Company’s common stock which are issuable based on achievement of the 2022 calendar revenue target, which had an aggregate grant date fair value of $20.1 million. In addition, all employees must remain employed through the payout date, and certain employees have an additional vesting period of up to two years from the acquisition date. The vesting upon achievement of the 2022 calendar revenue target is considered a performance condition, and the effects of that performance condition are not reflected in the grant date fair value of the awards. The Company used the stock price as of December 1, 2021 for the fair value of restricted shares. As of June 30, 2022, the Company determined that 200,673 shares are expected to vest based on the probability of the performance condition that will be achieved under this equity award program. The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. The Company recorded approximately $7.8 million in stock-based compensation expense for the nine months ended June 30, 2022 related to these awards. The grant date fair value was determined to be $87.06 per share for restricted shares. As of June 30, 2022, the unrecognized compensation costs related to these awards were $9.7 million. The Company expects to recognize those costs over a weighted average period of 0.8 years.

11. Net loss per share attributable to common stockholders
The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders:
19


Three months ended
June 30,
Nine months ended
June 30,
(in thousands, except per share data)2022202120222021
Numerator:  
Net loss attributable to common stockholders$(60,517)$(40,037)$(166,748)$(110,856)
Denominator:
Weighted average shares used in computing net loss per share, basic and diluted56,28748,96353,00547,881
Net loss per share attributable to common stockholders, basic and diluted$(1.08)$(0.82)$(3.15)$(2.32)

The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows:

Three and nine months ended
June 30,
(in thousands)20222021
Shares subject to options to purchase common stock2,5473,339
Shares subject to performance-based stock options294
Unvested restricted stock units and performance stock units 1,831726
Unvested shares of common stock issued upon early exercise of stock options6
Shares subject to employee stock purchase plan6621
Total4,7384,092

12. Geographic, product and industry information
The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States of America, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia.

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Americas$35,797 $19,264 $87,636 $55,161 
EMEA15,48212,65845,20731,694
APAC4,8343,09613,4167,527
Total$56,113 $35,018 $146,259 $94,382 

The table below sets forth revenues by products.

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Synthetic genes$17,400 $11,164 $45,088 $29,228 
Oligo pools3,2592,0178,7555,367
DNA libraries1,4221,1474,6504,188
Antibody discovery6,2421,99317,6434,379
NGS tools27,79018,69770,12351,220
Total$56,113 $35,018 $146,259 $94,382 

20

The table below sets forth revenues by industry.

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Industrial chemicals/materials$16,733 $9,422 $43,533 $25,214 
Academic research9,5017,74826,87318,297
Healthcare29,43717,35674,40849,896
Food/agricultural4424921,445975
Total$56,113 $35,018 $146,259 $94,382 

13. Business acquisition
On December 1, 2021, the Company acquired all of the outstanding stock of AbX Biologics, Inc. (“Abveris”), a privately-held company providing in vivo antibody discovery services. Abveris offers animal-based antibody discovery and screening services for its customers using the Berkeley Lights Beacon Platform and its proprietary DiversimAb and DivergimAb mouse models, which the Company can humanize using its antibody optimization solution.
The acquisition date fair value of the consideration transferred for Abveris was $102.6 million, consisting of cash totaling $9.5 million, 759,601 shares of the Company’s common stock valued at $66.1 million based on the Company’s closing stock price on December 1, 2021, employee stock awards issued to certain Abveris employees valued at $6.4 million, contingent consideration of $8.5 million, holdbacks of $12.8 million, and an estimated net working capital adjustment of $0.7 million.
The contingent consideration is subject to the attainment of the calendar year 2022 revenue target. The contingent consideration becomes payable after December 31, 2022 and will be settled in a combination of cash and up to 334,939 shares of the Company’s common stock. The acquisition date fair value of the contingent consideration was based on forecasted revenue of Abveris relative to the 2022 revenue target as well as the Company’s stock price as of December 1, 2021.
The Company maintains an indemnity and adjustment holdback for the purposes of providing security against any adjustment to the amounts at closing. The indemnity holdback period extends for 18 months from the anniversary of the closing date. The indemnity holdback will be settled by transferring up to 128,351 shares of the Company’s stock, 15,304 options of the Company’s common stock and an immaterial amount of cash. The fair value of the indemnity holdback was $12.5 million as of the acquisition date. The adjustment holdback will be settled by transferring up to 3,416 shares of the Company’s stock, 408 options of the Company’s common stock and an immaterial amount of cash. The holdback adjustment liability was $0.3 million as of the acquisition date.
Additionally, a working capital adjustment of $0.7 million decreased the total purchase price. The purchase price continues to be subject to adjustment for working capital adjustments as allowed under terms of the agreement.
Post-combination compensation expense excluded from the purchase price includes employee stock awards issued to certain Abveris employees valued at $41.0 million. This includes awards valued at $17.7 million which vest over a two year service period following the acquisition date and awards valued at $3.2 million with no future vesting requirements, which were deemed accelerated by the Company at the acquisition date and expensed within the three months ended December 31, 2021. Finally, post-combination expense includes awards valued at approximately $17.5 million which vest based on achievement of the calendar year 2022 revenue target and continuing employment through the payout date, and for certain employees, additional continuing employment through the two years anniversary of the acquisition date.
This acquisition was accounted for using the acquisition method of accounting in accordance with the business combination guidance in ASC 805. Under the acquisition accounting method, the total estimated purchase price was allocated to the identifiable assets acquired and liabilities assumed based on their fair values. The excess of the purchase price over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed has been recorded as goodwill. Management’s estimate of the fair values of the acquired intangible assets at December 1, 2021 is preliminary and subject to change and is based on established and accepted valuation techniques performed with the assistance of third-party valuation specialists. Additional information, which existed as of the acquisition date but is yet unknown to the Company, may become known to the Company during the remainder of the measurement period, which will not exceed twelve months from the acquisition date. Changes to amounts will be recorded as adjustments to the provisional amounts recognized as of the acquisition date and may result in a corresponding adjustment to goodwill in the
21

period in which new information becomes available. The goodwill that arose from the acquisition consists of synergies expected from integrating Abveris into the Company’s operations and customer base. The goodwill recognized is not expected to be deductible for income tax purposes.

The following table summarizes the preliminary fair value amounts of the assets acquired and liabilities assumed as of the acquisition date, as well as the purchase consideration:

(in thousands)December 1, 2021
Assets acquired 
Cash and cash equivalents$1,306 
Accounts receivable2,309
Other current assets and prepaid expenses1,654
Property, plant and equipment 1,078
Other non-current assets2,970
Intangible assets46,500
Liabilities assumed
Current liabilities3,549
Non-current liabilities846
Deferred tax liability10,545
Fair value of assets acquired and liabilities assumed$40,877 
Goodwill61,768
Total purchase price$102,645 
Consideration transferred
Cash$9,467 
Company common stock72,514
Contingent consideration8,500
Holdback liabilities12,838
Net working capital adjustment(674)
Fair value of purchase consideration$102,645 

The following table summarizes the preliminary estimate of the intangible assets as of the acquisition date:

(in thousands except for years)Estimated
Weighted
Average
Useful Lives
in Years
Estimated Fair
Value
Developed technology14$30,900
Customer relationships1014,700
Trade name3900
Estimated fair value of acquired intangible assets$46,500

The Company estimated the fair value of the developed technology intangible asset and a portion of the customer relationships intangible assets using an excess earnings model. An additional portion of the customer relationships intangible assets was valued using the with and without method. The Company estimated the fair value of the trade name intangible asset using a relief from royalty approach. These fair value measurements were based on significant inputs not observable in the market and thus represent a Level 3 measurement. Key assumptions include the level and timing of expected future revenue, conditions and demands specific to each intangible asset over its remaining useful life, and discount rates the Company believes to be consistent with the inherent risks associated with each type of asset, which was approximately 9.6%. The fair value of these intangible assets is primarily affected by the projected revenues, gross margins, operating expenses, the technology obsolescence curve, and the anticipated timing of the projected income
22

associated with each intangible asset coupled with the discount rates used to derive their estimated present values. The Company believes the level and timing of expected future cash flows appropriately reflects market participant assumptions.
The Company included the financial results of Abveris in its condensed consolidated financial statements from the date of acquisition. The Company incurred transaction costs related to the acquisition of $1.5 million, which were recorded as an operating expense on the condensed consolidated statements of operations and comprehensive loss for the nine months ended June 30, 2022.
The following table provides a reconciliation of contingent consideration and holdbacks balances from acquisition date to June 30, 2022:

(in thousands)Contingent
consideration
HoldbacksTotal
Balance at December 1, 2021 – acquisition date $8,500 $12,164 $20,664 
Change in fair value during the period (5,200)(7,097)(12,297)
Balance at June 30, 2022
$3,300 $5,067 $8,367 

The estimated fair value of the contingent consideration liability decreased as a result of the change in the Company’s stock price from December 1, 2021, and the probability of the attainment of the calendar year 2022 revenue target as calculated using the Monte Carlo simulation model. The estimated fair value of the holdback liability decreased as a result of the change in the Company’s stock price as of June 30, 2022. For the nine months ended June 30, 2022, the Company recognized a gain of $12.3 million relating to the change in fair value of acquisition consideration in its condensed consolidated statement of operations.
The post-combination effect from net deferred tax liability assumed from the Abveris acquisition also caused a release of the Company’s deferred income tax valuation allowance. On the acquisition date, the release resulted in an income tax benefit of $10.5 million.
The following unaudited pro forma financial information presents the combined results of operations for the Company and Abveris as if the Abveris acquisition had occurred on October 1, 2020. The pro forma information contains the actual operating results of the Company Abveris, adjusted to include the pro forma impact of acquisition, which is primarily additional expense as a result of the amortization of identifiable intangible assets. The unaudited pro forma financial information is prepared for comparative purposes only and does not purport to be indicative of the actual operating results that would have been recorded had the Abveris acquisition actually taken place on October 1, 2020 and should not be taken as indicative of future consolidated operating results. Additionally, the unaudited pro forma financial results do not include any anticipated synergies or other expected benefits from the Abveris acquisition.

Three months ended June 30,Nine months ended June 30,
(in thousands) 2022202120222021
Revenues$56,113 $37,600 $148,705 $102,713 
Net loss attributable to common stockholders$(60,517)$(38,853)$(165,681)$(106,461)

Issuance of contingent consideration for iGenomX acquisition
In December 2021, the Company determined that the transition milestones specified in the iGenomX acquisition agreement were completed, and the Company became obligated to issue 59,190 shares of its common stock to satisfy the contingent consideration. The shares of common stock, valued at $4.6 million, were subsequently issued by the Company during January 2022 along with an immaterial cash payment for fractional shares.

14. Investment in variable interest entity
On November 1, 2021, the Company contributed certain assets and licensed certain intellectual property rights to the newly formed Revelar Biotherapeutics, Inc. (“Revelar”), an independently operated, new biotechnology company, to develop and commercialize an antibody, discovered and optimized by Twist Biopharma, a division of the Company. The Company granted a license to Revelar for the exclusive development of an antibody lead along with a series of back up compounds for the potential treatment of SARS-CoV-2. While the licensed antibody neutralized all known variants of concern through Omicron, it does not neutralize the BA.4 and BA.5 variants and Revelar will pursue a partner for the antibody at this time. In addition, Revelar may license up to five additional antibody therapeutics over the next four years, each of which will be subject to additional upfront, milestone and royalty payments to the Company. The Company committed to invest up to
23

$10.0 million in seed funding based on Revelar’s progress in the development of the lead antibody and the potential licensing of additional antibody therapeutics, of which the Company made an initial investment of $5.0 million in a simple agreement for future equity (“SAFE”), and two additional investments of $2.5 million each, as of the date of these consolidated financial statements as described below. In exchange for the assignment of certain contractual rights and the license to the antibody, and its back-up compounds, the Company received stock of Revelar amounting to an ownership percentage as of the date of these financial statements of 49.80%, excluding shares and options reserved for future stock awards and further excluding shares that Revelar may issue to the Company upon conversion of its SAFEs.

On February 3, 2022, the Company purchased an additional SAFE issued by Revelar for $2.5 million pursuant to the Asset License and Contract Assignment Agreement between the parties. In exchange for the SAFE, the Company obtained the right to receive shares of Revelar issued in a future preferred stock financing.
On April 6, 2022, the Company purchased an additional SAFE issued by Revelar for $2.5 million pursuant to the Asset License and Contract Assignment Agreement between the parties. In exchange for the SAFE, the Company obtained the right to receive shares of Revelar issued in a future preferred stock financing.

The Company determined that Revelar is a VIE as the entity lacks sufficient equity to finance its activities without additional support. Additionally, the Company determined that it has (a) the power to direct the activities that significantly impact Revelar’s economic performance and (b) the obligation to absorb losses of, and the right to receive benefits from, Revelar that are potentially significant to Revelar. As a result, the Company is deemed to be the primary beneficiary of Revelar and is required to consolidate Revelar in accordance with ASC 810.

Revelar incurred a net loss of approximately $6.0 million and $13.1 million for the three and nine months ended June 30, 2022, and the decrease in net assets was fully absorbed by the Company.
Total assets included on the consolidated balance sheet for Revelar as of June 30, 2022 were $7.4 million, primarily consisting of cash and cash equivalents. Total liabilities included on the consolidated balance sheet for Revelar as of June 30, 2022 were $10.5 million, primarily consisting of accounts payable, accrued expenses and non-current liability relating to the SAFEs.



* * * * *
24

Item 2. Management’s discussion and analysis of financial condition and results of operations
You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes that are included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the fiscal year ended September 30, 2021 filed with the U.S. Securities and Exchange Commission, or the SEC, on November 23, 2021, or our Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current plans, expectations and beliefs that involve risks and uncertainties including the effect of the COVID-19 pandemic and our response thereto. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the section entitled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. In preparing this MD&A, we presume that readers have access to and have read the MD&A in our Annual Report on Form 10-K, pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K.
Overview
We are an innovative synthetic biology and genomics company that has developed a scalable DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip, approximately the size of a large mobile phone. We have combined this technology with proprietary software, scalable commercial infrastructure, and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost than our competitors. We are leveraging our unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sample preparation, and antibody libraries for drug discovery and development.
Additionally, we believe our platform will enable new value-added opportunities, such as discovery partnerships for biologic drugs, and will enable new applications for synthetic DNA, such as digital data storage. We sell our synthetic DNA and synthetic DNA-based products to a customer base of approximately 3,000 customers across a broad range of industries.
We launched the first application of our platform, synthetic genes and oligo pools, in April 2016 to disrupt the gene synthesis market and make legacy DNA synthesis methods obsolete.
We have grown rapidly and generated revenues of $56.1 million and $35.0 million in the three months ended June 30, 2022 and 2021, respectively, while incurring net losses of $60.5 million and $40.0 million for the three months ended June 30, 2022 and 2021, respectively. Since our inception, we have incurred significant operating losses. To support our growth, we have increased our number of employees and increased investment in our manufacturing capabilities. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the success of our existing products and development and commercialization of additional products in the synthetic biology industry, biologic drug industry or data storage industry.
For the three months ended June 30, 2022 and 2021, we served approximately 1,900 and 1,800 customers, respectively.
Highlights from three months ended June 30, 2022 compared with three months ended June 30, 2021 included:
Revenue growth of 60% to $56.1 million from $35.0 million, primarily due to order growth in NGS tools, synthetic genes and antibody discovery; and
Our gross margins were 45% and 40%, respectively.

We have built a scalable commercial platform that enables us to reach a diverse customer base in a variety of industries including industrial chemicals/materials, academic research, healthcare, food, agriculture and data storage. To address this diverse customer base, we have employed a multi-channel strategy comprised of a direct sales force targeting synthetic DNA customers, international distributors, and an e-commerce platform. Launched in fiscal 2018, our e-commerce platform allows customers to design, validate and place on-demand orders of customized DNA online. This is a key component of our strategy to address and support our diverse and growing customer base, as well as support commercial productivity, enhance the customer experience, and promote loyalty.

In the three months ended June 30, 2022, our net revenues increased to $56.1 million from net revenues of $48.1 million in the three months ended March 31, 2022. Our synthetic gene revenue of $17.4 million in the three months ended June 30, 2022 increased from $14.2 million in the three months ended March 31, 2022, primarily due to an increase in our top
25

customers and growth in the healthcare and industrial chemical industries. Our revenues from NGS tools increased to $27.8 million in the three months ended June 30, 2022, from $23.1 million in the three months ended March 31, 2022, primarily due to an increase in revenue from our top customers and growth in the healthcare and industrial chemical industries. Our research and development expenses increased from $31.2 million in the three months ended March 31, 2022 to $36.8 million in the three months ended June 30, 2022 primarily due to increases in payroll expenses related to increased headcount and stock-based compensation expense relating to Revelar and production material costs.


Investment in Revelar
On November 1, 2021, we contributed certain assets and licensed certain intellectual property rights to Revelar, an independently operated, new biotechnology company, to develop and commercialize an antibody, discovered and optimized by Twist Biopharma. We granted a license to Revelar for the exclusive development of an antibody lead along with a series of back up compounds for the potential treatment of SARS-CoV-2. While the licensed antibody neutralized all known variants of concern through Omicron, it does not neutralize the BA.4 and BA.5 variants and Revelar will pursue a partner for the antibody at this time. We have provided Revelar with $10.0 million in seed funding. We do not intend to provide additional funding to Revelar in the foreseeable future.

COVID-19 considerations
During the three months ended June 30, 2022, our revenues were not significantly affected by the COVID-19 pandemic. However, the extent to which the COVID-19 pandemic affects our future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including the recurrence, severity and/or duration of the ongoing pandemic, and current or future domestic and international actions to contain and treat COVID-19.
We are and have been following public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions and the promotion of social distancing and work-from-home arrangements. We have taken and continue to take a variety of measures to ensure the availability and functioning of our critical infrastructure, to promote the safety and security of our employees and to support the communities in which we operate. These measures include increasing our inventory, requiring remote working arrangements for employees not integral in physically making and shipping our products or who do not need specialized equipment to perform their work, weekly testing for all onsite employees, investing in personal protective equipment, and providing paid sick leave to affected employees.
Due to the evolving nature of the situation, we are not able at this time to estimate the effect of COVID-19 on our financial results and operations, but the effect could be material for the remainder of fiscal year 2022 and/or during any future period affected either directly or indirectly by this pandemic. For further discussion of the risks relating to COVID-19, see Part II, Item 1A. “Risk Factors—We are subject to risks associated with COVID-19.”

Financial overview
The following table summarizes certain selected historical financial results:

Three months ended
Nine months ended
June 30,June 30,
(in thousands)2022202120222021
Revenues$56,113 $35,018 $146,259 $94,382 
Loss from operations(61,163)(42,118)(177,905)(112,915)
Net loss attributable to common stockholders(60,517)(40,037)(166,748)(110,856)

Revenues
We generate revenue from sales of synthetic genes, oligo pools, NGS tools, DNA libraries and antibody discovery services. Our ability to increase our revenues will depend on our ability to further penetrate the domestic and international markets, generate sales through our direct sales force, and over time from our e-commerce platform and launch of new products.
26

Revenues by geography
We have one reportable segment from the sale of synthetic DNA products. The following table shows our revenues by geography, based on our customers’ shipping addresses. Americas consists of United States of America, Canada, Mexico, and South America; EMEA consists of Europe, Middle East and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia and Australia.

Three months ended June 30,Nine months ended June 30,
(in thousands, except percentages)2022% 2021% 2022% 2021%
Americas$35,797 64 %$19,264 55 %$87,636 60 %$55,161 58 %
EMEA15,48227 %12,65836 %45,20731 %31,69434 %
APAC4,834%3,096%13,416%7,527%
Total revenues$56,113 100 %$35,018 100 %$146,259 100 %$94,382 100 %

Revenues by product
The table below sets forth revenues by product:

Three months ended June 30,Nine months ended June 30,
(in thousands, except percentages)2022% 2021% 2022% 2021%
Synthetic genes$17,400 31 %$11,164 32 %$45,088 31 %$29,228 31 %
Oligo pools3,259 %2,017%8,755%5,367%
DNA libraries1,422 %1,147%4,650%4,188%
Antibody discovery6,242 12 %1,993%17,64312 %4,379%
NGS tools27,790 49 %18,69753 %70,12348 %51,22054 %
Total revenues$56,113 100 %$35,018 100 %$146,259 100 %$94,382 100 %

Revenues by industry
The table below sets forth revenues by industry:

Three months ended June 30,Nine months ended June 30,
(in thousands, except percentages)2022% 2021% 2022% 2021%
Industrial chemicals/materials$16,733 30 %$9,422 27 %$43,533 30 %$25,214 27 %
Academic research9,501 17 %7,74822 %26,87318 %18,29719 %
Healthcare29,437 52 %17,35650 %74,40851 %49,89653 %
Food/agriculture442 %492%1,445%975%
Total revenues$56,113 100 %$35,018 100 %$146,259 100 %$94,382 100 %

Product shipments including synthetic genes
Shipments of all products and number of genes shipped in the three months ended June 30, 2022, March 31, 2022, December 31, 2021, September 30, 2021, June 30, 2021, March 31, 2021, December 31, 2020, and September 30, 2020 were as follows:

Three months ended
June 30,March 31,December 31, September 30,
June 30,
March 31, December 31,September 30,
(in thousands)20222022202120212021202120202020
Number of genes shipped16312412591107908487
Number of shipments15141312141198
27


Comparison of the three months ended June 30, 2022 and 2021
Revenues

Three months ended
June 30,
(in thousands, except percentages) 20222021Change%
Revenues$56,113 $35,018 $21,095 60 %

In the three months ended June 30, 2022, revenues increased to $56.1 million from $35.0 million in the three months ended June 30, 2021. The revenue increase reflects growth in synthetic genes revenue of $6.2 million, NGS tools revenue of $9.1 million and antibody discovery revenue of $4.2 million. Our synthetic genes revenue grew mainly due to growth in our customers quarter over quarter across in the industrial chemicals and healthcare industries. In the three months ended June 30, 2022, we shipped approximately 163,000 genes compared to approximately 107,000 genes in the three months ended June 30, 2021, an increase of 52%. Synthetic gene pricing to our customers was relatively constant period-over-period. The primary reason for NGS tools revenue growth was the adoption of our product by our top customers in the healthcare industry. We do not believe that pricing changes had a meaningful impact on the revenue changes for NGS tools period-over-period. Our Antibody services revenue grew year over year due to an increase in the Twist Antibody discovery project revenue and also increased revenue attributable to the Abveris acquisition.

Cost of revenues

Three months ended
June 30,
(in thousands, except percentages)20222021Change%
Cost of revenues$30,974 $20,933 $10,041 48 %

In the three months ended June 30, 2022, cost of revenues increased to $31.0 million from $20.9 million in the three months ended June 30, 2021. The increase was primarily due to an increase in the consumption of reagents and production materials costs of $6.3 million associated with increased production due to higher sales volumes and product shipments. The increase in the payroll and stock-based compensation expense of $3.0 million was due to growth in Gene volume and increasing capacity for Genes and new products. Abveris's cost of $2.7 million contributed to the increase in the cost of revenues. Depreciation expense also increased by $0.8 million associated with investing in equipment to support the increase in the capacity.
Research and development expenses

Three months ended
June 30,
(in thousands, except percentages)20222021Change%
Research and development$36,840 $19,838 $17,002 86 %

In the three months ended June 30, 2022, research and development expenses increased to $36.8 million from $19.8 million in the three months ended June 30, 2021. Revelar's cost of $6.0 million and Abveris's cost of $0.9 million contributed to the increase of research and development costs. The increases were primarily in payroll and stock-based compensation expense of $9.5 million associated with increasing our research and development headcount, an increase in the consumption of reagents and production materials costs of $7.0 million due to an increase in research activities and material prices, in outside services and consulting costs of $0.7 million, primarily associated with the development activities for our data storage technology, and in maintenance costs of $0.2 million.
Selling, general and administrative

Three months ended
June 30,
(in thousands, except percentages)20222021Change%
Selling, general and administrative$53,693 $34,478 $19,215 56 %

28

In the three months ended June 30, 2022, selling, general and administrative expenses increased to $53.7 million from $34.5 million in the three months ended June 30, 2021, primarily due to increases in payroll expenses of $13.1 million related to increased headcount in our commercial organization, and included $7.3 million higher stock-based compensation expenses and $0.6 million higher sales commission. Consulting costs increased by $0.7 million, legal costs by $0.6 million, depreciation and amortization expenses by $0.8 million, advertising expenses by $0.7 million, travel costs by $1.5 million, and rent and facility expenses by $1.7 million, mainly due to our Wilsonville facility lease expense.
Change in fair value of contingent consideration and holdbacks
Three months ended
June 30,
(in thousands, except percentages)20222021Change%
Change in fair value of contingent consideration and holdbacks$(4,231)$1,887 $(6,118)(324)%

In the three months ended June 30, 2022, we recognized the change in fair value of contingent consideration and holdbacks of $4.2 million related to the acquisition of Abveris primarily as a result of the change of our stock price as of June 30, 2022.
Interest, and other income (expense), net

Three months ended
June 30,
(in thousands, except percentages)20222021Change%
Interest income$722 $86 $636 740 %
Interest expense— (70)70 (100)%
Other expense(225)(312)87 (28)%
Total interest and other income (expense), net$497 $(296)$793 (268)%

In the three months ended June 30, 2022, interest income was $0.7 million compared to $0.1 million in the three months ended June 30, 2021, resulting from our short-term and long-term investments. The decrease in interest expense was related to the reduction in the amount of debt outstanding under our credit facility with Silicon Valley Bank.
Benefit from income taxes

Three months ended
June 30,
(in thousands, except percentages)20222021Change%
Benefit from income taxes$149 $2,377 $(2,228)(94)%

We recorded an income tax benefit of $0.1 million in the three months ended June 30, 2022. In the three months ended June 30, 2021, we recorded an income tax benefit of $2.4 million mainly as a result of the business acquisition.



Comparison of the nine months ended June 30, 2022 and 2021
Revenues

Nine months ended
June 30,
(in thousands, except percentages) 20222021Change%
Revenues$146,259 $94,382 $51,877 55 %

In the nine months ended June 30, 2022, revenues increased to $146.3 million from $94.4 million in the nine months ended June 30, 2021. The revenue increase reflects growth in synthetic genes revenue of $15.9 million, NGS tools revenue of $18.9 million, oligo pools revenue of $3.4 million and antibody discovery revenue of $13.2 million. Our synthetic genes revenue grew mainly due to growth in our customers across all industries including industrial chemicals, healthcare and
29

academic research. In the nine months ended June 30, 2022, we shipped approximately 412,000 genes compared to approximately 281,000 genes in the nine months ended June 30, 2021, an increase of 47%. Synthetic gene pricing to our customers was relatively constant period-over-period. The primary reason for NGS tools revenue growth was an increase in the revenue from our top customers and the adoption of our product by customers across all industries. We do not believe that pricing changes had a meaningful impact on the revenue changes for NGS tools period-over-period. Our Antibody services revenue grew year over year due to an increase in the Twist Antibody discovery project revenue and also increased revenue attributable to the Abveris acquisition.
Cost of revenues

Nine months ended
June 30,
(in thousands, except percentages)20222021Change%
Cost of revenues$87,744 $58,123 $29,621 51 %

In the nine months ended June 30, 2022, cost of revenues increased to $87.7 million from $58.1 million in the nine months ended June 30, 2021. The increase was primarily due to an increase in the consumption of reagents and production materials costs of $16.8 million associated with increased production due to higher sales volumes and product shipments. The increase in payroll and stock-based compensation expense of $8.3 million was due to growth in Gene volume and increasing capacity for Genes and new products. Abveris's cost of $4.9 million contributed to the increase in the cost of revenues. Depreciation expense increased by $2.1 million associated with investing in the equipments to support the increase in the capacity, information technology costs increased by $1.1 million, maintenance cost increased by $0.9 million and facility costs increased by $0.4 million.
Research and development expenses

Nine months ended
June 30,
(in thousands, except percentages)20222021Change%
Research and development$90,701 $49,629 $41,072 83 %

In the nine months ended June 30, 2022, research and development expenses increased to $90.7 million from $49.6 million in the nine months ended June 30, 2021. Revelar's cost of $13.1 million and Abveris cost of $3.2 million contributed to the increase of research and development costs.The increases were primarily in payroll and stock-based compensation expense of $22.9 million associated with increasing our research and development headcount, an increase in the consumption of reagents and production materials costs of $12.1 million primarily due to an increase in research activities and material prices, an increase in outside services and consulting costs of $5.6 million, primarily associated with the development activities for our data storage technology, and an increase in maintenance costs of $0.2 million. Grant reimbursements, which are netted against our research and development expenses, were $3.6 million in the nine months ended June 30, 2022, as compared to $1.6 million in the nine months ended June 30, 2021, reflecting the timing of the reimbursements.
Selling, general and administrative

Nine months ended
June 30,
(in thousands, except percentages)20222021Change%
Selling, general and administrative$158,790 $97,658 $61,132 63 %

In the nine months ended June 30, 2022, selling, general and administrative expenses increased to $158.8 million from $97.7 million in the nine months ended June 30, 2021, primarily due to increases in payroll expenses of $43.4 million related to increased headcount in our commercial organization, and included $23.8 million higher of stock-based compensation expenses and $3.6 million higher sales commission. Consulting costs increased by $3.0 million, legal costs by $1.2 million, depreciation and amortization expenses by $2.5 million, online services by $0.9 million, advertising costs by $1.3 million, travel costs by $2.6 million and rent expense by $4.0 million, mainly due to our Wilsonville facility lease expense.
30

Change in fair value of contingent consideration and holdbacks
Nine months ended
June 30,
(in thousands, except percentages)20222021Change%
Change in fair value of contingent consideration and holdbacks$(13,071)$1,887 $(14,958)(793)%

In the nine months ended June 30, 2022, we recognized the change in the fair value of the contingent consideration and holdbacks of $12.3 million and $0.8 million related to the acquisitions of Abveris and iGenomX, respectively, primarily as a result of the change in our stock price as of June 30, 2022.
Interest, and other income (expense), net

Nine months ended
June 30,
(in thousands, except percentages)20222021Change%
Interest income$1,134 $377 $757 201 %
Interest expense(54)(284)230 (81)%
Other expense(626)(305)(321)(105)%
Total interest and other income (expense), net$454 $(212)$666 (314)%

In the nine months ended June 30, 2022, interest income was $1.1 million compared to $0.4 million in the nine months ended June 30, 2021, resulting from our short-term and long-term investments. The decrease in interest expense was related to the reduction in the amount of debt outstanding under our credit facility with Silicon Valley Bank.
Benefit from income taxes

Nine months ended
June 30,
(in thousands, except percentages)20222021Change%
Benefit from income taxes$10,703 $2,271 $8,432 371 %

We recorded an income tax benefit of $10.7 million in the nine months ended June 30, 2022 mainly as a result of the acquisition of Abveris. In the nine months ended June 30, 2021, we recorded income tax benefit of $2.3 million mainly as a result of the acquisition of Abveris.


Liquidity and capital resources
Sources of liquidity
To date, we have financed our operations principally through public equity raises, private placements of our convertible preferred stock, borrowings from credit facilities and revenue from our commercial operations.
Since our inception on February 4, 2013 and through June 30, 2022, we have received an aggregate of $1,333.7 million in net proceeds from the issuance of equity securities and an aggregate of $13.8 million from debt. As of June 30, 2022, we had a balance of $376.2 million of cash and cash equivalents and $151.3 million in short-term investments.

Operating capital requirements
Our primary uses of capital are, and we expect will continue to be for the near future, compensation and related expenses, manufacturing costs, laboratory and related supplies, legal and other regulatory expenses and general overhead costs and the capital expenditures for our facility expansion including our “Factory of the Future” in Wilsonville, Oregon. We had $18.8 million in commitments for capital expenditures as of June 30, 2022.
31


Cash flows
The following table summarizes our sources and uses of cash and cash equivalents:

Nine months ended
June 30,
(in thousands)20222021
Net cash used in operating activities$(123,118)$(77,441)
Net cash used in investing activities(235,713)132,244 
Net cash provided by financing activities269,294 327,607 

Operating activities
Net cash used in operating activities was $123.1 million in the nine months ended June 30, 2022 and consisted primarily of a net loss of $166.7 million adjusted for non-cash items including depreciation and amortization expenses of $11.6 million, deferred tax liability of $11.2 million, stock-based compensation expense of $60.6 million, non-cash lease expense of $2.6 million, change in fair value of contingent consideration of $13.1 million, and a net change in operating assets and liabilities of $7.9 million. The change in operating assets and liabilities was mainly due to increases in accounts receivable of $10.3 million, inventories of $11.2 million and prepaid expenses of $2.7 million, offset by decreases in other non-current assets of $6.8 million, accrued compensation of $5.5 million, accrued expenses of $0.6 million and other liabilities of $3.0 million.
In the nine months ended June 30, 2021, net cash used in operating activities was $77.4 million and consisted primarily of a net loss of $110.9 million adjusted for non-cash items, including depreciation and amortization expenses of $7.3 million, stock-based compensation expense of $27.8 million, and a change in operating assets and liabilities of $5.4 million. The change in operating assets and liabilities was mainly due to increases in inventory of $8.9 million and other liabilities of $1.9 million and decreases in accounts payable of $5.2 million and accrued expenses of $1.5 million.
Investing activities
In the nine months ended June 30, 2022, our investing activities used net cash of $235.7 million. The use of net cash resulted primarily from the net impact of purchases, sale and maturity of investments of $142.2 million, new businesses acquired of $8.2 million and purchases of laboratory property, equipment and computers of $85.4 million.
In the nine months ended June 30, 2021, our net cash provided by investing activities was $132.2 million primarily as a result of the net impact of purchases and maturity of investments of $151.7 million, and purchases of laboratory property, equipment and computers of $19.0 million.
Financing activities
Net cash provided by financing activities was $269.3 million in the nine months ended June 30, 2022, which consisted of $269.8 million in proceeds from a public offering of our common stock, net of underwriting discounts and commissions and offering expenses, $2.4 million from proceeds from issuance of shares under the 2018 ESPP and $4.8 million from the exercise of stock options, offset by $1.6 million in principal payments on long term debt and $6.1 million in repurchases of common stock for income tax withholdings.
In the nine months ended June 30, 2021, net cash provided by financing activities was $327.6 million, which consisted of $323.9 million in proceeds from a public offering of our common stock, net of underwriting discounts and commissions and offering expenses, $2.8 million from proceeds from issuance of shares under the 2018 ESPP and $11.7 million from the exercise of stock options, offset by $2.5 million in principal payments on long term debt and $8.2 million in repurchases of common stock for income tax withholdings.

Off-balance sheet arrangements
We do not have any off-balance sheet arrangements.

32

Contractual obligations and other commitments
Our contractual obligations have not materially changed from those reported in our Annual Report on Form 10-K other than transactions noted below.
On August 6, 2021, Abveris, which was subsequently acquired by us, entered into a 10-year, 5-month operating lease for approximately 22,000 square-feet of office space located in Quincy, Massachusetts, to further expand operations. Upon execution of the lease agreement, Abveris provided the landlord an approximate $0.6 million irrevocable letter of credit as a security deposit. Abveris will pay an initial annual base rent of approximately $1.2 million, which is subject to scheduled 2% annual increases, plus certain operating expenses. We have the right to sublease the facility, subject to landlord consent. The lease commenced on March 3, 2022. As of lease commencement date, the total future minimum lease payments under the agreement were $13.2 million.

Critical accounting policies and significant management estimates
The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the reasonableness of its estimates. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily available from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.
We believe the following critical accounting policies require that we make significant judgments and estimates in preparing our consolidated financial statements.
Revenue recognition
Our revenue is generated through the sale of synthetic biology tools, such as synthetic genes, or clonal genes and fragments, oligonucleotide pools, or oligo pools, NGS tools and DNA libraries. We recognize revenue when control of the products is transferred to the customer and at a transaction price that is determined based on the agreed upon rates in the applicable order or master supply agreement applied to the quantity of synthetic DNA that was manufactured and shipped to the customer.
Contracts with customers are in the written form of a purchase order or a quotation, which outline the promised goods and the agreed upon price. Such orders are often accompanied by a Master Supply or Distribution Agreement that establishes the terms and conditions, rights of the parties, delivery terms, and pricing. We assess collectability based on a number of factors, including past transaction history and creditworthiness of the customer.
For all of our contracts to date, other than Biopharma contracts, the customer orders a specified quantity of a synthetic DNA sequence; therefore, the delivery of the ordered quantity per the purchase order is accounted for as one performance obligation.
The transaction price is determined based on the agreed upon rates in the purchase order or master supply agreements applied to the quantity of synthetic DNA that was manufactured and shipped to the customer. Our contracts include only one performance obligation—the shipment of the product to the customer. Accordingly, all of the transaction price, net of any discounts, is allocated to the one performance obligation. Our sales are primarily subject to Ex Works (as defined in Incoterms 2010) and delivery terms and revenue is recorded at the point in time when products are picked up by the customer’s freight forwarder, as we have determined that this is the point in time that product control transfers to the customer. Therefore, upon shipment of the product, there are no remaining performance obligations. Our shipping and handling activities are performed before the customer obtains control of the goods and therefore are considered a fulfillment cost. We have elected to exclude all sales and value added taxes from the measurement of the transaction price. We have not adjusted the transaction price for significant financing since the time period between the transfer of goods and payment is less than one year. We have elected the practical expedient of not disclosing the consideration allocated to remaining performance obligations and an explanation of when those amounts are expected to be recognized as revenue since the duration of our contracts is less than one year.
We recognize revenue at a point in time when control of the products is transferred to the customer.
33

Our Biopharma revenue currently primarily consists of research and development agreements with third parties that may or may not provide for up-front and milestone-based payments. Our research and development agreements may include more than one performance obligation. At the inception of the agreement, we assess whether each obligation represents a separate performance obligation or whether such obligations should be combined as a single performance obligation. The transaction price for each agreement is determined based on the amount of consideration we expect to be entitled to for satisfying all performance obligations within the agreement. We assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. In agreements where we satisfy performance obligation(s) over time, we recognize development revenue typically using an input method based on our costs incurred relative to the total expected cost which determines the extent of our progress toward completion. As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the transaction price and progress towards completion. We review our estimate of the transaction price and progress toward completion based on the best information available to recognize the cumulative progress toward completion as of the end of each reporting period and make revisions to such estimates as necessary. Also, these research and development agreements may include license payments. We recognize revenue from functional license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. A functional license has significant standalone functionality because it can be used “as is” for performing a specific task.
We had contract assets of $4.0 million and contract liabilities of $2.5 million as of June 30, 2022. For all periods presented, there was no revenue recognized in a reporting period from performance obligations satisfied in previous periods.
Based on the nature of our contracts with customers, which are recognized over a term of less than 12 months, we have elected to use the practical expedient whereby costs to obtain a contract are expensed as they are incurred.
We state our revenues net of any taxes collected from customers that are required to be remitted to various government agencies. The amount of taxes collected from customers and payable to governmental entities is included on the balance sheet as part of “Accrued expenses and other current liabilities.”

Stock-based compensation
We have granted stock-based awards, consisting of stock options and restricted stock, to our employees, certain non-employee consultants and certain members of our board of directors. We measure stock-based compensation expense for restricted stock and stock options granted to our employees and directors on the date of grant and recognize the corresponding compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. We measure stock-based compensation expense for restricted stock and stock options granted to non-employee consultants on the date of grant and recognize the corresponding compensation expense of those awards over the period in which the related services are received. We adjust for actual forfeitures as they occur.
We have granted performance-based stock units (PSUs) ) and performance stock options (PSOs) to executive officers and senior level employees. We value PSUs using a grant date fair value equal to the closing share price of our common stock on the date of grant. We value PSOs using the Black-Scholes method to calculate the fair value at the grant date without regard to the vesting condition and will recognize compensation cost for the units that are expected to vest.

Business combinations
Accounting for a business acquisition requires management to make significant estimates and assumptions as of acquisition date, which are inherently uncertain. Intangible assets we have recognized from such transaction, includes goodwill, development technology and customer relationships. Significant judgment was exercised in determining the fair value of the developed technology intangible assets acquired, which included estimates and assumptions related to the projected revenues (specifically volume of sales), discount rate, and technology obsolescence curve.
Critical estimates in valuing certain of the intangible assets we have acquired include, but are not limited to, projected revenues, technology obsolescence and discount rate. The rates used to discount expected future revenue to present value are typically derived from a weighted-average cost of capital analysis and adjusted to reflect inherent risks. Unanticipated events and circumstances may occur that could affect either the accuracy or validity of such assumptions, estimates or actual results.

34

Goodwill
Determining when to test for impairment, the reporting unit, the assets and liabilities of the reporting unit, and the fair value of the reporting unit requires significant judgment and involves the use of significant estimates and assumptions. We test goodwill for impairment in our fourth quarter each year, or more frequently if indicators of an impairment exist, to determine whether it is more likely than not that the fair value of the reporting unit with goodwill is less than its carrying value. For reporting units for which this assessment concludes that it is more likely than not that the fair value is more than its carrying value, goodwill is considered not impaired and we are not required to perform the goodwill impairment test. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance, and other relevant events and factors affecting the fair value of the reporting unit. For reporting units for which this assessment concludes that it is more likely than not that the fair value is below the carrying value, goodwill is tested for impairment by determining the fair value of the reporting unit and comparing it to the carrying value of the net assets assigned to the reporting unit. If the fair value of the reporting unit exceeds its carrying value, goodwill is considered not impaired. If the carrying value of the reporting unit exceeds its fair value, we would record an impairment loss up to the difference between the carrying value and implied fair value.

Recent issued accounting pronouncements
For a description of accounting changes and recent accounting pronouncements, including the expected dates of adoption and estimated effects, if any, on our condensed consolidated financial statements, see Note 2, “Summary of significant accounting policies” in Item 1 of Part I of this Quarterly Report on Form 10-Q for a further discussion of the impairment analysis of acquisition related intangible assets.

Item 3. Quantitative and qualitative disclosures about market risk
Interest rate sensitivity
We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents, and marketable securities of $527.6 million and $477.9 million as of June 30, 2022 and September 30, 2021, respectively, which consisted of primarily of money market funds and marketable securities, largely composed of investment grade, short to intermediate term fixed income securities.
The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and short-term duration, according to our board-approved investment policy. Our investments are subject to interest rate risk and could fall in value if market interest rates increase. A hypothetical 10% relative change in interest rates during any of the periods presented would not have a material impact on our condensed consolidated financial statements.
Foreign currency sensitivity
The majority of our transactions occur in U.S. dollars. However, we do have certain transactions that are denominated in currencies other than the U.S. dollar, primarily the Euro, Chinese Yuan, and British Pound, and we therefore are subject to foreign exchange risk. The fluctuation in the value of the U.S. dollar against other currencies affects the reported amounts of expenses, assets and liabilities primarily associated with a limited number of manufacturing activities.
We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the effects of changes in foreign currency exchange rates. The counterparties to these forward foreign currency exchange contracts are creditworthy multinational commercial banks, which minimizes the risk of counterparty nonperformance. We regularly review our exposure and may, as part of this review, make changes to it.

Inflation risk

While we have experienced increased operating costs in recent periods, which we believe are due in part to the recent growth in inflation, we do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could adversely affect our business, financial condition and results of operations.


35

Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that such information required to be disclosed is accumulated and communicated to management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure.
Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
The Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), with the assistance from other members of management, have evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2022, and based on their evaluation, the CEO and CFO concluded that the disclosure controls and procedures were not effective as of such date due to the material weaknesses in internal control over financial reporting that were disclosed in our Part II, Item 9A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2021.
Notwithstanding the material weakness, the Company performed additional analysis and other post-closing procedures to determine its consolidated financial statements are prepared in accordance with generally accepted accounting principles. Accordingly, management believes that the unaudited condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.
Previously Identified Material Weaknesses
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements would not be prevented or detected on a timely basis.
Refer to the management report on internal control over financial reporting for the material weaknesses in Part II, Item 9A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and continue to exist as of June 30, 2022.
Remediation Plan of Material Weaknesses
As previously described in Part II, Item 9A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2021, we are continuing to enhance our overall control environment and are devoting substantial effort by enhancing our manual or automated controls to remediate the identified material weaknesses. For a more comprehensive discussion of the remedial measures undertaken to address these material weaknesses, refer to Part II, Item 9A, “Remediation of Material Weaknesses,” of our Annual Report on Form 10-K.

Additional changes and improvements may be identified and adopted as we continue to evaluate and implement our remediation plans. These material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that the enhanced control is operating effectively.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. Other information

Item 1. Legal proceedings
36

We are subject to various legal proceedings and claims arising in the ordinary course of business. Although occasional adverse decisions or settlements may occur, management believes that the final disposition of such matters will not have a material adverse effect on our business, financial position, results of operations or cash flows.

Item 1A. Risk factors
Risk Factor Summary
Investing in our common stock involves a high degree of risk. You should carefully consider all information in the Annual Report on Form 10-K and in subsequent reports we file with SEC prior to investing in our common stock. These risks are discussed more fully in the section titled “Risk Factors” below. These risks and uncertainties include, but are not limited to, the following:
We are subject to risks associated with COVID-19;
We have incurred net losses in every period to date, and we expect to continue to incur significant losses as we develop our business and may never achieve profitability;
We may require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product manufacturing and development and other operations;
If we are unable to maintain adequate revenue growth or do not successfully manage such growth, our business and growth prospects will be harmed;
Rapidly changing technology and extensive competition in synthetic biology could make the products we are developing and producing obsolete or non-competitive unless we continue to develop and manufacture new and improved products and pursue new market opportunities;
The continued success of our business relies heavily on our disruptive technologies and products and our position in the market as a leading provider of synthetic DNA using a silicon chip;
We depend on one single-source supplier for a critical component for our DNA synthesis process. The loss of this supplier or its failure to supply us with the necessary component on a timely basis, could cause delays in the future capacity of our DNA synthesis process and adversely affect our business;
We depend on the continuing efforts of our senior management team and other key personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified researchers, engineering and other personnel, our ability to develop our products could be harmed, and we may be unable to achieve our goals;
We may engage in strategic transactions, including acquisitions and divestitures that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, or prove not to be successful;
Our products could in the future be subject to additional regulation by the U.S. Food and Drug Administration or other domestic and international regulatory agencies, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations;
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business;
Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain; and
If we are unable to obtain, maintain and enforce intellectual property protection, others may be able to make, use, or sell products and technologies substantially the same as ours, which could adversely affect our ability to compete in the market.
The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding other statements in this Quarterly Report on Form 10-Q. The following information should be read in
37

conjunction with Part 1, Item 2 “Management’s discussion and analysis of financial condition and results of operations” and our unaudited condensed consolidated financial statements and related notes in Part I, Item 1, “Financial statements” of this Form 10-Q. The risks and uncertainties described below are not the only ones we face. Additional risk and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. If any of the events or circumstances described in the following risk factors actually occur, our business, operating results, financial condition, cash flows, and prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.
Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results, and stock price.
Because of the following factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.
Risks related to our business
We are subject to risks associated with COVID-19.
Our global operations expose us to risks associated with COVID-19 that has spread globally. The continued spread of COVID-19 and the appearance of variants have led to disruption to business and economic activity and related uncertainty and volatility in the global capital markets, which increases the cost of, and adversely impacts access to, capital and increases economic uncertainty. The COVID-19 pandemic has caused an economic slowdown and will continue to impact business and economic activity globally. While our financial results for the six months ended June 30, 2022 have not been significantly affected by the COVID-19 outbreak, impacts from COVID-19 may, in the future, adversely affect our operations, supply chains, distribution systems and customer demand, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking or may take in the future. Due to the health risks caused by the COVID-19 pandemic to employees who operate and monitor our internal controls and due to the previous requirement and potential future requirements that a large number of employees work remotely, the COVID-19 pandemic impact on staffing could cause challenges for the effective operation of our internal controls. The unanticipated loss or unavailability of key employees due to the COVID-19 outbreak could harm our ability to operate or execute our business strategy. We may not be successful in finding and integrating suitable successors in the event of key employee loss or unavailability. The effectiveness of our sales teams may be negatively impacted by the lack of or reduction in travel resulting in their reduced ability to engage with decision-makers. Our NGS business may be negatively impacted by the sequencing capacity dedicated to COVID-19 related orders. Our shipments may be subject to higher freight costs. Our customers may delay payments for shipments received. A significant portion (approximately 19%) of our business is in the academic markets and the demand for our products in this customer segment has been affected by a reduction in their research grants and may continue to be so affected in the future. Supply chain disruptions may result in the lack of raw materials or component shortages, delay in the release of new products or deliveries of products or compressed margins due to an increase in material costs. Due to these impacts and measures, we may experience significant and unpredictable reductions in demand for our products and our customers may postpone or cancel their existing orders. Due to the COVID-19 pandemic, we and many other employers in the United States and Europe required all employees whose duties can be performed remotely, to work from home and not to go into our offices. This increase in employee telecommuting activity could increase the risk of a security breach of our information technology systems. If the COVID-19 pandemic continues and business and economic conditions persist or worsen, we may experience a decline in sales activities and customer orders or cancellations of existing orders, and it remains uncertain what impact these declines will have on future sales and customer orders once conditions begin to improve. In addition to existing travel restrictions, while many countries have re-opened their borders to U.S. travelers, countries may again impose or expand travel restrictions and impose or resume prolonged quarantines if there is a resurgence of COVID-19 cases, which would significantly impact our ability to support our business operations and customers in those locations and the ability of our employees to access their places of work to produce products, or significantly hamper our products from moving through the supply chain. For example, we may face a shortage of dry ice and other materials which are essential to delivering our products to our customers due to the increased demand for such products due to the COVID-19 vaccination distribution, COVID-19 testing and COVID-19 antibody development. As a result, given the evolving nature of the business and economic conditions in response to the virus, and the uncertainty as to how quickly and effectively mitigation measures, such as vaccines, will be widely available and adopted by the public, the COVID-19 pandemic may negatively affect our revenue growth, and it is uncertain how materially COVID-19 will affect our global operations if these impacts persist or worsen over an extended period of time. Any of these impacts would have an adverse effect on our business, financial
38

condition and results of operations, and at this point, the extent of the impact of COVID-19 remains uncertain. In addition, our ability to raise capital in the future may also be negatively affected.

We have incurred net losses in every period to date, and we expect to continue to incur significant losses as we develop our business and may never achieve profitability.
We have incurred net losses each year since inception and have generated limited revenue from product sales to date. We expect to incur increasing costs as we grow our business. We cannot be certain if or when we will produce sufficient revenue from our operations to support our costs. Even if profitability is achieved, we may not be able to sustain profitability. We incurred net losses of $152.1 million, $139.9 million and $107.7 million for the years ended September 30, 2021, 2020 and 2019, respectively. As of June 30, 2022, we had an accumulated deficit of $777.3 million. We expect to incur substantial losses and negative cash flow for the foreseeable future. We may incur significant losses in the future for a number of reasons, many of which are beyond our control, including the other risks described in this Form 10-Q, the market acceptance of our products, business and economic conditions resulting from the ongoing COVID-19 pandemic, future product development, and our market penetration and margins. In addition, inflationary pressure could adversely impact our financial results by increasing operating costs. We may not fully offset these cost increases by raising prices for our products and services, which could result in downward pressure on our margins. Further, our clients may choose to reduce their business with us if we increase our pricing.

We may require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product manufacturing and development and other operations.
Since our inception, substantially all of our resources have been dedicated to the development of our DNA synthesis platform and our sample preparation kit for NGS. We believe that we will continue to expend substantial resources for the foreseeable future as we continue to expand our production capabilities and enter additional markets we may choose to pursue, including new COVID-19 testing products, pharmaceutical biologics drug discovery and digital data storage in DNA. These expenditures are expected to include costs associated with research and development, increasing manufacturing and supply capabilities as well as marketing and selling existing and new products. In addition, other unanticipated costs may arise.
We expect that our existing cash and cash equivalents will be sufficient to fund our planned operating expenses, capital expenditure requirements and debt service payments through at least the next 12 months. However, our operating plan may change as a result of factors currently unknown to us, and as a result, we have sought and may in the future need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Such financing may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business.
Our future capital requirements depend on many factors, including:
the number and characteristics of any additional products or manufacturing processes we develop or acquire to serve new or existing markets;
the scope, progress, results and costs of researching and developing future products or improvements to existing products or manufacturing processes, including increasing our manufacturing capabilities;
the cost of manufacturing our DNA synthesis equipment and tools, our NGS sample preparation kits, and any future products we successfully commercialize;
our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;
the costs of expanding our sales and marketing capabilities in the United States and in other geographies;
any lawsuits related to our products or commenced against us or any regulatory actions or proceedings commenced;
the expenses needed to attract and retain skilled personnel;
39

the costs associated with being a public company;
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and
the timing, receipt and amount of sales of, or royalties on, any future approved products, if any.
Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to:
delay, limit, reduce or terminate our manufacturing, research and development activities; or
delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to generate revenue and achieve profitability.
If we are unable to maintain adequate revenue growth or do not successfully manage such growth, our business and growth prospects will be harmed.
We have experienced significant revenue growth in a short period of time. We may not achieve similar growth rates in future periods. Investors should not rely on our operating results for any prior periods as an indication of our future operating performance. To effectively manage our anticipated future growth, we must continue to maintain and enhance our manufacturing, sales, financial and customer support administration systems, processes and controls. Failure to effectively manage our anticipated growth could lead us to over-invest or under-invest in development, operational, and administrative infrastructure; result in weaknesses in our infrastructure, systems, or controls; give rise to operational mistakes, losses, loss of customers, productivity or business opportunities; and result in loss of employees and reduced productivity of remaining employees.
Our continued growth could require significant capital expenditures and might divert financial resources from other projects such as the development of new products and services. As additional products are commercialized, we may need to incorporate new equipment, implement new technology systems, or hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher manufacturing costs, declining product quality, deteriorating customer service, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business.
If our management is unable to effectively manage our anticipated growth, our expenses may increase more than expected, our revenue could decline or grow more slowly than expected and we may be unable to implement our business strategy. The quality of our products may suffer, which could negatively affect our reputation and harm our ability to retain and attract customers.
Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, causing the value of our common stock to decline substantially.
Numerous factors, many of which are outside our control, may cause or contribute to significant fluctuations in our quarterly and annual operating results. These fluctuations may make financial planning and forecasting difficult. In addition, these fluctuations may result in unanticipated decreases in our available cash, which could negatively affect our business and prospects. In addition, one or more of such factors may cause our revenue or operating expenses in one period to be disproportionately higher or lower relative to the others. As a result, comparing our operating results on a period-to-period basis might not be meaningful. You should not rely on our past results as indicative of our future performance. Moreover, our stock price might be based on expectations of future performance that are unrealistic or that we might not meet and, if our revenue or operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially.
Our operating results have varied in the past. As a result, our operating results could be unpredictable, particularly on a quarterly basis. In addition to other risk factors listed in this section, some of the important factors that may cause fluctuations in our quarterly and annual operating results are further described in “Risk factors—Risks relating to owning our stock.”
In addition, a significant portion of our operating expense is relatively fixed in nature, and planned expenditures are based in part on expectations regarding future revenue. Accordingly, unexpected revenue shortfalls might decrease our gross
40

margins and could cause significant changes in our operating results from quarter to quarter. If this occurs, the trading price of our common stock could fall substantially.
If we are unable to attract new customers and retain and grow sales from our existing customers, our business will be materially and adversely affected.
In order to grow our business, we must continue to attract new customers and retain and grow sales from our existing customers on a cost-effective basis. To do this, we aim to attract new and existing buyers of synthetic DNA and NGS tool kits, convert makers of synthetic DNA into buyers of synthetic DNA, monetize our antibody discovery platform by entering into partnerships and achieve widespread market acceptance by delivering both our current product offerings and new products and technologies at low-cost, with high-quality, reliable turn-around times and throughput, superior e-commerce services and effective technical support. We cannot guarantee that our efforts to provide these key requirements will be consistently acceptable to, and meet the performance expectations of, our customers and potential customers. If we are unable to successfully attract and retain customers, our business, financial position and results of operations would be negatively impacted.
If we, or our partners or suppliers, experience a significant disruption in, or breach in security of, information technology systems, or fail to implement new systems and software successfully, our business could be adversely affected. Cyberattacks and security vulnerabilities could lead to reduced revenue, increased costs, liability claims, or harm to our reputation or competitive position.
We rely on several centralized information technology systems throughout our company to provide products, keep financial records, process orders, manage inventory, process shipments to customers and operate other critical functions. In addition, we currently generate a growing portion of our revenue through sales on our e-commerce platform. We manage our website and e-commerce platform internally and as a result any compromise of our security or misappropriation of proprietary information could have a material adverse effect on our business, financial condition and results of operations. We rely on encryption and authentication technology licensed from third parties to provide the security and authentication necessary to effect secure Internet transmission of confidential information, such as credit and other proprietary information. We announced on February 12, 2020 that our information security management system received ISO 27001:2013 certification, an information security standard published by the International Organization for Standardization (ISO), the world’s largest developer of voluntary international standards, and the International Electrotechnical Commission. Even though our information security management system received ISO 27001:2013 certification, our, and our partners’ or suppliers’, information technology systems have been and may still be susceptible to damage, disruptions or shutdowns due to power outages, hardware failures, computer viruses, cyberattacks such as phishing, social engineering, ransomware and other malware attacks, telecommunication failures, user errors, catastrophes or other unforeseen events. Our, or our partners’ or suppliers’ information technology systems also may experience interruptions, delays or cessations of service or produce errors in connection with system integration, software upgrades or system migration work that takes place from time to time. If we were to experience a prolonged system disruption in the information technology systems that involve our interactions with customers or suppliers, including negatively impacting our order fulfillment and order entry on our e-commerce platform, it could result in the loss of sales and customers and significant incremental costs, which could adversely affect our business. In addition, security breaches of our, or our partners’ or suppliers’, information technology systems could result in the misappropriation or unauthorized disclosure of confidential information belonging to us or to our employees, partners, customers or suppliers, which could result in our suffering significant financial or reputational damage. The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. Further, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws. We would also be exposed to a risk of litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.

Our actual operating results may differ significantly from our guidance.
From time to time, we may release guidance in our quarterly earnings conference calls, quarterly earnings releases, or otherwise, regarding our future performance that represents our management’s estimates as of the date of release. This guidance, which includes forward-looking statements, is based on projections prepared by our management. This guidance is not prepared with a view toward compliance with published guidelines of the American Institute of Certified Public Accountants (AICPA) regarding projections or the SEC regarding forward-looking statements, and neither our independent registered public accounting firm nor any other independent expert or outside party compiles or examines the projections. Accordingly, no such person will express any opinion or any other form of assurance with respect to the projections.
Projections are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are
41

beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. Our aim is to state possible outcomes as high and low ranges to provide a sensitivity analysis as variables are changed but are not intended to imply that actual results could not fall outside of the suggested ranges. The principal reason that we release guidance is to provide a basis for our management to discuss our business outlook with analysts and investors. We do not accept any responsibility for any projections or reports published by any such third parties.
Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the guidance furnished by us will not materialize or will vary significantly from actual results. Accordingly, our guidance is only an estimate of what management believes is realizable as of the date of release. Actual results may vary from our guidance and the variations may be material. In light of the foregoing, investors are urged not to rely upon our guidance in making an investment decision regarding our common stock.
Any failure to successfully implement our operating strategy or the occurrence of any of the events or circumstances set forth in the “Risk factors” section in this Form 10-Q could result in the actual operating results being different from our guidance, and the differences may be adverse and material.
Rapidly changing technology and extensive competition in synthetic biology could make the products we are developing and producing obsolete or non-competitive unless we continue to develop and manufacture new and improved products and pursue new market opportunities.
The synthetic biology industry is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry demands and standards. Our future success will depend on our ability to continually improve the products we are developing and producing, to develop and introduce new products that address the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of technological and scientific advances. These new market opportunities may be outside the scope of our proven expertise or in areas which have unproven market demand, and the utility and value of new products and services developed by us may not be accepted in the markets served by the new products. Our inability to gain market acceptance of existing products in new markets or market acceptance of new products could harm our future operating results. Our future success also depends on our ability to manufacture these new and improved products to meet customer demand in a timely and cost-effective manner, including our ability to resolve manufacturing issues that may arise as we commence production of any new products we develop. Unanticipated difficulties or delays in replacing existing products with new products we introduce or in manufacturing improved or new products in sufficient quantities to meet customer demand could diminish future demand for our products and harm our future operating results.
In addition, there is extensive competition in the synthetic biology industry, and our future success will depend on our ability to maintain a competitive position with respect to technological advances. Technological development by others may result in our technologies, as well as products developed using our technologies, becoming obsolete. Our ability to compete successfully will depend on our ability to develop proprietary technologies and products that are technologically superior to and/or are less expensive than our competitors’ technologies and products. Our competitors may be able to develop competing and/or superior technologies and processes and compete more aggressively and sustain that competition over a longer period of time.
The continued success of our business relies heavily on our disruptive technologies and products and our position in the market as a leading provider or synthetic DNA using a silicon chip.
Our future profitability will depend on our ability to successfully execute and maintain a sustainable business model and generate continuous streams of revenue. Our business model is premised on the fact that we are the only DNA synthesis provider to synthesize DNA on a silicon chip on a large commercial level and the competitive advantages this creates. Our DNA synthesis methods, among other things, reduce the amount of raw materials required, speed up the synthesis process and deliver large volumes of high-quality synthetic DNA at low unit cost. However, if other competitors develop and commercialize a manufacturing process using a silicon chip or other similar technologies providing for the development of competitive synthetic DNA products at scale, this could be disruptive to our business model and could adversely affect our business prospects, financial condition and results of operations. If we are unable to convert a sufficient number of current manufacturers of synthetic DNA to buyers of our synthetic DNA, surpass our competitors regarding certain industry-related data points, and effectively implement our e-commerce platform which facilitates efficient order entry and fulfillment for our customers, our business, prospects, financial condition and results of operation will be adversely affected.

42

If we are unable to expand into adjacent addressable markets, our business may be materially and adversely affected.
Our future revenue growth and market potential may depend on our ability to leverage our DNA synthesis platform together with our custom libraries and other proprietary tools, such as our antibody discovery and optimization platform, in adjacent businesses such as pharmaceutical biologics drug discovery and digital data storage in DNA. There can be no assurance that we can continue to utilize our antibody libraries to accelerate the lead identification and lead optimization steps of antibody discovery or to discover more effective antibody drugs. In addition, our technology may not develop in a way that allows data storage in DNA to become cost competitive with traditional data storage media or in a way that otherwise enables us to address the markets opportunities that we believe exist. If we are unable to expand into adjacent addressable markets, our business, financial position and results of operations could be negatively impacted.
A significant portion of our sales depends on customers’ budgets that may be subject to significant and unexpected variation, including seasonality.
Our customers’ spending on research and development impacts our sales and profitability. Our customers and potential customers include chemicals/materials, diagnostics, therapeutics, food/agriculture, and their budgets can have a significant effect on the demand for our products. Their research and development budgets are based on a wide variety of factors, including factors beyond our control, such as:
the allocation of available resources to make purchases;
funding from government sources;
funding from research grants;
changes in government programs that provide funding to research institutions and companies;
the spending priorities among various types of research equipment;
policies regarding capital expenditures during recessionary periods;
political climate or macroeconomic conditions, including economic downturns or market uncertainty or reduced spending in response to emergency situations, such as the outbreak of COVID-19;
inability to raise sufficient funds in the capital markets;

changes in the regulatory environment;
differences in budgetary cycles;
inflationary pressures; and
market acceptance of relatively new technologies, such as ours.
Any decrease in spending or change in spending priorities of our customers and potential customers could significantly reduce the demand for our products. As we expand into new geographic markets, our revenue may be impacted by seasonal trends in the different regions, the seasonality of customer budgets in those regions and the mix of domestic versus international sales. In addition, access to capital markets is critical to many of our customers’ ability to fund their operations, including purchase our products and services. Traditionally, biotechnology and life sciences companies have funded their research and development expenditures through raising capital in the equity markets. Declines and uncertainties in these markets in the past have severely restricted raising new capital and have affected companies’ ability to fund existing research and development efforts. For example, in the third quarter of fiscal year 2022, we believe two customers cancelled orders due to funding concerns. Moreover, we have no control over the timing and volume of purchases by these customers and potential customers, and as a result, revenue from these sources may vary significantly due to factors that can be difficult to forecast. Any delay or reduction in purchases by customers and potential customers or our inability to forecast fluctuations in demand could harm our future operating results.



43

We generally do not have long-term contracts with our customers requiring them to purchase any specified quantities from us.
We generally do not have long-term contracts with our customers requiring them to purchase any specified quantities from us and without such contracts our customers are not obligated to order or reorder our products. As a result, we cannot accurately predict our customers’ decisions to reduce or cease purchasing our products. Additionally, even where we enter into contracts with our customers, there is no guarantee that such agreements will be negotiated on terms that are commercially favorable to us in the long-term. Therefore, if many of our customers were to substantially reduce their transaction volume or cease ordering products from us, this could materially and adversely affect our financial performance.
We may be unable to successfully increase our market share and expand our customer base.
Our ability to achieve profitability depends on our being able to increase our market share and expand our customer base. Although members of our sales and marketing teams have considerable industry experience and have engaged in marketing activities for our products, in the future we must expand our sales, marketing, distribution and customer support capabilities with the appropriate technical expertise to effectively market our products. Furthermore, it takes six to nine months to recruit, onboard and ramp sales personnel to full capability. New hires and sales personnel who operate at full capability are currently encountering challenging sales conditions due to business and operational difficulties arising from the COVID-19 pandemic, and may not be fully productive while these conditions persist or worsen. To perform sales, marketing, distribution and customer support successfully, we will face a number of risks, including that:
we may not be able to attract, retain and manage the sales, marketing and service workforce necessary to publicize and gain broader market acceptance of our technology;
the time and cost of establishing a specialized sales, marketing and service force for a particular product or service, which may be difficult to justify in light of the revenue generated;
our field sales personnel may not be able to access our customers’ premises which could delay the adoption and ordering of our products; and
our sales, marketing and service force may be unable to initiate and execute successful commercialization activities with respect to new products or markets we may seek to enter.
If our sales and marketing efforts, or those of any third-party sales and distribution partners, are not successful, our new technologies and products may not gain market acceptance, which could materially impact our business operations.
The United Kingdom’s (“U.K.”) referendum to exit from the European Union (“E.U.”) will continue to have uncertain effects and could adversely impact our business, results of operations and financial condition.
As a result of a referendum in June 2016, the U.K. withdrew from the E.U. (“Brexit”) on January 31, 2020. It began a transition period in which to negotiate a new trading relationship for goods and services that ended on December 31, 2020. During the time since the June 2016 referendum, there have been periods of significant volatility in the global stock markets and currency exchange rates, as well as challenging market conditions in the U.K. On December 24, 2020, the U.K. and E.U. announced they had entered into a post-Brexit deal on certain aspects of trade and other strategic and political issues. We are continuing to evaluate our own risks and uncertainty related to ascertain what financial, trade, regulatory and legal implications this new Brexit trade deal could have on our U.K. and European business operations. This uncertainty also includes the impact on our customers’ business operations and capital planning as well as the overall impact on the biotechnology industry in the U.K. While we have not experienced any direct material financial impact since the 2016 referendum, we cannot predict its future implications, and Brexit and its related effects could result in a negative impact on our consolidated financial position and results of operations.
If we are unable to expand our DNA synthesis manufacturing capacity, we could lose revenue and our business could be harmed.
In order to expand our manufacturing capacity of new and existing products, we need to either build additional internal manufacturing capacity, contract with one or more partners, or both. We are currently building a new production facility in Wilsonville, Oregon but we cannot guarantee that such a facility will allow us to effectively increase our manufacturing capacity which could impact our revenue growth. Our technology and the production process for our DNA synthesis equipment and tools are complex, involving specialized parts, and we may encounter unexpected difficulties in the
44

manufacture, improvement or increasing the capacity of our DNA synthesis equipment and tools, and addressing these difficulties may cause us to divert our time and resources from our other product offerings. There is no assurance that we will be able to continue to increase manufacturing capacity internally or that we will find one or more suitable partners to help us towards this objective, in order to meet the volume and quality requirements necessary for success in our existing and potential markets. Manufacturing and product quality issues may arise as we continue to increase the scale of our production. If our DNA synthesis equipment and tools do not consistently produce DNA products that meet our customers’ performance expectations, our reputation may be harmed, and we may be unable to generate sufficient revenue to become profitable. Any delay or inability in expanding our manufacturing capacity could diminish our ability to develop or sell our products, which could result in lost revenue and materially harm our business, financial condition and results of operations.

We are substantially dependent on the success of our synthetic DNA products.
To date, we have invested a substantial portion of our efforts and financial resources towards the research and development and commercialization of our synthetic DNA products. The DNA synthesis business is very capital intensive, particularly for early-stage companies that do not have significant off-setting revenues and which are making significant investments in the commercialization and marketing of their products.
Substantially all of our revenue generated to date is from our synthetic DNA products. Our financial results are dependent on strengthening our core business while diversifying into other developing sectors such as pharmaceutical biologics drug discovery, creating useful DNA libraries and data storage.
Our near-term prospects, including our ability to finance our research and development activities and initiatives and enter into strategic collaborations, will depend heavily on the successful development and commercialization of our synthetic DNA products. These initiatives will be substantially dependent on our ability to generate revenue from our synthetic DNA products and obtain other funding necessary to support these initiatives. Our inability to continue these initiatives and initiate new research and development efforts could result in a failure to develop new products, improve upon existing products such that sectors like pharmaceutical biologics drug discovery, DNA library creation and data storage may never be fully developed, and expand our addressable market which could have a material and adverse impact on our sales, business, financial position and results of operations.
We depend on one single-source supplier for a critical component for our DNA synthesis process. The loss of this supplier or its failure to supply us with the necessary component on a timely basis, could cause delays in the future capacity of our DNA synthesis process and adversely affect our business.
We depend on one single-source supplier for a critical component for our DNA synthesis process. We do not currently have the infrastructure or capability internally to manufacture this component. Although we have a reserve of supplies and although alternative suppliers exist for this critical component of our synthesis process, our existing DNA synthesis manufacturing process has been designed based on the functions, limitations, features and specifications of the components that we currently utilize. We have a supply agreement in place with this component supplier. However, there can be no assurance that our supply of this component will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. Additionally, we do not have any control over the process or timing of the acquisition or manufacture of materials by our supplier and cannot ensure that it will deliver to us the component we order on time, or at all.
The loss of this component provided by this supplier could require us to change the design of our manufacturing process based on the functions, limitations, features and specifications of the replacement components. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business. Our dependence on this single-source supplier exposes us to certain risks, including the following:
our supplier may cease or reduce production or deliveries, raise prices or renegotiate terms;
we may be unable to locate a suitable replacement on acceptable terms or on a timely basis, if at all;
45

if there is a disruption to our single-source supplier’s operations, and if we are unable to enter into arrangements with alternative suppliers, we will have no other means of completing our synthesis process until they restore the affected facilities or we or they procure alternative manufacturing facilities or sources of supply;
delays caused by supply issues may harm our reputation, frustrate our customers and cause them to turn to our competitors for future projects; and
our ability to progress our DNA synthesis products could be materially and adversely impacted if the single-source supplier upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory, operational or reputational issues.

Moreover, to meet anticipated market demand, our single-source supplier may need to increase manufacturing capacity, which could involve significant challenges. This may require us and our supplier to invest substantial additional funds and hire and retain the technical personnel who have the necessary experience. Neither we nor our supplier may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all.
We must continue to secure and maintain sufficient and stable supplies of raw materials. Any shortage of raw materials or materials necessary for our production capabilities may adversely affect our business.
Although historically we have not experienced price increases due to unexpected shortages in raw materials or other materials and other unanticipated events, there is no assurance that our supply of raw materials or other materials will not be significantly adversely affected in the future, which may in turn adversely affect our business, prospects, financial condition and results of operation.

In addition, as we grow, our existing suppliers may not be able to meet our increasing demand, and we may need to find additional suppliers. There is no assurance that we will always be able to secure suppliers who provide raw materials at the specification, quantity and quality levels that we demand (or at all) or be able to negotiate acceptable fees and terms of services with any such suppliers. Identifying a suitable supplier is an involved process that requires us to become satisfied with their quality control, responsiveness and service, financial stability and labor and other ethical practices. Even if we are able to expand existing sources, we may encounter delays in production and added costs as a result of the time it takes to train suppliers in our methods, products and quality control standards.
We typically do not enter into agreements with our suppliers but secure our raw materials and component parts we use in our equipment on a purchase order basis. Our suppliers may reduce or cease their supply of raw materials, component parts and outsourced services and products to us at any time in the future. If the supply of raw materials, component parts and the outsourced services and products is interrupted due to shortages or other reasons, our production processes may be delayed. If any such event occurs, our operation and financial position may be adversely affected.

A deterioration of our relationship with any of our suppliers, or problems experienced by these suppliers, could lead to shortages in our production capacity for some or all of our products. In such case, we may not be able to fulfill the demand of existing customers or supply new customers. In addition, shortages of raw materials or component parts or an increase in the cost of the raw materials or component parts we use could result in decreased revenue or could impair our ability to maintain or expand our business.

While we have experienced increased operating costs in recent periods, which we believe are due in part to the recent growth in inflation, we do not believe that inflation has had a material effect on our business, financial condition or results of operations. In the event of significant price increases for raw materials, we may have to pass the increased raw materials costs to our customers. However, we cannot assure you that we will be able to raise the prices of our products sufficiently to cover increased costs resulting from increases in the cost of our raw materials or overcome the interruption of a sufficient supply of qualified raw materials for our products. As a result, a price increase for our raw materials may negatively impact our business, financial position and results of operations.

We may encounter difficulties in managing our growth, and these difficulties could impair our profitability.
Currently, we are working simultaneously on multiple projects, expanding our capacity as well as targeting several market sectors, including activities in the chemicals/materials, diagnostics, therapeutics, food and data storage sectors. In addition, we work to renew our ISO certifications from time to time. These diversified operations and activities place significant demands on our limited resources and require us to substantially expand the capabilities of our technical, administrative and operational resources.
46

If we are unable to manage this growth and the periodic ISO recertification of our manufacturing facilities effectively, our shipments to our customers could be impacted, our time and resources could be diverted from other products and offerings and our business and operating results could suffer. In addition, if we fail to timely deliver products or meet quantity requirements under our contracts with customers, we may offer discounts to them, and customers' minimum purchase requirements, if applicable, may be reduced. Our ability to manage our operations and costs, including research and development, costs of components, manufacturing, sales and marketing, requires us to continue to enhance our operational, financial and management controls, reporting systems and procedures and to attract and retain sufficient numbers of talented employees. Failure to attract and retain sufficient numbers of talented employees will further strain our human resources and could impede our growth.



Our revenue, results of operations, cash flows and reputation in the marketplace may suffer upon the loss of a limited number of large customers.
We have derived, and believe we may continue to derive, a significant portion of our revenues from a limited number of large customers. Our customers may buy less of our products depending on their own technological developments, end-user demand for our products and internal budget cycles. In addition, existing customers may choose to produce some or all of their synthetic DNA requirements internally by using or developing manufacturing capabilities organically or by using capabilities from acquisitions of assets or entities from third parties with such capabilities. The loss of any significant customer or a significant reduction in the amount of product ordered by Ginkgo or any other significant customer would adversely affect our revenue, results of operations, cash flows and reputation in the marketplace.
We depend on the continuing efforts of our senior management team and other key personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified researchers, engineering and other personnel, our ability to develop our products could be harmed, and we may be unable to achieve our goals.
Our future success depends upon the continuing services of members of our senior management team and scientific and engineering personnel. We are highly dependent on Dr. Emily Leproust, our President and Chief Executive Officer, who is employed “at will,” meaning we or she may terminate the employment relationship at any time. In particular, our researchers and engineers are critical to our future technological and product innovations, and we will need to hire additional qualified personnel. We may not be able to attract and retain qualified personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. Our industry, particularly in the San Francisco Bay Area, is characterized by high demand and intense competition for talent, and the turnover rate can be high. We compete for qualified management and scientific personnel with other life science companies, academic institutions and research institutions, particularly those focusing on genomics.
Many of these employees could leave our company with little or no prior notice and would be free to work for a competitor. If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we might not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. In addition, we do not have “key person” life insurance policies covering members of our management team or other key personnel except Dr. Leproust. While we conduct succession planning to identify the person(s) for key positions who possess the skills and capabilities to take on the responsibilities filled by our leaders, we cannot assure you that these strategies will successfully mitigate the loss of any key personnel. The loss of any of these individuals or our inability to attract or retain qualified personnel, including researchers, engineers and others, could prevent us from pursuing collaborations and adversely affect our product development and introductions, business growth prospects, results of operations and financial condition.

We may engage in strategic transactions, including acquisitions that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, or prove not to be successful.
In the future, we may enter into transactions to acquire other businesses, products or technologies and our ability to do so successfully cannot be ensured. While historically we have not completed many acquisitions, we recently closed a few business acquisitions in the first quarter of 2022 and we are continuing to pursue opportunities in the life sciences industry that complement and expand our synthetic DNA product and our other products in both local and international markets. If we identify suitable opportunities, we may not be able to make such acquisitions on favorable terms or at all. Any
47

acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, as we did for the business acquisitions, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by any indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. In addition, we cannot guarantee that we will be able to fully recover the costs of such acquisitions or that we will be successful in leveraging any such strategic transactions into increased business, revenue or profitability. We also cannot predict the number, timing or size of any future acquisitions or the effect that any such transactions might have on our operating results.
From time to time, we may consider other strategic transactions, including collaborations. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration. Any such collaboration may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management’s time and attention to manage a collaboration, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Antitrust or other competition laws may also limit our ability to acquire or work collaboratively with certain businesses or to fully realize the benefits of a strategic transactions to acquire or collaborate with other businesses. Accordingly, although there can be no assurance that we will undertake or successfully complete any collaborations, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our products and technologies.
As we expand our development and commercialization activities outside of the United States, we will be subject to an increased risk of inadvertently conducting activities in a manner that violates the U.S. Foreign Corrupt Practices Act and similar laws. If that occurs, we may be subject to civil or criminal penalties which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
We are subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, which prohibits corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. We are also subject to the UK Anti-Bribery Act, which prohibits both domestic and international bribery, as well as bribery across both public and private sectors. We require that our employees review our Code of Business Conduct and Ethics, our Anti-Money Laundering Policy and our Anti-Corruption Policy on an annual basis.
In the course of establishing and expanding our commercial operations and complying with non-U.S. regulatory requirements, we will need to establish and expand business relationships with various third parties and we will interact more frequently with foreign officials, including regulatory authorities. Expanded programs to maintain compliance with such laws will be costly and may not be effective. Any interactions with any such parties or individuals where compensation is provided that are found to be in violation of such laws could result in substantial fines and penalties and could materially harm our business. Furthermore, any finding of a violation under one country’s laws may increase the likelihood that we will be prosecuted and be found to have violated another country’s laws. We require that our employees annually certify that they understand and will comply with our Code of Business Conduct and Ethics Policy, our Anti-Money Laundering Policy, our Anti-Corruption Policy as well as the UK Modern Slavery Act of 2015. Even so, if our business practices outside the United States are found to be in violation of the FCPA, UK Anti-Bribery Act, antitrust or other similar laws, we may be subject to significant civil and criminal penalties which could have a material adverse effect on our financial condition and results of operations.
We could engage in exporting or related activity that contravenes international trade restraints, or regulatory authorities could promulgate more far reaching international trade restraints, which could give rise to one or more of substantial legal liability, impediments to our business and reputational damage.
48

Our international business activities must comport with U.S. export controls and other international trade restraints, including the U.S. Department of Commerce’s Export Administration Regulations and economic sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls.
We have established an international trade compliance program that encompasses best practices for preventing, detecting and addressing noncompliance with international trade restraints. Furthermore, to date our exports have not been licensable under export controls; however, we could fail to observe the compliance program requirements in a manner that leaves us in noncompliance with export controls or other international trade restraints. In addition, authorities could promulgate international trade restraints that impinge on our ability to pursue our business as planned. One or more of resulting legal penalties, restraints on our business or reputational damage could have material adverse effects on our business and financial condition.
We operate in a highly competitive industry and if we are not able to compete effectively, our business and operating results will likely be harmed.
We face competition from a broad range of providers of core synthetic biology products such as GenScript Biotech Corporation, DNA Script, Inc., GENEWIZ (owned by Azenta), Integrated DNA Technologies, Inc. (owned by Danaher Corporation), DNA 2.0 Inc. d/b/a/ ATUM, GeneArt (owned by Thermo Fisher Scientific Inc.), Eurofins Genomics LLC, Sigma-Aldrich Corporation (owned by Charles River Laboratories, Inc.) (an indirect wholly owned subsidiary of Merck & Company), Promega Corporation, OriGene Technologies, Inc., Blue Heron Biotech, LLC and others. Additionally, we compete with both large and emerging providers in the life sciences tools and diagnostics industries focused on sample preparation for NGS such as Thermo Fisher Scientific Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Agilent, and Roche NimbleGen, Inc. In the antibody discovery market, we compete with clinical research organizations, such as Curia, GenScript, and Genovac (formerly part of Aldevron, LLC), and antibody discovery biotechnology companies, such as Fair Journey/Iontas, Adimab, Distributed Bio (owned by Charles River), Ablexis, Specifica, OmniAb and AbCellera Biologics Inc. In the emerging field of DNA digital data storage, we compete with Catalog Technologies, Inc., Helixworks, Iridia, Inc., Roswell, Microsoft, Genscript, Molecular Assemblies, Ansa Biotechnologies, various academic institutions, and other emerging competitors.We may not be successful in maintaining our competitive position for a number of reasons. Some of our current competitors, as well as many of our potential competitors, have significant name recognition, substantial intellectual property portfolios, longer operating histories, greater resources to invest in new technologies, substantial experience in new product development and manufacturing capabilities and more established distribution channels to deliver products to customers than we do. These competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. Our competitors may develop disruptive technologies or products that are comparable or superior to our technologies and products. In light of these advantages, even though we believe our technology is superior to the products offerings of our competitors, current or potential customers might accept competitive products in lieu of purchasing our products. Increased competition is likely to result in continued pricing pressures, which could harm our sales, profitability or market share. Our failure to continue competing effectively or winning additional business with our existing customers could materially and adversely affect our business, financial condition or results of operations.

We may be subject to significant pricing pressures and if we are unable to pass on any cost increase to our customers, our business, financial position and results of operations could be adversely affected.

Over time, increasing customer demand for lower prices could force us to discount our products and result in lower margins. The impact may be further exacerbated if we are unable to successfully control production costs. In addition, if due to rising market prices, our suppliers increase prices or reduce discounts on their supplies, we may be unable to pass on any cost increase to our customers, thereby resulting in reduced margins and profits. Furthermore, changes in our product mix may negatively affect our gross margins. Overall, these pricing pressures may adversely affect our business, financial position and results of operations.
Ethical, legal and social concerns surrounding the use of genetic information could reduce demand for our technology.

Our products may be used to create DNA sequences of humans, agricultural crops and other living organisms. Our products could be used in a variety of applications, which may have underlying ethical, legal and social concerns. Governmental authorities could, for safety, social or other purposes, impose limits on or implement regulation of the use of gene synthesis. Such concerns or governmental restrictions could limit the use of our DNA synthesis products, which could have a material adverse effect on our business, financial condition and results of operations. In addition, public perception about the safety and environmental hazards of, and ethical concerns over, genetically engineered products and processes could influence public acceptance of our technologies, products and processes. These concerns could result in increased expenses, regulatory scrutiny, delays or other impediments to our programs.

49

We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.
We work with materials, including chemicals, biological agents, and compounds and DNA samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties.
In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which could cause an interruption of our commercialization efforts, research and development programs and business operations, as well as environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. While our property insurance policy provides limited coverage in the event of contamination from hazardous and biological products and the resulting cleanup costs, we do not currently have any additional insurance coverage for legal liability for claims arising from the handling, storage or disposal of hazardous materials.
Accordingly, in the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected.
We could develop DNA sequences or engage in other activity that contravenes biosecurity requirements, or regulatory authorities could promulgate more far reaching biosecurity requirements that our standard business practices cannot accommodate, which could give rise to substantial legal liability, impede our business and damage our reputation.
The Federal Select Agent Program, or the FSAP, involves rules administered by the Centers for Disease Control and Prevention and Toxins and the Animal and Plant Health Inspection Service that regulate possession, use and transfer of biological select agents and toxins that have the potential to pose a severe threat to public, animal or plant health or to animal or plant products.
We have established a comprehensive biosecurity program under which we follow biosafety and biosecurity best practices and avoid DNA synthesis activities that implicate FSAP rules; however, we could err in our observance of compliance program requirements in a manner that leaves us in noncompliance with FSAP or other biosecurity rules. In addition, authorities could promulgate new biosecurity requirements that restrictions our operations. One or more resulting legal penalties, restraints on our business or reputational damage could have material adverse effects on our business and financial condition.
Third parties may use our products in ways that could damage our reputation.
After our customers have received our products, we do not have any control over their use and our customers may use them in ways that are harmful to our reputation as a supplier of synthetic DNA products. In addition, while we have established a biosecurity program designed to comply with biosafety and biosecurity requirements and perform export control screening in an effort to ensure that third parties do not obtain our products for malevolent purposes, we cannot guarantee that these preventative measures will eliminate or reduce the risk of the domestic and global opportunities for the misuse of our products. Accordingly, in the event of such misuse, our reputation, future revenue and operating results may suffer.
Any damage to our reputation or brand may materially and adversely affect our business, financial condition and results of operations.
We believe that developing and maintaining our brand is important to our success and that our financial success is influenced by the perception of our brand by our customers. Furthermore, the importance of our brand recognition may become even greater to the extent that competitors offer more products similar to ours. Many factors, some of which are beyond our control, are important to maintaining our reputation and brand. These factors include our ability to comply with ethical, social, product, labor and environmental standards. Any actual or perceived failure in compliance with such standards could damage our reputation and brand.
Because we are subject to existing and potential additional governmental regulation, the markets for our products may be narrowed.
50

We are subject, both directly and indirectly, to the adverse impact of existing and potential future government regulation of our operations and markets. For example, the export of our products is subject to strict regulatory control in a number of jurisdictions. The failure to satisfy export control criteria or obtain necessary clearances could delay or prevent the shipment of products, which could adversely affect our revenues and profitability. Moreover, the life sciences industry, which is currently the primary market for our technology, has historically been heavily regulated. There are, for example, laws in several jurisdictions restricting research in genetic engineering, which can operate to narrow our markets. Given the evolving nature of this industry, legislative bodies or regulatory authorities may adopt additional regulation that adversely affects our market opportunities. Our business is also directly affected by a wide variety of government regulations applicable to business enterprises generally and to companies operating in the life science industry in particular. Failure to comply with these regulations or obtain or maintain necessary permits and licenses could result in a variety of fines or other censures or an interruption in our business operations which may have a negative impact on our ability to generate revenues and could increase the cost of operating our business.
Our products could in the future be subject to additional regulation by the U.S. Food and Drug Administration or other domestic and international regulatory agencies, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.
The FDA regulates medical devices, including in vitro diagnostics, or IVDs. IVDs are a category of medical devices that include reagents, instruments, and systems intended for use in diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. IVDs are intended for use in the collection, preparation, and examination of specimens taken from the human body. An RUO IVD product is an IVD product that is in the laboratory research phase of development. As such, an RUO IVD is not intended for use in clinical investigations or in clinical practice. Such RUO products do not require premarket clearance or approval from the FDA, provided that they are labeled “For Research Use Only. Not For Use In Diagnostic Procedures” pursuant to FDA regulations. Our IVD products are not intended for clinical or diagnostic use, and we market and label them as RUO. However, the FDA may disagree with our assessment that our products are properly marketed as RUO and may determine that our products are subject to pre-market clearance, approval, or other regulatory requirements. If the FDA determines that our products are subject to such requirements, we could be subject to enforcement action, including administrative and judicial sanctions, and additional regulatory controls and submissions for our tests, all of which could be burdensome.
In the future, certain of our products or related applications could be subject to additional FDA regulation. Even where a product is not subject to FDA clearance or approval requirements, the FDA may impose restrictions as to the types of customers to which we can market and sell our products. Such regulation and restrictions may materially and adversely affect our business, financial condition and results of operations. Other regulatory regimes that do not currently present material challenges but that could in the future present material challenges include export controls and biosecurity.
Many countries have laws and regulations that could affect our products and which could limit our ability to sell our products in those countries. The number and scope of these requirements are increasing. We may not be able to obtain regulatory approvals in such countries or may incur significant costs in obtaining or maintaining foreign regulatory approvals. For example, the European Union, or EU, is transitioning from the existing European Directive 98/79/EC on in vitro diagnostic medical devices, or IVD Directive (IVDD), to the In Vitro Diagnostic Device Regulation (EU) 2017/746, or IVDR, which imposes stricter requirements for the marketing and sale of medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance. The IVDR is expected to become effective in May 2022. It is likely that we will be impacted by this new regulation, either directly as a manufacturer of IVDs, or indirectly as a supplier to customers who are placing IVDs in the EU market for clinical or diagnostic use.
Complying with the requirements of the IVDR may require us to incur significant expenditures. Failure to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations or chemical regulations to the EU requirements.
Certain of our potential customers may require that we become certified under the Clinical Laboratory Improvement Amendments of 1988.
Although we are not currently subject to the Clinical Laboratory Improvement Amendment of 1988, or CLIA, we may in the future be required by certain customers to obtain a CLIA certification. CLIA, which extends federal oversight over clinical laboratories by requiring that they be certified by the federal government or by a federally approved accreditation agency, is designed to ensure the quality and reliability of clinical laboratories by mandating specific standards in the areas of personnel qualifications, administration and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. If our customers require a CLIA certification, we will have to continually expend time,
51

money and effort to ensure that we meet the applicable quality and safety requirements, which may divert the attention of management and disrupt our core business operations.
Our manufacturing operations in the United States currently depend primarily on one facility. If this facility is destroyed or we experience any manufacturing difficulties, disruptions, or delays, this could limit supply of our product or adversely affect our ability to sell products or conduct our clinical trials, and our business would be adversely impacted.
While we are in the process of building out a second manufacturing facility in Wilsonville, Oregon, a substantial portion of our manufacturing currently takes place at our headquarters in South San Francisco, California. If regulatory, manufacturing, or other problems require us to discontinue production at this facility, we will not be able to manufacture our synthetic genes, oligo pools or NGS tool or create our DNA libraries, which would adversely impact our business. If this facility or the equipment in it is significantly damaged or destroyed by fire, flood, power loss, or similar events, or is shut down for health and safety or other reasons, we may not be able to quickly or inexpensively replace our manufacturing capacity or replace the facility at all. In the event of a temporary or protracted loss of this facility or equipment, we might not be able to transfer manufacturing to another third party. Even if we could transfer manufacturing from one facility to another, the shift would likely be expensive and time-consuming, particularly if we were to maintain the current manufacturing standards procedures at such alternative facility.
Natural disasters, public health crises, political crises, and other catastrophic events or other events outside of our control may damage our facilities or the facilities of third parties on which we depend, and could impact our ability to sell products.
Our headquarters in South San Francisco is located near known earthquake fault zones and is vulnerable to damage from earthquakes. An earthquake or other natural disaster or power shortages or outages could disrupt operations or impair critical systems at our headquarters or at any of our other facilities throughout the world. We, our suppliers, third-party service providers and customers are vulnerable to damage from natural disasters, including fire, floods or monsoons, power loss, communications failures, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict and similar events. If any disaster were to occur, our ability to operate our business at any of our facilities could be seriously, or potentially completely, impaired. In addition, the nature of our activities could cause significant delays in our research programs and commercial activities and make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.
Delivery of our products could be delayed or disrupted by factors beyond our control, and we could lose customers as a result.
We rely on third-party carriers for the timely delivery of our products. As a result, we are subject to carrier disruptions and increased costs that are beyond our control, including travel restrictions, employee strikes, inclement weather and increased fuel costs. Any failure to deliver products to our customers in a timely and accurate manner may damage our reputation and brand and could cause us to lose customers. If our relationship with any of these third-party carriers is terminated or impaired or if any of these third parties are unable to deliver our products, the delivery and acceptance of our products by our customers may be delayed which could harm our business and financial results. The failure to deliver our products in a timely manner may harm our relationship with our customers, increase our costs and otherwise disrupt our operations.
Doing business internationally creates operational and financial risks for our business.
During our fiscal years ended September 30, 2021, 2020 and 2019, 42%, 36%, and 34%, respectively, of our revenue was generated from customers located outside of the United States. In connection with our growth strategy, we intend to further expand in international markets. Conducting and launching operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones and consumes significant management resources. If we fail to coordinate and manage these activities effectively, our business, financial condition or results of operations could be adversely affected. International sales entail a variety of risks, including longer payment cycles and difficulties in collecting accounts receivable outside of the United States, currency exchange fluctuations, challenges in staffing and managing foreign operations, tariffs and other trade barriers, (including tariffs enacted and proposed by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods), unexpected changes in legislative or regulatory requirements of foreign countries into which we sell our products, difficulties in obtaining export licenses or in overcoming other trade barriers, laws and business practices favoring local companies, political and economic instability,
52

difficulties protecting or procuring intellectual property rights, and restrictions resulting in delivery delays and significant taxes or other burdens of complying with a variety of foreign laws.
Changes in the value of the relevant currencies may affect the cost of certain items required in our operations. Changes in currency exchange rates may also affect the relative prices at which we are able to sell products in the same market. Our revenue from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers’ local currency could make our products more expensive, impacting our ability to compete. Our costs of materials from international suppliers may increase if in order to continue doing business with us they raise their prices as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. The recent global financial downturn has led to a high level of volatility in foreign currency exchange rates and that level of volatility may continue, which could adversely affect our business, financial condition or results of operations.

Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.
In general, under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to use its pre-change net operating loss carryforwards, or NOLs, to offset future taxable income. We have experienced at least one ownership change in the past, and we may experience ownership changes in the future. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code. Furthermore, our ability to use NOLs of companies that we may acquire in the future may be subject to limitations. For these reasons, we may not be able to use a material portion of the NOLs reflected on our balance sheet, even if we attain profitability.
The enactment of legislation implementing changes in taxation of international business activities, the adoption of other corporate tax reform policies, or changes in tax legislation or policies could impact our future financial position and results of operations.
Corporate tax reform, base-erosion efforts and tax transparency continue to be high priorities in many tax jurisdictions where we intend to have business operations. As a result, policies regarding corporate income and other taxes in numerous jurisdictions are under heightened scrutiny and tax reform legislation is being proposed or enacted in a number of jurisdictions. For example, the Tax Cuts and Jobs Act of 2017, or the Tax Act, signed into law on December 22, 2017, adopting broad U.S. corporate income tax reform, among other things, reduced the U.S. corporate income tax rate, but imposed base-erosion prevention measures on non-U.S. earnings of U.S. entities as well as a one-time mandatory deemed repatriation tax on accumulated non-U.S. earnings of U.S. entities.
In addition, many countries are beginning to implement legislation and other guidance to align their international tax rules with the Organization for Economic Co-operation and Development’s Base Erosion and Profit Shifting recommendations and action plan that aim to standardize and modernize global corporate tax policy, including changes to cross-border tax, transfer-pricing documentation rules, and nexus-based tax incentive practices.
Such legislative initiatives may materially and adversely affect our plans to expand internationally and may negatively impact our financial condition and results of operations generally.
Our inability to collect on our accounts receivable by a significant number of customers may have an adverse effect on our business, financial condition and results of operations.
Sales to our customers are generally made on open credit terms. Management maintains an allowance for potential credit losses. If our customers’ cash flow, working capital, financial conditions or results of operations deteriorate, they may be unable or even unwilling to pay trade receivables owed to us promptly or at all. As a result, we could be exposed to a certain level of credit risk. If a major customer experiences, or a significant number of customers experience, financial difficulties, the effect on us could be material and have an adverse effect on our business, financial condition and results of operations.
Risks related to being a public company
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business.
53

As a public company, we are required to comply with Section 404 of the Sarbanes Oxley Act of 2002 (“SOX”), which requires, among other things, that companies maintain disclosure controls and procedures to ensure timely disclosure of material information, and that management review the effectiveness of those controls on a quarterly basis. Because we ceased to be an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) with our transition to large accelerated filer status as of September 30, 2020, we are also now subject to Section 404(b) of SOX, which requires that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting in the Annual Report on Form 10-K for the year ended September 30, 2021, among other additional requirements. Effective internal controls are necessary for us to provide reliable financial reports and to help prevent fraud, and our management and other personnel devote a substantial amount of time to these compliance requirements. These rules and regulations also increase our legal and financial compliance costs and make some activities more time-consuming and costly.
As disclosed in Part II—Item 9A, “Controls and Procedures”, of the Annual Report on Form 10-K, we identified material weaknesses in our internal control over financial reporting related to controls surrounding our journal entry process, revenue order entry process, and information technology general controls. As a result, management concluded that our internal control over financial reporting was not effective as of September 30, 2021. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement in a company’s annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified in Item 9A in the Annual Report on Form 10-K did not result in any misstatement of our financial statements for any period presented. We have designed and have begun implementation of a remediation plan for these material weaknesses. However, our remediation efforts may be inadequate, and we may in the future discover other areas of our internal controls that require remediation.

We cannot be certain that we will be able to maintain adequate controls over our financial processes and reporting in the future. If we fail to maintain effective internal controls, investors may lose confidence in the accuracy and completeness or our financial reports, the market price of our securities may be negatively affected, and we could be subject to sanctions or investigation by regulatory authorities, such as the SEC or Nasdaq.
The requirements of being a public company may strain our resources and require a substantial amount of management’s attention.
As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the Nasdaq listing requirements and other applicable securities rules and regulations. The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. Stockholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact, in ways we cannot currently anticipate, the manner in which we operate our business. Compliance with these rules and regulations may cause us to incur additional accounting, legal and other expenses. We also incur costs associated with corporate governance requirements, including requirements under securities laws, as well as rules and regulations implemented by the SEC and Nasdaq, particularly as a large accelerated filer. These rules and regulations have increased our legal and financial compliance costs and we devote significant time to comply with these requirements. We are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.
Risks related to our intellectual property
Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain.
Our commercial success depends in part on our ability to protect our intellectual property and proprietary technologies. We rely on patent protection, where appropriate and available, as well as a combination of copyright, trade secret and trademark laws, and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage.
As of June 30, 2022, we own 37 issued U.S. patents and 27 issued international patents; three in China, three in Europe, seven in South Korea, four in Taiwan, five in Japan, one in Eurasia, one in Singapore, one in Israel, one in Hong Kong and one in Australia. There are 321 pending patent applications, including 94 in the United States, 204 international applications, and 23 applications filed under the Patent Cooperation Treaty. Additionally, we have exclusively licensed a patent portfolio containing 10 issued patents, including one U.S. patent and nine international patents, and 13 pending
54

applications, including three in the U.S. and ten international applications. We have also licensed a patent portfolio containing two pending applications, including one in the US and one PCT. We have further licensed another patent portfolio containing two issued US patents, three international patents, and five pending applications (one in the US and four international applications).
Several patent applications covering our technologies have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent, or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or, if applicable in the future, licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of products that we may develop. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our technologies or products. Furthermore, an interference proceeding can be provoked by a third party or instituted by the U.S. Patent and Trademark Office, or the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.
Patent law can be highly uncertain and involve complex legal and factual questions for which important principles remain unresolved. In the United States and in many international jurisdictions, policy regarding the breadth of claims allowed in patents can be inconsistent. The U.S. Supreme Court and the Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, international courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and international legislative bodies.
If we are unable to obtain, maintain and enforce intellectual property protection, others may be able to make, use, or sell products and technologies substantially the same as ours, which could adversely affect our ability to compete in the market.
We may not pursue or maintain patent protection for our products in every country or territory in which we sell our products and technologies. In addition, our pending U.S. and foreign patent applications may not issue as patents or may not issue in a form that will be sufficient to protect our proprietary technology and gain or keep our competitive advantage. Any patents we have obtained or do obtain may be subject to re-examination, reissue, opposition or other administrative proceedings, or may be challenged in litigation, and such challenges could result in a determination that the patent is invalid or unenforceable.
Patents have a limited lifespan. Patent terms may be shortened or lengthened by, for example, terminal disclaimers, patent term adjustments, supplemental protection certificates, and patent term extensions. Although extensions may be available, the life of a patent, and the protection it affords, is limited. Patent term extensions and supplemental protection certificates, and the like, may be impacted by the regulatory process and may not significantly lengthen patent term. Non-payment or delay in payment of patent fees or annuities, delay in patent filings or delay in extension filing, whether intentional or unintentional, may also result in the loss of patent rights important to our business. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents.
We cannot be certain that the steps we have taken will prevent unauthorized use or unauthorized reverse engineering of our technology. In addition, competitors may be able to design alternative methods or devices that avoid infringement of our patents. To the extent our intellectual property, including licensed intellectual property, offers inadequate protection, or is found to be invalid or unenforceable, we are exposed to a greater risk of direct competition. If our intellectual property does not provide adequate protection against our competitors’ products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.
Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we review our competitors’ products, and may in the future seek to enforce our patents or other rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough,
55

nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our products in any jurisdiction. For example, U.S. applications filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed. Therefore, patent applications covering our product candidates or technologies could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our products or the use of our products or technologies. The scope of a patent claim is determined by the interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates.
A court or other judicial body may decide that the patent we seek to enforce is invalid or unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that the patent in question does not cover the technology in question. An adverse result in any litigation could put one or more of our patents at risk of being invalidated or interpreted narrowly. Some of our competitors may be able to devote significantly more resources to intellectual property litigation and may have significantly broader patent portfolios to assert against us if we assert our rights against them.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on our technologies and products in all countries throughout the world would be prohibitively expensive. In addition, the laws of some non-U.S. countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from using our inventions in countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own technologies and products and may export otherwise infringing products to territories where we have patent protection. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, put our own patents at risk of being invalidated or interpreted narrowly put our patent applications at risk of not being issued, and provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if any of our patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.
In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our
56

trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.
Trade secrets and know-how can be difficult to protect as trade secrets, and know-how will over time be disseminated within the industry through independent development, the publication of journal articles, and the movement of personnel skilled in the art from company to company. In addition, because we may rely on third parties in the development of our products, we may, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with third parties prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If we are unable to prevent unauthorized material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.
Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either lawfully or through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. Competitors could willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. In addition, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.
We may be involved in lawsuits to protect or enforce our patents and proprietary rights, to determine the scope, coverage and validity of others’ proprietary rights, or to defend against third-party claims of intellectual property infringement that could require us to spend significant time and money and could prevent us from selling our products or impact our stock price.
Litigation may be necessary for us to enforce our patent and proprietary rights and/or to determine the scope, coverage and validity of others’ proprietary rights. Litigation on these matters has been prevalent in our industry and we expect that this will continue. As the biotechnology and synthetic biology industries expand and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our technologies and products of which we are not aware or that we may need to challenge to continue our operations as currently contemplated. In addition, our competitors and others may have patents or may in the future obtain patents and claim that the use of our products or processes infringes these patents. As we move into new markets and applications for our products and processes, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us.
Patent infringement suits can be expensive, lengthy and disruptive to business operations and the outcome following legal assertions of invalidity and unenforceability is unpredictable. We could incur substantial costs and divert the attention of our management and technical personnel in prosecuting or defending against any claims and may harm our reputation. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. There can be no assurance that we will prevail in any suit initiated against us by third parties, successfully settle or otherwise resolve patent infringement claims. If we are unable to successfully settle claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time- consuming litigation and may be prevented from or experience substantial delays in marketing our technologies and products. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products, and could result in the award of substantial damages against us, including treble damages and attorneys’ fees and costs in the event that we are found to be a willful infringer of third-party patents.
In the event of a successful claim of infringement against us, we may be required to obtain one or more licenses from third parties, which we may not be able to obtain at a reasonable cost, if at all. We could, therefore, incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins. In addition, we could encounter delays in product introductions while we attempt to develop alternative methods or products to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any required licenses
57

on favorable terms could prevent us from commercializing our products, and the risk of a prohibition on the sale of any of our products could adversely affect our ability to grow and gain market acceptance for our products.
Suppliers of certain equipment and technology platforms on which we rely for our business may also be subject to patent infringement lawsuits. Even if we are not a named party in such lawsuits, if such suppliers are enjoined by a court to stop selling their equipment and technology platforms or supporting our existing equipment and technology platforms, we may not have an alternative source for such equipment and technology platforms, which may have a material adverse effect on our business.
We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We were previously involved in litigation of this kind with Agilent. While we have settled this dispute, there can be no assurance that future litigation will not be initiated by these parties. Some of our employees were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our products and technologies. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Finally, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.
In addition, our agreements with some of our suppliers, distributors, customers and other entities with whom we do business may require us to defend or indemnify these parties to the extent they become involved in infringement claims against us, including the claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify any of these third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.
We may not be successful in obtaining or maintaining necessary rights to our products and technologies through acquisitions and in-licenses, and our intellectual property agreements with third parties may involve unfavorable terms or be subject to disagreements over contract interpretation.
We may find that our programs require the use of proprietary rights held by third parties, and the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our products and technologies. The licensing and acquisition of third-party intellectual property rights is a competitive area, and other companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These companies may have a competitive advantage over us due to their size, financial resources and greater commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we so choose to enter into such arrangements. We also may be unable to license or acquire third-party intellectual property rights on terms that would be favorable to us or would allow us to make an appropriate return on our investment.
We engage in discussions regarding other possible commercial and cross-licensing agreements with third parties from time to time. There can be no assurance that these discussions will lead to the execution of commercial license or cross-license agreements or that such agreements will be on terms that are favorable to us. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same
58

rights and compete with us. In addition, if we enter into cross-licensing agreements, there is no assurance that we will be able to effectively compete against others who are licensed under our patents.
In addition, provisions in our licensing and other intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.
We have not yet registered some of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.
Some of our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.
In addition, third parties may file first for our trademarks in certain countries. If they succeed in registering such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks for marketing our products and technologies in those countries. Over the long-term, if we are unable to establish name recognition based on our trademarks, then our marketing abilities may be materially adversely impacted.
We depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from selling our products.
We rely on, or may in the future rely on, licenses in order to be able to use various proprietary technologies that are material to our business. We do not or will not own the patents that underlie these licenses. Our rights to use the technology we license are subject to the negotiation of, continuation of and compliance with the terms of those licenses. In some cases, we do not or will not control the prosecution, maintenance, or filing of the patents to which we hold licenses, or the enforcement of these patents against third parties. Some of our patents and patent applications were either acquired from another company who acquired those patents and patent applications from yet another company or are licensed from a third party. For example, Twist Bioscience acquired Genome Compiler Corporation in 2016, and Genome Compiler had a non-exclusive license to U.S. Patent No—7,805,252 owned by DNA 2.0. Thus, these patents and patent applications are not written by us or our attorneys, and we did not have control over the drafting and prosecution. The former patent owners and our licensors might not have given the same attention to the drafting and prosecution of these patents and applications as we would have if we had been the owners of the patents and applications and had control over the drafting and prosecution. We cannot be certain that drafting and/or prosecution of the licensed patents and patent applications by the licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.
Our rights to use the technology we license is subject to the validity of the owner’s intellectual property rights. Enforcement of our licensed patents or defense or any claims asserting the invalidity of these patents is often subject to the control or cooperation of our licensors. Legal action could be initiated against the owners of the intellectual property that we license. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent these other companies or institutions from continuing to license intellectual property that we may need to operate our business.
Our licenses contain or will contain provisions that allow the licensor to terminate the license upon specific conditions. Our rights under the licenses are subject to or will be subject to our continued compliance with the terms of the license, including the payment of royalties due under the license.
Termination of these licenses could prevent us from marketing some or all of our products. Because of the complexity of our products and the patents we have licensed, determining the scope of the license and related royalty obligation can be difficult and can lead to disputes between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant to the license. If a licensor believed we were not paying the royalties due under the license or were otherwise not in compliance with the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful, we might be barred from producing and selling some or all of our products.
Risks relating to owning our common stock
59

We have never paid dividends on our capital stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.
We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after any price appreciation as the only way to realize any future gains on their investments. Furthermore, we are party to a credit agreement with SVB which contains negative covenants that limit our ability to pay dividends. For more information, see the section of this Form 10-Q captioned “Management’s discussion and analysis of financial condition and results of operation—Liquidity and capital resources.” For more information regarding the negative covenants in our loan and security agreement with Silicon Valley Bank, see “Risk factors—Our credit facility contains restrictions that limit our flexibility in operating our business.”
Our charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock.
Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:
providing for a classified board of directors with staggered, three-year terms;
authorizing our board of directors to issue preferred stock with voting or other rights or preferences that could discourage a takeover attempt or delay changes in control;
prohibiting cumulative voting in the election of directors;
providing that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;
prohibiting the adoption, amendment or repeal of our amended and restated bylaws or the repeal of the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors without the required approval of at least 66.67% of the shares entitled to vote at an election of directors;
prohibiting stockholder action by written consent;
limiting the persons who may call special meetings of stockholders; and
requiring advance notification of stockholder nominations and proposals.
These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, the provisions of Section 203 of the Delaware General Corporate Law, or the DGCL, govern us. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time without the consent of our board of directors.
These and other provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and under Delaware law could discourage potential takeover attempts, reduce the price investors might be willing to pay in the future for shares of our common stock and result in the market price of our common stock being lower than it would be without these provisions.
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of
60

fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, any action asserting a claim against us arising pursuant to any provisions of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, any action or proceeding asserting a claim as to which the Delaware General Corporation Law confers jurisdiction upon the Court of Chancery of the State of Delaware or any action asserting a claim against us that is governed by the internal affairs doctrine, subject in each case to the Court of Chancery having personal jurisdiction over the parties named as defendants therein. The exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. The choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. If a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we might incur additional costs associated with resolving such action in other jurisdictions.
In addition, our amended and restated certificate of incorporation provides that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.
The enforceability of similar federal court choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find our federal court choice of forum provision to be inapplicable or unenforceable. If a court were to find either of the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions. Additionally, while the Delaware Supreme Court recently determined that choice of forum provisions for actions arising under the Securities Act are facially valid, a stockholder may nevertheless seek to bring such a claim arising under the Securities Act against us, our directors, officers, or other employees in a venue other than in the federal district courts of the United States of America. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation, and this may require significant additional costs associated with resolving such action in other jurisdictions.
General risk factors
The market price of our common stock is likely to be volatile and could fluctuate or decline, resulting in a substantial loss of your investment.
The market price of our common stock could be subject to wide fluctuations in response to, among other things, the factors described in this “Risk factors” section or otherwise, and other factors beyond our control, such as fluctuations in the valuations of companies perceived by investors to be comparable to us.
Furthermore, the stock markets have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market fluctuations, as well as general economic, systemic, political and market conditions, such as recessions, interest rate changes or international currency fluctuations, may negatively affect the market price of our common stock.
Factors that could cause the market price of our common stock to fluctuate significantly include:
actual or anticipated fluctuations in our financial condition and operating results, including fluctuations in our quarterly and annual results;
announcements of technological innovations by us or our competitors;
overall conditions in our industry and the markets in which we operate;
addition or loss of significant customers, or other developments with respect to significant customers;
changes in laws or regulations applicable to our products;
actual or anticipated changes in our growth rate relative to our competitors;
61

announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
additions or departures of key personnel;
competition from existing products or new products that may emerge;
issuance of new or updated research or reports by securities analysts;
fluctuations in the valuation of companies perceived by investors to be comparable to us;
disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain intellectual property protection for our technologies;
announcement or expectation of additional financing efforts;
sales of our common stock by us or our stockholders;
the addition or removal of our stock to or from a stock index fund;
share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
the expiration of contractual lock-up agreements with our executive officers, directors and stockholders, which we have entered into and may enter into in the future from time to time;
general economic and market conditions, including economic downturns or uncertainty in financial markets; and
other factors beyond our control, such as terrorism, war, natural disasters and pandemics.
In the past, many companies that have experienced volatility in the market price of their stock have become subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could harm our business.
If securities or industry analysts do not publish research or reports about our business or publish negative reports about our business, our share price and trading volume could decline.
The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business and we will not have any control over such analysts. If one or more of the analysts who cover us downgrade our shares or change their opinion of our shares, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.
Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause the stock price of our common stock to decline.
As we have in the past, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. We have also issued and expect to issue common stock to employees and directors pursuant to our equity incentive plans. If we sell common stock, convertible securities or other equity securities in future transactions, or common stock is issued pursuant to equity incentive plans, investors may be materially diluted. New investors in such subsequent transactions could gain rights, preferences and privileges senior to those of holders of our common stock.
Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.
62

In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:
we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law which provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful;
we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;
we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;
we will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification;
the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and
we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.

Evolving expectations around corporate responsibility practices, specifically related to environmental, social and
governance (“ESG”) matters, may expose us to reputational and other risks.

Investors, stockholders, customers, suppliers and other third parties are increasingly focusing on ESG and corporate social responsibility endeavors and reporting. Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third parties are also increasingly focused on ESG practices. Companies that do not adapt to or comply with the evolving investor or stakeholder expectations and standards, or which are perceived to have not responded appropriately, may suffer from reputational damage and result in the business, financial condition and/or stock price of a company being materially and adversely affected. Further, this increased focus on ESG issues may result in new regulations and/or third-party requirements that could adversely impact our business, or certain shareholders reducing or eliminating their holdings of our stock. Additionally, an allegation or perception that we have not taken sufficient action in these areas could negatively harm our reputation.

Item 2. Unregistered sales of equity securities and use of proceeds
Sales of unregistered securities
None.

Item 3. Defaults upon senior securities
None.

Item 4. Mine safety disclosures
Not applicable.

Item 5. Other information
Prior Senior Business Advisor Agreement with Nelson C. Chan

Prior to the date Nelson C. Chan joined our board of directors in May 2019, under a Senior Business Advisor Agreement dated November 1, 2017 with the Company (the “Legacy Advisor Agreement”), he provided data storage advisory services to us and was entitled to an option to purchase 7,070 shares of our common stock (the “Option Award”).
63


Since Mr. Chan’s appointment to our board of directors, he has provided no advisory services to the Company and has solely served as an independent director.

As previously disclosed in our proxy statements, at the time of Mr. Chan’s appointment to our board of directors in May 2019, it was discovered that the Option Award had not been granted. To address our failure to fulfill our obligation to Mr. Chan under the Legacy Advisor Agreement without compromising his independence under Nasdaq rules, the Legacy Advisor Agreement was amended to ensure that the value of the payments he was entitled to receive under the Legacy Advisor Agreement would not exceed $120,000 in any rolling 12-month period. All payments under the Legacy Advisor Agreement were solely to provide Mr. Chan what he was owed prior to his appointment to our board of directors.

In August 2022, Mr. Chan received the final payment of $119,999 under the Legacy Advisor Agreement. Following this final payment, the Company will have no further obligations to Mr. Chan under the Legacy Advisory Agreement.


64

›Item 6. Exhibits

Exhibit
Number
Description 
Filed / Furnished /
Incorporated from
Form
31.1Filed herewith
31.2Filed herewith
32.1†Furnished herewith
32.2†Furnished herewith
101
The following materials from Twist Bioscience Corp.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in iXBRL (inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Stockholders’ Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to Unaudited Condensed Consolidated Financial Statements, tagged as blocks of text.
Filed herewith
104
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline XBRL (included in Exhibit 101).
Filed herewith
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Twist Bioscience Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, regardless of any general incorporation language contained in any filing.

65

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

August 8, 2022Twist Bioscience Corporation
By:/s/ James M. Thorburn
James M. Thorburn
Chief Financial Officer
(Authorized officer)


66
EX-31.1 2 twst-20220630x10qxex311.htm EX-31.1 Document
EX-31.1 2 twst-20211231xex31d1.htm EXHIBIT 31.1


Exhibit 31.1
Certification of Principal Executive Officer
pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002

I, Emily M. Leproust, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Twist Bioscience Corporation for the quarter ended June 30, 2022;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Emily M. Leproust
Emily M. Leproust
President and Chief Executive Officer
(Principal Executive Officer)
Date: August 8, 2022

EX-31.2 3 twst-20220630x10qxex312.htm EX-31.2 Document
EX-31.2 3 twst-20211231xex31d2.htm EXHIBIT 31.2


Exhibit 31.2
Certification of Principal Financial Officer
pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002

I, James M. Thorburn, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Twist Bioscience Corporation for the quarter ended June 30, 2022;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ James M. Thorburn
James M. Thorburn
Chief Financial Officer
Date: August 8, 2022

EX-32.1 4 twst-20220630x10qxex321.htm EX-32.1 Document
EX-32.1 4 twst-20211231xex32d1.htm EXHIBIT 32.1


Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002

In connection with the Quarterly Report of Twist Bioscience Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Emily M. Leproust, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 8, 2022
/s/ Emily M. Leproust
Emily M. Leproust
President and Chief Executive Officer
(Principal Executive Officer)

EX-32.2 5 twst-20220630x10qxex322.htm EX-32.2 Document
EX-32.2 5 twst-20211231xex32d2.htm EXHIBIT 32.2


Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002

In connection with the Quarterly Report of Twist Bioscience Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James M. Thorburn, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 8, 2022
/s/ James M. Thorburn
James M. Thorburn
Chief Financial Officer

EX-101.SCH 6 twst-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - The Company (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of significant accounting policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Fair value measurement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Fair Value Measurement - Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2112104 - Disclosure - Balance sheet components link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Balance sheet components (Tables) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Balance sheet components - Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Balance sheet components - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Balance sheet components - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417409 - Disclosure - Balance sheet components - Other non-current assets (Details) link:presentationLink link:calculationLink link:definitionLink 2418410 - Disclosure - Balance sheet components - Accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2419411 - Disclosure - Balance sheet components - Accrued compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2420412 - Disclosure - Balance sheet components - Other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2421413 - Disclosure - Balance sheet components - Other non current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2122105 - Disclosure - Goodwill and intangible assets link:presentationLink link:calculationLink link:definitionLink 2323304 - Disclosure - Goodwill and intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2424414 - Disclosure - Goodwill and intangible assets - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2425415 - Disclosure - Goodwill and intangible assets - Intangible Assets Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2126106 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2327305 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - Commitments and contingencies - Operating Leases On Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2429417 - Disclosure - Commitments and contingencies - Minimum Rental Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2429417 - Disclosure - Commitments and contingencies - Minimum Rental Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2430418 - Disclosure - Commitments and contingencies - Lease Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2131107 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 2432419 - Disclosure - Related party transactions - (Details) link:presentationLink link:calculationLink link:definitionLink 2133108 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2434420 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2135109 - Disclosure - Common stock link:presentationLink link:calculationLink link:definitionLink 2436421 - Disclosure - Common stock (Details) link:presentationLink link:calculationLink link:definitionLink 2137110 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 2338306 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2439422 - Disclosure - Stock-based compensation - Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2440423 - Disclosure - Stock-based compensation - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 2441424 - Disclosure - Stock-based compensation - Summary of PSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2442425 - Disclosure - Stock-based compensation - Activity Under Options (Details) link:presentationLink link:calculationLink link:definitionLink 2443426 - Disclosure - Stock-based compensation - Activity Under Performance Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2444427 - Disclosure - Stock-based compensation - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2445428 - Disclosure - Stock-based compensation - Reserved For Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 2446429 - Disclosure - Stock-based compensation - Abveris Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2147111 - Disclosure - Net loss per share attributable to common stockholders link:presentationLink link:calculationLink link:definitionLink 2348307 - Disclosure - Net loss per share attributable to common stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 2449430 - Disclosure - Net loss per share attributable to common stockholders - Computation (Details) link:presentationLink link:calculationLink link:definitionLink 2450431 - Disclosure - Net loss per share attributable to common stockholders - Anti-dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 2151112 - Disclosure - Geographic, product and industry information link:presentationLink link:calculationLink link:definitionLink 2352308 - Disclosure - Geographic, product and industry information (Tables) link:presentationLink link:calculationLink link:definitionLink 2453432 - Disclosure - Geographic, product and industry information - Geographic Region (Details) link:presentationLink link:calculationLink link:definitionLink 2454433 - Disclosure - Geographic, product and industry information - By Product (Details) link:presentationLink link:calculationLink link:definitionLink 2455434 - Disclosure - Geographic, product and industry information - By Industry (Details) link:presentationLink link:calculationLink link:definitionLink 2156113 - Disclosure - Business acquisition link:presentationLink link:calculationLink link:definitionLink 2357309 - Disclosure - Business acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 2458435 - Disclosure - Business acquisition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2459436 - Disclosure - Business acquisition - Assets acquired and liabilities assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2460437 - Disclosure - Business acquisition - Preliminary estimate of the intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 2461438 - Disclosure - Business acquisition - Change in contingent consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2462439 - Disclosure - Business acquisition - Pro forma financial results (Details) link:presentationLink link:calculationLink link:definitionLink 2163114 - Disclosure - Investment in variable interest entity link:presentationLink link:calculationLink link:definitionLink 2464440 - Disclosure - Investment in variable interest entity (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 twst-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 twst-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 twst-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Food/agricultural Food Or Agriculture [Member] Food and agriculture. Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Non-current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities Percentage of payroll deduction to purchase common stock Percentage Of Payroll Deduction On Eligible Common Stock Percentage of payroll deduction on eligible common stock. Work-in-process Inventory, Work in Process, Gross Tradenames & Trademarks Trademarks and Trade Names [Member] Vesting of restricted stock units (in shares) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss attributable to common stockholders Net loss attributable to common stockholders Net Income (Loss) Attributable to Parent Consolidated Entities [Axis] Consolidated Entities [Axis] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Operating lease right-of-use assets Operating Lease, Right-of-Use Asset 2018 ESPP Two Thousand And Eighteen Employee Stock Purchase Plan [Member] Two thousand and eighteen employee stock purchase plan. Accrued compensation Accrued compensation Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Expected to vest (in usd per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Range [Domain] Statistical Measurement [Domain] Net working capital adjustment Net working capital adjustment Net working capital adjustment Net working capital adjustment Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code EMEA EMEA [Member] Forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Weighted average remaining contractual term, Expected to vest Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Term Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Term Lease weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Other non-current assets Other non-current assets Other Assets, Noncurrent Period of additional antibody therapeutics that maybe licensed Period Of Additional Antibody Therapeutics License The period that additional antibody therapeutics maybe licensed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. Equity (in shares) Business Combination, Consideration, Shares, Transferred, Equity Interests Issued and Issuable Amount of Shares on equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Expected dividend rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Entity File Number Entity File Number Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Accrued bonus Accrued Bonuses, Current Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total amortization expense related to intangible assets Amortization of Intangible Assets Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Intangible assets Estimated Fair Value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Estimated Weighted Average Useful Lives in Years Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Antidilutive securities excluded from computation of earnings per share amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Lease weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Summary of Inventories Schedule of Inventory, Current [Table Text Block] Change in fair value of contingent considerations and holdbacks Change In Fair Value Of Contingent Consideration And Indemnity Holdback The amount of changes in fair value of contingent consideration and indemnity holdback. Contingent consideration and holdbacks Contingent Consideration And Indemnity Holdback [Member] The member stands for Contingent Consideration And Indemnity Holdback. Research and development Research and Development Expense [Member] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Annual automatic Increase in share reserved for issuance (as a percent) Common Stock Capital Shares Reserved For Future Issuance Annual Automatic Increase Percentage The minimum common stock capital shares reserved for future issuance annual automatic increase, as percent to the outstanding shares. Sale of Stock [Axis] Sale of Stock [Axis] Liability Class [Axis] Liability Class [Axis] Loss absorbed by reporting entity Variable Interest Entity, Initial Consolidation, Gain (Loss) Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Bad debt expense Financing Receivable, Credit Loss, Expense (Reversal) Business Combination and Asset Acquisition [Abstract] Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Business Acquisition [Axis] Business Acquisition [Axis] Title of Individual [Domain] Title of Individual [Domain] Change in unrealized loss on investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Aggregate intrinsic value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Equity Award [Domain] Award Type [Domain] Local Phone Number Local Phone Number Schedule of Reconciliation of Contingent Consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Assets Assets: Assets [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Weighted average remaining contractual term (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Granted (in shares) Equity awards restricted shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Goodwill and intangible assets Goodwill and Intangible Assets Disclosure [Text Block] Synthetic genes Synthetic Genes [Member] Synthetic genes. Increase in intangible assets Finite-lived Intangible Assets Acquired Proceeds from exercise of stock options Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Beginning balance (in shares) Ending balance (in shares) Beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Trade name Trade Names [Member] Accumulated deficit Retained Earnings [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Deposits Deposits Noncurrent liabilities: Liabilities, Noncurrent [Abstract] Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Accrued Expenses And Other Current Liabilities Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Ownership percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Related Party [Axis] Related Party [Axis] Accounts receivable, net Increase (Decrease) in Accounts Receivable Operating lease right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Summary of Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Percentage of PSUs that may vest based on performance Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Repurchases of common stock for income tax withholding (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Summary of Noncurrent Liabilities Other Noncurrent Liabilities [Table Text Block] Contingent consideration (in shares) Business Combination, Shares, Contingent Consideration Amount of shares liability arising from contingent consideration in a business combination. Contingent consideration and holdbacks Business Combination, Contingent Consideration, Liability, Current Net loss per share attributable to common stockholders—basic (in usd per share) Earnings Per Share, Basic Operating lease expense Operating Lease, Expense 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three DNA libraries Dna And Biopharma Libraries [Member] DNA and Biopharma Libraries. Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Balance as of September 30, 2021 Balance as of June 30, 2022 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair value of assets acquired and liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Quincy, Massachusetts Quincy, Massachusetts [Member] Quincy, Massachusetts Raw materials Inventory, Raw Materials, Gross Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] NGS tools Ngs Tools [Member] NGS Tools Member Commercial paper Commercial Paper [Member] Repurchases of common stock for income tax withholding Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Operating lease payments Operating Lease, Payments Fair value of consideration transferred Fair value of purchase consideration Business Combination, Consideration Transferred Summary of Revenue by Geographic Region Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Aggregate intrinsic value, vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Plan Name [Axis] Plan Name [Axis] Assets Assets, Fair Value Disclosure [Abstract] Prepaid Expense Prepaid Expense Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Amortization of debt discount Foreign Currency Transaction Gain (Loss), Unrealized Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Awards with vesting requirements Share Based Awards With Vesting Requirements [Member] Share-based awards with vesting requirements. Change in fair value of acquisition consideration Change In Fair Value Of Acquisition Consideration Change In Fair Value Of Acquisition Consideration Total liabilities and stockholders’ equity Liabilities and Equity Additional SAFE issued Purchased Additional Future Equity to Asset License and Contract Assignment Agreement Represents the additional purchase of future equity "SAFE" to asset license and contract assignment agreement between the parties. Other accrued expenses Other Accrued Liabilities, Current Americas Americas [Member] Additional paid-in capital Additional Paid in Capital Weighted average remaining contractual term (years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Proceeds from public offerings, net of underwriting discounts, commissions and offering expenses Proceeds from Issuance Initial Public Offering Accounts payable Increase (Decrease) in Accounts Payable Other non-current assets Other Assets, Noncurrent, Excluding Convertible Receivable Amount of noncurrent assets classified as other, excluding convertible receivable. Goodwill And Intangible Assets [Line Items] Goodwill And Intangible Assets [Line Items] Goodwill And Intangible Assets [Line Items] Summary of Other Non-Current Assets Schedule of Other Current Assets [Table Text Block] Income Tax Contingency [Table] Income Tax Contingency [Table] Net loss per share attributable to common stockholders Earnings Per Share [Text Block] Awards aggregate fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments, Granted, Fair Value The aggregate grant-date fair value of share-based awards granted during the reporting period as calculated by applying the disclosed option pricing methodology. Non-cash lease expense Operating Lease, Impairment Loss Operating expenses: Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] The Company Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Change in fair value during the period Change in fair value during the period Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Affiliated Entity Affiliated Entity [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Effect of exchange rates on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Total financial liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Selling, general and administrative Selling, General and Administrative Expense Additional antibody therapeutics that may license Additional Antibody Therapeutics License, Maximum The maximum number of additional antibody therapeutics that maybe licensed over the next four years. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Performance Stock Option Performance Stock Option [Member] Performance Stock Option Schedule of Supplemental Balance Sheet Information Relating to Companies Operating Lease Supplemental Balance Sheet Information Relating To Companies Operating Lease [Table Text Block] Supplemental balance sheet information relating to companies operating lease [Table text block]. Entity Address, State or Province Entity Address, State or Province Adjustment holdback shares (in shares) Business Combination, Adjustment Holdback, Shares The number of adjustment holdback shares in a business combination agreement. Issuance of shares from business acquisition Stock Issued During Period, Value, Acquisitions Current liabilities: Liabilities, Current [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses Stock Issued During Period, Value, New Issues Share-Based Compensation Arrangement By Share-based Payment Award, Outstanding [Roll Forward] Share-Based Compensation Arrangement By Share-based Payment Award, Outstanding [Roll Forward] Share-Based Compensation Arrangement By Share-based Payment Award, Outstanding Change in operating lease liabilities. Increase (Decrease) in Operating Lease Liability Business acquisition, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Shares expected to vest Share Based Compensation By Share Based Payment Arrangement Instruments Other Than Options Expected To Vest Outstanding Share based compensation by share based payment arrangement instruments other than options expected to vest outstanding. Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Stock-based compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Weighted average remaining contractual term, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares) Stock Issued During Period, Shares, New Issues Oligo pools Oligo Pools [Member] Oligo pools. Professional services fees payable Accrued Professional Fees, Current Other non-current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Tenant improvements Tenant Improvements Total operating lease liabilities Operating Lease, Liability Summary of Revenue by Product Revenue from External Customers by Products and Services [Table Text Block] Document Transition Report Document Transition Report Common stock, $0.00001 par value—100,000 and 100,000 shares authorized at June 30, 2022 and September 30, 2021, respectively; 56,344 and 49,499 shares issued and outstanding at June 30, 2022 and September 30, 2021, respectively Common Stock, Value, Issued Unrecognized stock-based compensation expense, period for recognition Recognize cost weighted average period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward] Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward] Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability Beginning balance (in usd per share) Ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Increase in goodwill Goodwill, Acquired During Period Basis of presentation and use of estimates Basis of Accounting, Policy [Policy Text Block] Performance Shares Performance Shares [Member] Commitments and contingencies Commitments and Contingencies Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Subsequent Public Offering Subsequent Public Offering1 [Member] Subsequent Public Offering 1 Entity Emerging Growth Company Entity Emerging Growth Company Remainder of 2022 Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Business acquisition Business Combination Disclosure [Text Block] Operating lease base rent annual percentage increase Operating Lease Annual Base Rent Percentage Increase Operating Lease Annual Base Rent Percentage Increase Summary of Stock Option Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Other Commitments [Table] Other Commitments [Table] Proceeds from issuance of debt Proceeds from Issuance of Debt Ownership [Axis] Ownership [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cover [Abstract] Cover [Abstract] Total operating expenses Costs and Expenses Expected to vest (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Number Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Number Write off property and equipment Property, Plant, And Equipment, Writeoff Property, Plant, And Equipment, Writeoff Net loss attributable to common stockholders Business Acquisition, Pro Forma Net Income (Loss) Summary of Other Current Liabilities Other Current Liabilities [Table Text Block] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Sale of stock, consideration received Sale of Stock, Consideration Received on Transaction Income tax benefit, due to deferred tax liability as part of business acquisition Business Acquisition, Income Tax Benefit, Due To Deferred Tax Liability Represents the amount of income tax beneft due to the deferred tax liability as a part of business acquisition. Work-in-process inventory included gross consigned Inventory, Work in Process, Net of Reserves Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Other comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Financial Instrument [Axis] Financial Instrument [Axis] Selling, general and administrative Selling, General and Administrative Expenses [Member] Accrued expenses Accrued expenses Accrued Liabilities, Current Assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Accrued vacation Accrued Vacation, Current Option Share-based Payment Arrangement, Option [Member] Net of underwriting discounts, commissions and offering expenses Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Document Quarterly Report Document Quarterly Report Common stock Common Stock [Member] Interest income Investment Income, Interest Geographic, product and industry information Segment Reporting Disclosure [Text Block] Loss from operations Operating Income (Loss) Aggregate intrinsic value, Expected to vest Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Aggregate Intrinsic Value Options consideration Business Combination, Consideration Transferred, Options Issued and Issuable Amount of options of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Current portion of operating lease liability Less: current portion Operating Lease, Liability, Current Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Stock-based compensation Share-based Payment Arrangement, Noncash Expense Additional paid-in capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Deferred tax liability Increase (Decrease) in Deferred Income Taxes Accrued expenses Increase (Decrease) in Accrued Liabilities Other income (expense), net Other Nonoperating Income (Expense) Initial annual base rent Initial Annual Base Rent Amount of initial annual base rent. Other liabilities Increase (Decrease) in Other Operating Liabilities Issuance of common stock in connection with the business acquisition Stock Issued Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other current liabilities Other current liabilities Other Liabilities, Current Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Performance Stock Unit Performance Stock Unit [Member] Performance Stock Unit Executive Officers and Senior Level Employees Executive Officers And Senior Level Employees [Member] Executive officers and senior level employees. Total liabilities Total liabilities Liabilities Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value South San Francisco, California South San Francisco California [Member] Represents the information pertaining to South San Francisco, California. Summary of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate intrinsic value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Expected to vest (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Schedule of Future Minimum Rental Payments for Operating Leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Common stock, issued (in shares) Common Stock, Shares, Issued City Area Code City Area Code Indemnity holdbacks period Business Combination, Indemnity Holdbacks Period The period the indemnity holdbacks in business combination agreement is extends, e, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen day. Operating lease area Lessee, Operating Lease, Area The area leased by lessee in lease agreement classified as operating lease. Antibody discovery Antibody Discovery [Member] Antibody discovery Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Discount rate Business Combination Discount Rate Discount rate used to determine estimated fair value of acquired intangible assets Variable interest entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Contingent consideration Business Combination Contingent Consideration The contingent consideration in a business combination. Interest expense Interest Expense Accrued compensation Increase (Decrease) in Employee Related Liabilities Other non current liabilities Other Liabilities Non Current Other Than Contingent Consideration Amount of liabilities classified as other, due after one year or if longer, other business acquisition contingent consideration. Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Unvested restricted stock units and performance stock units Unvested Restricted Stock Units And Performance Stock Units [Member] Unvested Restricted Stock Units And Performance Stock Units Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Operating lease term Lessee, Operating Lease, Term of Contract Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Summary of Preliminary Fair Value Amounts of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Issuance of shares under the employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Other accrued compensation Other Employee-related Liabilities, Current Business Acquisition [Line Items] Business Acquisition [Line Items] U.S. government treasury bills US Treasury Securities [Member] Summary of Cash, Cash Equivalents and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Entity Registrant Name Entity Registrant Name Academic research Academic Research [Member] Academic research. Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Contingent consideration, shares issuable up to (in shares) Business Combination, Contingent Consideration, Liability, Shares Issuable Business Combination, Contingent Consideration, Liability, Shares Issuable Short-term investments Short-term Investments Forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Benefit from income taxes Income tax benefit Income Tax Expense (Benefit) Accounts receivable, net Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag APAC Asia Pacific [Member] Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Total minimum lease payments Future minimum payments Lessee, Operating Lease, Liability, to be Paid Sale of Stock [Domain] Sale of Stock [Domain] Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventories Total inventories Inventory, Net Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Holdback Business Combination, Contingent Consideration, Liability, Noncurrent Proceeds from issuance of common stock under employee stock purchase plan Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan Unrecognized compensation cost, options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Summary of Accrued Compensation Schedule of Accrued Compensation [Table Text Block] Tabular disclosure of the components accrued compensation. Current portion of long-term debt Long-term Debt, Current Maturities Product and Service [Axis] Product and Service [Axis] Contingent consideration Contingent Consideration [Member] Represents the contingent consideration. Repurchases of common stock for income tax withholding Payments To Repurchases Of Common Stock For Tax Withholding Payments To Repurchases Of Common Stock For Tax Withholding Common stock Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Excluding Issued to Employees Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination, excluding shares issued to employees Vested (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Share based compensation by share based payment arrangement equity instruments other than options unrecognized compensation Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Shares subject to performance-based stock options Stock Options Based On Performance [Member] Stock Options Based On Performance [Member] Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Shares subject to employee stock purchase plan Shares Subject To Employee Stock Purchase Plan [Member] Represents shares subject to employee stock purchase plan. 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Repurchases of early exercised stock options (in shares) Stock Repurchased During Period, Shares Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Shares issued during the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Company common stock Company common stock Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Statement [Line Items] Statement [Line Items] Holdbacks Indemnity Holdback [Member] Represents the indemnity holdback. Issuance of shares from business acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Industrial chemicals/materials Industrial Chemicals [Member] Industrial Chemicals. Restricted cash, non-current Restricted Cash, Noncurrent Contingent consideration Business Combination Contingent Consideration Liability Present Value Amount of present value of liability arising from contingent consideration in a business combination Purchases of investments Payments to Acquire Investments Raw materials purchased from related party investor Related Party Transaction, Purchases from Related Party Contingent consideration – additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Proceeds from maturity of investments Proceeds from Sale, Maturity and Collection of Investments 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four ESPP eligible employee common stock purchase price ratio Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] iGenomX Igenomx International Genomics Corporatio [Member] Represents information pertaining to iGenomX International Genomics Corporation. Post combination compensation expenses includes employee stock awards Business Combination Post Business Compensation Expense Includes Employee Stock Awards Amount represents the business combination post business compensation expense includes employee stock awards Segment Reporting [Abstract] Segment Reporting [Abstract] Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items] Investment in variable interest entity Investment in variable interest entity No definition available. Weighted average Amortization period in years Finite-Lived Intangible Asset, Useful Life Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Granted (in shares) Stock options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Stock-Based Compensation Expenses Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Change in right-of-use asset Increase Decrease In Operating Lease Right Of Use Asset The increase (decrease) during the reporting period in operating lease right of use assets. Title of 12(b) Security Title of 12(b) Security Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Awards without vesting requirements Share Based Awards Without Vesting Requirements [Member] Represents share based awards without besting requirements. Proceeds of underwritten public offering common stock Proceeds from Issuance of Common Stock Total assets Total assets Assets Realized gain on investments Realized Investment Gains (Losses) Plan Name [Domain] Plan Name [Domain] Common stock, authorized (in shares) Common Stock, Shares Authorized Weighted average remaining contractual term, Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Healthcare Health Care [Member] Title of Individual [Axis] Title of Individual [Axis] Document Type Document Type Consideration transferred Business Combination, Consideration Transferred [Abstract] Product and Service [Domain] Product and Service [Domain] Schedule of Nonvested Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Research and development Research and Development Expense Balance sheet components Supplemental Balance Sheet Disclosures [Text Block] Summary of Revenue by Industry Schedule Of Revenue From External Customers And Long Lived Assets By Industry [Table Text Block] Tabular disclosure of revenue from external customers and long lived assets by industry. Summary of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] iGenomX Igenomx International Genomics Corporation [Member] It represents information pertaining to its igenomx international genomics corporation member. Balance at December 1, 2021 – acquisition date Balance at June 30, 2022 Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of significant accounting policies Significant Accounting Policies [Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Indemnity holdback shares (in shares) Business Combination, Indemnity Holdback, Shares The maximum holdback shares that can can be transferred as indemnity holdback shares in a business combination agreement. Geographical [Axis] Geographical [Axis] Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares) Weighted average shares used in computing net loss per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Net loss per share attributable to common stockholders—diluted (in usd per share) Net loss per share attributable to common stockholders, diluted (in usd per share) Earnings Per Share, Diluted Abx Biologics Inc. Abveris Abx Biologics Inc. [Member] Represents the Abx Biologics Inc. Sale of stock, share price (in usd per share) Sale of Stock, Price Per Share Income taxes paid, net of refunds Income Taxes Paid, Net Accrued commissions Accrued Commissions, Current Carrying value as of the balance sheet date of accrued commissions classified as current. Indemnity holdback consideration Business Combination Indemnity Holdback Consideration Liability Amount of indemnity consideration holdback. Accrued payroll and related taxes Accrued Payroll Taxes, Current Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Cost of revenues Cost of Revenue Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Vesting period Vesting period from acquisition date Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Weighted average remaining contractual term, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Related Party Transaction [Line Items] Related Party Transaction [Line Items] Industry Sectors [Domain] Industry Sectors [Domain] Industry sectors. Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Fair value measurement Fair Value Disclosures [Text Block] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Accounts payable Accounts Payable, Current Non-cash interest expense Other Noncash Expense Depreciation and amortization Depreciation, Depletion and Amortization Unvested shares of common stock issued upon early exercise of stock options Early Exercise Of Stock Options [Member] Early Exercise Of Stock Options [Member] Goodwill And Intangible Assets [Table] Goodwill And Intangible Assets [Table] Goodwill And Intangible Assets [Table] Accumulated Other comprehensive income AOCI Attributable to Parent [Member] Minimum annual increase in share reserved for issuance Minimum Increase Common Stock Capital Shares Reserved For Future Issuance Minimum increase common stock capital shares reserved for future issuance. Inventories Increase (Decrease) in Inventories Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Property and equipment additions included in accounts payable and accrued expenses Liabilities Assumed Adjustment holdback options (in shares) Business Combination, Adjustment Holdback, Options The number of adjustment holdback options in a business combination agreement. Document Period End Date Document Period End Date Entity Central Index Key Entity Central Index Key Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Consolidated Entities [Domain] Consolidated Entities [Domain] Indemnity holdback options (in shares) Business Combination, Indemnity Holdback, Options The number of indemnity holdback options in a business combination agreement. Income Statement Location [Domain] Income Statement Location [Domain] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Additional shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Customer Relationships Customer Relationships [Member] Revelar Revelar Biotherapeutics Inc [Member] Represents the Revelar Biotherapeutics Inc. Property and equipment, net Property, Plant and Equipment, Net Net exercise of stock warrants (in shares) Net Exercise Of Common Stock Warrants Shares Net exercise of common stock warrants (in shares). Other non-current liabilities Other non-current liabilities Other Liabilities, Noncurrent Repayments of long-term debt Repayments of Long-term Debt Trading Symbol Trading Symbol Earnings Per Share [Abstract] Earnings Per Share [Abstract] Revenues Business Acquisition, Pro Forma Revenue Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Finished goods Inventory, Finished Goods, Gross Beginning balance (in usd per share) Ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Other Commitments [Line Items] Other Commitments [Line Items] Liabilities Liabilities, Fair Value Disclosure [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Holdback liabilities Business Combination, Consideration Transferred, Liabilities Incurred Stock based compensation expense Share-based Payment Arrangement, Expense Entity Current Reporting Status Entity Current Reporting Status Numerator: Earnings Per Share, Basic and Diluted [Abstract] Weighted average grant date fair value per share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Trade receivables Accounts Receivable, before Allowance for Credit Loss, Current Discount accretion on investment securities Accretion (Amortization) of Discounts and Premiums, Investments Aggregate intrinsic value, Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Industry Sectors [Axis] Industry Sectors [Axis] Information by industry sector. Sale of stock, shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Investment in variable interest entity Variable Interest Entity Disclosure [Text Block] Income and sales taxes payable Taxes Payable, Current Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets: Assets, Current [Abstract] Gross carrying amount Finite-Lived Intangible Assets, Gross Aggregate number of common stock shares reserved for issuance Beginning balance (in shares) Ending balance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Summary of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Nonvested Performance-based Units Activity Schedule of Nonvested Performance-based Units Activity [Table Text Block] Total financial assets Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares) Weighted average shares used in computing net loss per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Over-Allotment Option Over-Allotment Option [Member] Income taxes Income Tax Disclosure [Text Block] Related Party [Domain] Related Party [Domain] Schedule of Activity Under Option and Performance Stock Options Share-based Payment Arrangement, Option, Activity [Table Text Block] Common stock Stockholders' Equity Note Disclosure [Text Block] Transaction costs Business Combination Transaction Costs The amount of transaction costs related to acquisition. Summary of Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other current liabilities Other Liabilities, Current, Other Than Contingent Consideration and Taxes Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer, other business acquisition contingent consideration and taxes payable. Expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Class of Stock [Line Items] Class of Stock [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Value of adjustment holdback Business Combination, Adjustment Holdback, Value The value of adjustment holdback of shares and options in a business combination agreement. Other receivables Other Receivables, Gross, Current Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Issuance of shares under the employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Other current assets and prepaid expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Entity Shell Company Entity Shell Company Less: tenant improvement allowance (receipt anticipated in 2022) Tenant Improvement, Allowance Tenant Improvement, Allowance Total current liabilities Liabilities, Current Shares subject to options to purchase common stock Employee Stock [Member] Cash consideration Cash Payments to Acquire Businesses, Gross Investment amount Variable Interest Entity, Financial or Other Support, Amount Convertible note receivable Convertible Note Receivable Amount of receivable from parties in nontrade transactions and is convertible to the borrowers shares of stocks, per agreement. Money market funds Money Market Funds [Member] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Revenues Revenue Revenue from Contract with Customer, Including Assessed Tax Summary of Preliminary Estimate of Intangible Assets Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Ownership [Domain] Ownership [Domain] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Statement [Table] Statement [Table] Public offering expense adjustment Prior Quarter Public Offering Expenses Adjustment Prior Quarter Public Offering Expenses Adjustment Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other non-current assets Increase (Decrease) in Other Noncurrent Assets Unrecognized compensation cost, stock options Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Statistical Measurement [Axis] Statistical Measurement [Axis] Indemnity holdbacks Holdback Liabilities Holdback liabilities Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Operating lease security deposit with the lessor Deposits Assets, Noncurrent Intangible assets, net Net book value Finite-Lived Intangible Assets, Net Goodwill Goodwill Cost of revenues Cost of Sales [Member] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Developed Technology Developed Technology Rights [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Related party transactions Related Party Transactions Disclosure [Text Block] EX-101.PRE 10 twst-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 twst-20220630_g1.jpg begin 644 twst-20220630_g1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover Page - shares
9 Months Ended
Jun. 30, 2022
Aug. 04, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-38720  
Entity Registrant Name Twist Bioscience Corporation  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 46-2058888  
Entity Address, Address Line One 681 Gateway Blvd  
Entity Address, City or Town South San Francisco  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94080  
City Area Code 800  
Local Phone Number 719-0671  
Title of 12(b) Security Common Stock  
Trading Symbol TWST  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   56,363,518
Amendment Flag false  
Entity Central Index Key 0001581280  
Current Fiscal Year End Date --09-30  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Current assets:    
Cash and cash equivalents $ 376,249 $ 465,829
Short-term investments 151,342 12,034
Accounts receivable, net 41,195 28,549
Inventories 43,022 31,800
Prepaid expenses and other current assets 12,309 8,283
Total current assets 624,117 546,495
Property and equipment, net 127,011 44,122
Operating lease right-of-use assets 76,165 61,580
Goodwill 85,811 22,434
Intangible assets, net 61,115 18,262
Restricted cash, non-current 1,572 1,530
Other non-current assets 3,872 7,674
Total assets [1] 979,663 702,097
Current liabilities:    
Accounts payable 21,014 14,900
Accrued expenses 9,499 6,437
Accrued compensation 27,698 22,327
Current portion of operating lease liability 14,352 8,213
Current portion of long-term debt 0 1,552
Other current liabilities 20,123 9,623
Total current liabilities 92,686 63,052
Operating lease liability, net of current portion 64,244 53,156
Other non-current liabilities 2,056 5,068
Total liabilities [1] 158,986 121,276
Commitments and contingencies
Stockholders’ equity    
Common stock, $0.00001 par value—100,000 and 100,000 shares authorized at June 30, 2022 and September 30, 2021, respectively; 56,344 and 49,499 shares issued and outstanding at June 30, 2022 and September 30, 2021, respectively 0 0
Additional paid-in capital 1,599,355 1,190,828
Accumulated other comprehensive income (1,377) 546
Accumulated deficit (777,301) (610,553)
Total stockholders’ equity 820,677 580,821
Total liabilities and stockholders’ equity $ 979,663 $ 702,097
[1] The Company’s consolidated assets as of June 30, 2022 include $7,429 in assets of the variable interest entity, or “VIE”, that can only be used to settle obligations of the VIE. Cash as of June 30, 2022 was $6,989; prepaid expenses as of June 30, 2022 were $433 and deposits as of June 30, 2022 were $7. The Company’s consolidated liabilities as of June 30, 2022 were $10,494 in liabilities of the VIE who creditors have no recourse to the Company. These liabilities include accounts payable of $6,412 as of June 30, 2022; accrued expenses and other current liabilities of $2,082 as of June 30, 2022; and other non-current liabilities of $2,000 as of June 30, 2022.
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Common stock, par value (in usd per share) $ 0.00001 $ 0.00001
Common stock, authorized (in shares) 100,000 100,000
Common stock, issued (in shares) 56,344 49,499
Common stock, outstanding (in shares) 56,344 49,499
Total assets [1] $ 979,663 $ 702,097
Cash and cash equivalents 376,249 465,829
Total liabilities [1] 158,986 121,276
Accounts payable 21,014 14,900
Other current liabilities 20,123 $ 9,623
Variable Interest Entity, Primary Beneficiary    
Total assets 7,429  
Cash and cash equivalents 6,989  
Prepaid Expense 433  
Deposits 7  
Total liabilities 10,494  
Accounts payable 6,412  
Accrued expenses and other current liabilities 2,082  
Other current liabilities $ 2,000  
[1] The Company’s consolidated assets as of June 30, 2022 include $7,429 in assets of the variable interest entity, or “VIE”, that can only be used to settle obligations of the VIE. Cash as of June 30, 2022 was $6,989; prepaid expenses as of June 30, 2022 were $433 and deposits as of June 30, 2022 were $7. The Company’s consolidated liabilities as of June 30, 2022 were $10,494 in liabilities of the VIE who creditors have no recourse to the Company. These liabilities include accounts payable of $6,412 as of June 30, 2022; accrued expenses and other current liabilities of $2,082 as of June 30, 2022; and other non-current liabilities of $2,000 as of June 30, 2022.
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Statement of Comprehensive Income [Abstract]        
Revenues $ 56,113 $ 35,018 $ 146,259 $ 94,382
Operating expenses:        
Cost of revenues 30,974 20,933 87,744 58,123
Research and development 36,840 19,838 90,701 49,629
Selling, general and administrative 53,693 34,478 158,790 97,658
Change in fair value of contingent considerations and holdbacks (4,231) 1,887 (13,071) 1,887
Total operating expenses 117,276 77,136 324,164 207,297
Loss from operations (61,163) (42,118) (177,905) (112,915)
Interest income 722 86 1,134 377
Interest expense 0 (70) (54) (284)
Other income (expense), net (225) (312) (626) (305)
Loss before income taxes (60,666) (42,414) (177,451) (113,127)
Benefit from income taxes 149 2,377 10,703 2,271
Net loss attributable to common stockholders (60,517) (40,037) (166,748) (110,856)
Other comprehensive loss:        
Change in unrealized loss on investments (404) (12) (1,794) (10)
Foreign currency translation adjustment (498) 250 (129) 351
Comprehensive loss $ (61,419) $ (39,799) $ (168,671) $ (110,515)
Net loss per share attributable to common stockholders—basic (in usd per share) $ (1.08) $ (0.82) $ (3.15) $ (2.32)
Net loss per share attributable to common stockholders—diluted (in usd per share) $ (1.08) $ (0.82) $ (3.15) $ (2.32)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares) 56,287 48,963 53,005 47,881
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares) 56,287 48,963 53,005 47,881
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated Other comprehensive income
Accumulated deficit
Beginning balance (in shares) at Sep. 30, 2020   45,083      
Beginning balance at Sep. 30, 2020 $ 336,262 $ 0 $ 794,630 $ 87 $ (458,455)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)   3,136      
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses 323,861   323,861    
Net exercise of stock warrants (in shares)   22      
Vesting of restricted stock units (in shares)   178      
Exercise of stock options (in shares)   629      
Exercise of stock options 11,756   11,756    
Issuance of shares under the employee stock purchase plan (in shares)   49      
Issuance of shares under the employee stock purchase plan 2,787   2,787    
Repurchases of early exercised stock options (in shares)   (2)      
Repurchases of common stock for income tax withholding (in shares)   (69)      
Repurchases of common stock for income tax withholding (8,227)   (8,227)    
Issuance of shares from business acquisition (in shares)   237      
Issuance of shares from business acquisition 26,773   26,773    
Stock-based compensation 27,751   27,751    
Other comprehensive income 341     341  
Net loss (110,856)       (110,856)
Ending balance (in shares) at Jun. 30, 2021   49,263      
Ending balance at Jun. 30, 2021 610,448 $ 0 1,179,331 428 (569,311)
Beginning balance (in shares) at Mar. 31, 2021   48,860      
Beginning balance at Mar. 31, 2021 614,181 $ 0 1,143,265 190 (529,274)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Public offering expense adjustment (26)   (26)    
Vesting of restricted stock units (in shares)   57      
Exercise of stock options (in shares)   132      
Exercise of stock options 2,619   2,619    
Repurchases of common stock for income tax withholding (in shares)   (23)      
Repurchases of common stock for income tax withholding (2,476)   (2,476)    
Issuance of shares from business acquisition (in shares)   237      
Issuance of shares from business acquisition 26,773   26,773    
Stock-based compensation 9,176   9,176    
Other comprehensive income 238     238  
Net loss (40,037)       (40,037)
Ending balance (in shares) at Jun. 30, 2021   49,263      
Ending balance at Jun. 30, 2021 610,448 $ 0 1,179,331 428 (569,311)
Beginning balance (in shares) at Sep. 30, 2021   49,499      
Beginning balance at Sep. 30, 2021 580,821 $ 0 1,190,828 546 (610,553)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)   5,227      
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses 269,824   269,824    
Vesting of restricted stock units (in shares)   263      
Exercise of stock options (in shares)   417      
Exercise of stock options 4,701   4,701    
Issuance of shares under the employee stock purchase plan (in shares)   50      
Issuance of shares under the employee stock purchase plan 2,394   2,394    
Repurchases of common stock for income tax withholding (in shares)   (101)      
Repurchases of common stock for income tax withholding (6,130)   (6,130)    
Issuance of shares from business acquisition (in shares)   989      
Issuance of shares from business acquisition 77,122   77,122    
Stock-based compensation 60,616   60,616    
Other comprehensive income (1,923)     (1,923)  
Net loss (166,748)       (166,748)
Ending balance (in shares) at Jun. 30, 2022   56,344      
Ending balance at Jun. 30, 2022 820,677 $ 0 1,599,355 (1,377) (777,301)
Beginning balance (in shares) at Mar. 31, 2022   56,234      
Beginning balance at Mar. 31, 2022 863,361 $ 0 1,580,620 (475) (716,784)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses 6   6    
Vesting of restricted stock units (in shares)   100      
Exercise of stock options (in shares)   48      
Exercise of stock options 766   766    
Repurchases of common stock for income tax withholding (in shares)   (38)      
Repurchases of common stock for income tax withholding (2,080)   (2,080)    
Stock-based compensation 20,043   20,043    
Other comprehensive income (902)     (902)  
Net loss (60,517)       (60,517)
Ending balance (in shares) at Jun. 30, 2022   56,344      
Ending balance at Jun. 30, 2022 $ 820,677 $ 0 $ 1,599,355 $ (1,377) $ (777,301)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Stockholders’ Equity (unaudited) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2022
Jun. 30, 2021
Statement of Stockholders' Equity [Abstract]      
Net of underwriting discounts, commissions and offering expenses $ 17,676 $ 17,676 $ 21,139
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities    
Net loss $ (166,748) $ (110,856)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 11,562 7,319
Deferred tax liability (11,177) 0
Loss on disposal of property and equipment 0 2
Non-cash lease expense 2,594 1,044
Stock-based compensation 60,616 27,751
Discount accretion on investment securities 1,056 501
Realized gain on investments 0 (5)
Change in fair value of acquisition consideration (13,071) 1,887
Non-cash interest expense 3 58
Bad debt expense (146) 183
Amortization of debt discount 4 70
Write off property and equipment 70 0
Changes in assets and liabilities:    
Accounts receivable, net (10,284) (1,912)
Inventories (11,237) (8,914)
Prepaid expenses and other current assets (2,736) (1,617)
Other non-current assets 6,829 (2,333)
Accounts payable 466 5,194
Accrued expenses 608 1,546
Accrued compensation 5,519 4,588
Other liabilities 2,954 (1,947)
Net cash used in operating activities (123,118) (77,441)
Cash flows from investing activities    
Purchases of property and equipment (85,395) (18,972)
Business acquisition, net of cash acquired (8,160) (483)
Purchases of investments (217,639) (58,795)
Proceeds from maturity of investments 75,481 210,494
Net cash (used in) provided by investing activities (235,713) 132,244
Cash flows from financing activities    
Proceeds from exercise of stock options 4,764 11,686
Proceeds from public offerings, net of underwriting discounts, commissions and offering expenses 269,824 323,861
Proceeds from issuance of common stock under employee stock purchase plan 2,394 2,787
Repayments of long-term debt (1,558) (2,500)
Repurchases of common stock for income tax withholding (6,130) (8,227)
Net cash provided by financing activities 269,294 327,607
Effect of exchange rates on cash, cash equivalents and restricted cash (1) 153
Net increase (decrease) in cash, cash equivalents, and restricted cash (89,538) 382,563
Cash, cash equivalents, and restricted cash at beginning of period 467,359 94,246
Cash, cash equivalents, and restricted cash at end of period 377,821 476,809
Supplemental disclosure of cash flow information    
Interest paid 9 145
Income taxes paid, net of refunds 130 47
Non-cash investing and financing activities    
Property and equipment additions included in accounts payable and accrued expenses 6,562 1,777
Operating lease right-of-use assets obtained in exchange for operating lease liabilities 19,494 33,617
Issuance of common stock in connection with the business acquisition $ 77,122 $ 26,773
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2
The Company
9 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company The Company
Twist Bioscience Corporation (the Company) was incorporated in the state of Delaware on February 4, 2013. The Company is a synthetic biology company that has developed a disruptive DNA synthesis platform. DNA is used in many applications across different industries: industrial chemicals/materials, academic, healthcare and food/agriculture. The Company’s fiscal year ends on September 30.
The Company has generated net losses in all periods since its inception. As of June 30, 2022, the Company had an accumulated deficit of $777.3 million and has not generated positive cash flows from operations since inception. Losses are expected to continue as the Company continues to invest in product development, manufacturing, and sales and marketing.
Since its inception, the Company has received an aggregate of $1,333.7 million in net proceeds from the issuance of equity securities and an aggregate of $13.8 million from debt. Management believes that these proceeds combined with existing cash balances on hand will be sufficient to fund operations for at least one year from the issuance of these consolidated financial statements. However, if the Company needs to obtain additional financing to fund operations beyond this period, there can be no assurance that it will be successful in raising additional financing on terms which are acceptable to the Company.
If the Company requires but is unable to obtain additional funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.
During the three and nine months ended June 30, 2022, financial results of the Company were not significantly affected by the COVID-19 pandemic, which continues to have global impact. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which continue to evolve and are difficult to predict, including mutations in the SARS-CoV-2 virus, which have resulted and may in the future result in strains that are more contagious and less responsive to current treatment methods, and current or future domestic and international actions to contain it and treat it.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies
9 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of significant accounting policies Summary of significant accounting policies
Basis of presentation and use of estimates
The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2021 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 23, 2021. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2021 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three and nine months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending September 30, 2022 or any interim period.
The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. The Company consolidates Revelar Biotherapeutics, Inc. (“Revelar”) as a variable interest entity (“VIE”) for which it is the primary beneficiary (see Note 14 “Investment in variable interest entity” for further information). All intercompany balances and accounts are eliminated in consolidation.
The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows:

(in thousands)June 30,
2022
September 30,
2021
Cash and cash equivalents$376,249 $465,829 
Restricted cash, non-current1,572 1,530 
Total cash, cash equivalents and restricted cash$377,821 $467,359 

Significant accounting policies
There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K other than the following variable interest entities policy.
Variable interest entities
The Company consolidates a VIE in which the Company is deemed to be the primary beneficiary. An entity is generally a VIE if it meets any of the following criteria: (i) the entity has insufficient equity to finance its activities without additional subordinated financial support from other parties, (ii) the equity investors cannot make significant decisions about the entity’s operations or (iii) the voting rights of some investors are not proportional to their obligations to absorb the expected losses of the entity or receive the expected returns of the entity and substantially all of the entity’s activities involve or are conducted on behalf of the investor with disproportionately few voting rights. The Company periodically makes judgments in determining whether its investees are VIEs and, for each reporting period, the Company assesses whether it is the primary beneficiary of its VIE. As of June 30, 2022, the Company was deemed the primary beneficiary of Revelar. See Note 14 “Investment in variable interest entity.”
Recent accounting pronouncements
Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considered the applicability and impact of all recent ASUs. ASUs not listed below were assessed and determined to be not applicable to the Company’s consolidated financial position and results of operations.
Recent accounting pronouncements adopted
In December 2019, the FASB issued ASU 2019 12, Simplifying the Accounting for Income Taxes. The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders’ equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. The Company adopted this standard effective October 1, 2021. The adoption of ASU 2019 12 did not have an impact on the Company’s consolidated financial statements for either period presented.
Recently issued accounting pronouncement not yet adopted
In November 2021, the FASB issued ASU 2021 10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.
In June 2016, the FASB issued ASU 2016 13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard requires entities to use the new “expected credit loss” impairment model for most financial assets measured at amortized cost, including trade and other receivables and held-to-maturity debt securities, and modifies the impairment model for available-for-sale debt securities. The standard is effective for the
Company for the fiscal year ending September 30, 2024, including interim periods within that fiscal year. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value measurement
9 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair value measurement Fair value measurement
The Company assesses the fair value of financial instruments based on the provisions of ASC 820, Fair Value Measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company short-term and long-term investments primarily utilize broker quotes in a non-active market for valuation of its investments.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.
As of June 30, 2022, financial assets and liabilities measured and recognized at fair value are as follows:

(in thousands)Level 1Level 2Level 3Fair value
Assets    
Money market funds$324,824 $— $— $324,824 
Commercial paper— 39,977 — 39,977 
U.S. government treasury bills111,365 — — 111,365 
Total financial assets$436,189 $39,977 $— $476,166 
Liabilities
Contingent consideration and holdbacks$— $9,567 $3,300 $12,867 
Total financial liabilities $— $9,567 $3,300 $12,867 

As of September 30, 2021, financial assets and liabilities measured and recognized at fair value are as follows:

(in thousands)Level 1Level 2Level 3Fair value
Assets    
Money market funds$430,438 $— $— $430,438 
U.S. government treasury bills12,034— — 12,034
Total financial assets$442,472 $— $— $442,472 
Liabilities
Contingent consideration and indemnity holdback$— $9,856 $— $9,856 
Total financial liabilities$— $9,856 $— $9,856 
As of June 30, 2022 gross unrealized losses for cash equivalents and investments was $1.8 million. As of September 30, 2021, gross unrealized gains and unrealized losses for cash equivalents and investments were not material. As of June 30, 2022 and September 30, 2021, all marketable securities had a contractual maturity of less than one year.

The following table provides a reconciliation of beginning and ending balances of the Level 3 financial liabilities during the three months ended June 30, 2022:

(in thousands)Total
Balance as of September 30, 2021
$— 
Contingent consideration – additions8,500
Change in fair value (5,200)
Balance as of June 30, 2022
$3,300 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components
9 Months Ended
Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]  
Balance sheet components Balance sheet components
The Company’s accounts receivable, net balance consists of the following:

(in thousands)June 30,
2022
September 30,
2021
Trade receivables$36,615 $26,549 
Other receivables4,7582,337
Allowance for doubtful accounts(178)(337)
Accounts receivable, net$41,195 $28,549 

Inventories consist of the following:

(in thousands)June 30,
2022
September 30,
2021
Raw materials$30,909 $18,778 
Work-in-process3,8794,837
Finished goods8,2348,185
$43,022 $31,800 

The work-in-process inventory included gross consigned inventory of $1.5 million and $1.9 million as of June 30, 2022 and September 30, 2021, respectively.
Other non-current assets
The other non-current assets consist of the following:
(in thousands)June 30,
2022
September 30,
2021
Convertible note receivable$$3,021
Other non-current assets3,8724,653
$3,872$7,674
Accrued expenses
The accrued expenses consist of the following:
(in thousands)June 30,
2022
September 30,
2021
Professional services fees payable$5,044$5,057
Other accrued expenses4,4551,380
$9,499$6,437

Accrued compensation
The accrued compensation consists of the following:
(in thousands)June 30,
2022
September 30,
2021
Accrued vacation$6,285 $4,643 
Accrued bonus9,091 8,584 
Accrued commissions4,257 3,330 
Accrued payroll and related taxes5,932 4,676 
Other accrued compensation2,133 1,094 
$27,698 $22,327 

Other current liabilities
The other current liabilities consist of the following:
(in thousands)June 30,
2022
September 30,
2021
Contingent consideration and holdbacks$12,867$5,186
Income and sales taxes payable3,8512,440
Other current liabilities3,4051,997
$20,123 $9,623 

Other non-current liabilities
The other non-current liabilities consist of the following:

(in thousands) June 30,
2022
September 30,
2021
Holdback$$4,671
Other non current liabilities2,056397
$2,056$5,068
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and intangible assets
9 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and intangible assets Goodwill and intangible assets
During the nine months ended June 30, 2022, goodwill and intangible assets increased by $63.4 million and $46.5 million, respectively, as a result of a business acquisition. See Note 13, “Business acquisition”. Total amortization expense related to intangible assets was $1.4 million for the three months ended June 30, 2022 and less than $0.1 million for the three months ended June 30, 2021. Total amortization expense related to intangible assets was $3.6 million and $0.2 million for the nine months ended June 30, 2022 and 2021, respectively.
The intangible assets balances are presented below:

June 30, 2022
(in thousands, except for years)Weighted average
Amortization period
in years
Gross
carrying
amount
Accumulated
amortization
Net book
value
Developed Technology15$50,020 $(3,560)$46,460 
Customer Relationships1015,210 (1,280)13,930 
Tradenames & Trademarks3900 (175)725 
Total indefinite-lived intangible assets$66,130 $(5,015)$61,115 

September 30, 2021
(in thousands, except for years)Weighted average
Amortization period
in years
Gross
carrying
amount
Accumulated
amortization
Net book
value
Developed Technology16$19,120 $(1,361)$17,759 
Customer Relationships2510 (7)503 
Total indefinite-lived intangible assets$19,630 $(1,368)$18,262 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and contingencies
9 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
The Company may be subject to litigation, claims and disputes in the ordinary course of business. There is an inherent risk in any litigation or dispute and no assurance can be given as to the outcome of any claims.
Indemnifications
In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by corporate law. The Company also has directors’ and officers’ insurance.
Leases
The Company leases certain of its facilities under non-cancellable operating leases expiring at various dates through 2044. The Company is also responsible for utilities, maintenance, insurance, and property taxes under these leases.
Certain leases include options to renew or terminate at the Company’s discretion. The lease terms include periods covered by these options if it is reasonably certain the Company will renew or not terminate. The Company’s lease agreements do not contain any material residual value guarantees or restrictive covenants.
Supplemental balance sheet information related to the Company’s operating leases as of June 30, 2022 was as follows:
(in thousands)June 30,
2022
Assets: 
Operating lease right-of-use asset$76,165 
Current liabilities:
Current portion of operating lease liabilities$14,352 
Noncurrent liabilities:
Operating lease liabilities, net of current portion$64,244 

Future minimum lease payments under all non-cancelable operating leases that have commenced as of June 30, 2022 are as follows:

(in thousands)Operating
leases
Years ending September 30: 
Remainder of 2022
$3,281 
202313,990
202413,385
202513,724
202612,298
Thereafter97,081
Total minimum lease payments$153,759 
Less: imputed interest(57,737)
Less: tenant improvement allowance (receipt anticipated in 2022)
(17,426)
Total operating lease liabilities$78,596 
Less: current portion(14,352)
Operating lease liabilities, net of current portion$64,244 

For the remainder of 2022, future minimum lease payments are comprised of the anticipated receipt of tenant improvement allowances totaling $17.4 million anticipated to be received in 2022, partially offset by non-cancelable operating lease payments of $3.3 million. The statement of cash flows for the nine months ended June 30, 2022, include changes in right-of-use assets and operating lease liabilities of $14.6 million and $17.2 million, respectively. For the nine months ended June 30, 2021, changes in right-of-use assets and operating lease liabilities were $29.1 million and $30.1 million, respectively.
During the three and nine months ended June 30, 2022, operating lease expense was $4.1 million and $11.5 million, respectively. Cash payments for amounts included in the measurement of operating lease liabilities were $3.7 million and $9.1 million for the three and nine months ended June 30, 2022, respectively. As of June 30, 2022, the weighted-average remaining lease term was 15.5 years and the weighted-average discount rate was 6.4%.
On July 28, 2021, the Company entered into a 7-year operating lease for approximately 21,000 square-feet of office space located in South San Francisco, California, to further expand the Company operations. Upon execution of the lease agreement, the Company provided the landlord an approximate $0.2 million security deposit. The Company will pay an initial annual base rent of approximately $1.7 million, which is subject to scheduled 3% annual increases, plus certain operating expenses. The Company has the right to sublease the facility, subject to landlord consent. The lease commenced on October 1, 2021. As of lease commencement date, the total future minimum lease payments under the agreement were $13.1 million.

On August 6, 2021, Abveris, which was subsequently acquired by the Company, entered into a 10-year, 5-month operating lease for approximately 22,000 square-feet of office space located in Quincy, Massachusetts, to further expand operations. Upon execution of the lease agreement, the Company provided the landlord an approximate $0.6 million irrevocable letter of credit as a security deposit. The Company will pay an initial annual base rent of approximately $1.2 million, which is subject to scheduled 2% annual increases, plus certain operating expenses. The Company has the right to sublease the
facility, subject to landlord consent. The lease commenced on March 3, 2022. As of lease commencement date, the total future minimum lease payments under the agreement were $13.2 million.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Related party transactions
9 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
Related party transactions Related party transactionsDuring the three months ended June 30, 2022 and 2021, the Company purchased raw materials from a related party investor in the amount of $3.1 million and $1.2 million, respectively. During the nine months ended June 30, 2022 and 2021, the Company purchased raw materials from a related party in the amount of $6.5 million and $3.5 million, respectively. Payable balances and receivable balances with the related party were immaterial as of June 30, 2022 and September 30, 2021.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Income taxes
9 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
Income taxes Income taxesIn determining quarterly provisions for income taxes, the Company uses the annual estimated effective tax rate applied to the actual year-to-date profit or loss, adjusted for discrete items arising in that quarter. The Company’s annual estimated effective tax rate differs from the U.S. federal statutory rate primarily as a result of state taxes, foreign taxes, and changes in the Company’s valuation allowance against its deferred tax assets. For the three and nine months ended June 30, 2022, the Company recorded $0.1 million and $10.7 million income tax benefit mainly due to the deferred tax liability assumed as part of the acquisition of AbX Biologics, Inc. (see Note 13, “Business acquisition”). For the three and nine months ended June 30, 2021, the Company recorded $2.4 million and $2.3 million income tax benefit due to the deferred tax liability assumed as part of the Business acquisition.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Common stock
9 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Common stock Common stockIn December 2020, the Company completed an underwritten public offering of 3,136,362 shares of its common stock at a price to the public of $110.00 per share, including the full exercise of underwriters’ option to purchase an additional 409,090 shares of common stock. The Company received total net proceeds from the offering of $323.9 million, net of estimated underwriting discounts and commissions and offering expenses.In February 2022, the Company completed an underwritten public offering of 5,227,272 shares of its common stock at a price to the public of $55.00 per share, including the full exercise of underwriters’ option to purchase an additional 681,818 shares of common stock. The Company received total net proceeds from the offering of $269.8 million, net of underwriting discounts and commissions and offering expenses.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation
9 Months Ended
Jun. 30, 2022
Share-based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
2018 Equity Incentive Plan

Any shares subject to outstanding awards under the 2013 Plan that are canceled or repurchased subsequent to the 2018 Plan’s effective date are returned to the pool of shares reserved for issuance under the 2018 Plan. Awards granted under the 2018 Plan may be non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, and performance units.

Restricted Stock Units

Restricted stock primarily consists of restricted stock unit awards (RSUs) which have been granted to employees. The value of an RSU award is based on the Company’s stock price on the date of grant. Forfeitures of RSUs are recognized as they occur. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock.

Activity with respect to the Company’s restricted stock units during the nine months ended June 30, 2022 was as follows:
(in thousands, except per share data)Number
of
Shares
Weighted
average
grant date
fair value
per share
Weighted
average
remaining
contractual
term (years)
Aggregate
Intrinsic
Value
Outstanding at September 30, 2021
698$73.27 2.7$74,613 
Restricted stock units granted94672.37
Restricted stock units vested(263)72.53
Restricted stock units forfeited(125)75.37
Outstanding at June 30, 2022
1,256$72.54 2.9$43,883 
Expected to vest at June 30, 2022
1,256$72.54 2.9$43,883 

As of June 30, 2022, there was $83.4 million of total unrecognized compensation cost related to these issuances that is expected to be recognized over a weighted average period of 2.9 years.
Performance Stock Units
Performance stock unit awards (“PSUs”) were granted to certain employees that will vest upon achievement of operational milestones related to the Wilsonville facility, to Company executives that will vest upon achievement of revenue and gross profit metrics as determined by the board, and to certain consultants that will vest upon achievement of operational milestones. Stock compensation expense for PSUs is recorded over the vesting period based on the grant date fair value of the awards and probability of the achievement of specified performance targets. The grant date fair value is equal to the closing share price of the Company’s common stock on the date of grant. PSUs generally vest over a one to three-year service period following the grant date, provided that the recipient is a Company employee at the time of vesting and the achievement of performance targets applicable to each award. The percentage of PSUs that vest will depend on the achievement of specified performance targets at the end of the performance period and can range from 0% to 150% of the number of units granted. Forfeitures of PSUs are recognized as they occur. As of June 30, 2022, the unrecognized compensation costs related to these awards was $29.4 million. The Company expects to recognize those costs over a weighted average period of 1.7.

Activity under the PSUs during the nine months ended June 30, 2022 is summarized below:
(in thousands, except per share data)Number of sharesWeighted average grant date fair valueWeighted average remaining contractual termAggregate intrinsic value
Outstanding at September 30, 2021
10$3.59 2.3$1,016 
Performance stock units granted63178.83
Performance stock units vested(13)31.29
Performance stock units forfeited(53)85.32
Outstanding at June 30, 2022
575$84.93 1.7$20,099 
Vested or expected to vest and exercisable at June 30, 2022
575$84.93 1.7$20,099 

Options
Stock options entitle the holder to purchase, at the end of the vesting term, a specified number of shares of Company common stock at an exercise price per share equal to the closing market price of the common stock on the date of grant. Stock options typically have a contractual life from the date of the grant and a vesting schedule as established by the board of directors. The fair value of each services based stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company historically had been a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, it estimated its expected stock price volatility based on the historical volatility of publicly traded peer companies through the period ended June 30, 2022 and utilized the “simplified” method for awards that qualify as “plain-vanilla” options. As determined under the simplified method, the expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award, the risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award, the expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Forfeitures of options are recognized as they occur.
(in thousands, except per share data)Number of sharesWeighted average exercise priceWeighted average remaining contractual termAggregate intrinsic value
Outstanding at September 30, 2021
2,875 $22.83 7.1$242,012 
Options granted22326.36
Options vested(416)11.509,845 
Options forfeited(135)32.02
Outstanding at June 30, 2022
2,547$24.80 6.6$34,111 
Vested or expected to vest and exercisable at June 30, 2022
2,547$24.80 6.6$34,111 
As of June 30, 2022, the unrecognized compensation costs related to these awards was $15.4 million. The Company expects to recognize those costs over a weighted average period of 1.3.
Performance Stock Options
On September 1, 2020, the board of directors approved the implementation of a revised annual equity award program for executive officers, senior level employees and consultants to be granted as performance-based stock options ("PSOs") under the 2018 Plan. The number of PSOs ultimately earned under the awards to executive officers and senior level employees is calculated based on the achievement of a certain total revenue threshold during the fiscal year ending September 30, 2022. The percentage of performance stock options that vest will depend on the board of directors’ determination of total revenue at the end of the performance period and can range from 0% to 150% of the number of options granted. The number of PSOs ultimately earned under the awards to a consultant is calculated based on the achievement of certain operational milestones.

The provisions of the PSO are considered a performance condition, and the effects of that performance condition are not reflected in the grant date fair value of the awards. The Company used the Black-Scholes method to calculate the fair value at the grant date without regard to the vesting condition and will recognize compensation cost for the options that are expected to vest. Forfeitures of PSOs are recognized as they occur. The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. As of June 30, 2022, the Company determined that 293,730 shares are expected to vest based on the probability of the performance condition that will be achieved under this equity award program.

Activity under the equity incentive plans during the nine months ended June 30, 2022 is summarized below:

(in thousands, except per share data)Number of sharesWeighted average exercise priceWeighted average remaining contractual termAggregate intrinsic value
Outstanding at September 30, 2021
257$70.62 8.9$9,331 
Performance stock options granted7520.02
Performance stock options vested(19)19.16296 
Performance stock options forfeited(19)67.85
Outstanding at June 30, 2022
294$63.27 8.5$206 
Vested or expected to vest and exercisable at June 30, 2022
294$63.27 8.5$206 


As of June 30, 2022, the unrecognized compensation costs related to these awards was $2.3 million. The Company expects to recognize those costs over a weighted average period of 0.7 years.

Total stock-based compensation expense recognized was as follows:
Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Cost of revenues$1,228 $773 $3,347 $1,990 
Research and development5,6422,75314,5067,180
Selling, general and administrative12,9895,65042,41018,581
Total stock-based compensation$19,859 $9,176 $60,263 $27,751 

2018 Employee Stock Purchase Plan
On September 26, 2018, the board of directors adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"). The number of shares reserved for issuance under the 2018 ESPP upon approval was 275,225 shares of the Company’s common stock, and it increases automatically on the first day of each fiscal year, following the fiscal year in which the 2018 ESPP becomes effective, by a number equal to the least of 249,470 shares, 1% of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. The number of shares reserved for issuance at June 30, 2022 was as follows:

(In thousands)Shares
available
Outstanding at September 30, 2021
355
Additional shares authorized249
Shares issued during the period(50)
Outstanding at June 30, 2022
554

Subject to any plan limitations, the 2018 ESPP allows eligible service providers (through qualified and non-qualified offerings) to contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The offering periods begin in February and August of each year, except for the initial offering period which commenced with the initial public offering in October 2018 and ended on August 20, 2019. The common shares issuable under the 2018 ESPP were registered pursuant to a registration statement on Form S-8 on November 26, 2018.
Unless otherwise determined by the board of directors, the Company’s common stock will be purchased for the accounts of employees participating in the 2018 ESPP at a price per share that is the lesser of 85% of the fair market value of the Company’s common stock on the first and last trading day of the offering period. During the three and nine months ended June 30, 2022 and 2021, activity under the 2018 ESPP was immaterial.

Abveris Acquisition
As discussed further in Note 13 “Business acquisition”, on December 1, 2021, the Company completed the acquisition of AbX Biologics, Inc. and granted certain equity awards to new employees. These equity awards included up to 231,876 restricted shares of the Company’s common stock which are issuable based on achievement of the 2022 calendar revenue target, which had an aggregate grant date fair value of $20.1 million. In addition, all employees must remain employed through the payout date, and certain employees have an additional vesting period of up to two years from the acquisition date. The vesting upon achievement of the 2022 calendar revenue target is considered a performance condition, and the effects of that performance condition are not reflected in the grant date fair value of the awards. The Company used the stock price as of December 1, 2021 for the fair value of restricted shares. As of June 30, 2022, the Company determined that 200,673 shares are expected to vest based on the probability of the performance condition that will be achieved under this equity award program. The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. The Company recorded approximately $7.8 million in stock-based compensation expense for the nine months ended June 30, 2022 related to these awards. The grant date fair value was determined to be $87.06 per share for restricted shares. As of June 30, 2022, the unrecognized compensation costs related to these awards were $9.7 million. The Company expects to recognize those costs over a weighted average period of 0.8 years.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Net loss per share attributable to common stockholders
9 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Net loss per share attributable to common stockholders Net loss per share attributable to common stockholdersThe following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders:
Three months ended
June 30,
Nine months ended
June 30,
(in thousands, except per share data)2022202120222021
Numerator:  
Net loss attributable to common stockholders$(60,517)$(40,037)$(166,748)$(110,856)
Denominator:
Weighted average shares used in computing net loss per share, basic and diluted56,28748,96353,00547,881
Net loss per share attributable to common stockholders, basic and diluted$(1.08)$(0.82)$(3.15)$(2.32)

The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows:

Three and nine months ended
June 30,
(in thousands)20222021
Shares subject to options to purchase common stock2,5473,339
Shares subject to performance-based stock options294
Unvested restricted stock units and performance stock units 1,831726
Unvested shares of common stock issued upon early exercise of stock options6
Shares subject to employee stock purchase plan6621
Total4,7384,092
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Geographic, product and industry information
9 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Geographic, product and industry information Geographic, product and industry information
The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States of America, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia.

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Americas$35,797 $19,264 $87,636 $55,161 
EMEA15,48212,65845,20731,694
APAC4,8343,09613,4167,527
Total$56,113 $35,018 $146,259 $94,382 

The table below sets forth revenues by products.

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Synthetic genes$17,400 $11,164 $45,088 $29,228 
Oligo pools3,2592,0178,7555,367
DNA libraries1,4221,1474,6504,188
Antibody discovery6,2421,99317,6434,379
NGS tools27,79018,69770,12351,220
Total$56,113 $35,018 $146,259 $94,382 
The table below sets forth revenues by industry.

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Industrial chemicals/materials$16,733 $9,422 $43,533 $25,214 
Academic research9,5017,74826,87318,297
Healthcare29,43717,35674,40849,896
Food/agricultural4424921,445975
Total$56,113 $35,018 $146,259 $94,382 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Business acquisition
9 Months Ended
Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Business acquisition Business acquisition
On December 1, 2021, the Company acquired all of the outstanding stock of AbX Biologics, Inc. (“Abveris”), a privately-held company providing in vivo antibody discovery services. Abveris offers animal-based antibody discovery and screening services for its customers using the Berkeley Lights Beacon Platform and its proprietary DiversimAb and DivergimAb mouse models, which the Company can humanize using its antibody optimization solution.
The acquisition date fair value of the consideration transferred for Abveris was $102.6 million, consisting of cash totaling $9.5 million, 759,601 shares of the Company’s common stock valued at $66.1 million based on the Company’s closing stock price on December 1, 2021, employee stock awards issued to certain Abveris employees valued at $6.4 million, contingent consideration of $8.5 million, holdbacks of $12.8 million, and an estimated net working capital adjustment of $0.7 million.
The contingent consideration is subject to the attainment of the calendar year 2022 revenue target. The contingent consideration becomes payable after December 31, 2022 and will be settled in a combination of cash and up to 334,939 shares of the Company’s common stock. The acquisition date fair value of the contingent consideration was based on forecasted revenue of Abveris relative to the 2022 revenue target as well as the Company’s stock price as of December 1, 2021.
The Company maintains an indemnity and adjustment holdback for the purposes of providing security against any adjustment to the amounts at closing. The indemnity holdback period extends for 18 months from the anniversary of the closing date. The indemnity holdback will be settled by transferring up to 128,351 shares of the Company’s stock, 15,304 options of the Company’s common stock and an immaterial amount of cash. The fair value of the indemnity holdback was $12.5 million as of the acquisition date. The adjustment holdback will be settled by transferring up to 3,416 shares of the Company’s stock, 408 options of the Company’s common stock and an immaterial amount of cash. The holdback adjustment liability was $0.3 million as of the acquisition date.
Additionally, a working capital adjustment of $0.7 million decreased the total purchase price. The purchase price continues to be subject to adjustment for working capital adjustments as allowed under terms of the agreement.
Post-combination compensation expense excluded from the purchase price includes employee stock awards issued to certain Abveris employees valued at $41.0 million. This includes awards valued at $17.7 million which vest over a two year service period following the acquisition date and awards valued at $3.2 million with no future vesting requirements, which were deemed accelerated by the Company at the acquisition date and expensed within the three months ended December 31, 2021. Finally, post-combination expense includes awards valued at approximately $17.5 million which vest based on achievement of the calendar year 2022 revenue target and continuing employment through the payout date, and for certain employees, additional continuing employment through the two years anniversary of the acquisition date.
This acquisition was accounted for using the acquisition method of accounting in accordance with the business combination guidance in ASC 805. Under the acquisition accounting method, the total estimated purchase price was allocated to the identifiable assets acquired and liabilities assumed based on their fair values. The excess of the purchase price over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed has been recorded as goodwill. Management’s estimate of the fair values of the acquired intangible assets at December 1, 2021 is preliminary and subject to change and is based on established and accepted valuation techniques performed with the assistance of third-party valuation specialists. Additional information, which existed as of the acquisition date but is yet unknown to the Company, may become known to the Company during the remainder of the measurement period, which will not exceed twelve months from the acquisition date. Changes to amounts will be recorded as adjustments to the provisional amounts recognized as of the acquisition date and may result in a corresponding adjustment to goodwill in the
period in which new information becomes available. The goodwill that arose from the acquisition consists of synergies expected from integrating Abveris into the Company’s operations and customer base. The goodwill recognized is not expected to be deductible for income tax purposes.

The following table summarizes the preliminary fair value amounts of the assets acquired and liabilities assumed as of the acquisition date, as well as the purchase consideration:

(in thousands)December 1, 2021
Assets acquired 
Cash and cash equivalents$1,306 
Accounts receivable2,309
Other current assets and prepaid expenses1,654
Property, plant and equipment 1,078
Other non-current assets2,970
Intangible assets46,500
Liabilities assumed
Current liabilities3,549
Non-current liabilities846
Deferred tax liability10,545
Fair value of assets acquired and liabilities assumed$40,877 
Goodwill61,768
Total purchase price$102,645 
Consideration transferred
Cash$9,467 
Company common stock72,514
Contingent consideration8,500
Holdback liabilities12,838
Net working capital adjustment(674)
Fair value of purchase consideration$102,645 

The following table summarizes the preliminary estimate of the intangible assets as of the acquisition date:

(in thousands except for years)Estimated
Weighted
Average
Useful Lives
in Years
Estimated Fair
Value
Developed technology14$30,900
Customer relationships1014,700
Trade name3900
Estimated fair value of acquired intangible assets$46,500

The Company estimated the fair value of the developed technology intangible asset and a portion of the customer relationships intangible assets using an excess earnings model. An additional portion of the customer relationships intangible assets was valued using the with and without method. The Company estimated the fair value of the trade name intangible asset using a relief from royalty approach. These fair value measurements were based on significant inputs not observable in the market and thus represent a Level 3 measurement. Key assumptions include the level and timing of expected future revenue, conditions and demands specific to each intangible asset over its remaining useful life, and discount rates the Company believes to be consistent with the inherent risks associated with each type of asset, which was approximately 9.6%. The fair value of these intangible assets is primarily affected by the projected revenues, gross margins, operating expenses, the technology obsolescence curve, and the anticipated timing of the projected income
associated with each intangible asset coupled with the discount rates used to derive their estimated present values. The Company believes the level and timing of expected future cash flows appropriately reflects market participant assumptions.
The Company included the financial results of Abveris in its condensed consolidated financial statements from the date of acquisition. The Company incurred transaction costs related to the acquisition of $1.5 million, which were recorded as an operating expense on the condensed consolidated statements of operations and comprehensive loss for the nine months ended June 30, 2022.
The following table provides a reconciliation of contingent consideration and holdbacks balances from acquisition date to June 30, 2022:

(in thousands)Contingent
consideration
HoldbacksTotal
Balance at December 1, 2021 – acquisition date $8,500 $12,164 $20,664 
Change in fair value during the period (5,200)(7,097)(12,297)
Balance at June 30, 2022
$3,300 $5,067 $8,367 

The estimated fair value of the contingent consideration liability decreased as a result of the change in the Company’s stock price from December 1, 2021, and the probability of the attainment of the calendar year 2022 revenue target as calculated using the Monte Carlo simulation model. The estimated fair value of the holdback liability decreased as a result of the change in the Company’s stock price as of June 30, 2022. For the nine months ended June 30, 2022, the Company recognized a gain of $12.3 million relating to the change in fair value of acquisition consideration in its condensed consolidated statement of operations.
The post-combination effect from net deferred tax liability assumed from the Abveris acquisition also caused a release of the Company’s deferred income tax valuation allowance. On the acquisition date, the release resulted in an income tax benefit of $10.5 million.
The following unaudited pro forma financial information presents the combined results of operations for the Company and Abveris as if the Abveris acquisition had occurred on October 1, 2020. The pro forma information contains the actual operating results of the Company Abveris, adjusted to include the pro forma impact of acquisition, which is primarily additional expense as a result of the amortization of identifiable intangible assets. The unaudited pro forma financial information is prepared for comparative purposes only and does not purport to be indicative of the actual operating results that would have been recorded had the Abveris acquisition actually taken place on October 1, 2020 and should not be taken as indicative of future consolidated operating results. Additionally, the unaudited pro forma financial results do not include any anticipated synergies or other expected benefits from the Abveris acquisition.

Three months ended June 30,Nine months ended June 30,
(in thousands) 2022202120222021
Revenues$56,113 $37,600 $148,705 $102,713 
Net loss attributable to common stockholders$(60,517)$(38,853)$(165,681)$(106,461)

Issuance of contingent consideration for iGenomX acquisition
In December 2021, the Company determined that the transition milestones specified in the iGenomX acquisition agreement were completed, and the Company became obligated to issue 59,190 shares of its common stock to satisfy the contingent consideration. The shares of common stock, valued at $4.6 million, were subsequently issued by the Company during January 2022 along with an immaterial cash payment for fractional shares.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Investment in variable interest entity
9 Months Ended
Jun. 30, 2022
Investment in variable interest entity  
Investment in variable interest entity Investment in variable interest entityOn November 1, 2021, the Company contributed certain assets and licensed certain intellectual property rights to the newly formed Revelar Biotherapeutics, Inc. (“Revelar”), an independently operated, new biotechnology company, to develop and commercialize an antibody, discovered and optimized by Twist Biopharma, a division of the Company. The Company granted a license to Revelar for the exclusive development of an antibody lead along with a series of back up compounds for the potential treatment of SARS-CoV-2. While the licensed antibody neutralized all known variants of concern through Omicron, it does not neutralize the BA.4 and BA.5 variants and Revelar will pursue a partner for the antibody at this time. In addition, Revelar may license up to five additional antibody therapeutics over the next four years, each of which will be subject to additional upfront, milestone and royalty payments to the Company. The Company committed to invest up to
$10.0 million in seed funding based on Revelar’s progress in the development of the lead antibody and the potential licensing of additional antibody therapeutics, of which the Company made an initial investment of $5.0 million in a simple agreement for future equity (“SAFE”), and two additional investments of $2.5 million each, as of the date of these consolidated financial statements as described below. In exchange for the assignment of certain contractual rights and the license to the antibody, and its back-up compounds, the Company received stock of Revelar amounting to an ownership percentage as of the date of these financial statements of 49.80%, excluding shares and options reserved for future stock awards and further excluding shares that Revelar may issue to the Company upon conversion of its SAFEs.

On February 3, 2022, the Company purchased an additional SAFE issued by Revelar for $2.5 million pursuant to the Asset License and Contract Assignment Agreement between the parties. In exchange for the SAFE, the Company obtained the right to receive shares of Revelar issued in a future preferred stock financing.
On April 6, 2022, the Company purchased an additional SAFE issued by Revelar for $2.5 million pursuant to the Asset License and Contract Assignment Agreement between the parties. In exchange for the SAFE, the Company obtained the right to receive shares of Revelar issued in a future preferred stock financing.

The Company determined that Revelar is a VIE as the entity lacks sufficient equity to finance its activities without additional support. Additionally, the Company determined that it has (a) the power to direct the activities that significantly impact Revelar’s economic performance and (b) the obligation to absorb losses of, and the right to receive benefits from, Revelar that are potentially significant to Revelar. As a result, the Company is deemed to be the primary beneficiary of Revelar and is required to consolidate Revelar in accordance with ASC 810.

Revelar incurred a net loss of approximately $6.0 million and $13.1 million for the three and nine months ended June 30, 2022, and the decrease in net assets was fully absorbed by the Company.
Total assets included on the consolidated balance sheet for Revelar as of June 30, 2022 were $7.4 million, primarily consisting of cash and cash equivalents. Total liabilities included on the consolidated balance sheet for Revelar as of June 30, 2022 were $10.5 million, primarily consisting of accounts payable, accrued expenses and non-current liability relating to the SAFEs.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies (Policies)
9 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of presentation and use of estimates
Basis of presentation and use of estimates
The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2021 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 23, 2021. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2021 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three and nine months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending September 30, 2022 or any interim period.
The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. The Company consolidates Revelar Biotherapeutics, Inc. (“Revelar”) as a variable interest entity (“VIE”) for which it is the primary beneficiary (see Note 14 “Investment in variable interest entity” for further information). All intercompany balances and accounts are eliminated in consolidation.
Variable interest entities Variable interest entitiesThe Company consolidates a VIE in which the Company is deemed to be the primary beneficiary. An entity is generally a VIE if it meets any of the following criteria: (i) the entity has insufficient equity to finance its activities without additional subordinated financial support from other parties, (ii) the equity investors cannot make significant decisions about the entity’s operations or (iii) the voting rights of some investors are not proportional to their obligations to absorb the expected losses of the entity or receive the expected returns of the entity and substantially all of the entity’s activities involve or are conducted on behalf of the investor with disproportionately few voting rights. The Company periodically makes judgments in determining whether its investees are VIEs and, for each reporting period, the Company assesses whether it is the primary beneficiary of its VIE. As of June 30, 2022, the Company was deemed the primary beneficiary of Revelar.
Recent accounting pronouncements
Recent accounting pronouncements
Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considered the applicability and impact of all recent ASUs. ASUs not listed below were assessed and determined to be not applicable to the Company’s consolidated financial position and results of operations.
Recent accounting pronouncements adopted
In December 2019, the FASB issued ASU 2019 12, Simplifying the Accounting for Income Taxes. The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders’ equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. The Company adopted this standard effective October 1, 2021. The adoption of ASU 2019 12 did not have an impact on the Company’s consolidated financial statements for either period presented.
Recently issued accounting pronouncement not yet adopted
In November 2021, the FASB issued ASU 2021 10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.
In June 2016, the FASB issued ASU 2016 13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard requires entities to use the new “expected credit loss” impairment model for most financial assets measured at amortized cost, including trade and other receivables and held-to-maturity debt securities, and modifies the impairment model for available-for-sale debt securities. The standard is effective for the
Company for the fiscal year ending September 30, 2024, including interim periods within that fiscal year. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies (Tables)
9 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of Cash, Cash Equivalents and Restricted Cash
The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows:

(in thousands)June 30,
2022
September 30,
2021
Cash and cash equivalents$376,249 $465,829 
Restricted cash, non-current1,572 1,530 
Total cash, cash equivalents and restricted cash$377,821 $467,359 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value measurement (Tables)
9 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
As of June 30, 2022, financial assets and liabilities measured and recognized at fair value are as follows:

(in thousands)Level 1Level 2Level 3Fair value
Assets    
Money market funds$324,824 $— $— $324,824 
Commercial paper— 39,977 — 39,977 
U.S. government treasury bills111,365 — — 111,365 
Total financial assets$436,189 $39,977 $— $476,166 
Liabilities
Contingent consideration and holdbacks$— $9,567 $3,300 $12,867 
Total financial liabilities $— $9,567 $3,300 $12,867 

As of September 30, 2021, financial assets and liabilities measured and recognized at fair value are as follows:

(in thousands)Level 1Level 2Level 3Fair value
Assets    
Money market funds$430,438 $— $— $430,438 
U.S. government treasury bills12,034— — 12,034
Total financial assets$442,472 $— $— $442,472 
Liabilities
Contingent consideration and indemnity holdback$— $9,856 $— $9,856 
Total financial liabilities$— $9,856 $— $9,856 
Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments
The following table provides a reconciliation of beginning and ending balances of the Level 3 financial liabilities during the three months ended June 30, 2022:

(in thousands)Total
Balance as of September 30, 2021
$— 
Contingent consideration – additions8,500
Change in fair value (5,200)
Balance as of June 30, 2022
$3,300 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components (Tables)
9 Months Ended
Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]  
Summary of Accounts Receivable
The Company’s accounts receivable, net balance consists of the following:

(in thousands)June 30,
2022
September 30,
2021
Trade receivables$36,615 $26,549 
Other receivables4,7582,337
Allowance for doubtful accounts(178)(337)
Accounts receivable, net$41,195 $28,549 
Summary of Inventories
Inventories consist of the following:

(in thousands)June 30,
2022
September 30,
2021
Raw materials$30,909 $18,778 
Work-in-process3,8794,837
Finished goods8,2348,185
$43,022 $31,800 
Summary of Other Non-Current Assets
The other non-current assets consist of the following:
(in thousands)June 30,
2022
September 30,
2021
Convertible note receivable$$3,021
Other non-current assets3,8724,653
$3,872$7,674
Summary of Accrued Expenses
The accrued expenses consist of the following:
(in thousands)June 30,
2022
September 30,
2021
Professional services fees payable$5,044$5,057
Other accrued expenses4,4551,380
$9,499$6,437
Summary of Accrued Compensation
The accrued compensation consists of the following:
(in thousands)June 30,
2022
September 30,
2021
Accrued vacation$6,285 $4,643 
Accrued bonus9,091 8,584 
Accrued commissions4,257 3,330 
Accrued payroll and related taxes5,932 4,676 
Other accrued compensation2,133 1,094 
$27,698 $22,327 
Summary of Other Current Liabilities
The other current liabilities consist of the following:
(in thousands)June 30,
2022
September 30,
2021
Contingent consideration and holdbacks$12,867$5,186
Income and sales taxes payable3,8512,440
Other current liabilities3,4051,997
$20,123 $9,623 
Summary of Noncurrent Liabilities
The other non-current liabilities consist of the following:

(in thousands) June 30,
2022
September 30,
2021
Holdback$$4,671
Other non current liabilities2,056397
$2,056$5,068
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and intangible assets (Tables)
9 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of Intangible Assets
The intangible assets balances are presented below:

June 30, 2022
(in thousands, except for years)Weighted average
Amortization period
in years
Gross
carrying
amount
Accumulated
amortization
Net book
value
Developed Technology15$50,020 $(3,560)$46,460 
Customer Relationships1015,210 (1,280)13,930 
Tradenames & Trademarks3900 (175)725 
Total indefinite-lived intangible assets$66,130 $(5,015)$61,115 

September 30, 2021
(in thousands, except for years)Weighted average
Amortization period
in years
Gross
carrying
amount
Accumulated
amortization
Net book
value
Developed Technology16$19,120 $(1,361)$17,759 
Customer Relationships2510 (7)503 
Total indefinite-lived intangible assets$19,630 $(1,368)$18,262 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and contingencies (Tables)
9 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Supplemental Balance Sheet Information Relating to Companies Operating Lease Supplemental balance sheet information related to the Company’s operating leases as of June 30, 2022 was as follows:
(in thousands)June 30,
2022
Assets: 
Operating lease right-of-use asset$76,165 
Current liabilities:
Current portion of operating lease liabilities$14,352 
Noncurrent liabilities:
Operating lease liabilities, net of current portion$64,244 
Schedule of Future Minimum Rental Payments for Operating Leases
Future minimum lease payments under all non-cancelable operating leases that have commenced as of June 30, 2022 are as follows:

(in thousands)Operating
leases
Years ending September 30: 
Remainder of 2022
$3,281 
202313,990
202413,385
202513,724
202612,298
Thereafter97,081
Total minimum lease payments$153,759 
Less: imputed interest(57,737)
Less: tenant improvement allowance (receipt anticipated in 2022)
(17,426)
Total operating lease liabilities$78,596 
Less: current portion(14,352)
Operating lease liabilities, net of current portion$64,244 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation (Tables)
9 Months Ended
Jun. 30, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of Nonvested Restricted Stock Units Activity Activity with respect to the Company’s restricted stock units during the nine months ended June 30, 2022 was as follows:
(in thousands, except per share data)Number
of
Shares
Weighted
average
grant date
fair value
per share
Weighted
average
remaining
contractual
term (years)
Aggregate
Intrinsic
Value
Outstanding at September 30, 2021
698$73.27 2.7$74,613 
Restricted stock units granted94672.37
Restricted stock units vested(263)72.53
Restricted stock units forfeited(125)75.37
Outstanding at June 30, 2022
1,256$72.54 2.9$43,883 
Expected to vest at June 30, 2022
1,256$72.54 2.9$43,883 
Schedule of Nonvested Performance-based Units Activity
Activity under the PSUs during the nine months ended June 30, 2022 is summarized below:
(in thousands, except per share data)Number of sharesWeighted average grant date fair valueWeighted average remaining contractual termAggregate intrinsic value
Outstanding at September 30, 2021
10$3.59 2.3$1,016 
Performance stock units granted63178.83
Performance stock units vested(13)31.29
Performance stock units forfeited(53)85.32
Outstanding at June 30, 2022
575$84.93 1.7$20,099 
Vested or expected to vest and exercisable at June 30, 2022
575$84.93 1.7$20,099 
Schedule of Activity Under Option and Performance Stock Options
(in thousands, except per share data)Number of sharesWeighted average exercise priceWeighted average remaining contractual termAggregate intrinsic value
Outstanding at September 30, 2021
2,875 $22.83 7.1$242,012 
Options granted22326.36
Options vested(416)11.509,845 
Options forfeited(135)32.02
Outstanding at June 30, 2022
2,547$24.80 6.6$34,111 
Vested or expected to vest and exercisable at June 30, 2022
2,547$24.80 6.6$34,111 
Activity under the equity incentive plans during the nine months ended June 30, 2022 is summarized below:

(in thousands, except per share data)Number of sharesWeighted average exercise priceWeighted average remaining contractual termAggregate intrinsic value
Outstanding at September 30, 2021
257$70.62 8.9$9,331 
Performance stock options granted7520.02
Performance stock options vested(19)19.16296 
Performance stock options forfeited(19)67.85
Outstanding at June 30, 2022
294$63.27 8.5$206 
Vested or expected to vest and exercisable at June 30, 2022
294$63.27 8.5$206 
Schedule of Stock-Based Compensation Expenses Total stock-based compensation expense recognized was as follows:
Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Cost of revenues$1,228 $773 $3,347 $1,990 
Research and development5,6422,75314,5067,180
Selling, general and administrative12,9895,65042,41018,581
Total stock-based compensation$19,859 $9,176 $60,263 $27,751 
Summary of Stock Option Valuation Assumptions The number of shares reserved for issuance at June 30, 2022 was as follows:
(In thousands)Shares
available
Outstanding at September 30, 2021
355
Additional shares authorized249
Shares issued during the period(50)
Outstanding at June 30, 2022
554
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Net loss per share attributable to common stockholders (Tables)
9 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders:
Three months ended
June 30,
Nine months ended
June 30,
(in thousands, except per share data)2022202120222021
Numerator:  
Net loss attributable to common stockholders$(60,517)$(40,037)$(166,748)$(110,856)
Denominator:
Weighted average shares used in computing net loss per share, basic and diluted56,28748,96353,00547,881
Net loss per share attributable to common stockholders, basic and diluted$(1.08)$(0.82)$(3.15)$(2.32)
Summary of Calculation of Diluted Net Loss Per Share
The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows:

Three and nine months ended
June 30,
(in thousands)20222021
Shares subject to options to purchase common stock2,5473,339
Shares subject to performance-based stock options294
Unvested restricted stock units and performance stock units 1,831726
Unvested shares of common stock issued upon early exercise of stock options6
Shares subject to employee stock purchase plan6621
Total4,7384,092
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Geographic, product and industry information (Tables)
9 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Summary of Revenue by Geographic Region
The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States of America, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia.

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Americas$35,797 $19,264 $87,636 $55,161 
EMEA15,48212,65845,20731,694
APAC4,8343,09613,4167,527
Total$56,113 $35,018 $146,259 $94,382 
Summary of Revenue by Product
The table below sets forth revenues by products.

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Synthetic genes$17,400 $11,164 $45,088 $29,228 
Oligo pools3,2592,0178,7555,367
DNA libraries1,4221,1474,6504,188
Antibody discovery6,2421,99317,6434,379
NGS tools27,79018,69770,12351,220
Total$56,113 $35,018 $146,259 $94,382 
Summary of Revenue by Industry
The table below sets forth revenues by industry.

Three months ended
June 30,
Nine months ended
June 30,
(in thousands)2022202120222021
Industrial chemicals/materials$16,733 $9,422 $43,533 $25,214 
Academic research9,5017,74826,87318,297
Healthcare29,43717,35674,40849,896
Food/agricultural4424921,445975
Total$56,113 $35,018 $146,259 $94,382 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Business acquisition (Tables)
9 Months Ended
Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Summary of Preliminary Fair Value Amounts of Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary fair value amounts of the assets acquired and liabilities assumed as of the acquisition date, as well as the purchase consideration:

(in thousands)December 1, 2021
Assets acquired 
Cash and cash equivalents$1,306 
Accounts receivable2,309
Other current assets and prepaid expenses1,654
Property, plant and equipment 1,078
Other non-current assets2,970
Intangible assets46,500
Liabilities assumed
Current liabilities3,549
Non-current liabilities846
Deferred tax liability10,545
Fair value of assets acquired and liabilities assumed$40,877 
Goodwill61,768
Total purchase price$102,645 
Consideration transferred
Cash$9,467 
Company common stock72,514
Contingent consideration8,500
Holdback liabilities12,838
Net working capital adjustment(674)
Fair value of purchase consideration$102,645 
Summary of Preliminary Estimate of Intangible Assets
The following table summarizes the preliminary estimate of the intangible assets as of the acquisition date:

(in thousands except for years)Estimated
Weighted
Average
Useful Lives
in Years
Estimated Fair
Value
Developed technology14$30,900
Customer relationships1014,700
Trade name3900
Estimated fair value of acquired intangible assets$46,500
Schedule of Reconciliation of Contingent Consideration
The following table provides a reconciliation of contingent consideration and holdbacks balances from acquisition date to June 30, 2022:

(in thousands)Contingent
consideration
HoldbacksTotal
Balance at December 1, 2021 – acquisition date $8,500 $12,164 $20,664 
Change in fair value during the period (5,200)(7,097)(12,297)
Balance at June 30, 2022
$3,300 $5,067 $8,367 
Summary of Pro Forma Information
Three months ended June 30,Nine months ended June 30,
(in thousands) 2022202120222021
Revenues$56,113 $37,600 $148,705 $102,713 
Net loss attributable to common stockholders$(60,517)$(38,853)$(165,681)$(106,461)
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2
The Company (Details) - USD ($)
$ in Thousands
9 Months Ended
Jun. 30, 2022
Sep. 30, 2021
Class of Warrant or Right [Line Items]    
Accumulated deficit $ 777,301 $ 610,553
Subsequent Public Offering    
Class of Warrant or Right [Line Items]    
Proceeds of underwritten public offering common stock 1,333,700  
Proceeds from issuance of debt $ 13,800  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2020
Accounting Policies [Abstract]        
Cash and cash equivalents $ 376,249 $ 465,829    
Restricted cash, non-current 1,572 1,530    
Total cash, cash equivalents and restricted cash $ 377,821 $ 467,359 $ 476,809 $ 94,246
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Assets    
Total financial assets $ 476,166 $ 442,472
Liabilities    
Total financial liabilities 12,867 9,856
Money market funds    
Assets    
Total financial assets 324,824 430,438
Commercial paper    
Assets    
Total financial assets 39,977  
U.S. government treasury bills    
Assets    
Total financial assets 111,365 12,034
Contingent consideration and holdbacks    
Liabilities    
Total financial liabilities 12,867 9,856
Level 1    
Assets    
Total financial assets 436,189 442,472
Liabilities    
Total financial liabilities 0 0
Level 1 | Money market funds    
Assets    
Total financial assets 324,824 430,438
Level 1 | Commercial paper    
Assets    
Total financial assets 0  
Level 1 | U.S. government treasury bills    
Assets    
Total financial assets 111,365 12,034
Level 1 | Contingent consideration and holdbacks    
Liabilities    
Total financial liabilities 0 0
Level 2    
Assets    
Total financial assets 39,977 0
Liabilities    
Total financial liabilities 9,567 9,856
Level 2 | Money market funds    
Assets    
Total financial assets 0 0
Level 2 | Commercial paper    
Assets    
Total financial assets 39,977  
Level 2 | U.S. government treasury bills    
Assets    
Total financial assets 0 0
Level 2 | Contingent consideration and holdbacks    
Liabilities    
Total financial liabilities 9,567 9,856
Level 3    
Assets    
Total financial assets 0 0
Liabilities    
Total financial liabilities 3,300 0
Level 3 | Money market funds    
Assets    
Total financial assets 0 0
Level 3 | Commercial paper    
Assets    
Total financial assets 0  
Level 3 | U.S. government treasury bills    
Assets    
Total financial assets 0 0
Level 3 | Contingent consideration and holdbacks    
Liabilities    
Total financial liabilities $ 3,300 $ 0
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value measurement - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Fair Value Disclosures [Abstract]        
Change in unrealized loss on investments $ (404) $ (12) $ (1,794) $ (10)
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurement - Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments (Details)
$ in Thousands
9 Months Ended
Jun. 30, 2022
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Balance as of September 30, 2021 $ 0
Contingent consideration – additions 8,500
Change in fair value (5,200)
Balance as of June 30, 2022 $ 3,300
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components - Receivable (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]    
Trade receivables $ 36,615 $ 26,549
Other receivables 4,758 2,337
Allowance for doubtful accounts (178) (337)
Accounts receivable, net $ 41,195 $ 28,549
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components - Inventory (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]    
Raw materials $ 30,909 $ 18,778
Work-in-process 3,879 4,837
Finished goods 8,234 8,185
Total inventories $ 43,022 $ 31,800
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components - Narrative (Details) - USD ($)
$ in Millions
Jun. 30, 2022
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]    
Work-in-process inventory included gross consigned $ 1.5 $ 1.9
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components - Other non-current assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]    
Convertible note receivable $ 0 $ 3,021
Other non-current assets 3,872 4,653
Other non-current assets $ 3,872 $ 7,674
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components - Accrued expenses (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]    
Professional services fees payable $ 5,044 $ 5,057
Other accrued expenses 4,455 1,380
Accrued expenses $ 9,499 $ 6,437
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components - Accrued compensation (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]    
Accrued vacation $ 6,285 $ 4,643
Accrued bonus 9,091 8,584
Accrued commissions 4,257 3,330
Accrued payroll and related taxes 5,932 4,676
Other accrued compensation 2,133 1,094
Accrued compensation $ 27,698 $ 22,327
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components - Other current liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]    
Contingent consideration and holdbacks $ 12,867 $ 5,186
Income and sales taxes payable 3,851 2,440
Other current liabilities 3,405 1,997
Other current liabilities $ 20,123 $ 9,623
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2
Balance sheet components - Other non current liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]    
Holdback $ 0 $ 4,671
Other non current liabilities 2,056 397
Other non-current liabilities $ 2,056 $ 5,068
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and intangible assets - Goodwill (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Goodwill And Intangible Assets [Line Items]        
Total amortization expense related to intangible assets $ 1.4   $ 3.6  
iGenomX        
Goodwill And Intangible Assets [Line Items]        
Increase in goodwill     63.4  
Increase in intangible assets     $ 46.5  
Maximum        
Goodwill And Intangible Assets [Line Items]        
Total amortization expense related to intangible assets   $ 0.1   $ 0.2
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and intangible assets - Intangible Assets Balances (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Jun. 30, 2022
Sep. 30, 2021
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 66,130 $ 19,630
Accumulated amortization (5,015) (1,368)
Net book value $ 61,115 $ 18,262
Developed Technology    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted average Amortization period in years 15 years 16 years
Gross carrying amount $ 50,020 $ 19,120
Accumulated amortization (3,560) (1,361)
Net book value $ 46,460 $ 17,759
Customer Relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted average Amortization period in years 10 years 2 years
Gross carrying amount $ 15,210 $ 510
Accumulated amortization (1,280) (7)
Net book value $ 13,930 $ 503
Tradenames & Trademarks    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted average Amortization period in years 3 years  
Gross carrying amount $ 900  
Accumulated amortization (175)  
Net book value $ 725  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and contingencies - Operating Leases On Balance Sheet (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Assets:    
Operating lease right-of-use assets $ 76,165 $ 61,580
Current liabilities:    
Current portion of operating lease liability 14,352 8,213
Noncurrent liabilities:    
Operating lease liability, net of current portion $ 64,244 $ 53,156
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and contingencies - Minimum Rental Payments (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]    
Remainder of 2022 $ 3,281  
2023 13,990  
2024 13,385  
2025 13,724  
2026 12,298  
Thereafter 97,081  
Total minimum lease payments 153,759  
Less: imputed interest (57,737)  
Less: tenant improvement allowance (receipt anticipated in 2022) (17,426)  
Total operating lease liabilities 78,596  
Less: current portion (14,352) $ (8,213)
Operating lease liability, net of current portion $ 64,244 $ 53,156
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and contingencies - Lease Contracts (Details)
ft² in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Aug. 06, 2021
USD ($)
ft²
Jul. 28, 2021
USD ($)
ft²
Jun. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Mar. 03, 2022
USD ($)
Oct. 01, 2021
USD ($)
Other Commitments [Line Items]              
Tenant improvements     $ 17,400 $ 17,400      
Remainder of 2022     3,281 3,281      
Change in right-of-use asset       14,600 $ 29,100    
Change in operating lease liabilities.       17,200 $ 30,100    
Operating lease expense     4,100 11,500      
Operating lease payments     $ 3,700 $ 9,100      
Lease weighted-average remaining lease term     15 years 6 months 15 years 6 months      
Lease weighted average discount rate     6.40% 6.40%      
Future minimum payments     $ 153,759 $ 153,759      
South San Francisco, California              
Other Commitments [Line Items]              
Operating lease term   7 years          
Operating lease area | ft²   21          
Operating lease security deposit with the lessor   $ 200          
Initial annual base rent   $ 1,700          
Operating lease base rent annual percentage increase   3.00%          
Future minimum payments             $ 13,100
Quincy, Massachusetts              
Other Commitments [Line Items]              
Operating lease term 10 years 5 months            
Operating lease area | ft² 22            
Operating lease security deposit with the lessor $ 600            
Initial annual base rent $ 1,200            
Operating lease base rent annual percentage increase 2.00%            
Future minimum payments           $ 13,200  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.2
Related party transactions - (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Affiliated Entity        
Related Party Transaction [Line Items]        
Raw materials purchased from related party investor $ 3.1 $ 1.2 $ 6.5 $ 3.5
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.2
Income taxes (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Abx Biologics Inc.        
Income Tax Contingency [Line Items]        
Income tax benefit, due to deferred tax liability as part of business acquisition $ 0.1 $ 2.4 $ 10.7 $ 2.3
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.2
Common stock (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended
Feb. 28, 2022
Dec. 31, 2020
Subsequent Public Offering    
Class of Stock [Line Items]    
Sale of stock, shares issued (in shares) 5,227,272 3,136,362
Sale of stock, share price (in usd per share) $ 55.00 $ 110.00
Sale of stock, consideration received   $ 323.9
Over-Allotment Option    
Class of Stock [Line Items]    
Sale of stock, shares issued (in shares) 681,818 409,090
Sale of stock, consideration received $ 269.8  
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs)
$ / shares in Units, shares in Thousands, $ in Thousands
9 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Number of Shares    
Beginning balance (in shares) | shares 698  
Granted (in shares) | shares 946  
Vested (in shares) | shares (263)  
Forfeited (in shares) | shares (125)  
Ending balance (in shares) | shares 1,256 698
Expected to vest (in shares) | shares 1,256  
Weighted average grant date fair value per share    
Beginning balance (in usd per share) | $ / shares $ 73.27  
Granted (in usd per share) | $ / shares 72.37  
Vested (in usd per share) | $ / shares 72.53  
Forfeited (in usd per share) | $ / shares 75.37  
Ending balance (in usd per share) | $ / shares 72.54 $ 73.27
Expected to vest (in usd per share) | $ / shares $ 72.54  
Weighted average remaining contractual term (years)    
Weighted average remaining contractual term, Outstanding 2 years 10 months 24 days 2 years 8 months 12 days
Weighted average remaining contractual term, Expected to vest 2 years 10 months 24 days  
Aggregate Intrinsic Value    
Aggregate intrinsic value, Outstanding | $ $ 43,883 $ 74,613
Aggregate intrinsic value, Expected to vest | $ $ 43,883  
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Additional information (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 01, 2020
Sep. 26, 2018
Jun. 30, 2022
Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized compensation cost, options     $ 15.4  
Aggregate number of common stock shares reserved for issuance     554,000 355,000
2018 ESPP        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Aggregate number of common stock shares reserved for issuance   275,225    
Minimum annual increase in share reserved for issuance   249,470    
Annual automatic Increase in share reserved for issuance (as a percent)   1.00%    
Percentage of payroll deduction to purchase common stock   15.00%    
ESPP eligible employee common stock purchase price ratio   85.00%    
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized compensation cost, stock options     $ 83.4  
Unrecognized stock-based compensation expense, period for recognition     2 years 10 months 24 days  
Performance Stock Unit        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized stock-based compensation expense, period for recognition     1 year 8 months 12 days  
Share based compensation by share based payment arrangement equity instruments other than options unrecognized compensation     $ 29.4  
Performance Stock Unit | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period     1 year  
Percentage of PSUs that may vest based on performance     0.00%  
Performance Stock Unit | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period     3 years  
Percentage of PSUs that may vest based on performance     150.00%  
Option        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized stock-based compensation expense, period for recognition     1 year 3 months 18 days  
Expected dividend rate     0.00%  
Performance Stock Option        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized stock-based compensation expense, period for recognition     8 months 12 days  
Unrecognized compensation cost, options     $ 2.3  
Performance Stock Option | Executive Officers and Senior Level Employees        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares expected to vest     293,730  
Performance Stock Option | Minimum | Executive Officers and Senior Level Employees        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Percentage of PSUs that may vest based on performance 0.00%      
Performance Stock Option | Maximum | Executive Officers and Senior Level Employees        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Percentage of PSUs that may vest based on performance 150.00%      
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Summary of PSU Activity (Details) - Performance Stock Unit
$ / shares in Units, shares in Thousands, $ in Thousands
9 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Number of Shares    
Beginning balance (in shares) | shares 10  
Granted (in shares) | shares 631  
Vested (in shares) | shares (13)  
Forfeited (in shares) | shares (53)  
Ending balance (in shares) | shares 575 10
Expected to vest (in shares) | shares 575  
Weighted average grant date fair value per share    
Beginning balance (in usd per share) | $ / shares $ 3.59  
Granted (in usd per share) | $ / shares 78.83  
Vested (in usd per share) | $ / shares 31.29  
Forfeited (in usd per share) | $ / shares 85.32  
Ending balance (in usd per share) | $ / shares 84.93 $ 3.59
Expected to vest (in usd per share) | $ / shares $ 84.93  
Weighted average remaining contractual term (years)    
Weighted average remaining contractual term, Outstanding 1 year 8 months 12 days 2 years 3 months 18 days
Weighted average remaining contractual term, Expected to vest 1 year 8 months 12 days  
Aggregate Intrinsic Value    
Aggregate intrinsic value, Outstanding | $ $ 20,099 $ 1,016
Aggregate intrinsic value, Expected to vest | $ $ 20,099  
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Activity Under Options (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
9 Months Ended 12 Months Ended
Jun. 30, 2022
Sep. 30, 2021
Number of shares    
Beginning balance (in shares) 2,547 2,875
Granted (in shares) 223  
Vested (in shares) (416)  
Forfeited (in shares) (135)  
Ending balance (in shares) 2,547 2,875
Expected to vest (in shares) 2,547  
Weighted average exercise price    
Beginning balance (in usd per share) $ 22.83  
Granted (in usd per share) 26.36  
Vested (in usd per share) 11.50  
Forfeited (in usd per share) 32.02  
Ending balance (in usd per share) 24.80 $ 22.83
Expected to vest (in usd per share) $ 24.80  
Weighted average remaining contractual term (years)    
Weighted average remaining contractual term, Outstanding 6 years 7 months 6 days 7 years 1 month 6 days
Weighted average remaining contractual term, Expected to vest 6 years 7 months 6 days  
Aggregate intrinsic value    
Aggregate intrinsic value, Outstanding $ 34,111 $ 242,012
Aggregate intrinsic value, vest 9,845  
Aggregate intrinsic value, Expected to vest $ 34,111  
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Activity Under Performance Stock Options (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
9 Months Ended 12 Months Ended
Jun. 30, 2022
Sep. 30, 2021
Number of shares    
Beginning balance (in shares) 2,875  
Stock options granted (in shares) 223  
Vested (in shares) (416)  
Forfeited (in shares) (135)  
Ending balance (in shares) 2,547 2,875
Expected to vest (in shares) 2,547  
Weighted average exercise price    
Beginning balance (in usd per share) $ 22.83  
Granted (in usd per share) 26.36  
Vested (in usd per share) 11.50  
Forfeited (in usd per share) 32.02  
Ending balance (in usd per share) 24.80 $ 22.83
Expected to vest (in usd per share) $ 24.80  
Weighted average remaining contractual term (years)    
Weighted average remaining contractual term, Outstanding 6 years 7 months 6 days 7 years 1 month 6 days
Weighted average remaining contractual term, Expected to vest 6 years 7 months 6 days  
Aggregate intrinsic value    
Aggregate intrinsic value, Outstanding $ 34,111 $ 242,012
Aggregate intrinsic value, vest 9,845  
Aggregate intrinsic value, Expected to vest $ 34,111  
Performance Stock Option    
Number of shares    
Beginning balance (in shares) 257  
Stock options granted (in shares) 75  
Vested (in shares) (19)  
Forfeited (in shares) (19)  
Ending balance (in shares) 294 257
Expected to vest (in shares) 294  
Weighted average exercise price    
Beginning balance (in usd per share) $ 70.62  
Granted (in usd per share) 20.02  
Vested (in usd per share) 19.16  
Forfeited (in usd per share) 67.85  
Ending balance (in usd per share) 63.27 $ 70.62
Expected to vest (in usd per share) $ 63.27  
Weighted average remaining contractual term (years)    
Weighted average remaining contractual term, Outstanding 8 years 6 months 8 years 10 months 24 days
Weighted average remaining contractual term, Expected to vest 8 years 6 months  
Aggregate intrinsic value    
Aggregate intrinsic value, Outstanding $ 206 $ 9,331
Aggregate intrinsic value, vest 296  
Aggregate intrinsic value, Expected to vest $ 206  
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock based compensation expense $ 19,859 $ 9,176 $ 60,263 $ 27,751
Cost of revenues        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock based compensation expense 1,228 773 3,347 1,990
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock based compensation expense 5,642 2,753 14,506 7,180
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock based compensation expense $ 12,989 $ 5,650 $ 42,410 $ 18,581
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Reserved For Issuance (Details)
shares in Thousands
9 Months Ended
Jun. 30, 2022
shares
Share-Based Compensation Arrangement By Share-based Payment Award, Outstanding [Roll Forward]  
Beginning balance (in shares) 355
Additional shares authorized (in shares) 249
Shares issued during the period (in shares) (50)
Ending balance (in shares) 554
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Abveris Acquisition (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Dec. 01, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock based compensation expense   $ 19,859 $ 9,176 $ 60,263 $ 27,751
Abveris          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Awards aggregate fair value $ 20,100        
Vesting period 2 years        
Stock based compensation expense       7,800  
Unrecognized compensation cost   $ 9,700   $ 9,700  
Recognize cost weighted average period       9 months 18 days  
Abveris | Performance Shares          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Equity awards restricted shares 231,876        
Shares expected to vest   200,673   200,673  
Granted (in usd per share)       $ 87.06  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.22.2
Net loss per share attributable to common stockholders - Computation (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Numerator:        
Net loss attributable to common stockholders $ (60,517) $ (40,037) $ (166,748) $ (110,856)
Denominator:        
Weighted average shares used in computing net loss per share, basic (in shares) 56,287 48,963 53,005 47,881
Weighted average shares used in computing net loss per share, diluted (in shares) 56,287 48,963 53,005 47,881
Net loss per share attributable to common stockholders—basic (in usd per share) $ (1.08) $ (0.82) $ (3.15) $ (2.32)
Net loss per share attributable to common stockholders, diluted (in usd per share) $ (1.08) $ (0.82) $ (3.15) $ (2.32)
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.22.2
Net loss per share attributable to common stockholders - Anti-dilutive (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share amount (in shares) 4,738 4,092 4,738 4,092
Shares subject to options to purchase common stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share amount (in shares) 2,547 3,339 2,547 3,339
Shares subject to performance-based stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share amount (in shares) 294 0 294 0
Unvested restricted stock units and performance stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share amount (in shares) 1,831 726 1,831 726
Unvested shares of common stock issued upon early exercise of stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share amount (in shares) 0 6 0 6
Shares subject to employee stock purchase plan        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share amount (in shares) 66 21 66 21
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.22.2
Geographic, product and industry information - Geographic Region (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Segment Reporting Information [Line Items]        
Revenue $ 56,113 $ 35,018 $ 146,259 $ 94,382
Americas        
Segment Reporting Information [Line Items]        
Revenue 35,797 19,264 87,636 55,161
EMEA        
Segment Reporting Information [Line Items]        
Revenue 15,482 12,658 45,207 31,694
APAC        
Segment Reporting Information [Line Items]        
Revenue $ 4,834 $ 3,096 $ 13,416 $ 7,527
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.22.2
Geographic, product and industry information - By Product (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Segment Reporting Information [Line Items]        
Revenue $ 56,113 $ 35,018 $ 146,259 $ 94,382
Synthetic genes        
Segment Reporting Information [Line Items]        
Revenue 17,400 11,164 45,088 29,228
Oligo pools        
Segment Reporting Information [Line Items]        
Revenue 3,259 2,017 8,755 5,367
DNA libraries        
Segment Reporting Information [Line Items]        
Revenue 1,422 1,147 4,650 4,188
Antibody discovery        
Segment Reporting Information [Line Items]        
Revenue 6,242 1,993 17,643 4,379
NGS tools        
Segment Reporting Information [Line Items]        
Revenue $ 27,790 $ 18,697 $ 70,123 $ 51,220
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.22.2
Geographic, product and industry information - By Industry (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Segment Reporting Information [Line Items]        
Revenue $ 56,113 $ 35,018 $ 146,259 $ 94,382
Industrial chemicals/materials        
Segment Reporting Information [Line Items]        
Revenue 16,733 9,422 43,533 25,214
Academic research        
Segment Reporting Information [Line Items]        
Revenue 9,501 7,748 26,873 18,297
Healthcare        
Segment Reporting Information [Line Items]        
Revenue 29,437 17,356 74,408 49,896
Food/agricultural        
Segment Reporting Information [Line Items]        
Revenue $ 442 $ 492 $ 1,445 $ 975
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.22.2
Business acquisition - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 7 Months Ended 9 Months Ended
Dec. 01, 2021
Jan. 31, 2022
Dec. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2022
Jun. 30, 2021
Business Acquisition [Line Items]                
Income tax benefit       $ (149) $ (2,377)   $ (10,703) $ (2,271)
Abveris                
Business Acquisition [Line Items]                
Fair value of consideration transferred $ 102,645              
Cash consideration $ 9,467              
Equity (in shares) 759,601              
Common stock $ 66,100              
Options consideration 6,400              
Contingent consideration 8,500              
Indemnity holdbacks 12,800              
Net working capital adjustment $ 674              
Contingent consideration, shares issuable up to (in shares) 334,939              
Indemnity holdbacks period 18 months              
Indemnity holdback shares (in shares) 128,351              
Indemnity holdback options (in shares) 15,304              
Indemnity holdback consideration $ 12,500              
Adjustment holdback shares (in shares) 3,416              
Adjustment holdback options (in shares) 408              
Value of adjustment holdback $ 300              
Post combination compensation expenses includes employee stock awards     $ 41,000          
Vesting period from acquisition date 2 years              
Discount rate       9.60%   9.60% 9.60%  
Transaction costs             $ 1,500  
Change in fair value during the period           $ 12,297 $ (12,300)  
Income tax benefit $ 10,500              
Company common stock $ 72,514              
Abveris | Awards with vesting requirements                
Business Acquisition [Line Items]                
Post combination compensation expenses includes employee stock awards     $ 17,700          
Vesting period from acquisition date     2 years          
Abveris | Awards without vesting requirements                
Business Acquisition [Line Items]                
Post combination compensation expenses includes employee stock awards     $ 3,200          
Abveris | Performance Shares                
Business Acquisition [Line Items]                
Post combination compensation expenses includes employee stock awards     $ 17,500          
iGenomX                
Business Acquisition [Line Items]                
Contingent consideration (in shares)     59,190          
Company common stock   $ 4,600            
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.22.2
Business acquisition - Assets acquired and liabilities assumed (Details) - USD ($)
$ in Thousands
Dec. 01, 2021
Jun. 30, 2022
Sep. 30, 2021
Liabilities assumed      
Goodwill   $ 85,811 $ 22,434
Abveris      
Assets acquired      
Cash and cash equivalents $ 1,306    
Accounts receivable 2,309    
Other current assets and prepaid expenses 1,654    
Property, plant and equipment 1,078    
Other non-current assets 2,970    
Intangible assets 46,500    
Liabilities assumed      
Current liabilities 3,549    
Non-current liabilities 846    
Deferred tax liability 10,545    
Fair value of assets acquired and liabilities assumed 40,877    
Goodwill 61,768    
Total purchase price 102,645    
Consideration transferred      
Cash 9,467    
Company common stock 72,514    
Contingent consideration 8,500    
Holdback liabilities 12,838    
Net working capital adjustment (674)    
Fair value of purchase consideration $ 102,645    
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.22.2
Business acquisition - Preliminary estimate of the intangible assets (Details) - Abveris
$ in Thousands
Dec. 01, 2021
USD ($)
Business Acquisition [Line Items]  
Estimated Fair Value $ 46,500
Developed Technology  
Business Acquisition [Line Items]  
Estimated Weighted Average Useful Lives in Years 14 years
Estimated Fair Value $ 30,900
Customer Relationships  
Business Acquisition [Line Items]  
Estimated Weighted Average Useful Lives in Years 10 years
Estimated Fair Value $ 14,700
Trade name  
Business Acquisition [Line Items]  
Estimated Weighted Average Useful Lives in Years 3 years
Estimated Fair Value $ 900
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.22.2
Business acquisition - Change in contingent consideration (Details) - Abveris - USD ($)
$ in Thousands
7 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2022
Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward]    
Balance at December 1, 2021 – acquisition date $ 20,664  
Change in fair value during the period (12,297) $ 12,300
Balance at June 30, 2022 8,367 8,367
Contingent consideration    
Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward]    
Balance at December 1, 2021 – acquisition date 8,500  
Change in fair value during the period (5,200)  
Balance at June 30, 2022 3,300 3,300
Holdbacks    
Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward]    
Balance at December 1, 2021 – acquisition date 12,164  
Change in fair value during the period (7,097)  
Balance at June 30, 2022 $ 5,067 $ 5,067
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.22.2
Business acquisition - Pro forma financial results (Details) - Abveris - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Business Acquisition [Line Items]        
Revenues $ 56,113 $ 37,600 $ 148,705 $ 102,713
Net loss attributable to common stockholders $ (60,517) $ (38,853) $ (165,681) $ (106,461)
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.22.2
Investment in variable interest entity (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Apr. 06, 2022
USD ($)
Feb. 03, 2022
USD ($)
Nov. 01, 2021
USD ($)
therapeutic
Jun. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Variable Interest Entity [Line Items]            
Total assets [1]       $ 979,663 $ 979,663 $ 702,097
Total liabilities [1]       158,986 158,986 $ 121,276
Revelar            
Variable Interest Entity [Line Items]            
Additional SAFE issued $ 2,500 $ 2,500        
Variable Interest Entity, Primary Beneficiary            
Variable Interest Entity [Line Items]            
Total assets       7,429 7,429  
Total liabilities       10,494 10,494  
Variable Interest Entity, Primary Beneficiary | Revelar            
Variable Interest Entity [Line Items]            
Additional antibody therapeutics that may license | therapeutic     5      
Period of additional antibody therapeutics that maybe licensed     4 years      
Investment amount     $ 5,000      
Ownership percentage     49.80%      
Loss absorbed by reporting entity       6,000 13,100  
Total assets       7,400 7,400  
Total liabilities       $ 10,500 $ 10,500  
Variable Interest Entity, Primary Beneficiary | Revelar | Maximum            
Variable Interest Entity [Line Items]            
Investment amount     $ 10,000      
[1] The Company’s consolidated assets as of June 30, 2022 include $7,429 in assets of the variable interest entity, or “VIE”, that can only be used to settle obligations of the VIE. Cash as of June 30, 2022 was $6,989; prepaid expenses as of June 30, 2022 were $433 and deposits as of June 30, 2022 were $7. The Company’s consolidated liabilities as of June 30, 2022 were $10,494 in liabilities of the VIE who creditors have no recourse to the Company. These liabilities include accounts payable of $6,412 as of June 30, 2022; accrued expenses and other current liabilities of $2,082 as of June 30, 2022; and other non-current liabilities of $2,000 as of June 30, 2022.
XML 83 twst-20220630_htm.xml IDEA: XBRL DOCUMENT 0001581280 2021-10-01 2022-06-30 0001581280 2022-08-04 0001581280 2022-06-30 0001581280 2021-09-30 0001581280 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-06-30 0001581280 2022-04-01 2022-06-30 0001581280 2021-04-01 2021-06-30 0001581280 2020-10-01 2021-06-30 0001581280 us-gaap:CommonStockMember 2022-03-31 0001581280 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001581280 us-gaap:RetainedEarningsMember 2022-03-31 0001581280 2022-03-31 0001581280 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001581280 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001581280 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001581280 us-gaap:CommonStockMember 2022-06-30 0001581280 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001581280 us-gaap:RetainedEarningsMember 2022-06-30 0001581280 us-gaap:CommonStockMember 2021-03-31 0001581280 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001581280 us-gaap:RetainedEarningsMember 2021-03-31 0001581280 2021-03-31 0001581280 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001581280 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001581280 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001581280 us-gaap:CommonStockMember 2021-06-30 0001581280 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001581280 us-gaap:RetainedEarningsMember 2021-06-30 0001581280 2021-06-30 0001581280 us-gaap:CommonStockMember 2021-09-30 0001581280 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001581280 us-gaap:RetainedEarningsMember 2021-09-30 0001581280 us-gaap:CommonStockMember 2021-10-01 2022-06-30 0001581280 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-06-30 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2022-06-30 0001581280 us-gaap:RetainedEarningsMember 2021-10-01 2022-06-30 0001581280 us-gaap:CommonStockMember 2020-09-30 0001581280 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001581280 us-gaap:RetainedEarningsMember 2020-09-30 0001581280 2020-09-30 0001581280 us-gaap:CommonStockMember 2020-10-01 2021-06-30 0001581280 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-06-30 0001581280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2021-06-30 0001581280 us-gaap:RetainedEarningsMember 2020-10-01 2021-06-30 0001581280 twst:SubsequentPublicOffering1Member 2021-10-01 2022-06-30 0001581280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0001581280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001581280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001581280 us-gaap:MoneyMarketFundsMember 2022-06-30 0001581280 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0001581280 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001581280 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001581280 us-gaap:CommercialPaperMember 2022-06-30 0001581280 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0001581280 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001581280 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001581280 us-gaap:USTreasurySecuritiesMember 2022-06-30 0001581280 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001581280 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001581280 us-gaap:FairValueInputsLevel3Member 2022-06-30 0001581280 us-gaap:FairValueInputsLevel1Member twst:ContingentConsiderationAndIndemnityHoldbackMember 2022-06-30 0001581280 us-gaap:FairValueInputsLevel2Member twst:ContingentConsiderationAndIndemnityHoldbackMember 2022-06-30 0001581280 us-gaap:FairValueInputsLevel3Member twst:ContingentConsiderationAndIndemnityHoldbackMember 2022-06-30 0001581280 twst:ContingentConsiderationAndIndemnityHoldbackMember 2022-06-30 0001581280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001581280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001581280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001581280 us-gaap:MoneyMarketFundsMember 2021-09-30 0001581280 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001581280 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001581280 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001581280 us-gaap:USTreasurySecuritiesMember 2021-09-30 0001581280 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001581280 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001581280 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001581280 us-gaap:FairValueInputsLevel1Member twst:ContingentConsiderationAndIndemnityHoldbackMember 2021-09-30 0001581280 us-gaap:FairValueInputsLevel2Member twst:ContingentConsiderationAndIndemnityHoldbackMember 2021-09-30 0001581280 us-gaap:FairValueInputsLevel3Member twst:ContingentConsiderationAndIndemnityHoldbackMember 2021-09-30 0001581280 twst:ContingentConsiderationAndIndemnityHoldbackMember 2021-09-30 0001581280 twst:IgenomxInternationalGenomicsCorporatioMember 2021-10-01 2022-06-30 0001581280 srt:MaximumMember 2021-04-01 2021-06-30 0001581280 srt:MaximumMember 2020-10-01 2021-06-30 0001581280 us-gaap:DevelopedTechnologyRightsMember 2021-10-01 2022-06-30 0001581280 us-gaap:DevelopedTechnologyRightsMember 2022-06-30 0001581280 us-gaap:CustomerRelationshipsMember 2021-10-01 2022-06-30 0001581280 us-gaap:CustomerRelationshipsMember 2022-06-30 0001581280 us-gaap:TrademarksAndTradeNamesMember 2021-10-01 2022-06-30 0001581280 us-gaap:TrademarksAndTradeNamesMember 2022-06-30 0001581280 us-gaap:DevelopedTechnologyRightsMember 2020-10-01 2021-09-30 0001581280 us-gaap:DevelopedTechnologyRightsMember 2021-09-30 0001581280 us-gaap:CustomerRelationshipsMember 2020-10-01 2021-09-30 0001581280 us-gaap:CustomerRelationshipsMember 2021-09-30 0001581280 twst:SouthSanFranciscoCaliforniaMember 2021-07-28 0001581280 twst:SouthSanFranciscoCaliforniaMember 2021-07-28 2021-07-28 0001581280 twst:SouthSanFranciscoCaliforniaMember 2021-10-01 0001581280 twst:QuincyMassachusettsMember 2021-08-06 0001581280 twst:QuincyMassachusettsMember 2021-08-06 2021-08-06 0001581280 twst:QuincyMassachusettsMember 2022-03-03 0001581280 srt:AffiliatedEntityMember 2022-04-01 2022-06-30 0001581280 srt:AffiliatedEntityMember 2021-04-01 2021-06-30 0001581280 srt:AffiliatedEntityMember 2021-10-01 2022-06-30 0001581280 srt:AffiliatedEntityMember 2020-10-01 2021-06-30 0001581280 twst:AbxBiologicsInc.Member 2022-04-01 2022-06-30 0001581280 twst:AbxBiologicsInc.Member 2021-10-01 2022-06-30 0001581280 twst:AbxBiologicsInc.Member 2021-04-01 2021-06-30 0001581280 twst:AbxBiologicsInc.Member 2020-10-01 2021-06-30 0001581280 twst:SubsequentPublicOffering1Member 2020-12-01 2020-12-31 0001581280 twst:SubsequentPublicOffering1Member 2020-12-31 0001581280 us-gaap:OverAllotmentOptionMember 2020-12-01 2020-12-31 0001581280 twst:SubsequentPublicOffering1Member 2022-02-01 2022-02-28 0001581280 twst:SubsequentPublicOffering1Member 2022-02-28 0001581280 us-gaap:OverAllotmentOptionMember 2022-02-01 2022-02-28 0001581280 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001581280 us-gaap:RestrictedStockUnitsRSUMember 2020-10-01 2021-09-30 0001581280 us-gaap:RestrictedStockUnitsRSUMember 2021-10-01 2022-06-30 0001581280 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0001581280 srt:MinimumMember twst:PerformanceStockUnitMember 2021-10-01 2022-06-30 0001581280 srt:MaximumMember twst:PerformanceStockUnitMember 2021-10-01 2022-06-30 0001581280 twst:PerformanceStockUnitMember 2022-06-30 0001581280 twst:PerformanceStockUnitMember 2021-10-01 2022-06-30 0001581280 twst:PerformanceStockUnitMember 2021-09-30 0001581280 twst:PerformanceStockUnitMember 2020-10-01 2021-09-30 0001581280 us-gaap:EmployeeStockOptionMember 2021-10-01 2022-06-30 0001581280 2020-10-01 2021-09-30 0001581280 srt:MinimumMember twst:ExecutiveOfficersAndSeniorLevelEmployeesMember twst:PerformanceStockOptionMember 2020-09-01 2020-09-01 0001581280 srt:MaximumMember twst:ExecutiveOfficersAndSeniorLevelEmployeesMember twst:PerformanceStockOptionMember 2020-09-01 2020-09-01 0001581280 twst:ExecutiveOfficersAndSeniorLevelEmployeesMember twst:PerformanceStockOptionMember 2022-06-30 0001581280 twst:PerformanceStockOptionMember 2021-09-30 0001581280 twst:PerformanceStockOptionMember 2020-10-01 2021-09-30 0001581280 twst:PerformanceStockOptionMember 2021-10-01 2022-06-30 0001581280 twst:PerformanceStockOptionMember 2022-06-30 0001581280 us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0001581280 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0001581280 us-gaap:CostOfSalesMember 2021-10-01 2022-06-30 0001581280 us-gaap:CostOfSalesMember 2020-10-01 2021-06-30 0001581280 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001581280 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001581280 us-gaap:ResearchAndDevelopmentExpenseMember 2021-10-01 2022-06-30 0001581280 us-gaap:ResearchAndDevelopmentExpenseMember 2020-10-01 2021-06-30 0001581280 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0001581280 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-04-01 2021-06-30 0001581280 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-10-01 2022-06-30 0001581280 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-10-01 2021-06-30 0001581280 twst:TwoThousandAndEighteenEmployeeStockPurchasePlanMember 2018-09-26 0001581280 twst:TwoThousandAndEighteenEmployeeStockPurchasePlanMember 2018-09-26 2018-09-26 0001581280 us-gaap:PerformanceSharesMember twst:AbxBiologicsInc.Member 2021-12-01 2021-12-01 0001581280 twst:AbxBiologicsInc.Member 2021-12-01 2021-12-01 0001581280 us-gaap:PerformanceSharesMember twst:AbxBiologicsInc.Member 2022-06-30 0001581280 us-gaap:PerformanceSharesMember twst:AbxBiologicsInc.Member 2021-10-01 2022-06-30 0001581280 twst:AbxBiologicsInc.Member 2022-06-30 0001581280 us-gaap:EmployeeStockMember 2021-10-01 2022-06-30 0001581280 us-gaap:EmployeeStockMember 2022-04-01 2022-06-30 0001581280 us-gaap:EmployeeStockMember 2021-04-01 2021-06-30 0001581280 us-gaap:EmployeeStockMember 2020-10-01 2021-06-30 0001581280 twst:StockOptionsBasedOnPerformanceMember 2022-04-01 2022-06-30 0001581280 twst:StockOptionsBasedOnPerformanceMember 2021-10-01 2022-06-30 0001581280 twst:StockOptionsBasedOnPerformanceMember 2021-04-01 2021-06-30 0001581280 twst:StockOptionsBasedOnPerformanceMember 2020-10-01 2021-06-30 0001581280 twst:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember 2022-04-01 2022-06-30 0001581280 twst:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember 2021-10-01 2022-06-30 0001581280 twst:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember 2021-04-01 2021-06-30 0001581280 twst:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember 2020-10-01 2021-06-30 0001581280 twst:EarlyExerciseOfStockOptionsMember 2022-04-01 2022-06-30 0001581280 twst:EarlyExerciseOfStockOptionsMember 2021-10-01 2022-06-30 0001581280 twst:EarlyExerciseOfStockOptionsMember 2021-04-01 2021-06-30 0001581280 twst:EarlyExerciseOfStockOptionsMember 2020-10-01 2021-06-30 0001581280 twst:SharesSubjectToEmployeeStockPurchasePlanMember 2022-04-01 2022-06-30 0001581280 twst:SharesSubjectToEmployeeStockPurchasePlanMember 2021-10-01 2022-06-30 0001581280 twst:SharesSubjectToEmployeeStockPurchasePlanMember 2021-04-01 2021-06-30 0001581280 twst:SharesSubjectToEmployeeStockPurchasePlanMember 2020-10-01 2021-06-30 0001581280 srt:AmericasMember 2022-04-01 2022-06-30 0001581280 srt:AmericasMember 2021-04-01 2021-06-30 0001581280 srt:AmericasMember 2021-10-01 2022-06-30 0001581280 srt:AmericasMember 2020-10-01 2021-06-30 0001581280 us-gaap:EMEAMember 2022-04-01 2022-06-30 0001581280 us-gaap:EMEAMember 2021-04-01 2021-06-30 0001581280 us-gaap:EMEAMember 2021-10-01 2022-06-30 0001581280 us-gaap:EMEAMember 2020-10-01 2021-06-30 0001581280 srt:AsiaPacificMember 2022-04-01 2022-06-30 0001581280 srt:AsiaPacificMember 2021-04-01 2021-06-30 0001581280 srt:AsiaPacificMember 2021-10-01 2022-06-30 0001581280 srt:AsiaPacificMember 2020-10-01 2021-06-30 0001581280 twst:SyntheticGenesMember 2022-04-01 2022-06-30 0001581280 twst:SyntheticGenesMember 2021-04-01 2021-06-30 0001581280 twst:SyntheticGenesMember 2021-10-01 2022-06-30 0001581280 twst:SyntheticGenesMember 2020-10-01 2021-06-30 0001581280 twst:OligoPoolsMember 2022-04-01 2022-06-30 0001581280 twst:OligoPoolsMember 2021-04-01 2021-06-30 0001581280 twst:OligoPoolsMember 2021-10-01 2022-06-30 0001581280 twst:OligoPoolsMember 2020-10-01 2021-06-30 0001581280 twst:DnaAndBiopharmaLibrariesMember 2022-04-01 2022-06-30 0001581280 twst:DnaAndBiopharmaLibrariesMember 2021-04-01 2021-06-30 0001581280 twst:DnaAndBiopharmaLibrariesMember 2021-10-01 2022-06-30 0001581280 twst:DnaAndBiopharmaLibrariesMember 2020-10-01 2021-06-30 0001581280 twst:AntibodyDiscoveryMember 2022-04-01 2022-06-30 0001581280 twst:AntibodyDiscoveryMember 2021-04-01 2021-06-30 0001581280 twst:AntibodyDiscoveryMember 2021-10-01 2022-06-30 0001581280 twst:AntibodyDiscoveryMember 2020-10-01 2021-06-30 0001581280 twst:NgsToolsMember 2022-04-01 2022-06-30 0001581280 twst:NgsToolsMember 2021-04-01 2021-06-30 0001581280 twst:NgsToolsMember 2021-10-01 2022-06-30 0001581280 twst:NgsToolsMember 2020-10-01 2021-06-30 0001581280 twst:IndustrialChemicalsMember 2022-04-01 2022-06-30 0001581280 twst:IndustrialChemicalsMember 2021-04-01 2021-06-30 0001581280 twst:IndustrialChemicalsMember 2021-10-01 2022-06-30 0001581280 twst:IndustrialChemicalsMember 2020-10-01 2021-06-30 0001581280 twst:AcademicResearchMember 2022-04-01 2022-06-30 0001581280 twst:AcademicResearchMember 2021-04-01 2021-06-30 0001581280 twst:AcademicResearchMember 2021-10-01 2022-06-30 0001581280 twst:AcademicResearchMember 2020-10-01 2021-06-30 0001581280 us-gaap:HealthCareMember 2022-04-01 2022-06-30 0001581280 us-gaap:HealthCareMember 2021-04-01 2021-06-30 0001581280 us-gaap:HealthCareMember 2021-10-01 2022-06-30 0001581280 us-gaap:HealthCareMember 2020-10-01 2021-06-30 0001581280 twst:FoodOrAgricultureMember 2022-04-01 2022-06-30 0001581280 twst:FoodOrAgricultureMember 2021-04-01 2021-06-30 0001581280 twst:FoodOrAgricultureMember 2021-10-01 2022-06-30 0001581280 twst:FoodOrAgricultureMember 2020-10-01 2021-06-30 0001581280 twst:AbxBiologicsInc.Member 2021-12-01 0001581280 twst:AbxBiologicsInc.Member 2021-12-01 2021-12-31 0001581280 twst:ShareBasedAwardsWithVestingRequirementsMember twst:AbxBiologicsInc.Member 2021-12-01 2021-12-31 0001581280 twst:ShareBasedAwardsWithoutVestingRequirementsMember twst:AbxBiologicsInc.Member 2021-12-01 2021-12-31 0001581280 us-gaap:PerformanceSharesMember twst:AbxBiologicsInc.Member 2021-12-01 2021-12-31 0001581280 twst:AbxBiologicsInc.Member us-gaap:DevelopedTechnologyRightsMember 2021-12-01 2021-12-01 0001581280 twst:AbxBiologicsInc.Member us-gaap:DevelopedTechnologyRightsMember 2021-12-01 0001581280 twst:AbxBiologicsInc.Member us-gaap:CustomerRelationshipsMember 2021-12-01 2021-12-01 0001581280 twst:AbxBiologicsInc.Member us-gaap:CustomerRelationshipsMember 2021-12-01 0001581280 twst:AbxBiologicsInc.Member us-gaap:TradeNamesMember 2021-12-01 2021-12-01 0001581280 twst:AbxBiologicsInc.Member us-gaap:TradeNamesMember 2021-12-01 0001581280 twst:AbxBiologicsInc.Member twst:ContingentConsiderationMember 2021-12-01 0001581280 twst:AbxBiologicsInc.Member twst:IndemnityHoldbackMember 2021-12-01 0001581280 twst:AbxBiologicsInc.Member twst:ContingentConsiderationMember 2021-12-02 2022-06-30 0001581280 twst:AbxBiologicsInc.Member twst:IndemnityHoldbackMember 2021-12-02 2022-06-30 0001581280 twst:AbxBiologicsInc.Member 2021-12-02 2022-06-30 0001581280 twst:AbxBiologicsInc.Member twst:ContingentConsiderationMember 2022-06-30 0001581280 twst:AbxBiologicsInc.Member twst:IndemnityHoldbackMember 2022-06-30 0001581280 twst:IgenomxInternationalGenomicsCorporationMember 2021-12-01 2021-12-31 0001581280 twst:IgenomxInternationalGenomicsCorporationMember 2022-01-01 2022-01-31 0001581280 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember twst:RevelarBiotherapeuticsIncMember 2021-11-01 0001581280 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember twst:RevelarBiotherapeuticsIncMember 2021-11-01 2021-11-01 0001581280 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember twst:RevelarBiotherapeuticsIncMember srt:MaximumMember 2021-11-01 2021-11-01 0001581280 twst:RevelarBiotherapeuticsIncMember 2022-04-06 2022-04-06 0001581280 twst:RevelarBiotherapeuticsIncMember 2022-02-03 2022-02-03 0001581280 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember twst:RevelarBiotherapeuticsIncMember 2022-04-01 2022-06-30 0001581280 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember twst:RevelarBiotherapeuticsIncMember 2021-10-01 2022-06-30 0001581280 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember twst:RevelarBiotherapeuticsIncMember 2022-06-30 shares iso4217:USD iso4217:USD shares pure utr:sqft twst:therapeutic false 0001581280 --09-30 2022 Q3 P10Y5M P1Y P2Y 10-Q true 2022-06-30 false 001-38720 Twist Bioscience Corporation DE 46-2058888 681 Gateway Blvd South San Francisco CA 94080 800 719-0671 Common Stock TWST NASDAQ Yes Yes Large Accelerated Filer false false false 56363518 376249000 465829000 151342000 12034000 41195000 28549000 43022000 31800000 12309000 8283000 624117000 546495000 127011000 44122000 76165000 61580000 85811000 22434000 61115000 18262000 1572000 1530000 3872000 7674000 979663000 702097000 21014000 14900000 9499000 6437000 27698000 22327000 14352000 8213000 0 1552000 20123000 9623000 92686000 63052000 64244000 53156000 2056000 5068000 158986000 121276000 0.00001 0.00001 100000000 100000000 56344000 56344000 49499000 49499000 0 0 1599355000 1190828000 -1377000 546000 -777301000 -610553000 820677000 580821000 979663000 702097000 7429000 6989000 433000 7000 10494000 6412000 2082000 2000000 56113000 35018000 146259000 94382000 30974000 20933000 87744000 58123000 36840000 19838000 90701000 49629000 53693000 34478000 158790000 97658000 4231000 -1887000 13071000 -1887000 117276000 77136000 324164000 207297000 -61163000 -42118000 -177905000 -112915000 722000 86000 1134000 377000 0 70000 54000 284000 -225000 -312000 -626000 -305000 -60666000 -42414000 -177451000 -113127000 -149000 -2377000 -10703000 -2271000 -60517000 -40037000 -166748000 -110856000 -404000 -12000 -1794000 -10000 -498000 250000 -129000 351000 -61419000 -39799000 -168671000 -110515000 -1.08 -1.08 -0.82 -0.82 -3.15 -3.15 -2.32 -2.32 56287000 56287000 48963000 48963000 53005000 53005000 47881000 47881000 56234000 0 1580620000 -475000 -716784000 863361000 17676000 6000 6000 100000 48000 766000 766000 38000 2080000 2080000 20043000 20043000 -902000 -902000 -60517000 -60517000 56344000 0 1599355000 -1377000 -777301000 820677000 48860000 0 1143265000 190000 -529274000 614181000 26000 26000 57000 132000 2619000 2619000 237000 26773000 26773000 23000 2476000 2476000 9176000 9176000 238000 238000 -40037000 -40037000 49263000 0 1179331000 428000 -569311000 610448000 49499000 0 1190828000 546000 -610553000 580821000 17676000 5227000 269824000 269824000 263000 417000 4701000 4701000 50000 2394000 2394000 101000 6130000 6130000 989000 77122000 77122000 60616000 60616000 -1923000 -1923000 -166748000 -166748000 56344000 0 1599355000 -1377000 -777301000 820677000 45083000 0 794630000 87000 -458455000 336262000 21139000 3136000 323861000 323861000 22000 178000 629000 11756000 11756000 49000 2787000 2787000 2000 237000 26773000 26773000 69000 8227000 8227000 27751000 27751000 341000 341000 -110856000 -110856000 49263000 0 1179331000 428000 -569311000 610448000 -166748000 -110856000 11562000 7319000 11177000 0 0 -2000 2594000 1044000 60616000 27751000 -1056000 -501000 0 5000 -13071000 1887000 3000 58000 -146000 183000 -4000 -70000 70000 0 10284000 1912000 11237000 8914000 2736000 1617000 -6829000 2333000 466000 5194000 608000 1546000 5519000 4588000 2954000 -1947000 -123118000 -77441000 85395000 18972000 8160000 483000 217639000 58795000 75481000 210494000 -235713000 132244000 4764000 11686000 269824000 323861000 2394000 2787000 1558000 2500000 6130000 8227000 269294000 327607000 -1000 153000 -89538000 382563000 467359000 94246000 377821000 476809000 9000 145000 130000 47000 6562000 1777000 19494000 33617000 77122000 26773000 The Company<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twist Bioscience Corporation (the Company) was incorporated in the state of Delaware on February 4, 2013. The Company is a synthetic biology company that has developed a disruptive DNA synthesis platform. DNA is used in many applications across different industries: industrial chemicals/materials, academic, healthcare and food/agriculture. The Company’s fiscal year ends on September 30.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has generated net losses in all periods since its inception. As of June 30, 2022, the Company had an accumulated deficit of $777.3 million and has not generated positive cash flows from operations since inception. Losses are expected to continue as the Company continues to invest in product development, manufacturing, and sales and marketing.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since its inception, the Company has received an aggregate of $1,333.7 million in net proceeds from the issuance of equity securities and an aggregate of $13.8 million from debt. Management believes that these proceeds combined with existing cash balances on hand will be sufficient to fund operations for at least one year from the issuance of these consolidated financial statements. However, if the Company needs to obtain additional financing to fund operations beyond this period, there can be no assurance that it will be successful in raising additional financing on terms which are acceptable to the Company.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Company requires but is unable to obtain additional funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three and nine months ended June 30, 2022, financial results of the Company were not significantly affected by the COVID-19 pandemic, which continues to have global impact. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which continue to evolve and are difficult to predict, including mutations in the SARS-CoV-2 virus, which have resulted and may in the future result in strains that are more contagious and less responsive to current treatment methods, and current or future domestic and international actions to contain it and treat it.</span></div> -777300000 1333700000 13800000 Summary of significant accounting policies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of presentation and use of estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2021 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 23, 2021. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2021 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three and nine months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending September 30, 2022 or any interim period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. The Company consolidates Revelar Biotherapeutics, Inc. (“Revelar”) as a variable interest entity (“VIE”) for which it is the primary beneficiary (see Note 14 “Investment in variable interest entity” for further information). All intercompany balances and accounts are eliminated in consolidation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">376,249 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">465,829 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,572 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,530 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">377,821 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">467,359 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Significant accounting policies</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K other than the following variable interest entities policy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Variable interest entities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company consolidates a VIE in which the Company is deemed to be the primary beneficiary. An entity is generally a VIE if it meets any of the following criteria: (i) the entity has insufficient equity to finance its activities without additional subordinated financial support from other parties, (ii) the equity investors cannot make significant decisions about the entity’s operations or (iii) the voting rights of some investors are not proportional to their obligations to absorb the expected losses of the entity or receive the expected returns of the entity and substantially all of the entity’s activities involve or are conducted on behalf of the investor with disproportionately few voting rights. The Company periodically makes judgments in determining whether its investees are VIEs and, for each reporting period, the Company assesses whether it is the primary beneficiary of its VIE. As of June 30, 2022, the Company was deemed the primary beneficiary of Revelar. See Note 14 “Investment in variable interest entity.”</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent accounting pronouncements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considered the applicability and impact of all recent ASUs. ASUs not listed below were assessed and determined to be not applicable to the Company’s consolidated financial position and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recent accounting pronouncements adopted</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019 12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Simplifying the Accounting for Income Taxes. The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders’ equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. The Company adopted this standard effective October 1, 2021. The adoption of ASU 2019 12 did not have an impact on the Company’s consolidated financial statements for either period presented.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently issued accounting pronouncement not yet adopted </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, the FASB issued ASU 2021 10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016 13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard requires entities to use the new “expected credit loss” impairment model for most financial assets measured at amortized cost, including trade and other receivables and held-to-maturity debt securities, and modifies the impairment model for available-for-sale debt securities. The standard is effective for the </span></div>Company for the fiscal year ending September 30, 2024, including interim periods within that fiscal year. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of presentation and use of estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K for the fiscal year ended September 30, 2021 (the Annual Report on Form 10-K) filed with the Securities and Exchange Commission on November 23, 2021. The condensed consolidated financial statements are unaudited and have been prepared on a basis consistent with that used to prepare the audited annual consolidated financial statements and include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The condensed consolidated balance sheet at September 30, 2021 is derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The operating results for the three and nine months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending September 30, 2022 or any interim period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly owned subsidiaries. The Company consolidates Revelar Biotherapeutics, Inc. (“Revelar”) as a variable interest entity (“VIE”) for which it is the primary beneficiary (see Note 14 “Investment in variable interest entity” for further information). All intercompany balances and accounts are eliminated in consolidation.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of the Company’s cash and cash equivalents and non-current portion of restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total cash, cash equivalents and restricted cash shown in the Company’s condensed consolidated statements of cash flows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">376,249 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">465,829 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted cash, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,572 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,530 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">377,821 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">467,359 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 376249000 465829000 1572000 1530000 377821000 467359000 Variable interest entitiesThe Company consolidates a VIE in which the Company is deemed to be the primary beneficiary. An entity is generally a VIE if it meets any of the following criteria: (i) the entity has insufficient equity to finance its activities without additional subordinated financial support from other parties, (ii) the equity investors cannot make significant decisions about the entity’s operations or (iii) the voting rights of some investors are not proportional to their obligations to absorb the expected losses of the entity or receive the expected returns of the entity and substantially all of the entity’s activities involve or are conducted on behalf of the investor with disproportionately few voting rights. The Company periodically makes judgments in determining whether its investees are VIEs and, for each reporting period, the Company assesses whether it is the primary beneficiary of its VIE. As of June 30, 2022, the Company was deemed the primary beneficiary of Revelar. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent accounting pronouncements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification (“ASC”). The Company considered the applicability and impact of all recent ASUs. ASUs not listed below were assessed and determined to be not applicable to the Company’s consolidated financial position and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recent accounting pronouncements adopted</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019 12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Simplifying the Accounting for Income Taxes. The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders’ equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. The Company adopted this standard effective October 1, 2021. The adoption of ASU 2019 12 did not have an impact on the Company’s consolidated financial statements for either period presented.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Recently issued accounting pronouncement not yet adopted </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, the FASB issued ASU 2021 10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. The amendments in this update require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016 13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard requires entities to use the new “expected credit loss” impairment model for most financial assets measured at amortized cost, including trade and other receivables and held-to-maturity debt securities, and modifies the impairment model for available-for-sale debt securities. The standard is effective for the </span></div>Company for the fiscal year ending September 30, 2024, including interim periods within that fiscal year. Early application is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. Fair value measurement<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses the fair value of financial instruments based on the provisions of ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1—Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company short-term and long-term investments primarily utilize broker quotes in a non-active market for valuation of its investments.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, financial assets and liabilities measured and recognized at fair value are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">324,824 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">324,824 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,977 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,977 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">436,189 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,977 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">476,166 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration and holdbacks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities </span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,567 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,300 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,867 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2021, financial assets and liabilities measured and recognized at fair value are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">430,438 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">430,438 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,034</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442,472 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442,472 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration and indemnity holdback</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,856 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,856 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022 gross unrealized losses for cash equivalents and investments was $1.8 million. As of September 30, 2021, gross unrealized gains and unrealized losses for cash equivalents and investments were not material. As of June 30, 2022 and September 30, 2021, all marketable securities had a contractual maturity of less than one year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of beginning and ending balances of the Level 3 financial liabilities during the three months ended June 30, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration – additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,500</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,200)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of June 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,300 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, financial assets and liabilities measured and recognized at fair value are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">324,824 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">324,824 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,977 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,977 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">111,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">436,189 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,977 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">476,166 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration and holdbacks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities </span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,567 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,300 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,867 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2021, financial assets and liabilities measured and recognized at fair value are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">430,438 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">430,438 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government treasury bills</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,034</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442,472 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442,472 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration and indemnity holdback</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,856 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,856 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 324824000 0 0 324824000 0 39977000 0 39977000 111365000 0 0 111365000 436189000 39977000 0 476166000 0 9567000 3300000 12867000 0 9567000 3300000 12867000 430438000 0 0 430438000 12034000 0 0 12034000 442472000 0 0 442472000 0 9856000 0 9856000 0 9856000 0 9856000 -1800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of beginning and ending balances of the Level 3 financial liabilities during the three months ended June 30, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration – additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,500</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,200)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance as of June 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,300 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 8500000 -5200000 3300000 Balance sheet components<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s accounts receivable, net balance consists of the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,615 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,549 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other receivables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,758</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,337</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(178)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(337)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,195 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,549 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories consist of the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,909 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,778 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,879</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,837</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,234</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,185</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,022 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,800 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The work-in-process inventory included gross consigned inventory of $1.5 million and $1.9 million as of June 30, 2022 and September 30, 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other non-current assets</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The other non-current assets consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Convertible note receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,872</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,653</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,872</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,674</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Accrued</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accrued expenses consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional services fees payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,057</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other accrued expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,455</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,380</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,499</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,437</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Accrued compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accrued compensation consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued vacation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,285 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,643 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,091 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued commissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and related taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,932 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,698 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,327 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other current liabilities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The other current liabilities consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration and holdbacks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,867</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,186</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income and sales taxes payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,851</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,440</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,405</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,997</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,123 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,623 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other non-current liabilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The other non-current liabilities consist of the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Holdback</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,671</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other non current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,056</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">397</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,056</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,068</span></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s accounts receivable, net balance consists of the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,615 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,549 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other receivables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,758</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,337</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(178)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(337)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,195 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,549 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 36615000 26549000 4758000 2337000 178000 337000 41195000 28549000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories consist of the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,909 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,778 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,879</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,837</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,234</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,185</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,022 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,800 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 30909000 18778000 3879000 4837000 8234000 8185000 43022000 31800000 1500000 1900000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The other non-current assets consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Convertible note receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,872</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,653</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,872</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,674</span></td></tr></table></div> 0 3021000 3872000 4653000 3872000 7674000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accrued expenses consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional services fees payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,057</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other accrued expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,455</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,380</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,499</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,437</span></td></tr></table></div> 5044000 5057000 4455000 1380000 9499000 6437000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accrued compensation consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued vacation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,285 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,643 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,091 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued commissions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and related taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,932 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,698 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,327 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6285000 4643000 9091000 8584000 4257000 3330000 5932000 4676000 2133000 1094000 27698000 22327000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The other current liabilities consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration and holdbacks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,867</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,186</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income and sales taxes payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,851</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,440</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,405</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,997</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,123 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,623 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12867000 5186000 3851000 2440000 3405000 1997000 20123000 9623000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The other non-current liabilities consist of the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Holdback</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,671</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other non current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,056</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">397</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,056</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,068</span></td></tr></table></div> 0 4671000 2056000 397000 2056000 5068000 Goodwill and intangible assets<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended June 30, 2022, goodwill and intangible assets increased by $63.4 million and $46.5 million, respectively, as a result of a business acquisition. See Note 13, “Business acquisition”. Total amortization expense related to intangible assets was $1.4 million for the three months ended June 30, 2022 and less than $0.1 million for the three months ended June 30, 2021. Total amortization expense related to intangible assets was $3.6 million and $0.2 million for the nine months ended June 30, 2022 and 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intangible assets balances are presented below:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except for years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average<br/>Amortization period<br/>in years</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net book<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Developed Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,020 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,560)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,460 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,210 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,280)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,930 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tradenames &amp; Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,130 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,015)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61,115 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except for years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average<br/>Amortization period<br/>in years</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net book<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Developed Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,120 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,361)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,759 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">503 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,630 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,368)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,262 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 63400000 46500000 1400000 100000 3600000 200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intangible assets balances are presented below:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except for years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average<br/>Amortization period<br/>in years</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net book<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Developed Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">50,020 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,560)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,460 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,210 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,280)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,930 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tradenames &amp; Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,130 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,015)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61,115 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except for years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average<br/>Amortization period<br/>in years</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net book<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Developed Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,120 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,361)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,759 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">503 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,630 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,368)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,262 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P15Y 50020000 3560000 46460000 P10Y 15210000 1280000 13930000 P3Y 900000 175000 725000 66130000 5015000 61115000 P16Y 19120000 1361000 17759000 P2Y 510000 7000 503000 19630000 1368000 18262000 Commitments and contingencies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may be subject to litigation, claims and disputes in the ordinary course of business. There is an inherent risk in any litigation or dispute and no assurance can be given as to the outcome of any claims.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Indemnifications</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by corporate law. The Company also has directors’ and officers’ insurance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases certain of its facilities under non-cancellable operating leases expiring at various dates through 2044. The Company is also responsible for utilities, maintenance, insurance, and property taxes under these leases.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain leases include options to renew or terminate at the Company’s discretion. The lease terms include periods covered by these options if it is reasonably certain the Company will renew or not terminate. The Company’s lease agreements do not contain any material residual value guarantees or restrictive covenants.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental balance sheet information related to the Company’s operating leases as of June 30, 2022 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use asset</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,165 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion of operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,352 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,244 </span></td><td style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future minimum lease payments under all non-cancelable operating leases that have commenced as of June 30, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Operating<br/>leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Years ending September 30:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Remainder of 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,281 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,990</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,385</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,724</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,298</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97,081</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153,759 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(57,737)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: tenant improvement allowance (receipt anticipated in 2022)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17,426)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78,596 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current portion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,352)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,244 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the remainder of 2022, future minimum lease payments are comprised of the anticipated receipt of tenant improvement allowances totaling $17.4 million anticipated to be received in 2022, partially offset by non-cancelable operating lease payments of $3.3 million. The statement of cash flows for the nine months ended June 30, 2022, include changes in right-of-use assets and operating lease liabilities of $14.6 million and $17.2 million, respectively. For the nine months ended June 30, 2021, changes in right-of-use assets and operating lease liabilities were $29.1 million and $30.1 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended June 30, 2022, operating lease expense was $4.1 million and $11.5 million, respectively. Cash payments for amounts included in the measurement of operating lease liabilities were $3.7 million and $9.1 million for the three and nine months ended June 30, 2022, respectively. As of June 30, 2022, the weighted-average remaining lease term was 15.5 years and the weighted-average discount rate was 6.4%.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 28, 2021, the Company entered into a 7-year operating lease for approximately 21,000 square-feet of office space located in South San Francisco, California, to further expand the Company operations. Upon execution of the lease agreement, the Company provided the landlord an approximate $0.2 million security deposit. The Company will pay an initial annual base rent of approximately $1.7 million, which is subject to scheduled 3% annual increases, plus certain operating expenses. The Company has the right to sublease the facility, subject to landlord consent. The lease commenced on October 1, 2021. As of lease commencement date, the total future minimum lease payments under the agreement were $13.1 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 6, 2021, Abveris, which was subsequently acquired by the Company, entered into a 10-year, 5-month operating lease for approximately 22,000 square-feet of office space located in Quincy, Massachusetts, to further expand operations. Upon execution of the lease agreement, the Company provided the landlord an approximate $0.6 million irrevocable letter of credit as a security deposit. The Company will pay an initial annual base rent of approximately $1.2 million, which is subject to scheduled 2% annual increases, plus certain operating expenses. The Company has the right to sublease the </span></div>facility, subject to landlord consent. The lease commenced on March 3, 2022. As of lease commencement date, the total future minimum lease payments under the agreement were $13.2 million. Supplemental balance sheet information related to the Company’s operating leases as of June 30, 2022 was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use asset</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,165 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion of operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,352 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,244 </span></td><td style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 76165000 14352000 64244000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future minimum lease payments under all non-cancelable operating leases that have commenced as of June 30, 2022 are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Operating<br/>leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Years ending September 30:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Remainder of 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,281 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,990</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,385</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,724</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,298</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97,081</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">153,759 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(57,737)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: tenant improvement allowance (receipt anticipated in 2022)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17,426)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78,596 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current portion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14,352)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,244 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3281000 13990000 13385000 13724000 12298000 97081000 153759000 57737000 17426000 78596000 14352000 64244000 17400000 3300000 14600000 17200000 29100000 30100000 4100000 11500000 3700000 9100000 P15Y6M 0.064 P7Y 21000 200000 1700000 0.03 13100000 22000 600000 1200000 0.02 13200000 Related party transactionsDuring the three months ended June 30, 2022 and 2021, the Company purchased raw materials from a related party investor in the amount of $3.1 million and $1.2 million, respectively. During the nine months ended June 30, 2022 and 2021, the Company purchased raw materials from a related party in the amount of $6.5 million and $3.5 million, respectively. Payable balances and receivable balances with the related party were immaterial as of June 30, 2022 and September 30, 2021. 3100000 1200000 6500000 3500000 Income taxesIn determining quarterly provisions for income taxes, the Company uses the annual estimated effective tax rate applied to the actual year-to-date profit or loss, adjusted for discrete items arising in that quarter. The Company’s annual estimated effective tax rate differs from the U.S. federal statutory rate primarily as a result of state taxes, foreign taxes, and changes in the Company’s valuation allowance against its deferred tax assets. For the three and nine months ended June 30, 2022, the Company recorded $0.1 million and $10.7 million income tax benefit mainly due to the deferred tax liability assumed as part of the acquisition of AbX Biologics, Inc. (see Note 13, “Business acquisition”). For the three and nine months ended June 30, 2021, the Company recorded $2.4 million and $2.3 million income tax benefit due to the deferred tax liability assumed as part of the Business acquisition. 100000 10700000 2400000 2300000 Common stockIn December 2020, the Company completed an underwritten public offering of 3,136,362 shares of its common stock at a price to the public of $110.00 per share, including the full exercise of underwriters’ option to purchase an additional 409,090 shares of common stock. The Company received total net proceeds from the offering of $323.9 million, net of estimated underwriting discounts and commissions and offering expenses.In February 2022, the Company completed an underwritten public offering of 5,227,272 shares of its common stock at a price to the public of $55.00 per share, including the full exercise of underwriters’ option to purchase an additional 681,818 shares of common stock. The Company received total net proceeds from the offering of $269.8 million, net of underwriting discounts and commissions and offering expenses. 3136362 110.00 409090 323900000 5227272 55.00 681818 269800000 Stock-based compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2018 Equity Incentive Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any shares subject to outstanding awards under the 2013 Plan that are canceled or repurchased subsequent to the 2018 Plan’s effective date are returned to the pool of shares reserved for issuance under the 2018 Plan. Awards granted under the 2018 Plan may be non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, and performance units.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Restricted Stock Units</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Restricted stock primarily consists of restricted stock unit awards (RSUs) which have been granted to employees. The value of an RSU award is based on the Company’s stock price on the date of grant. Forfeitures of RSUs are recognized as they occur. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Activity with respect to the Company’s restricted stock units during the nine months ended June 30, 2022 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:38.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.403%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted<br/>average<br/>grant date<br/>fair value<br/>per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate<br/>Intrinsic <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">698</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.27 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,613 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted stock units granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">946</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted stock units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(263)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted stock units forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(125)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,256</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.54 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected to vest at June 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,256</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.54 </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,883 </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, there was $83.4 million of total unrecognized compensation cost related to these issuances that is expected to be recognized over a weighted average period of 2.9 years.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Performance Stock Units</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Performance stock unit awards (“PSUs”) were granted to certain employees that will vest upon achievement of operational milestones related to the Wilsonville facility, to Company executives that will vest upon achievement of revenue and gross profit metrics as determined by the board, and to certain consultants that will vest upon achievement of operational milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stock compensation expense for PSUs is recorded over the vesting period based on the grant date fair value of the awards and probability of the achievement of specified performance targets. The grant date fair value is equal to the closing share price of the Company’s common stock on the date of grant. PSUs generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA0ZmI1M2QzYmVmZDQwOGJhZjAxZmFhNzZiZjhlMmZmL3NlYzowNGZiNTNkM2JlZmQ0MDhiYWYwMWZhYTc2YmY4ZTJmZl83MC9mcmFnOjNjZmY3OTRlZmVjNTRlODlhYjhlNjAwOGJiNTMzZmJmL3RleHRyZWdpb246M2NmZjc5NGVmZWM1NGU4OWFiOGU2MDA4YmI1MzNmYmZfMzg0ODI5MDcyMzg3Ng_0dc5a5f6-56a5-4270-8e99-5a3483add9c5">one</span> to three-year service period following the grant date, provided that the recipient is a Company employee at the time of vesting and the achievement of performance targets applicable to each award.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The percentage of PSUs that vest will depend on the achievement of specified performance targets at the end of the performance period and can range from 0% to 150% of the number of units granted. Forfeitures of PSUs are recognized as they occur.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June 30, 2022, the unrecognized compensation costs related to these awards was $29.4 million. The Company expects to recognize those costs over a weighted average period of 1.7.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Activity under the PSUs during the nine months ended June 30, 2022 is summarized below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:31.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest and exercisable at June 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">575</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84.93 </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,099 </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Options </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock options entitle the holder to purchase, at the end of the vesting term, a specified number of shares of Company common stock at an exercise price per share equal to the closing market price of the common stock on the date of grant. Stock options typically have a contractual life from the date of the grant and a vesting schedule as established by the board of directors. The fair value of each services based stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company historically had been a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, it estimated its expected stock price volatility based on the historical volatility of publicly traded peer companies through the period ended June 30, 2022 and utilized the “simplified” method for awards that qualify as “plain-vanilla” options. As determined under the simplified method, the expected term of stock options granted to non-employee consultants is equal to the contractual term of the option award, the risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award, the expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Forfeitures of options are recognized as they occur.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:31.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.83 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,012 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest and exercisable at June 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June 30, 2022, the unrecognized compensation costs related to these awards was $15.4 million. The Company expects to recognize those costs over a weighted average period of 1.3.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Performance Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 1, 2020, the board of directors approved the implementation of a revised annual equity award program for executive officers, senior level employees and consultants to be granted as performance-based stock options ("PSOs") under the 2018 Plan. The number of PSOs ultimately earned under the awards to executive officers and senior level employees is calculated based on the achievement of a certain total revenue threshold during the fiscal year ending September 30, 2022. The percentage of performance stock options that vest will depend on the board of directors’ determination of total revenue at the end of the performance period and can range from 0% to 150% of the number of options granted. The number of PSOs ultimately earned under the awards to a consultant is calculated based on the achievement of certain operational milestones. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provisions of the PSO are considered a performance condition, and the effects of that performance condition are not reflected in the grant date fair value of the awards. The Company used the Black-Scholes method to calculate the fair value at the grant date without regard to the vesting condition and will recognize compensation cost for the options that are expected to vest. Forfeitures of PSOs are recognized as they occur. The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. As of June 30, 2022, the Company determined that 293,730 shares are expected to vest based on the probability of the performance condition that will be achieved under this equity award program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Activity under the equity incentive plans during the nine months ended June 30, 2022 is summarized below:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:31.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.62 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,331 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock options vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock options forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest and exercisable at June 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.27 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June 30, 2022, the unrecognized compensation costs related to these awards was $2.3 million. The Company expects to recognize those costs over a weighted average period of 0.7 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total stock-based compensation expense recognized was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,228 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">773 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,347 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,990 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,642</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,753</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,506</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,180</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,989</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,650</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,410</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,581</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total stock-based compensation</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,859 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,176 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">60,263 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,751 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">2018 Employee Stock Purchase Plan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 26, 2018, the board of directors adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"). The number of shares reserved for issuance under the 2018 ESPP upon approval was 275,225 shares of the Company’s common stock, and it increases automatically on the first day of each fiscal year, following the fiscal year in which the 2018 ESPP becomes effective, by a number equal to the least of 249,470 shares, 1% of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. The number of shares reserved for issuance at June 30, 2022 was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares<br/>available</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additional shares authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">249</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares issued during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">554</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to any plan limitations, the 2018 ESPP allows eligible service providers (through qualified and non-qualified offerings) to contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The offering periods begin in February and August of each year, except for the initial offering period which commenced with the initial public offering in October 2018 and ended on August 20, 2019. The common shares issuable under the 2018 ESPP were registered pursuant to a registration statement on Form S-8 on November 26, 2018.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless otherwise determined by the board of directors, the Company’s common stock will be purchased for the accounts of employees participating in the 2018 ESPP at a price per share that is the lesser of 85% of the fair market value of the Company’s common stock on the first and last trading day of the offering period. During the three and nine months ended June 30, 2022 and 2021, activity under the 2018 ESPP was immaterial.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Abveris Acquisition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed further in Note 13 “Business acquisition”, on December 1, 2021, the Company completed the acquisition of AbX Biologics, Inc. and granted certain equity awards to new employees. These equity awards included up to 231,876 restricted shares of the Company’s common stock which are issuable based on achievement of the 2022 calendar revenue target, which had an aggregate grant date fair value of $20.1 million. In addition, all employees must remain employed through the payout date, and certain employees have an additional vesting period of up to two years from the acquisition date. The vesting upon achievement of the 2022 calendar revenue target is considered a performance condition, and the effects of that performance condition are not reflected in the grant date fair value of the awards. The Company used the stock price as of December 1, 2021 for the fair value of restricted shares. As of June 30, 2022, the Company determined that 200,673 shares are expected to vest based on the probability of the performance condition that will be achieved under this equity award program. The Company reassesses the probability of the performance condition at each reporting period and adjusts the compensation cost based on the probability assessment. The Company recorded approximately $7.8 million in stock-based compensation expense for the nine months ended June 30, 2022 related to these awards. The grant date fair value was determined to be $87.06 per share for restricted shares. As of June 30, 2022, the unrecognized compensation costs related to these awards were $9.7 million. The Company expects to recognize those costs over a weighted average period of 0.8 years.</span></div> Activity with respect to the Company’s restricted stock units during the nine months ended June 30, 2022 was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:38.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.403%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted<br/>average<br/>grant date<br/>fair value<br/>per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate<br/>Intrinsic <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">698</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.27 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,613 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted stock units granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">946</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted stock units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(263)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted stock units forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(125)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,256</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.54 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected to vest at June 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,256</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.54 </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,883 </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 698000 73.27 P2Y8M12D 74613000 946000 72.37 263000 72.53 125000 75.37 1256000 72.54 P2Y10M24D 43883000 1256000 72.54 P2Y10M24D 43883000 83400000 P2Y10M24D P3Y 0 1.50 29400000 P1Y8M12D <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Activity under the PSUs during the nine months ended June 30, 2022 is summarized below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:31.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest and exercisable at June 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">575</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84.93 </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,099 </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10000 3.59 P2Y3M18D 1016000 631000 78.83 13000 31.29 53000 85.32 575000 84.93 P1Y8M12D 20099000 575000 84.93 P1Y8M12D 20099000 0 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:31.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.83 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,012 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest and exercisable at June 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Activity under the equity incentive plans during the nine months ended June 30, 2022 is summarized below:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:31.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.62 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,331 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock options vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock options forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest and exercisable at June 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.27 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2875000 22.83 P7Y1M6D 242012000 223000 26.36 416000 11.50 9845000 135000 32.02 2547000 24.80 P6Y7M6D 34111000 2547000 24.80 P6Y7M6D 34111000 15400000 P1Y3M18D 0 1.50 293730 257000 70.62 P8Y10M24D 9331000 75000 20.02 19000 19.16 296000 19000 67.85 294000 63.27 P8Y6M 206000 294000 63.27 P8Y6M 206000 2300000 P0Y8M12D Total stock-based compensation expense recognized was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cost of revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,228 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">773 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,347 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,990 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,642</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,753</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,506</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,180</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,989</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,650</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,410</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,581</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total stock-based compensation</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,859 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,176 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">60,263 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,751 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1228000 773000 3347000 1990000 5642000 2753000 14506000 7180000 12989000 5650000 42410000 18581000 19859000 9176000 60263000 27751000 275225 249470 0.01 The number of shares reserved for issuance at June 30, 2022 was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares<br/>available</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additional shares authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">249</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares issued during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at June 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">554</span></td></tr></table> 355000 249000 50000 554000 0.15 0.85 231876 20100000 P2Y 200673 7800000 87.06 9700000 P0Y9M18D Net loss per share attributable to common stockholdersThe following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to common stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(60,517)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(40,037)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(166,748)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(110,856)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average shares used in computing net loss per share, basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,287</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,963</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,005</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,881</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.08)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.82)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.15)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.32)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and nine months ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares subject to options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,547</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,339</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares subject to performance-based stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">294</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested restricted stock units and performance stock units </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,831</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">726</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested shares of common stock issued upon early exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares subject to employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,738</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,092</span></td></tr></table></div> The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to common stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(60,517)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(40,037)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(166,748)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(110,856)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average shares used in computing net loss per share, basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,287</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,963</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,005</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47,881</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.08)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.82)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.15)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.32)</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -60517000 -40037000 -166748000 -110856000 56287000 56287000 48963000 48963000 53005000 53005000 47881000 47881000 -1.08 -1.08 -0.82 -0.82 -3.15 -3.15 -2.32 -2.32 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and nine months ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares subject to options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,547</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,339</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares subject to performance-based stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">294</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested restricted stock units and performance stock units </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,831</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">726</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested shares of common stock issued upon early exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares subject to employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,738</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,092</span></td></tr></table></div> 2547000 2547000 3339000 3339000 294000 294000 0 0 1831000 1831000 726000 726000 0 0 6000 6000 66000 66000 21000 21000 4738000 4738000 4092000 4092000 Geographic, product and industry information<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States of America, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Americas</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,797 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,264 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">87,636 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55,161 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EMEA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,482</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,658</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,207</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,694</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">APAC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,834</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,096</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,416</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,527</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,113 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,018 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146,259 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94,382 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below sets forth revenues by products.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Synthetic genes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,400 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,164 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,088 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,228 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Oligo pools</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,259</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,755</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,367</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">DNA libraries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,422</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,147</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,650</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,188</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Antibody discovery</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,242</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,993</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,643</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,379</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NGS tools</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,790</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,697</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">70,123</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,220</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,113 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,018 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146,259 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94,382 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below sets forth revenues by industry.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Industrial chemicals/materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,733 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,422 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,533 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,214 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Academic research</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,501</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,748</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,873</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,297</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,437</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,356</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,408</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,896</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Food/agricultural</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">492</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,445</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">975</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,113 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,018 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146,259 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94,382 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below sets forth revenues by geographic region, based on ship-to destinations. Americas consists of the United States of America, Canada, Mexico and South America; EMEA consists of Europe, the Middle East, and Africa; and APAC consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Americas</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,797 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,264 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">87,636 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55,161 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">EMEA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,482</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,658</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,207</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,694</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">APAC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,834</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,096</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,416</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,527</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,113 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,018 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146,259 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94,382 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 35797000 19264000 87636000 55161000 15482000 12658000 45207000 31694000 4834000 3096000 13416000 7527000 56113000 35018000 146259000 94382000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below sets forth revenues by products.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Synthetic genes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,400 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,164 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,088 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,228 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Oligo pools</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,259</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,755</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,367</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">DNA libraries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,422</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,147</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,650</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,188</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Antibody discovery</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,242</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,993</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,643</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,379</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NGS tools</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,790</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,697</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">70,123</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,220</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,113 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,018 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146,259 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94,382 </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 17400000 11164000 45088000 29228000 3259000 2017000 8755000 5367000 1422000 1147000 4650000 4188000 6242000 1993000 17643000 4379000 27790000 18697000 70123000 51220000 56113000 35018000 146259000 94382000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below sets forth revenues by industry.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Industrial chemicals/materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,733 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,422 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,533 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,214 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Academic research</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,501</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,748</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,873</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,297</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,437</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,356</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74,408</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,896</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Food/agricultural</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">492</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,445</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">975</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,113 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,018 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146,259 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94,382 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 16733000 9422000 43533000 25214000 9501000 7748000 26873000 18297000 29437000 17356000 74408000 49896000 442000 492000 1445000 975000 56113000 35018000 146259000 94382000 Business acquisition<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 1, 2021, the Company acquired all of the outstanding stock of AbX Biologics, Inc. (“Abveris”), a privately-held company providing in vivo antibody discovery services. Abveris offers animal-based antibody discovery and screening services for its customers using the Berkeley Lights Beacon Platform and its proprietary DiversimAb and DivergimAb mouse models, which the Company can humanize using its antibody optimization solution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The acquisition date fair value of the consideration transferred for Abveris was $102.6 million, consisting of cash totaling $9.5 million, 759,601 shares of the Company’s common stock valued at $66.1 million based on the Company’s closing stock price on December 1, 2021, employee stock awards issued to certain Abveris employees valued at $6.4 million, contingent consideration of $8.5 million, holdbacks of $12.8 million, and an estimated net working capital adjustment of $0.7 million. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The contingent consideration is subject to the attainment of the calendar year 2022 revenue target. The contingent consideration becomes payable after December 31, 2022 and will be settled in a combination of cash and up to 334,939 shares of the Company’s common stock. The acquisition date fair value of the contingent consideration was based on forecasted revenue of Abveris relative to the 2022 revenue target as well as the Company’s stock price as of December 1, 2021.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintains an indemnity and adjustment holdback for the purposes of providing security against any adjustment to the amounts at closing. The indemnity holdback period extends for 18 months from the anniversary of the closing date. The indemnity holdback will be settled by transferring up to 128,351 shares of the Company’s stock, 15,304 options of the Company’s common stock and an immaterial amount of cash. The fair value of the indemnity holdback was $12.5 million as of the acquisition date. The adjustment holdback will be settled by transferring up to 3,416 shares of the Company’s stock, 408 options of the Company’s common stock and an immaterial amount of cash. The holdback adjustment liability was $0.3 million as of the acquisition date. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, a working capital adjustment of $0.7 million decreased the total purchase price. The purchase price continues to be subject to adjustment for working capital adjustments as allowed under terms of the agreement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Post-combination compensation expense excluded from the purchase price includes employee stock awards issued to certain Abveris employees valued at $41.0 million. This includes awards valued at $17.7 million which vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA0ZmI1M2QzYmVmZDQwOGJhZjAxZmFhNzZiZjhlMmZmL3NlYzowNGZiNTNkM2JlZmQ0MDhiYWYwMWZhYTc2YmY4ZTJmZl83OS9mcmFnOjBlMmZjZWUyMzJjNTQ5NWRhZDhiNjIyMTM3YjU5ZDFmL3RleHRyZWdpb246MGUyZmNlZTIzMmM1NDk1ZGFkOGI2MjIxMzdiNTlkMWZfMjUwMQ_c0fa99b6-d2e0-439a-a558-8aeb08f3750b">two</span> year service period following the acquisition date and awards valued at $3.2 million with no future vesting requirements, which were deemed accelerated by the Company at the acquisition date and expensed within the three months ended December 31, 2021. Finally, post-combination expense includes awards valued at approximately $17.5 million which vest based on achievement of the calendar year 2022 revenue target and continuing employment through the payout date, and for certain employees, additional continuing employment through the two years anniversary of the acquisition date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This acquisition was accounted for using the acquisition method of accounting in accordance with the business combination guidance in ASC 805. Under the acquisition accounting method, the total estimated purchase price was allocated to the identifiable assets acquired and liabilities assumed based on their fair values. The excess of the purchase price over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed has been recorded as goodwill. Management’s estimate of the fair values of the acquired intangible assets at December 1, 2021 is preliminary and subject to change and is based on established and accepted valuation techniques performed with the assistance of third-party valuation specialists. Additional information, which existed as of the acquisition date but is yet unknown to the Company, may become known to the Company during the remainder of the measurement period, which will not exceed twelve months from the acquisition date. Changes to amounts will be recorded as adjustments to the provisional amounts recognized as of the acquisition date and may result in a corresponding adjustment to goodwill in the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">period in which new information becomes available. The goodwill that arose from the acquisition consists of synergies expected from integrating Abveris into the Company’s operations and customer base. The goodwill recognized is not expected to be deductible for income tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the preliminary fair value amounts of the assets acquired and liabilities assumed as of the acquisition date, as well as the purchase consideration:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 1, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,306 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,309</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current assets and prepaid expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,654</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,078</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,970</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,500</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,549</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">846</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,545</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,877 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61,768</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total purchase price</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102,645 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consideration transferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Company common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,514</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,500</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Holdback liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,838</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net working capital adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(674)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102,645 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the preliminary estimate of the intangible assets as of the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands except for years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Estimated<br/>Weighted<br/>Average<br/>Useful Lives<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,900</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,700</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">900</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Estimated fair value of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,500</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimated the fair value of the developed technology intangible asset and a portion of the customer relationships intangible assets using an excess earnings model. An additional portion of the customer relationships intangible assets was valued using the with and without method. The Company estimated the fair value of the trade name intangible asset using a relief from royalty approach. These fair value measurements were based on significant inputs not observable in the market and thus represent a Level 3 measurement. Key assumptions include the level and timing of expected future revenue, conditions and demands specific to each intangible asset over its remaining useful life, and discount rates the Company believes to be consistent with the inherent risks associated with each type of asset, which was approximately 9.6%. The fair value of these intangible assets is primarily affected by the projected revenues, gross margins, operating expenses, the technology obsolescence curve, and the anticipated timing of the projected income </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">associated with each intangible asset coupled with the discount rates used to derive their estimated present values. The Company believes the level and timing of expected future cash flows appropriately reflects market participant assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company included the financial results of Abveris in its condensed consolidated financial statements from the date of acquisition. The Company incurred transaction costs related to the acquisition of $1.5 million, which were recorded as an operating expense on the condensed consolidated statements of operations and comprehensive loss for the nine months ended June 30, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of contingent consideration and holdbacks balances from acquisition date to June 30, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Contingent<br/>consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Holdbacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 1, 2021 – acquisition date </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,500 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,164 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,664 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value during the period </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,200)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,097)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12,297)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,300 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,067 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,367 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimated fair value of the contingent consideration liability decreased as a result of the change in the Company’s stock price from December 1, 2021, and the probability of the attainment of the calendar year 2022 revenue target as calculated using the Monte Carlo simulation model. The estimated fair value of the holdback liability decreased as a result of the change in the Company’s stock price as of June 30, 2022. For the nine months ended June 30, 2022, the Company recognized a gain of $12.3 million relating to the change in fair value of acquisition consideration in its condensed consolidated statement of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The post-combination effect from net deferred tax liability assumed from the Abveris acquisition also caused a release of the Company’s deferred income tax valuation allowance. On the acquisition date, the release resulted in an income tax benefit of $10.5 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following unaudited pro forma financial information presents the combined results of operations for the Company and Abveris as if the Abveris acquisition had occurred on October 1, 2020. The pro forma information contains the actual operating results of the Company Abveris, adjusted to include the pro forma impact of acquisition, which is primarily additional expense as a result of the amortization of identifiable intangible assets. The unaudited pro forma financial information is prepared for comparative purposes only and does not purport to be indicative of the actual operating results that would have been recorded had the Abveris acquisition actually taken place on October 1, 2020 and should not be taken as indicative of future consolidated operating results. Additionally, the unaudited pro forma financial results do not include any anticipated synergies or other expected benefits from the Abveris acquisition.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,113 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,600 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">148,705 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102,713 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to common stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(60,517)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,853)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(165,681)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(106,461)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Issuance of contingent consideration for iGenomX acquisition</span></div>In December 2021, the Company determined that the transition milestones specified in the iGenomX acquisition agreement were completed, and the Company became obligated to issue 59,190 shares of its common stock to satisfy the contingent consideration. The shares of common stock, valued at $4.6 million, were subsequently issued by the Company during January 2022 along with an immaterial cash payment for fractional shares. 102600000 9500000 759601 66100000 6400000 8500000 12800000 700000 334939 P18M 128351 15304 12500000 3416 408 300000 700000 41000000 17700000 3200000 17500000 P2Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the preliminary fair value amounts of the assets acquired and liabilities assumed as of the acquisition date, as well as the purchase consideration:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 1, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,306 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,309</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other current assets and prepaid expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,654</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,078</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other non-current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,970</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,500</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,549</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">846</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,545</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,877 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61,768</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total purchase price</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102,645 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Consideration transferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Company common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,514</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,500</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Holdback liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,838</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net working capital adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(674)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value of purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102,645 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1306000 2309000 1654000 1078000 2970000 46500000 3549000 846000 10545000 40877000 61768000 102645000 9467000 72514000 8500000 12838000 674000 102645000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the preliminary estimate of the intangible assets as of the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands except for years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Estimated<br/>Weighted<br/>Average<br/>Useful Lives<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30,900</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,700</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">900</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Estimated fair value of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,500</span></td></tr></table></div> P14Y 30900000 P10Y 14700000 P3Y 900000 46500000 0.096 1500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of contingent consideration and holdbacks balances from acquisition date to June 30, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Contingent<br/>consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Holdbacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at December 1, 2021 – acquisition date </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,500 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,164 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,664 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value during the period </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,200)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,097)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12,297)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at June 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,300 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,067 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,367 </span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8500000 12164000 20664000 5200000 7097000 12297000 3300000 5067000 8367000 -12300000 10500000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Nine months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,113 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37,600 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">148,705 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">102,713 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to common stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(60,517)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(38,853)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(165,681)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(106,461)</span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 56113000 37600000 148705000 102713000 -60517000 -38853000 -165681000 -106461000 59190 4600000 Investment in variable interest entityOn November 1, 2021, the Company contributed certain assets and licensed certain intellectual property rights to the newly formed Revelar Biotherapeutics, Inc. (“Revelar”), an independently operated, new biotechnology company, to develop and commercialize an antibody, discovered and optimized by Twist Biopharma, a division of the Company. The Company granted a license to Revelar for the exclusive development of an antibody lead along with a series of back up compounds for the potential treatment of SARS-CoV-2. While the licensed antibody neutralized all known variants of concern through Omicron, it does not neutralize the BA.4 and BA.5 variants and Revelar will pursue a partner for the antibody at this time. In addition, Revelar may license up to five additional antibody therapeutics over the next four years, each of which will be subject to additional upfront, milestone and royalty payments to the Company. The Company committed to invest up to <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$10.0 million in seed funding based on Revelar’s progress in the development of the lead antibody and the potential licensing of additional antibody therapeutics, of which the Company made an initial investment of $5.0 million in a simple agreement for future equity (“SAFE”), and two additional investments of $2.5 million each, as of the date of these consolidated financial statements as described below. In exchange for the assignment of certain contractual rights and the license to the antibody, and its back-up compounds, the Company received stock of Revelar amounting to an ownership percentage as of the date of these financial statements of 49.80%, excluding shares and options reserved for future stock awards and further excluding shares that Revelar may issue to the Company upon conversion of its SAFEs.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 3, 2022, the Company purchased an additional SAFE issued by Revelar for $2.5 million pursuant to the Asset License and Contract Assignment Agreement between the parties. In exchange for the SAFE, the Company obtained the right to receive shares of Revelar issued in a future preferred stock financing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 6, 2022, the Company purchased an additional SAFE issued by Revelar for $2.5 million pursuant to the Asset License and Contract Assignment Agreement between the parties. In exchange for the SAFE, the Company obtained the right to receive shares of Revelar issued in a future preferred stock financing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determined that Revelar is a VIE as the entity lacks sufficient equity to finance its activities without additional support. Additionally, the Company determined that it has (a) the power to direct the activities that significantly impact Revelar’s economic performance and (b) the obligation to absorb losses of, and the right to receive benefits from, Revelar that are potentially significant to Revelar. As a result, the Company is deemed to be the primary beneficiary of Revelar and is required to consolidate Revelar in accordance with ASC 810.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revelar incurred a net loss of approximately $6.0 million and $13.1 million for the three and nine months ended June 30, 2022, and the decrease in net assets was fully absorbed by the Company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total assets included on the consolidated balance sheet for Revelar as of June 30, 2022 were $7.4 million, primarily consisting of cash and cash equivalents. Total liabilities included on the consolidated balance sheet for Revelar as of June 30, 2022 were $10.5 million, primarily consisting of accounts payable, accrued expenses and non-current liability relating to the SAFEs.</span></div> 5 P4Y 10000000 5000000 2500000 0.4980 2500000 2500000 6000000 13100000 7400000 10500000 The Company’s consolidated assets as of June 30, 2022 include $7,429 in assets of the variable interest entity, or “VIE”, that can only be used to settle obligations of the VIE. Cash as of June 30, 2022 was $6,989; prepaid expenses as of June 30, 2022 were $433 and deposits as of June 30, 2022 were $7. The Company’s consolidated liabilities as of June 30, 2022 were $10,494 in liabilities of the VIE who creditors have no recourse to the Company. These liabilities include accounts payable of $6,412 as of June 30, 2022; accrued expenses and other current liabilities of $2,082 as of June 30, 2022; and other non-current liabilities of $2,000 as of June 30, 2022. EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 254 341 1 true 58 0 false 6 false false R1.htm 0001001 - Document - Cover Page Sheet http://imetrix.edgar-online.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited Condensed Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Sheet http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (unaudited) Sheet http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited Condensed Consolidated Statements of Stockholders??? Equity (unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (unaudited) (Parenthetical) Sheet http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedParenthetical Condensed Consolidated Statements of Stockholders??? Equity (unaudited) (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 7 false false R8.htm 2101101 - Disclosure - The Company Sheet http://imetrix.edgar-online.com/role/TheCompany The Company Notes 8 false false R9.htm 2103102 - Disclosure - Summary of significant accounting policies Sheet http://imetrix.edgar-online.com/role/Summaryofsignificantaccountingpolicies Summary of significant accounting policies Notes 9 false false R10.htm 2107103 - Disclosure - Fair value measurement Sheet http://imetrix.edgar-online.com/role/Fairvaluemeasurement Fair value measurement Notes 10 false false R11.htm 2112104 - Disclosure - Balance sheet components Sheet http://imetrix.edgar-online.com/role/Balancesheetcomponents Balance sheet components Notes 11 false false R12.htm 2122105 - Disclosure - Goodwill and intangible assets Sheet http://imetrix.edgar-online.com/role/Goodwillandintangibleassets Goodwill and intangible assets Notes 12 false false R13.htm 2126106 - Disclosure - Commitments and contingencies Sheet http://imetrix.edgar-online.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 13 false false R14.htm 2131107 - Disclosure - Related party transactions Sheet http://imetrix.edgar-online.com/role/Relatedpartytransactions Related party transactions Notes 14 false false R15.htm 2133108 - Disclosure - Income taxes Sheet http://imetrix.edgar-online.com/role/Incometaxes Income taxes Notes 15 false false R16.htm 2135109 - Disclosure - Common stock Sheet http://imetrix.edgar-online.com/role/Commonstock Common stock Notes 16 false false R17.htm 2137110 - Disclosure - Stock-based compensation Sheet http://imetrix.edgar-online.com/role/Stockbasedcompensation Stock-based compensation Notes 17 false false R18.htm 2147111 - Disclosure - Net loss per share attributable to common stockholders Sheet http://imetrix.edgar-online.com/role/Netlosspershareattributabletocommonstockholders Net loss per share attributable to common stockholders Notes 18 false false R19.htm 2151112 - Disclosure - Geographic, product and industry information Sheet http://imetrix.edgar-online.com/role/Geographicproductandindustryinformation Geographic, product and industry information Notes 19 false false R20.htm 2156113 - Disclosure - Business acquisition Sheet http://imetrix.edgar-online.com/role/Businessacquisition Business acquisition Notes 20 false false R21.htm 2163114 - Disclosure - Investment in variable interest entity Sheet http://imetrix.edgar-online.com/role/Investmentinvariableinterestentity Investment in variable interest entity Notes 21 false false R22.htm 2204201 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesPolicies Summary of significant accounting policies (Policies) Policies 22 false false R23.htm 2305301 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesTables Summary of significant accounting policies (Tables) Tables http://imetrix.edgar-online.com/role/Summaryofsignificantaccountingpolicies 23 false false R24.htm 2308302 - Disclosure - Fair value measurement (Tables) Sheet http://imetrix.edgar-online.com/role/FairvaluemeasurementTables Fair value measurement (Tables) Tables http://imetrix.edgar-online.com/role/Fairvaluemeasurement 24 false false R25.htm 2313303 - Disclosure - Balance sheet components (Tables) Sheet http://imetrix.edgar-online.com/role/BalancesheetcomponentsTables Balance sheet components (Tables) Tables http://imetrix.edgar-online.com/role/Balancesheetcomponents 25 false false R26.htm 2323304 - Disclosure - Goodwill and intangible assets (Tables) Sheet http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsTables Goodwill and intangible assets (Tables) Tables http://imetrix.edgar-online.com/role/Goodwillandintangibleassets 26 false false R27.htm 2327305 - Disclosure - Commitments and contingencies (Tables) Sheet http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesTables Commitments and contingencies (Tables) Tables http://imetrix.edgar-online.com/role/Commitmentsandcontingencies 27 false false R28.htm 2338306 - Disclosure - Stock-based compensation (Tables) Sheet http://imetrix.edgar-online.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://imetrix.edgar-online.com/role/Stockbasedcompensation 28 false false R29.htm 2348307 - Disclosure - Net loss per share attributable to common stockholders (Tables) Sheet http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersTables Net loss per share attributable to common stockholders (Tables) Tables http://imetrix.edgar-online.com/role/Netlosspershareattributabletocommonstockholders 29 false false R30.htm 2352308 - Disclosure - Geographic, product and industry information (Tables) Sheet http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationTables Geographic, product and industry information (Tables) Tables http://imetrix.edgar-online.com/role/Geographicproductandindustryinformation 30 false false R31.htm 2357309 - Disclosure - Business acquisition (Tables) Sheet http://imetrix.edgar-online.com/role/BusinessacquisitionTables Business acquisition (Tables) Tables http://imetrix.edgar-online.com/role/Businessacquisition 31 false false R32.htm 2402401 - Disclosure - The Company (Details) Sheet http://imetrix.edgar-online.com/role/TheCompanyDetails The Company (Details) Details http://imetrix.edgar-online.com/role/TheCompany 32 false false R33.htm 2406402 - Disclosure - Summary of significant accounting policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails Summary of significant accounting policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details) Details 33 false false R34.htm 2409403 - Disclosure - Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 34 false false R35.htm 2410404 - Disclosure - Fair value measurement - Narrative (Details) Sheet http://imetrix.edgar-online.com/role/FairvaluemeasurementNarrativeDetails Fair value measurement - Narrative (Details) Details 35 false false R36.htm 2411405 - Disclosure - Fair Value Measurement - Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments (Details) Sheet http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofReconciliationofBeginningandEndingBalancesoftheLevel3InstrumentsDetails Fair Value Measurement - Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments (Details) Details 36 false false R37.htm 2414406 - Disclosure - Balance sheet components - Receivable (Details) Sheet http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails Balance sheet components - Receivable (Details) Details 37 false false R38.htm 2415407 - Disclosure - Balance sheet components - Inventory (Details) Sheet http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails Balance sheet components - Inventory (Details) Details 38 false false R39.htm 2416408 - Disclosure - Balance sheet components - Narrative (Details) Sheet http://imetrix.edgar-online.com/role/BalancesheetcomponentsNarrativeDetails Balance sheet components - Narrative (Details) Details 39 false false R40.htm 2417409 - Disclosure - Balance sheet components - Other non-current assets (Details) Sheet http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentassetsDetails Balance sheet components - Other non-current assets (Details) Details 40 false false R41.htm 2418410 - Disclosure - Balance sheet components - Accrued expenses (Details) Sheet http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedexpensesDetails Balance sheet components - Accrued expenses (Details) Details 41 false false R42.htm 2419411 - Disclosure - Balance sheet components - Accrued compensation (Details) Sheet http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails Balance sheet components - Accrued compensation (Details) Details 42 false false R43.htm 2420412 - Disclosure - Balance sheet components - Other current liabilities (Details) Sheet http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails Balance sheet components - Other current liabilities (Details) Details 43 false false R44.htm 2421413 - Disclosure - Balance sheet components - Other non current liabilities (Details) Sheet http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentliabilitiesDetails Balance sheet components - Other non current liabilities (Details) Details 44 false false R45.htm 2424414 - Disclosure - Goodwill and intangible assets - Goodwill (Details) Sheet http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails Goodwill and intangible assets - Goodwill (Details) Details 45 false false R46.htm 2425415 - Disclosure - Goodwill and intangible assets - Intangible Assets Balances (Details) Sheet http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails Goodwill and intangible assets - Intangible Assets Balances (Details) Details 46 false false R47.htm 2428416 - Disclosure - Commitments and contingencies - Operating Leases On Balance Sheet (Details) Sheet http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesOperatingLeasesOnBalanceSheetDetails Commitments and contingencies - Operating Leases On Balance Sheet (Details) Details 47 false false R48.htm 2429417 - Disclosure - Commitments and contingencies - Minimum Rental Payments (Details) Sheet http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails Commitments and contingencies - Minimum Rental Payments (Details) Details 48 false false R49.htm 2430418 - Disclosure - Commitments and contingencies - Lease Contracts (Details) Sheet http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails Commitments and contingencies - Lease Contracts (Details) Details 49 false false R50.htm 2432419 - Disclosure - Related party transactions - (Details) Sheet http://imetrix.edgar-online.com/role/RelatedpartytransactionsDetails Related party transactions - (Details) Details http://imetrix.edgar-online.com/role/Relatedpartytransactions 50 false false R51.htm 2434420 - Disclosure - Income taxes (Details) Sheet http://imetrix.edgar-online.com/role/IncometaxesDetails Income taxes (Details) Details http://imetrix.edgar-online.com/role/Incometaxes 51 false false R52.htm 2436421 - Disclosure - Common stock (Details) Sheet http://imetrix.edgar-online.com/role/CommonstockDetails Common stock (Details) Details http://imetrix.edgar-online.com/role/Commonstock 52 false false R53.htm 2439422 - Disclosure - Stock-based compensation - Restricted Stock Units Activity (Details) Sheet http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails Stock-based compensation - Restricted Stock Units Activity (Details) Details 53 false false R54.htm 2440423 - Disclosure - Stock-based compensation - Additional information (Details) Sheet http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails Stock-based compensation - Additional information (Details) Details 54 false false R55.htm 2441424 - Disclosure - Stock-based compensation - Summary of PSU Activity (Details) Sheet http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails Stock-based compensation - Summary of PSU Activity (Details) Details 55 false false R56.htm 2442425 - Disclosure - Stock-based compensation - Activity Under Options (Details) Sheet http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails Stock-based compensation - Activity Under Options (Details) Details 56 false false R57.htm 2443426 - Disclosure - Stock-based compensation - Activity Under Performance Stock Options (Details) Sheet http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails Stock-based compensation - Activity Under Performance Stock Options (Details) Details 57 false false R58.htm 2444427 - Disclosure - Stock-based compensation - Expense (Details) Sheet http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails Stock-based compensation - Expense (Details) Details 58 false false R59.htm 2445428 - Disclosure - Stock-based compensation - Reserved For Issuance (Details) Sheet http://imetrix.edgar-online.com/role/StockbasedcompensationReservedForIssuanceDetails Stock-based compensation - Reserved For Issuance (Details) Details 59 false false R60.htm 2446429 - Disclosure - Stock-based compensation - Abveris Acquisition (Details) Sheet http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails Stock-based compensation - Abveris Acquisition (Details) Details 60 false false R61.htm 2449430 - Disclosure - Net loss per share attributable to common stockholders - Computation (Details) Sheet http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersComputationDetails Net loss per share attributable to common stockholders - Computation (Details) Details 61 false false R62.htm 2450431 - Disclosure - Net loss per share attributable to common stockholders - Anti-dilutive (Details) Sheet http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails Net loss per share attributable to common stockholders - Anti-dilutive (Details) Details 62 false false R63.htm 2453432 - Disclosure - Geographic, product and industry information - Geographic Region (Details) Sheet http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails Geographic, product and industry information - Geographic Region (Details) Details 63 false false R64.htm 2454433 - Disclosure - Geographic, product and industry information - By Product (Details) Sheet http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails Geographic, product and industry information - By Product (Details) Details 64 false false R65.htm 2455434 - Disclosure - Geographic, product and industry information - By Industry (Details) Sheet http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails Geographic, product and industry information - By Industry (Details) Details 65 false false R66.htm 2458435 - Disclosure - Business acquisition - Narrative (Details) Sheet http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails Business acquisition - Narrative (Details) Details 66 false false R67.htm 2459436 - Disclosure - Business acquisition - Assets acquired and liabilities assumed (Details) Sheet http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails Business acquisition - Assets acquired and liabilities assumed (Details) Details 67 false false R68.htm 2460437 - Disclosure - Business acquisition - Preliminary estimate of the intangible assets (Details) Sheet http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails Business acquisition - Preliminary estimate of the intangible assets (Details) Details 68 false false R69.htm 2461438 - Disclosure - Business acquisition - Change in contingent consideration (Details) Sheet http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails Business acquisition - Change in contingent consideration (Details) Details 69 false false R70.htm 2462439 - Disclosure - Business acquisition - Pro forma financial results (Details) Sheet http://imetrix.edgar-online.com/role/BusinessacquisitionProformafinancialresultsDetails Business acquisition - Pro forma financial results (Details) Details 70 false false R71.htm 2464440 - Disclosure - Investment in variable interest entity (Details) Sheet http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails Investment in variable interest entity (Details) Details http://imetrix.edgar-online.com/role/Investmentinvariableinterestentity 71 false false All Reports Book All Reports twst-20220630.htm twst-20220630.xsd twst-20220630_cal.xml twst-20220630_def.xml twst-20220630_lab.xml twst-20220630_pre.xml twst-20220630x10qxex311.htm twst-20220630x10qxex312.htm twst-20220630x10qxex321.htm twst-20220630x10qxex322.htm twst-20220630_g1.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "twst-20220630.htm": { "axisCustom": 1, "axisStandard": 19, "contextCount": 254, "dts": { "calculationLink": { "local": [ "twst-20220630_cal.xml" ] }, "definitionLink": { "local": [ "twst-20220630_def.xml" ] }, "inline": { "local": [ "twst-20220630.htm" ] }, "labelLink": { "local": [ "twst-20220630_lab.xml" ] }, "presentationLink": { "local": [ "twst-20220630_pre.xml" ] }, "schema": { "local": [ "twst-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 524, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 3, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 8 }, "keyCustom": 54, "keyStandard": 287, "memberCustom": 28, "memberStandard": 30, "nsprefix": "twst", "nsuri": "http://imetrix.edgar-online.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://imetrix.edgar-online.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - Fair value measurement", "role": "http://imetrix.edgar-online.com/role/Fairvaluemeasurement", "shortName": "Fair value measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Balance sheet components", "role": "http://imetrix.edgar-online.com/role/Balancesheetcomponents", "shortName": "Balance sheet components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122105 - Disclosure - Goodwill and intangible assets", "role": "http://imetrix.edgar-online.com/role/Goodwillandintangibleassets", "shortName": "Goodwill and intangible assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126106 - Disclosure - Commitments and contingencies", "role": "http://imetrix.edgar-online.com/role/Commitmentsandcontingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131107 - Disclosure - Related party transactions", "role": "http://imetrix.edgar-online.com/role/Relatedpartytransactions", "shortName": "Related party transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133108 - Disclosure - Income taxes", "role": "http://imetrix.edgar-online.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135109 - Disclosure - Common stock", "role": "http://imetrix.edgar-online.com/role/Commonstock", "shortName": "Common stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137110 - Disclosure - Stock-based compensation", "role": "http://imetrix.edgar-online.com/role/Stockbasedcompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147111 - Disclosure - Net loss per share attributable to common stockholders", "role": "http://imetrix.edgar-online.com/role/Netlosspershareattributabletocommonstockholders", "shortName": "Net loss per share attributable to common stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151112 - Disclosure - Geographic, product and industry information", "role": "http://imetrix.edgar-online.com/role/Geographicproductandindustryinformation", "shortName": "Geographic, product and industry information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)", "role": "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "shortName": "Condensed Consolidated Balance Sheets (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156113 - Disclosure - Business acquisition", "role": "http://imetrix.edgar-online.com/role/Businessacquisition", "shortName": "Business acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2163114 - Disclosure - Investment in variable interest entity", "role": "http://imetrix.edgar-online.com/role/Investmentinvariableinterestentity", "shortName": "Investment in variable interest entity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of significant accounting policies (Policies)", "role": "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Summary of significant accounting policies (Tables)", "role": "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesTables", "shortName": "Summary of significant accounting policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - Fair value measurement (Tables)", "role": "http://imetrix.edgar-online.com/role/FairvaluemeasurementTables", "shortName": "Fair value measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Balance sheet components (Tables)", "role": "http://imetrix.edgar-online.com/role/BalancesheetcomponentsTables", "shortName": "Balance sheet components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323304 - Disclosure - Goodwill and intangible assets (Tables)", "role": "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsTables", "shortName": "Goodwill and intangible assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "twst:SupplementalBalanceSheetInformationRelatingToCompaniesOperatingLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327305 - Disclosure - Commitments and contingencies (Tables)", "role": "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesTables", "shortName": "Commitments and contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "twst:SupplementalBalanceSheetInformationRelatingToCompaniesOperatingLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338306 - Disclosure - Stock-based compensation (Tables)", "role": "http://imetrix.edgar-online.com/role/StockbasedcompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2348307 - Disclosure - Net loss per share attributable to common stockholders (Tables)", "role": "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersTables", "shortName": "Net loss per share attributable to common stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "role": "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2352308 - Disclosure - Geographic, product and industry information (Tables)", "role": "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationTables", "shortName": "Geographic, product and industry information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2357309 - Disclosure - Business acquisition (Tables)", "role": "http://imetrix.edgar-online.com/role/BusinessacquisitionTables", "shortName": "Business acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - The Company (Details)", "role": "http://imetrix.edgar-online.com/role/TheCompanyDetails", "shortName": "The Company (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i8395e809e47d4d60bfac789a8912a52b_D20211001-20220630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of significant accounting policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails", "shortName": "Summary of significant accounting policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "role": "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "shortName": "Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Fair value measurement - Narrative (Details)", "role": "http://imetrix.edgar-online.com/role/FairvaluemeasurementNarrativeDetails", "shortName": "Fair value measurement - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i0a817b01ac324d8eacf3d93ebdc9c0f9_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Fair Value Measurement - Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments (Details)", "role": "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofReconciliationofBeginningandEndingBalancesoftheLevel3InstrumentsDetails", "shortName": "Fair Value Measurement - Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i0a817b01ac324d8eacf3d93ebdc9c0f9_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Balance sheet components - Receivable (Details)", "role": "http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails", "shortName": "Balance sheet components - Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Balance sheet components - Inventory (Details)", "role": "http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails", "shortName": "Balance sheet components - Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcessNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Balance sheet components - Narrative (Details)", "role": "http://imetrix.edgar-online.com/role/BalancesheetcomponentsNarrativeDetails", "shortName": "Balance sheet components - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcessNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "role": "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "twst:ConvertibleNoteReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417409 - Disclosure - Balance sheet components - Other non-current assets (Details)", "role": "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentassetsDetails", "shortName": "Balance sheet components - Other non-current assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "twst:ConvertibleNoteReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418410 - Disclosure - Balance sheet components - Accrued expenses (Details)", "role": "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedexpensesDetails", "shortName": "Balance sheet components - Accrued expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "twst:ScheduleOfAccruedCompensationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419411 - Disclosure - Balance sheet components - Accrued compensation (Details)", "role": "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails", "shortName": "Balance sheet components - Accrued compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "twst:ScheduleOfAccruedCompensationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420412 - Disclosure - Balance sheet components - Other current liabilities (Details)", "role": "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails", "shortName": "Balance sheet components - Other current liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421413 - Disclosure - Balance sheet components - Other non current liabilities (Details)", "role": "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentliabilitiesDetails", "shortName": "Balance sheet components - Other non current liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424414 - Disclosure - Goodwill and intangible assets - Goodwill (Details)", "role": "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails", "shortName": "Goodwill and intangible assets - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425415 - Disclosure - Goodwill and intangible assets - Intangible Assets Balances (Details)", "role": "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails", "shortName": "Goodwill and intangible assets - Intangible Assets Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Commitments and contingencies - Operating Leases On Balance Sheet (Details)", "role": "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesOperatingLeasesOnBalanceSheetDetails", "shortName": "Commitments and contingencies - Operating Leases On Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429417 - Disclosure - Commitments and contingencies - Minimum Rental Payments (Details)", "role": "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails", "shortName": "Commitments and contingencies - Minimum Rental Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:TenantImprovements", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430418 - Disclosure - Commitments and contingencies - Lease Contracts (Details)", "role": "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails", "shortName": "Commitments and contingencies - Lease Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": "-5", "lang": "en-US", "name": "twst:IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i8043eedaea554c6591225535fd43c481_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited)", "role": "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i8043eedaea554c6591225535fd43c481_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i117a5b893f054468a2fdb54306a1242b_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432419 - Disclosure - Related party transactions - (Details)", "role": "http://imetrix.edgar-online.com/role/RelatedpartytransactionsDetails", "shortName": "Related party transactions - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i117a5b893f054468a2fdb54306a1242b_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i834931165f8c4653bda1249db95b84fa_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "twst:BusinessAcquisitionIncomeTaxBenefitDueToDeferredTaxLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434420 - Disclosure - Income taxes (Details)", "role": "http://imetrix.edgar-online.com/role/IncometaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i834931165f8c4653bda1249db95b84fa_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "twst:BusinessAcquisitionIncomeTaxBenefitDueToDeferredTaxLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i060cc897fc7447f79ee7b88e69d15518_D20220201-20220228", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436421 - Disclosure - Common stock (Details)", "role": "http://imetrix.edgar-online.com/role/CommonstockDetails", "shortName": "Common stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i060cc897fc7447f79ee7b88e69d15518_D20220201-20220228", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i64233df50157412499ef8844bb3a53da_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439422 - Disclosure - Stock-based compensation - Restricted Stock Units Activity (Details)", "role": "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "shortName": "Stock-based compensation - Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i4b56148ab33e457cbee88ff8f3d0ff69_D20211001-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440423 - Disclosure - Stock-based compensation - Additional information (Details)", "role": "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails", "shortName": "Stock-based compensation - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i1a2a7042887945a5ba531d7bca1d7967_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441424 - Disclosure - Stock-based compensation - Summary of PSU Activity (Details)", "role": "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails", "shortName": "Stock-based compensation - Summary of PSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i904a7f028e2543c0804d70ece159dbe3_D20211001-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442425 - Disclosure - Stock-based compensation - Activity Under Options (Details)", "role": "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "shortName": "Stock-based compensation - Activity Under Options (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i0a817b01ac324d8eacf3d93ebdc9c0f9_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443426 - Disclosure - Stock-based compensation - Activity Under Performance Stock Options (Details)", "role": "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails", "shortName": "Stock-based compensation - Activity Under Performance Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "idd6099e7622f4ba4a2b72e3cce084e31_D20211001-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444427 - Disclosure - Stock-based compensation - Expense (Details)", "role": "http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails", "shortName": "Stock-based compensation - Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "if52b2655b4e04680957fb2e3b0fefbaf_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i0a817b01ac324d8eacf3d93ebdc9c0f9_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445428 - Disclosure - Stock-based compensation - Reserved For Issuance (Details)", "role": "http://imetrix.edgar-online.com/role/StockbasedcompensationReservedForIssuanceDetails", "shortName": "Stock-based compensation - Reserved For Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited) (Parenthetical)", "role": "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446429 - Disclosure - Stock-based compensation - Abveris Acquisition (Details)", "role": "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "shortName": "Stock-based compensation - Abveris Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ic25a655240c040088abd706171c57e64_D20211201-20211201", "decimals": "-5", "lang": "en-US", "name": "twst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantedFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449430 - Disclosure - Net loss per share attributable to common stockholders - Computation (Details)", "role": "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersComputationDetails", "shortName": "Net loss per share attributable to common stockholders - Computation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450431 - Disclosure - Net loss per share attributable to common stockholders - Anti-dilutive (Details)", "role": "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails", "shortName": "Net loss per share attributable to common stockholders - Anti-dilutive (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453432 - Disclosure - Geographic, product and industry information - Geographic Region (Details)", "role": "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails", "shortName": "Geographic, product and industry information - Geographic Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i23a7dc6488ab409b8bb438e179fa5491_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454433 - Disclosure - Geographic, product and industry information - By Product (Details)", "role": "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails", "shortName": "Geographic, product and industry information - By Product (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i7ae2659063d64f21bac25230be4d068e_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455434 - Disclosure - Geographic, product and industry information - By Industry (Details)", "role": "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails", "shortName": "Geographic, product and industry information - By Industry (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "twst:ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByIndustryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i7349d7326aea4f7bb877b0dffe6e0083_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia578601cbefa4b0dba0a51ce0665ead9_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458435 - Disclosure - Business acquisition - Narrative (Details)", "role": "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "shortName": "Business acquisition - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ic25a655240c040088abd706171c57e64_D20211201-20211201", "decimals": "INF", "lang": "en-US", "name": "twst:BusinessCombinationConsiderationSharesTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459436 - Disclosure - Business acquisition - Assets acquired and liabilities assumed (Details)", "role": "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "shortName": "Business acquisition - Assets acquired and liabilities assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i6112885490d14f3a98801b5e275a4c06_I20211201", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i6112885490d14f3a98801b5e275a4c06_I20211201", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460437 - Disclosure - Business acquisition - Preliminary estimate of the intangible assets (Details)", "role": "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "shortName": "Business acquisition - Preliminary estimate of the intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "id4614e6ab6ed49709914ffac0913f80f_D20211201-20211201", "decimals": null, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i6112885490d14f3a98801b5e275a4c06_I20211201", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461438 - Disclosure - Business acquisition - Change in contingent consideration (Details)", "role": "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails", "shortName": "Business acquisition - Change in contingent consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i6112885490d14f3a98801b5e275a4c06_I20211201", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "role": "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i834931165f8c4653bda1249db95b84fa_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462439 - Disclosure - Business acquisition - Pro forma financial results (Details)", "role": "http://imetrix.edgar-online.com/role/BusinessacquisitionProformafinancialresultsDetails", "shortName": "Business acquisition - Pro forma financial results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i834931165f8c4653bda1249db95b84fa_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "ia54d170e2d79425689532fcb7839c9c7_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464440 - Disclosure - Investment in variable interest entity (Details)", "role": "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails", "shortName": "Investment in variable interest entity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i1be4b65fa56843ff95d27840f418c054_D20220406-20220406", "decimals": "-5", "lang": "en-US", "name": "twst:PurchasedAdditionalFutureEquityToAssetLicenseAndContractAssignmentAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - The Company", "role": "http://imetrix.edgar-online.com/role/TheCompany", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of significant accounting policies", "role": "http://imetrix.edgar-online.com/role/Summaryofsignificantaccountingpolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "twst-20220630.htm", "contextRef": "i3924a4d6b21a4540aec8f390aec57b14_D20211001-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 58, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://imetrix.edgar-online.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r278", "r424", "r425", "r428", "r542" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]", "terseLabel": "Americas" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "APAC" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r109", "r220", "r224", "r229", "r364", "r365", "r370", "r371", "r431", "r542" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r109", "r220", "r224", "r229", "r364", "r365", "r370", "r371", "r431", "r542" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r231", "r241", "r281", "r283", "r441", "r442", "r443", "r444", "r445", "r446", "r465", "r520", "r523", "r543", "r544" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails", "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r231", "r241", "r281", "r283", "r441", "r442", "r443", "r444", "r445", "r446", "r465", "r520", "r523", "r543", "r544" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r165", "r266", "r267", "r467", "r519", "r521" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r165", "r266", "r267", "r467", "r519", "r521" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r231", "r241", "r270", "r281", "r283", "r441", "r442", "r443", "r444", "r445", "r446", "r465", "r520", "r523", "r543", "r544" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails", "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r231", "r241", "r270", "r281", "r283", "r441", "r442", "r443", "r444", "r445", "r446", "r465", "r520", "r523", "r543", "r544" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails", "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r166", "r167", "r266", "r268", "r522", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails", "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r166", "r167", "r266", "r268", "r522", "r530", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails", "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r171", "r427" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "twst_AbxBiologicsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Abx Biologics Inc.", "label": "Abx Biologics Inc. [Member]", "terseLabel": "Abveris", "verboseLabel": "Abx Biologics Inc." } } }, "localname": "AbxBiologicsInc.Member", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionProformafinancialresultsDetails", "http://imetrix.edgar-online.com/role/IncometaxesDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails" ], "xbrltype": "domainItemType" }, "twst_AcademicResearchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Academic research.", "label": "Academic Research [Member]", "terseLabel": "Academic research" } } }, "localname": "AcademicResearchMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails" ], "xbrltype": "domainItemType" }, "twst_AccruedCommissionsCurrent": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails": { "order": 3.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued commissions classified as current.", "label": "Accrued Commissions, Current", "terseLabel": "Accrued commissions" } } }, "localname": "AccruedCommissionsCurrent", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails" ], "xbrltype": "monetaryItemType" }, "twst_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Expenses And Other Current Liabilities", "label": "Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "twst_AdditionalAntibodyTherapeuticsLicenseMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of additional antibody therapeutics that maybe licensed over the next four years.", "label": "Additional Antibody Therapeutics License, Maximum", "terseLabel": "Additional antibody therapeutics that may license" } } }, "localname": "AdditionalAntibodyTherapeuticsLicenseMaximum", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "integerItemType" }, "twst_AntibodyDiscoveryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Antibody discovery", "label": "Antibody Discovery [Member]", "terseLabel": "Antibody discovery" } } }, "localname": "AntibodyDiscoveryMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails" ], "xbrltype": "domainItemType" }, "twst_BusinessAcquisitionIncomeTaxBenefitDueToDeferredTaxLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of income tax beneft due to the deferred tax liability as a part of business acquisition.", "label": "Business Acquisition, Income Tax Benefit, Due To Deferred Tax Liability", "terseLabel": "Income tax benefit, due to deferred tax liability as part of business acquisition" } } }, "localname": "BusinessAcquisitionIncomeTaxBenefitDueToDeferredTaxLiability", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "twst_BusinessCombinationAdjustmentHoldbackOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of adjustment holdback options in a business combination agreement.", "label": "Business Combination, Adjustment Holdback, Options", "terseLabel": "Adjustment holdback options (in shares)" } } }, "localname": "BusinessCombinationAdjustmentHoldbackOptions", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "sharesItemType" }, "twst_BusinessCombinationAdjustmentHoldbackShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of adjustment holdback shares in a business combination agreement.", "label": "Business Combination, Adjustment Holdback, Shares", "terseLabel": "Adjustment holdback shares (in shares)" } } }, "localname": "BusinessCombinationAdjustmentHoldbackShares", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "sharesItemType" }, "twst_BusinessCombinationAdjustmentHoldbackValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of adjustment holdback of shares and options in a business combination agreement.", "label": "Business Combination, Adjustment Holdback, Value", "terseLabel": "Value of adjustment holdback" } } }, "localname": "BusinessCombinationAdjustmentHoldbackValue", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "twst_BusinessCombinationConsiderationSharesTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of Shares on equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration, Shares, Transferred, Equity Interests Issued and Issuable", "terseLabel": "Equity (in shares)" } } }, "localname": "BusinessCombinationConsiderationSharesTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "sharesItemType" }, "twst_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableExcludingIssuedToEmployees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination, excluding shares issued to employees", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Excluding Issued to Employees", "terseLabel": "Common stock" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableExcludingIssuedToEmployees", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "twst_BusinessCombinationConsiderationTransferredOptionsIssuedAndIssuable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of options of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Options Issued and Issuable", "terseLabel": "Options consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredOptionsIssuedAndIssuable", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "twst_BusinessCombinationContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The contingent consideration in a business combination.", "label": "Business Combination Contingent Consideration", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsideration", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "twst_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability", "label": "Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward]", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Liability [Roll Forward]" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityRollForward", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails" ], "xbrltype": "stringItemType" }, "twst_BusinessCombinationContingentConsiderationLiabilityPresentValue": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of present value of liability arising from contingent consideration in a business combination", "label": "Business Combination Contingent Consideration Liability Present Value", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityPresentValue", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "twst_BusinessCombinationContingentConsiderationLiabilitySharesIssuable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Liability, Shares Issuable", "label": "Business Combination, Contingent Consideration, Liability, Shares Issuable", "terseLabel": "Contingent consideration, shares issuable up to (in shares)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilitySharesIssuable", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "sharesItemType" }, "twst_BusinessCombinationDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount rate used to determine estimated fair value of acquired intangible assets", "label": "Business Combination Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "BusinessCombinationDiscountRate", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "percentItemType" }, "twst_BusinessCombinationIndemnityHoldbackConsiderationLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of indemnity consideration holdback.", "label": "Business Combination Indemnity Holdback Consideration Liability", "terseLabel": "Indemnity holdback consideration" } } }, "localname": "BusinessCombinationIndemnityHoldbackConsiderationLiability", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "twst_BusinessCombinationIndemnityHoldbackOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of indemnity holdback options in a business combination agreement.", "label": "Business Combination, Indemnity Holdback, Options", "terseLabel": "Indemnity holdback options (in shares)" } } }, "localname": "BusinessCombinationIndemnityHoldbackOptions", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "sharesItemType" }, "twst_BusinessCombinationIndemnityHoldbackShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum holdback shares that can can be transferred as indemnity holdback shares in a business combination agreement.", "label": "Business Combination, Indemnity Holdback, Shares", "terseLabel": "Indemnity holdback shares (in shares)" } } }, "localname": "BusinessCombinationIndemnityHoldbackShares", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "sharesItemType" }, "twst_BusinessCombinationIndemnityHoldbacksPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period the indemnity holdbacks in business combination agreement is extends, e, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen day.", "label": "Business Combination, Indemnity Holdbacks Period", "terseLabel": "Indemnity holdbacks period" } } }, "localname": "BusinessCombinationIndemnityHoldbacksPeriod", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "durationItemType" }, "twst_BusinessCombinationPostBusinessCompensationExpenseIncludesEmployeeStockAwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount represents the business combination post business compensation expense includes employee stock awards", "label": "Business Combination Post Business Compensation Expense Includes Employee Stock Awards", "terseLabel": "Post combination compensation expenses includes employee stock awards" } } }, "localname": "BusinessCombinationPostBusinessCompensationExpenseIncludesEmployeeStockAwards", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "twst_BusinessCombinationSharesContingentConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of shares liability arising from contingent consideration in a business combination.", "label": "Business Combination, Shares, Contingent Consideration", "terseLabel": "Contingent consideration (in shares)" } } }, "localname": "BusinessCombinationSharesContingentConsideration", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "sharesItemType" }, "twst_BusinessCombinationTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of transaction costs related to acquisition.", "label": "Business Combination Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessCombinationTransactionCosts", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "twst_ChangeInFairValueOfAcquisitionConsideration": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change In Fair Value Of Acquisition Consideration", "label": "Change In Fair Value Of Acquisition Consideration", "terseLabel": "Change in fair value of acquisition consideration" } } }, "localname": "ChangeInFairValueOfAcquisitionConsideration", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "twst_ChangeInFairValueOfContingentConsiderationAndIndemnityHoldback": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of changes in fair value of contingent consideration and indemnity holdback.", "label": "Change In Fair Value Of Contingent Consideration And Indemnity Holdback", "negatedLabel": "Change in fair value of contingent considerations and holdbacks" } } }, "localname": "ChangeInFairValueOfContingentConsiderationAndIndemnityHoldback", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "twst_CommonStockCapitalSharesReservedForFutureIssuanceAnnualAutomaticIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum common stock capital shares reserved for future issuance annual automatic increase, as percent to the outstanding shares.", "label": "Common Stock Capital Shares Reserved For Future Issuance Annual Automatic Increase Percentage", "terseLabel": "Annual automatic Increase in share reserved for issuance (as a percent)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAnnualAutomaticIncreasePercentage", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "percentItemType" }, "twst_ContingentConsiderationAndIndemnityHoldbackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The member stands for Contingent Consideration And Indemnity Holdback.", "label": "Contingent Consideration And Indemnity Holdback [Member]", "terseLabel": "Contingent consideration and holdbacks" } } }, "localname": "ContingentConsiderationAndIndemnityHoldbackMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "twst_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails" ], "xbrltype": "domainItemType" }, "twst_ConvertibleNoteReceivable": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentassetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivable from parties in nontrade transactions and is convertible to the borrowers shares of stocks, per agreement.", "label": "Convertible Note Receivable", "terseLabel": "Convertible note receivable" } } }, "localname": "ConvertibleNoteReceivable", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "twst_DnaAndBiopharmaLibrariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DNA and Biopharma Libraries.", "label": "Dna And Biopharma Libraries [Member]", "terseLabel": "DNA libraries" } } }, "localname": "DnaAndBiopharmaLibrariesMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails" ], "xbrltype": "domainItemType" }, "twst_EarlyExerciseOfStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Early Exercise Of Stock Options [Member]", "label": "Early Exercise Of Stock Options [Member]", "terseLabel": "Unvested shares of common stock issued upon early exercise of stock options" } } }, "localname": "EarlyExerciseOfStockOptionsMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "domainItemType" }, "twst_ExecutiveOfficersAndSeniorLevelEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive officers and senior level employees.", "label": "Executive Officers And Senior Level Employees [Member]", "terseLabel": "Executive Officers and Senior Level Employees" } } }, "localname": "ExecutiveOfficersAndSeniorLevelEmployeesMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "twst_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]", "label": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]", "terseLabel": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]" } } }, "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "twst_FoodOrAgricultureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Food and agriculture.", "label": "Food Or Agriculture [Member]", "terseLabel": "Food/agricultural" } } }, "localname": "FoodOrAgricultureMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails" ], "xbrltype": "domainItemType" }, "twst_GoodwillAndIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill And Intangible Assets [Line Items]", "label": "Goodwill And Intangible Assets [Line Items]", "terseLabel": "Goodwill And Intangible Assets [Line Items]" } } }, "localname": "GoodwillAndIntangibleAssetsLineItems", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "twst_GoodwillAndIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill And Intangible Assets [Table]", "label": "Goodwill And Intangible Assets [Table]", "terseLabel": "Goodwill And Intangible Assets [Table]" } } }, "localname": "GoodwillAndIntangibleAssetsTable", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "twst_HoldbackLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Holdback liabilities", "label": "Holdback Liabilities", "verboseLabel": "Indemnity holdbacks" } } }, "localname": "HoldbackLiabilities", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "twst_IgenomxInternationalGenomicsCorporatioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to iGenomX International Genomics Corporation.", "label": "Igenomx International Genomics Corporatio [Member]", "terseLabel": "iGenomX" } } }, "localname": "IgenomxInternationalGenomicsCorporatioMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails" ], "xbrltype": "domainItemType" }, "twst_IgenomxInternationalGenomicsCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents information pertaining to its igenomx international genomics corporation member.", "label": "Igenomx International Genomics Corporation [Member]", "terseLabel": "iGenomX" } } }, "localname": "IgenomxInternationalGenomicsCorporationMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "twst_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in operating lease right of use assets.", "label": "Increase Decrease In Operating Lease Right Of Use Asset", "terseLabel": "Change in right-of-use asset" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "monetaryItemType" }, "twst_IndemnityHoldbackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the indemnity holdback.", "label": "Indemnity Holdback [Member]", "terseLabel": "Holdbacks" } } }, "localname": "IndemnityHoldbackMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails" ], "xbrltype": "domainItemType" }, "twst_IndustrialChemicalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Industrial Chemicals.", "label": "Industrial Chemicals [Member]", "terseLabel": "Industrial chemicals/materials" } } }, "localname": "IndustrialChemicalsMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails" ], "xbrltype": "domainItemType" }, "twst_IndustrySectorsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by industry sector.", "label": "Industry Sectors [Axis]", "terseLabel": "Industry Sectors [Axis]" } } }, "localname": "IndustrySectorsAxis", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails" ], "xbrltype": "stringItemType" }, "twst_IndustrySectorsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Industry sectors.", "label": "Industry Sectors [Domain]", "terseLabel": "Industry Sectors [Domain]" } } }, "localname": "IndustrySectorsDomain", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails" ], "xbrltype": "domainItemType" }, "twst_InitialAnnualBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of initial annual base rent.", "label": "Initial Annual Base Rent", "terseLabel": "Initial annual base rent" } } }, "localname": "InitialAnnualBaseRent", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "monetaryItemType" }, "twst_InvestmentInConsolidatedVariableInterestEntitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Investment in variable interest entity", "terseLabel": "Investment in variable interest entity" } } }, "localname": "InvestmentInConsolidatedVariableInterestEntitiesAbstract", "nsuri": "http://imetrix.edgar-online.com/20220630", "xbrltype": "stringItemType" }, "twst_LesseeOperatingLeaseArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The area leased by lessee in lease agreement classified as operating lease.", "label": "Lessee, Operating Lease, Area", "terseLabel": "Operating lease area" } } }, "localname": "LesseeOperatingLeaseArea", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "decimalItemType" }, "twst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "twst_MinimumIncreaseCommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum increase common stock capital shares reserved for future issuance.", "label": "Minimum Increase Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Minimum annual increase in share reserved for issuance" } } }, "localname": "MinimumIncreaseCommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "sharesItemType" }, "twst_NetExerciseOfCommonStockWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net exercise of common stock warrants (in shares).", "label": "Net Exercise Of Common Stock Warrants Shares", "terseLabel": "Net exercise of stock warrants (in shares)" } } }, "localname": "NetExerciseOfCommonStockWarrantsShares", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "twst_NetWorkingCapitalAdjustment": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net working capital adjustment", "label": "Net working capital adjustment", "negatedLabel": "Net working capital adjustment", "terseLabel": "Net working capital adjustment" } } }, "localname": "NetWorkingCapitalAdjustment", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "twst_NgsToolsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NGS Tools Member", "label": "Ngs Tools [Member]", "terseLabel": "NGS tools" } } }, "localname": "NgsToolsMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails" ], "xbrltype": "domainItemType" }, "twst_OligoPoolsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oligo pools.", "label": "Oligo Pools [Member]", "terseLabel": "Oligo pools" } } }, "localname": "OligoPoolsMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails" ], "xbrltype": "domainItemType" }, "twst_OperatingLeaseAnnualBaseRentPercentageIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease Annual Base Rent Percentage Increase", "label": "Operating Lease Annual Base Rent Percentage Increase", "terseLabel": "Operating lease base rent annual percentage increase" } } }, "localname": "OperatingLeaseAnnualBaseRentPercentageIncrease", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "percentItemType" }, "twst_OtherAssetsNoncurrentExcludingConvertibleReceivable": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentassetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other, excluding convertible receivable.", "label": "Other Assets, Noncurrent, Excluding Convertible Receivable", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrentExcludingConvertibleReceivable", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "twst_OtherLiabilitiesCurrentOtherThanContingentConsiderationAndTaxes": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer, other business acquisition contingent consideration and taxes payable.", "label": "Other Liabilities, Current, Other Than Contingent Consideration and Taxes", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrentOtherThanContingentConsiderationAndTaxes", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "twst_OtherLiabilitiesNonCurrentOtherThanContingentConsideration": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or if longer, other business acquisition contingent consideration.", "label": "Other Liabilities Non Current Other Than Contingent Consideration", "terseLabel": "Other non current liabilities" } } }, "localname": "OtherLiabilitiesNonCurrentOtherThanContingentConsideration", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "twst_PaymentsToRepurchasesOfCommonStockForTaxWithholding": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Repurchases Of Common Stock For Tax Withholding", "label": "Payments To Repurchases Of Common Stock For Tax Withholding", "negatedLabel": "Repurchases of common stock for income tax withholding" } } }, "localname": "PaymentsToRepurchasesOfCommonStockForTaxWithholding", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "twst_PercentageOfPayrollDeductionOnEligibleCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of payroll deduction on eligible common stock.", "label": "Percentage Of Payroll Deduction On Eligible Common Stock", "terseLabel": "Percentage of payroll deduction to purchase common stock" } } }, "localname": "PercentageOfPayrollDeductionOnEligibleCommonStock", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "percentItemType" }, "twst_PerformanceStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Stock Option", "label": "Performance Stock Option [Member]", "terseLabel": "Performance Stock Option" } } }, "localname": "PerformanceStockOptionMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "twst_PerformanceStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Stock Unit", "label": "Performance Stock Unit [Member]", "terseLabel": "Performance Stock Unit" } } }, "localname": "PerformanceStockUnitMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "domainItemType" }, "twst_PeriodOfAdditionalAntibodyTherapeuticsLicense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period that additional antibody therapeutics maybe licensed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Period Of Additional Antibody Therapeutics License", "terseLabel": "Period of additional antibody therapeutics that maybe licensed" } } }, "localname": "PeriodOfAdditionalAntibodyTherapeuticsLicense", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "durationItemType" }, "twst_PriorQuarterPublicOfferingExpensesAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prior Quarter Public Offering Expenses Adjustment", "label": "Prior Quarter Public Offering Expenses Adjustment", "negatedTerseLabel": "Public offering expense adjustment" } } }, "localname": "PriorQuarterPublicOfferingExpensesAdjustment", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "twst_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan", "label": "Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan", "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "twst_PropertyPlantAndEquipmentWriteoff": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property, Plant, And Equipment, Writeoff", "label": "Property, Plant, And Equipment, Writeoff", "terseLabel": "Write off property and equipment" } } }, "localname": "PropertyPlantAndEquipmentWriteoff", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "twst_PurchasedAdditionalFutureEquityToAssetLicenseAndContractAssignmentAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the additional purchase of future equity \"SAFE\" to asset license and contract assignment agreement between the parties.", "label": "Purchased Additional Future Equity to Asset License and Contract Assignment Agreement", "terseLabel": "Additional SAFE issued" } } }, "localname": "PurchasedAdditionalFutureEquityToAssetLicenseAndContractAssignmentAgreement", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "monetaryItemType" }, "twst_QuincyMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quincy, Massachusetts", "label": "Quincy, Massachusetts [Member]", "terseLabel": "Quincy, Massachusetts" } } }, "localname": "QuincyMassachusettsMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "domainItemType" }, "twst_RevelarBiotherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Revelar Biotherapeutics Inc.", "label": "Revelar Biotherapeutics Inc [Member]", "terseLabel": "Revelar" } } }, "localname": "RevelarBiotherapeuticsIncMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "domainItemType" }, "twst_ScheduleOfAccruedCompensationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components accrued compensation.", "label": "Schedule of Accrued Compensation [Table Text Block]", "terseLabel": "Summary of Accrued Compensation" } } }, "localname": "ScheduleOfAccruedCompensationTableTextBlock", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsTables" ], "xbrltype": "textBlockItemType" }, "twst_ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByIndustryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers and long lived assets by industry.", "label": "Schedule Of Revenue From External Customers And Long Lived Assets By Industry [Table Text Block]", "terseLabel": "Summary of Revenue by Industry" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByIndustryTableTextBlock", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationTables" ], "xbrltype": "textBlockItemType" }, "twst_ShareBasedAwardsWithVestingRequirementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based awards with vesting requirements.", "label": "Share Based Awards With Vesting Requirements [Member]", "terseLabel": "Awards with vesting requirements" } } }, "localname": "ShareBasedAwardsWithVestingRequirementsMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "twst_ShareBasedAwardsWithoutVestingRequirementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents share based awards without besting requirements.", "label": "Share Based Awards Without Vesting Requirements [Member]", "terseLabel": "Awards without vesting requirements" } } }, "localname": "ShareBasedAwardsWithoutVestingRequirementsMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "twst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantedFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate grant-date fair value of share-based awards granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments, Granted, Fair Value", "terseLabel": "Awards aggregate fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantedFairValue", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "twst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Aggregate Intrinsic Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "monetaryItemType" }, "twst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Number", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Number", "terseLabel": "Expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "twst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value", "terseLabel": "Expected to vest (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "twst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Term", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "durationItemType" }, "twst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "stringItemType" }, "twst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Outstanding", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Outstanding [Roll Forward]", "terseLabel": "Share-Based Compensation Arrangement By Share-based Payment Award, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingRollForward", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationReservedForIssuanceDetails" ], "xbrltype": "stringItemType" }, "twst_ShareBasedCompensationByShareBasedPaymentArrangementInstrumentsOtherThanOptionsExpectedToVestOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based payment arrangement instruments other than options expected to vest outstanding.", "label": "Share Based Compensation By Share Based Payment Arrangement Instruments Other Than Options Expected To Vest Outstanding", "terseLabel": "Shares expected to vest" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentArrangementInstrumentsOtherThanOptionsExpectedToVestOutstanding", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "sharesItemType" }, "twst_SharesSubjectToEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents shares subject to employee stock purchase plan.", "label": "Shares Subject To Employee Stock Purchase Plan [Member]", "terseLabel": "Shares subject to employee stock purchase plan" } } }, "localname": "SharesSubjectToEmployeeStockPurchasePlanMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "domainItemType" }, "twst_SouthSanFranciscoCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to South San Francisco, California.", "label": "South San Francisco California [Member]", "terseLabel": "South San Francisco, California" } } }, "localname": "SouthSanFranciscoCaliforniaMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "domainItemType" }, "twst_StockOptionsBasedOnPerformanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options Based On Performance [Member]", "label": "Stock Options Based On Performance [Member]", "terseLabel": "Shares subject to performance-based stock options" } } }, "localname": "StockOptionsBasedOnPerformanceMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "domainItemType" }, "twst_SubsequentPublicOffering1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsequent Public Offering 1", "label": "Subsequent Public Offering1 [Member]", "terseLabel": "Subsequent Public Offering" } } }, "localname": "SubsequentPublicOffering1Member", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommonstockDetails", "http://imetrix.edgar-online.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "twst_SupplementalBalanceSheetInformationRelatingToCompaniesOperatingLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental balance sheet information relating to companies operating lease [Table text block].", "label": "Supplemental Balance Sheet Information Relating To Companies Operating Lease [Table Text Block]", "terseLabel": "Schedule of Supplemental Balance Sheet Information Relating to Companies Operating Lease" } } }, "localname": "SupplementalBalanceSheetInformationRelatingToCompaniesOperatingLeaseTableTextBlock", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesTables" ], "xbrltype": "textBlockItemType" }, "twst_SyntheticGenesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Synthetic genes.", "label": "Synthetic Genes [Member]", "terseLabel": "Synthetic genes" } } }, "localname": "SyntheticGenesMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails" ], "xbrltype": "domainItemType" }, "twst_TenantImprovementAllowance": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tenant Improvement, Allowance", "label": "Tenant Improvement, Allowance", "negatedLabel": "Less: tenant improvement allowance (receipt anticipated in 2022)" } } }, "localname": "TenantImprovementAllowance", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "twst_TwoThousandAndEighteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and eighteen employee stock purchase plan.", "label": "Two Thousand And Eighteen Employee Stock Purchase Plan [Member]", "terseLabel": "2018 ESPP" } } }, "localname": "TwoThousandAndEighteenEmployeeStockPurchasePlanMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "twst_UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested Restricted Stock Units And Performance Stock Units", "label": "Unvested Restricted Stock Units And Performance Stock Units [Member]", "terseLabel": "Unvested restricted stock units and performance stock units" } } }, "localname": "UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember", "nsuri": "http://imetrix.edgar-online.com/20220630", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36", "r434" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r172", "r173" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Trade receivables" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r21", "r172", "r173" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r95" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Discount accretion on investment securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r10", "r11", "r39" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails": { "order": 2.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued bonus" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedexpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedexpensesDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r11", "r39" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails": { "order": 4.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxes, Current", "terseLabel": "Accrued payroll and related taxes" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r10", "r11", "r39" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedexpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional services fees payable" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r10", "r39", "r269" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails": { "order": 1.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation, Current", "terseLabel": "Accrued vacation" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r56", "r57", "r58", "r505", "r528", "r529" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r55", "r58", "r65", "r66", "r67", "r111", "r112", "r113", "r368", "r524", "r525", "r559" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Estimated Weighted Average Useful Lives in Years" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r317", "r434" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r111", "r112", "r113", "r314", "r315", "r316", "r385" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Repurchases of common stock for income tax withholding" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r284", "r286", "r319", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r255", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Net of underwriting discounts, commissions and offering expenses" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r286", "r310", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r174", "r183", "r185", "r187" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r94", "r201", "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Total amortization expense related to intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r105", "r149", "r154", "r161", "r181", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r364", "r370", "r397", "r432", "r434", "r485", "r503" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesOperatingLeasesOnBalanceSheetDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r51", "r105", "r181", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r364", "r370", "r397", "r432", "r434" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r287", "r312" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation and use of estimates" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r280", "r282" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionProformafinancialresultsDetails", "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails", "http://imetrix.edgar-online.com/role/IncometaxesDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r280", "r282", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionProformafinancialresultsDetails", "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails", "http://imetrix.edgar-online.com/role/IncometaxesDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionProformafinancialresultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Summary of Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r340", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss attributable to common stockholders" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionProformafinancialresultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r340", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionProformafinancialresultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r352", "r353", "r356" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Fair value of consideration transferred", "totalLabel": "Fair value of purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred [Abstract]", "terseLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferredAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Company common stock", "verboseLabel": "Company common stock" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r350", "r352", "r353", "r358" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Holdback liabilities" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r93", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedLabel": "Change in fair value during the period", "terseLabel": "Change in fair value during the period" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r351", "r354", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at June\u00a030, 2022", "periodStartLabel": "Balance at December 1, 2021 \u2013 acquisition date" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r351", "r355" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration and holdbacks" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r351", "r355" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Holdback" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business acquisition" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Businessacquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "Assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other current assets and prepaid expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "terseLabel": "Current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets", "verboseLabel": "Estimated Fair Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r344", "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Fair value of assets acquired and liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities": { "auth_ref": [ "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities", "terseLabel": "Non-current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other non-current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r344", "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r345" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total purchase price" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r34", "r96" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total financial assets" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r90", "r96", "r101" ], "calculation": { "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r90", "r400" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommonstockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r263", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r217", "r491", "r509" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r214", "r215", "r216", "r218", "r532" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Commitmentsandcontingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Aggregate number of common stock shares reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationReservedForIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r111", "r112", "r385" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r434" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.00001 par value\u2014100,000 and 100,000 shares authorized at June\u00a030, 2022 and September\u00a030, 2021, respectively; 56,344 and 49,499 shares issued and outstanding at June\u00a030, 2022 and September\u00a030, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r73", "r496", "r514" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r369", "r373", "r375" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable interest entities" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r77", "r105", "r181", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r397" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r75" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Deposits": { "auth_ref": [ "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.", "label": "Deposits", "terseLabel": "Deposits" } } }, "localname": "Deposits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Operating lease security deposit with the lessor" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r94", "r147" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Stockbasedcompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r74", "r116", "r117", "r118", "r119", "r120", "r124", "r126", "r128", "r129", "r130", "r134", "r135", "r386", "r387", "r497", "r515" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Net loss per share attributable to common stockholders\u2014basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r74", "r116", "r117", "r118", "r119", "r120", "r126", "r128", "r129", "r130", "r134", "r135", "r386", "r387", "r497", "r515" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders\u2014diluted (in usd per share)", "verboseLabel": "Net loss per share attributable to common stockholders, diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r131", "r132", "r133", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per share attributable to common stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Netlosspershareattributabletocommonstockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r400" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "totalLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost, stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation expense, period for recognition", "verboseLabel": "Recognize cost weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Share based compensation by share based payment arrangement equity instruments other than options unrecognized compensation", "verboseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost, options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Shares subject to options to purchase common stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r65", "r66", "r67", "r111", "r112", "r113", "r115", "r121", "r123", "r137", "r182", "r255", "r262", "r314", "r315", "r316", "r331", "r332", "r385", "r401", "r402", "r403", "r404", "r405", "r407", "r524", "r525", "r526", "r559" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r388", "r389", "r390", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r388", "r389", "r390", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairvaluemeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r232", "r234", "r235", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r389", "r438", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Fairvaluemeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r232", "r271", "r272", "r277", "r279", "r389", "r438" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r232", "r234", "r235", "r271", "r272", "r277", "r279", "r389", "r439" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r232", "r234", "r235", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r389", "r440" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofReconciliationofBeginningandEndingBalancesoftheLevel3InstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r391", "r396" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairvaluemeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofReconciliationofBeginningandEndingBalancesoftheLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Contingent consideration \u2013 additions" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofReconciliationofBeginningandEndingBalancesoftheLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance as of June\u00a030, 2022", "periodStartLabel": "Balance as of September\u00a030, 2021" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofReconciliationofBeginningandEndingBalancesoftheLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r232", "r234", "r235", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r438", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r176", "r177", "r178", "r179", "r180", "r184", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r233", "r253", "r384", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r551", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted average Amortization period in years" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r207" ], "calculation": { "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r202", "r205", "r207", "r209", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r207", "r469" ], "calculation": { "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r202", "r206" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r207", "r468" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net book value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Increase in intangible assets" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r95", "r398", "r399" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Amortization of debt discount" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r94" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r197", "r198", "r434", "r484" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "verboseLabel": "Increase in goodwill" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and intangible assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Goodwillandintangibleassets" ], "xbrltype": "textBlockItemType" }, "us-gaap_HealthCareMember": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Service provided for prevention, maintenance, diagnosis or treatment of physical and mental health.", "label": "Health Care [Member]", "terseLabel": "Healthcare" } } }, "localname": "HealthCareMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r70", "r149", "r153", "r157", "r160", "r163", "r482", "r493", "r499", "r516" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/IncometaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r325", "r326", "r328", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/IncometaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r106", "r324", "r327", "r329", "r333", "r335", "r337", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r122", "r123", "r148", "r323", "r334", "r336", "r517" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Benefit from income taxes", "terseLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred tax liability" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r93", "r416" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Change in operating lease liabilities." } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r69", "r146", "r408", "r409", "r498" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r88", "r91", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r47" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r50", "r434" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r49" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r48" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r28", "r196" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process inventory included gross consigned" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r79", "r145" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r420" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Future minimum payments", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails", "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r420" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r420" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r420" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r420" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r420" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022", "verboseLabel": "Remainder of 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails", "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r420" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r105", "r155", "r181", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r365", "r370", "r371", "r397", "r432", "r433" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r105", "r181", "r397", "r434", "r486", "r507" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAssumed1": { "auth_ref": [ "r98", "r99", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.", "label": "Liabilities Assumed", "terseLabel": "Property and equipment additions included in accounts payable and accrued expenses" } } }, "localname": "LiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40", "r105", "r181", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r365", "r370", "r371", "r397", "r432", "r433", "r434" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesOperatingLeasesOnBalanceSheetDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r388" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "verboseLabel": "Total financial liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesOperatingLeasesOnBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r90", "r92", "r95" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r59", "r62", "r67", "r71", "r95", "r105", "r114", "r116", "r117", "r118", "r119", "r122", "r123", "r127", "r149", "r153", "r157", "r160", "r163", "r181", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r387", "r397", "r494", "r512" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss attributable to common stockholders", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r149", "r153", "r157", "r160", "r163" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r413" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r410" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Operating Lease, Impairment Loss", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r412" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r412" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current portion", "verboseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails", "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesOperatingLeasesOnBalanceSheetDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r412" ], "calculation": { "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesMinimumRentalPaymentsDetails", "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesOperatingLeasesOnBalanceSheetDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r414", "r416" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r411" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesOperatingLeasesOnBalanceSheetDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r419", "r421" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Lease weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r418", "r421" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Lease weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "The Company" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/TheCompany" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r12", "r39" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedexpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "totalLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentassetsDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r53" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r60", "r63", "r65", "r66", "r68", "r72", "r255", "r401", "r406", "r407", "r495", "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r54", "r56" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Change in unrealized loss on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://imetrix.edgar-online.com/role/FairvaluemeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Summary of Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails": { "order": 5.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Employee-related Liabilities, Current", "terseLabel": "Other accrued compensation" } } }, "localname": "OtherEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsAccruedcompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r39", "r434" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "totalLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthernoncurrentliabilitiesDetails", "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r95" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Other Noncash Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Summary of Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesGrossCurrent": { "auth_ref": [], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Gross, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommonstockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r82", "r357" ], "calculation": { "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash", "verboseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r82" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Business acquisition, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r84" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r83" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Shares" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r287", "r312" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r32", "r33" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r489", "r511" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid Expense", "terseLabel": "Prepaid Expense" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r85" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from public offerings, net of underwriting discounts, commissions and offering expenses" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds of underwritten public offering common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r85", "r313" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "verboseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r81" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from maturity of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r59", "r62", "r67", "r89", "r105", "r114", "r122", "r123", "r149", "r153", "r157", "r160", "r163", "r181", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r363", "r366", "r367", "r381", "r382", "r387", "r397", "r499" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r211", "r434", "r501", "r508" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanLossesExpensed": { "auth_ref": [ "r186", "r492" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "terseLabel": "Bad debt expense" } } }, "localname": "ProvisionForLoanLossesExpensed", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r518" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "negatedLabel": "Realized gain on investments" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r278", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Raw materials purchased from related party investor" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r278", "r424", "r428", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r422", "r423", "r425", "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related party transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Relatedpartytransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r87" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r322", "r466", "r545" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r8", "r17", "r101", "r531" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash, non-current" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r262", "r317", "r434", "r506", "r527", "r529" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://imetrix.edgar-online.com/role/TheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r111", "r112", "r113", "r115", "r121", "r123", "r182", "r314", "r315", "r316", "r331", "r332", "r385", "r524", "r526" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r143", "r144", "r152", "r158", "r159", "r165", "r166", "r169", "r265", "r266", "r467" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails", "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails", "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r417", "r421" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock, consideration received" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommonstockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommonstockDetails", "http://imetrix.edgar-online.com/role/TheCompanyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock, shares issued (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommonstockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, share price (in usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommonstockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Summary of Accounts Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersAntidilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Calculation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionChangeincontingentconsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Contingent Consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionAssetsacquiredandliabilitiesassumedDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails", "http://imetrix.edgar-online.com/role/BusinessacquisitionProformafinancialresultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r286", "r309", "r318" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "verboseLabel": "Schedule of Stock-Based Compensation Expenses" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Summary of Revenue by Product" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Summary of Preliminary Estimate of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r202", "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r13", "r29", "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Summary of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Performance-based Units Activity" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Summary of Other Non-Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of Preliminary Fair Value Amounts of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r426", "r428" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/RelatedpartytransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r14", "r101", "r483", "r504" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Summary of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/SummaryofsignificantaccountingpoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r76", "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Summary of Revenue by Geographic Region" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r149", "r150", "r156", "r200" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails", "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails", "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r287", "r312" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r291", "r301", "r303" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Activity Under Option and Performance Stock Options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Stock Option Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r43", "r103", "r138", "r139", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r248", "r253", "r256", "r257", "r258", "r259", "r260", "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommonstockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r364", "r365", "r370", "r371", "r372", "r374", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r140", "r141", "r142", "r149", "r151", "r157", "r161", "r162", "r163", "r164", "r165", "r168", "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Geographic, product and industry information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Geographicproductandindustryinformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByIndustryDetails", "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationByProductDetails", "http://imetrix.edgar-online.com/role/GeographicproductandindustryinformationGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r78" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r93" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "verboseLabel": "Vesting period from acquisition date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted average remaining contractual term (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)", "verboseLabel": "Equity awards restricted shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in usd per share)", "periodStartLabel": "Beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contractual term, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "verboseLabel": "Vesting of restricted stock units (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationExpenseDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationReservedForIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted average remaining contractual term (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock options granted (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r293", "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in usd per share)", "periodStartLabel": "Beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Expected to vest (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "negatedTerseLabel": "Shares issued during the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationReservedForIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r285", "r289" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionNarrativeDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAbverisAcquisitionDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of PSUs that may vest based on performance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Aggregate intrinsic value, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationRestrictedStockUnitsActivityDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationSummaryofPSUActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, Expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Aggregate intrinsic value, vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderOptionsDetails", "http://imetrix.edgar-online.com/role/StockbasedcompensationActivityUnderPerformanceStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "ESPP eligible employee common stock purchase price ratio" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/StockbasedcompensationAdditionalinformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Repurchases of common stock for income tax withholding (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r18", "r487", "r488", "r502" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r102", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Summaryofsignificantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r45", "r65", "r66", "r67", "r111", "r112", "r113", "r115", "r121", "r123", "r137", "r182", "r255", "r262", "r314", "r315", "r316", "r331", "r332", "r385", "r401", "r402", "r403", "r404", "r405", "r407", "r524", "r525", "r526", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r111", "r112", "r113", "r137", "r467" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r98", "r99", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of common stock in connection with the business acquisition" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r19", "r20", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of shares from business acquisition (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r19", "r20", "r255", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "verboseLabel": "Issuance of shares under the employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r19", "r20", "r255", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r255", "r262", "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r45", "r255", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of shares from business acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r19", "r20", "r255", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of shares under the employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r19", "r20", "r255", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in public offering, net of underwriting discounts and commissions and offering expenses" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r45", "r255", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r19", "r20", "r255", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchases of early exercised stock options (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r25", "r26", "r105", "r175", "r181", "r397", "r434" ], "calculation": { "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r104", "r240", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r254", "r262", "r264" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Commonstock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommonstockDetails", "http://imetrix.edgar-online.com/role/TheCompanyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance sheet components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Balancesheetcomponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income and sales taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BalancesheetcomponentsOthercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TenantImprovements": { "auth_ref": [ "r510" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.", "label": "Tenant Improvements", "terseLabel": "Tenant improvements" } } }, "localname": "TenantImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CommitmentsandcontingenciesLeaseContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/BusinessacquisitionPreliminaryestimateoftheintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Tradenames & Trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/GoodwillandintangibleassetsIntangibleAssetsBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r176", "r177", "r178", "r179", "r180", "r233", "r253", "r384", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r551", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r108", "r271", "r279", "r500" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. government treasury bills" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/FairValueMeasurementSummaryofCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.", "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "Investment in variable interest entity" } } }, "localname": "VariableInterestEntityDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/Investmentinvariableinterestentity" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of financial or other support the reporting entity has provided (explicitly or implicitly) to the Variable Interest Entity (VIE) that it was not previously contractually required to provide or that the reporting entity intends to provide, including, for example, situations in which the reporting entity assisted the VIE in obtaining another type of support.", "label": "Variable Interest Entity, Financial or Other Support, Amount", "terseLabel": "Investment amount" } } }, "localname": "VariableInterestEntityFinancialOrOtherSupportAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss": { "auth_ref": [ "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).", "label": "Variable Interest Entity, Initial Consolidation, Gain (Loss)", "terseLabel": "Loss absorbed by reporting entity" } } }, "localname": "VariableInterestEntityInitialConsolidationGainOrLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "Ownership percentage" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r364", "r365", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "http://imetrix.edgar-online.com/role/InvestmentinvariableinterestentityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r125", "r130" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders\u2014diluted (in shares)", "verboseLabel": "Weighted average shares used in computing net loss per share, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r124", "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders\u2014basic (in shares)", "verboseLabel": "Weighted average shares used in computing net loss per share, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com/role/NetlosspershareattributabletocommonstockholdersComputationDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r321": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r546": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r547": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r548": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r549": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r550": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r551": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r552": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r553": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r554": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r555": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r556": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r557": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r558": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" } }, "version": "2.1" } ZIP 91 0001628280-22-021593-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-021593-xbrl.zip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�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�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®I,]C5NGITO9HRH]G0_WS#=9 M+85295\K) MV:ZF9@@:2:NZ*T4MJ_4-I)'6,P/E/,!N)B$,; /;A7W$/K80>]>%F'\JRD4P MPF:CG.]NW(24BVH?Y:1([NP#%@W?/]*AB&7O9=$7"> MT&>U[9J_YJ76W#7_.IRWQZV.,DW/*M/,RO,/]$SP6&P*65(9B3-*&!08(!@2@&5/ 9)K@4CF=(Y=([VW6MY M:B:D%,ZL=[5XCL;B&+!NJW 5# -/?V<$O.)T3VK;.S)WO[718G%/*M&.OCW] M0-],\'69(OJ^JCBSGO%$0DZ)!D(A HP+3@''B@-&:49%HI'*D4]A[<,.O*;B M*U34KDOO>*=Z'\#HMEY? \[@$W1=IW._OX1(CTSNTVH'3M\^Z&3DG.W3*AXG M:I]YKD^&XF!L?'^OZG148@KSU^]+^Z//NYI\GY[*/#.&E69)1D N9&I6<&0, M!X80\"3/\PS'9H/@D03YZOI,S6]HQ+4!RY8>L:2QK6HE.O+73@18IV3.5Y=R M0N:XU+0,N.E@K7U3L];6S[FRUG[?8ZW]>UUGJK;\Y>?V?5G^^"9J061V:B5( M?ZSOSB<1]M6EG6 DV!_P._3,])W,J'VI:PW42GM367% M&X%OHD;DH!AZ+.U!L1QIY;T:4[]UT!FBSF7J?>WKDL%O-TE MMZU-GQ\LZ>,GM=EQ&,VT)67-$P:0PAE .L6 HB0#$&49I5!HFGF%1SOW/#7+ M; F[YDN;$+C9K K^M"EC8LV66%2%[TQJ(7/&72&:Y"TP* T06WRIYU>(-78$XW3LL>O+ _ * M_6JVU.N2>5^9';>PMK*L:SF#/"-8"0J8H-(8*T8 @1H!:"])8\AUK/!LH>XL M_Z2;N>HEA]-_LQXXP_.5G MXSM^W*B']0P1G8F$*A S83PW3#1@<08!25/CQE&S^TRDC^?6V=O4/+9ZQV.D M;=';OT2_68&C4F+/B,]NK-VL7# $![9FUX#G;;*<0 EJFKI['-4$.2E_:&K< M7NI)$<#*7%1[(K-7&?RK$JIX5O+SXON*+=9,E(>V2'"8B92 /$V-OY4)##B' M""@&TQ1B+8G&7@P /KU/S>18X>T.L3S.NK&%2'8*1*M: \_$?J_1<#-"@V$\ M=$1%#>^W"MX]V:-&^,C\O25^P&3[/JB%S:7WDF#<5/D^X!QEPO=JI,=%ZHGS MM:U%?:,62A>;=T_J^_*=TLKL<:7Y\=:1FQ&5H$1E L18:&/Q( 948@BTTAG4 M,- A%;1X]L5=;RX+TI M Z\?48>KW+'&Z55N"EK.WIMFX(PV-G:GT:?\Y5:CL0;&XWYXK $:Z>KXJZI+ MKJZCS;V*6+E7M/.D.)ADFV:*V/?6(7#8 MN](.TF#?$X9G\QDN5R__6*[^]7%19I+7Y7F^FB]T]:S6,Z4HQ#&'(%&0 Y0G M"G!))*!)+C4F*4:)USVW0Y]36_RLI*!8@,=*5C-/:Q7LC)T_23,I[U;V!KS< M%-PM?/@01%-S!#R)J:6\B*Z\M:U]+O"T#UD@=\D#"&:+ QQ*7^QWY M<,(9B.,C"O=7^Y+5J$=6-'DXMXNJGMCM>JTVZ_IN:D:(RF(H8Y##C *$-00, M(PQT O.849XR[G4\X=#GU"Q3+?(V3:Z,B:P+&=87L*R4WY?)YC+Z;@8I,*8# M&Z0&SEK<$LWJ.KN2^*:YU@Y)<^,,4&"^F\O]CDQ\XPS$,0..^ZN]*S0?%C)L MBAANL[]QAE&6QAF(N1( L40 1K$ "L&#'K5;7?H%[U>8^%XT3L4PD-? M]#;@_M0"=U_V+]?6 +>]/K)<&X-[U]P#FZZ>W52$]V1"%63TJV MPI2;XXD,(:X%1R#A. 9(:@*XM/LR*!G*.!0I]C)H9WN:FO&J!>W)G'0>4)RD M,LFT 519#MB8QH#(7 "NL4($)3&5V(>)*@R@(U!2#06HFYD/ M/ )KU!J"7D M "=E%Y$(RQ5YMK=Q22(O*7W$#GGQA6 U,K\JL;Q;%/^MY$=I.BAT8<\CJF.W M\C)S59(FM$0I*UN8'U:/-$M:MSH&;45K:\9HD;5TC=N M9]#5VMXT#PYQXC?\L Q=7C24N*]=DC0P[ YE3$/W>)57_WYB*G L=0NGE>UX!T$B. M9R/A<%[G&0R&<#D/NWH-?_.,NF>Y\L7I5JUT>J#,4Q4IO-< M AG;4@<08\!8H@&&G&4BR1B#7F0%9WN:F@VH9/.;^>=A=)O\0< 9^BSQ5/W& M'>';35.$,_PQXD5T@EJ&\[V-:APN*GUH'RZ_T--!D/_YM*XKHRUOI2R#9MG\ M"RODQ\5;]EALV+SLT]9#,KY,716I9'>>Q2Q+=9818SM(!A#""E!-E&74,S8$ M$LK]B)NN$69JAJ8.,GA:F+'XW1:66-Q%36[S^J9D="K6Z[+V:1EIIK5:]:=I MOVH8'5V8D09G:$=GIX:-]]@I$EE-;.!LK4M3N+92YV97GZW4**!;% #7L,[3 M-0*-ZV(%@.[($0O19D]WK61/W1[]Z"P1$$H"-"&QS:#C@!.>@CSG><)YC@5+ MO'RTO>:G9B]K\F3?TC%GL'-TS'HC,K"1<@?#W]TZJ7-8'VN_BW$=JY/J'7E3 MIY_J&3'&BI6M.*W>O&S_^K="K4Q#]R\_JV>CKPUTB@F#B1 4< HA0#K) ,\- M>#R-:<9AEDOI5$'"K]NI37,K:ED"7D5;84L'Z-/MW_O%E;FA[V80PF,ZL*&X M!D[_Z#,O=,(&H[EU/6YLFA<<1Z%J?F_[5Z![5Z?@_K]/;&5F]OSEJWIZZCJ DFFZS/ 1& M T_VG8AU@INEJ+G 5]LKQ[\+A^")_2<[&SV;OTOE4RG\G<_WS3JYLVU6CD*Q MN'M7K,5\N7Y:M6C/2:RAEHB!7" ,D%0$$)YJ +4Q&"3.:<:]+F <^IR:D?A) M+>]6[/&^$#>VGI%\$IMR UPLY--Z4Q*+:%L0P/_:UV4 W(Q)8%B'O@JNI(VV MXD8[>:/?!J&<]P H< +)Y7Y'3AMQ!N(X6<3]U9YU,!K.YE:Y&($)(9Q!H%#, MC&\B$: 9RT!&TQAKC56BA4\NPXD^O"S."%D,5J;(#EU37'NY\*UI<0)(-TMR M)3P#6XX=J?M =70ZU ];B.)$/^.6G3BOZ%&1B8Y'_PBUMF_O[E9E:0?C-ZV* MQ;H0Y5GH+$9IK)(T ;E,!$"Y+5:A"3=#E4,N; &+U(D$9%):3Y1:JZZOHC?HE3+L\= MX(O\/ZM(M_^7.?%2W1>^@&D5[#XG[/_@LMT7QN=UBW=?$NX*YOE6/M4>U7U) M<%]Q^-:R5=%X1K8R((_/U8S+),%"$L"$5 "E! )F?@84Q@FB(F9,.EV%A1)H M:JY?+>=^^8T>E.77C)&#?S8R\@.[5J=S6/=+=+0T:M(NUG44[VP%C M)VJ6Y_+XW$S"YZN7_W)CG;0?EP]-7C>MALJPYR_G^[R=8[B M.]4_>RK?_5;OG^;G9GI#'"<,!2<-S[%%'M@U[HLJI>,HQ=:+4/0"=*K_9JIG^> MPX=B+=C\GXJM/IB?K&>2ICF7.C5N56P\6F7^1I#$0.90:!E3R&,GPNZ./J9F MV+:!_)6:L\426)!%0.,:0:0]6E(3C*0Y"+-(94\%TY%1KN[F=HT+RUI MS=4B6G)ZAC>>AM3-";D>J#'NL+OX;#Z9KYZM[QN"[("QC)W0A U?/-W5N!&+ MG>H>!2EV/]V7P^8D2T.=U<-C@F/!8R"8C5#$F0"4*@DR2&2>9;'"?J77.WN; MFJEHT9O8ND[ 'C57\OKRRW1![&8S@@$WL.DXH(0!.TJ8 5*JG$ )3._2U>/( M_"T.RA\3M+B\U#.ATJP(MPMI_V.W*,]L;B]P;C=OV6KU4BSNJEB>'".,1&IV M%I)2@#0F@.;&K# ML99$28QBKR1+EUZG9EFLM.5U9+F*JIW,HP10KY=[;GS$O9)/ M<_59-Z3!'XI%L5$_%\_*&+^-^9Z*AE?XS9YG@@% M%!69K32! <>( F:-723,U"]8H8V_ZMC3AE3Z@5"C::52QA$?\ M)2J5BDJMHM]*O3Q/A:\;4A8 V["[P*HG&W2R& .]H M3QFDT5 W<>]4%<919>-\9S_4>H8HRR&!&<"6_PNQ# .*I0*ISA'F"6(R47XW M_$[]3N^BOQ$RVK ??:,IW"#O>Y?6%\97O4';PEJGW95B#WEGUH'2P#=EIWI^ MY?NQ#C NWXIUO1S*)!T7,IIE:<*@R#( I8@!4I " @4'#"J=)*E.%*?7100< M=SHU_^^Z:F1.,/>U0M>!]SI&Z$3ILB%-T'F(!K9 )SI^90-T'HK+]J?CW9YQ MIC9IY--RL=Q/2ZZO6682*9TSE@,NXQ2@+(\!X[D$),TYS)$D&?$Z.^ON;FHF MI\HT*^KD^-KP_.4F6BC']%I'E-WL3CCL!K8X%6QM2;<$ [6P(3D&G% )&^[8 MW>6XX8Y.ZA^%.[J]U2,5[*/9RA6V^.WBB%7&\\;2Y%2QB1(;3E:E&4V MN2M- 88T5I!D@E+HG-QULHNIF8Y:R(B54D;V9COJC/-UA;+;5H0!:'"/I,*F M$K#,^XV^AL#&(^?I:HQ&SV(JSGQ1H3*,.A'IS!DZ_>9X64"=DN_E]70_&6H# M5UK7741Y:X,A!)+-WOO]7WO-=!.;RUN]R$SVO+'?5 M<>!,8D)8KC0PVSL*4(X5X(A( [[$C&8I39D3B].IQJ=F@;85HLSB*EJ\U'6" M[T*),K'P]V)SOY_>6R80KXL>,9QMJ!VO!GL"./1-7ZO65L#+NA/*AKU[:W

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end

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